,ticker,content
0,IDXX,relative strength rs rating idexx laboratory idxx enter new percentile monday increase look best stock buy watch factor watch closely be relative price strength unique rating identify technical performance show stock price action last week measure other stock major index year market history show top perform stock often have higher rs rating launch biggest price move look best stock buy watch start hereidexx laboratory break earlier have fall back prior entry cup handle stock re watch clear buy point then retreat more original entry price consider fail base best stock form new consolidation also keep mind most recent pattern be later stage base involve more risk regard fundamental company have post quarters accelerate earning growth sale growth have also rise same period company earn rank peer medical system equipment industry group cantel medical cmd intuitive surgical isrg abaxis abax be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
1,IDXX,idexx laboratory idxx see welcome improvement relative strength rs rating monday increase look best stock buy watch factor watch closely be relative price strength ibd unique rs rating identify market leadership show stock price action last week compare other stock database history show market biggest winner tend have higher rs rating begin new price run look best stock buy watch start ibd stock be trading buy range clear buy point cup handle once stock move higher original entry consider buy range relative strength have enter new high ground sign stock be outperform general market term price performance take look revenue profit performance idexx laboratory have post rise ep growth last report top line growth have also moved higher same period company earn rank peer medical system equipment industry group intuitive surgical isrg cantel medical cmd iradime irmd be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
2,IDXX,re look stock be set base ahead next earning report here fit bill idexx laboratory idxx expect release latest number oct be trading approximately shy entry current formation be first stage flat base buy stock just ahead earning involve risk typically don have enough time build profit cushion latest quarterly number come be sure follow sound buy sell rule minimize exposure look best stock buy watch start company post earning share growth latest quarterly report sale rise analyst expect ep growth quarter growth full year annual ep estimate be recently revise upward idexx laboratory have composite rating earn rank peer medical system equipment industry group cantel medical cmd be rank stock group note date earning report be subject change check company update related earning calendar analyst estimate stock watchnew option strategy limit risk earning
3,IDXX,relative strength rs rating idexx laboratory idxx moved higher percentile friday get lift ibd proprietary rating identify price performance worst best score score show stock price behavior trail week compare other stock database decade market research reveal market biggest winner typically have rs rating least early stage move see idexx laboratory continue show renew price strength clear threshold see ibd help make more stock be work flat base entry see stock clear price volume least higher normal company show ep growth last quarter revenue rise keep eye company next round number nov idexx laboratory earn rank peer medical system equipment industry group cantel medical cmd fonar fonr intuitive surgical isrg be top highly rate stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
4,IDXX,idexx laboratory idxx see welcome improvement relative strength rs rating thursday upgrade exclusive rating investor business daily track market leadership worst best score grade show stock price performance last week hold other stock database decade market research reveal stock go make biggest gain often have rs rating north launch biggest climb see idexx laboratory continue show renew price strength clear threshold look best stock buy watch start hereidexx laboratory be try complete flat base entry see stock clear price heavy trade company show ep growth last quarter sale growth come company hold rank peer medical system equipment industry group fonar fonr be rank stock group related stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
5,IDXX,idexx laboratory idxx see positive improvement relative strength rs rating thursday rise ibd proprietary rating track price action worst best score rating show stock price performance last week compare other stock database history reveal market biggest winner tend have rs rating north early stage move see idexx laboratory continue show renew price strength clear threshold look winning stock try simple stock be build flat base entry see break volume least average company post earning growth latest quarterly report sale growth come company be expect report latest earning sale number nov company earn rank peer medical system equipment industry group cantel medical cmd fonar fonr intuitive surgical isrg be top highly rate stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
6,IDXX,idexx laboratory idxx break friday maker veterinary diagnostic product top wall street expectation first quarter raise guidance earning revenue growth stock market today idexx pop close blow past buy point time high share begin form cup handle base march time close previous high first quarter idexx report sale increase year year organic basis easily crushed consensus view sale idexx note organic growth companion animal group help drive strong result be pleased outstanding execution expand commercial team world first quarter result growth premium instrument placement chief executive officer ayer say written statement get newsletter deliver inbox more info product service privacy policy term useearning share grow vs year period be constant currency basis also top consensus earning cent share idexx also boost organic revenue outlook now see growth constant currency basis year adjust foreign exchange rate idexx keep guidance sale growth year firm also increase full year earning guidance penny midpoint share idexx lab be featured past week investor business daily leaderboard watchlist candidate related look next nvidia start simple build long term profit stock take many gain buy stock ahead earning report
7,IDXX,idexx laboratory idxx cater niche clientele keep push back launch next product trade multiple time earning xto investor sound big thank yet wall street pro laud veterinary diagnostic company management brilliant unbelievable grasp business simply put company execution continue be second none raymond james analyst john ransom say recent note client ransom go say further be not often player space dominant approximately market share be able maintain base highly competitive market yet idexx post placement number suggest even be gain share get newsletter deliver inbox more info product service privacy policy term thing niche market question be veterinary market sound small number be fewer veterinarian animal health clinic accord census bureau annually vet serve million very passionate customer pet owner well pet household have pet accord american pet product association translate nearly dog more cat not mention multitude bird fish other creature hang person home most recent annual survey reveal dog owner spend annual average routine surgical vet visit combine cat owner shell idexx be industry leader supply vet technology run clinic test blood work cater primarily beloved canine feline abroad raymond james ransom canaccord genuity analyst mark massaro peg company stateside market share hefty player abaxis abax have corner quarter american market smaller competitor heska hska have tenth vca unit antech diagnostic zoetis zts latter be acquire abaxis also number rival water treatment livestock product account sliver idexx revenue big money come companion animal diagnostic business include suite clinic product such chemistry panel rapid test kit veterinary instrument analyzer be also external laboratory service such diagnostic imaging testing companion animal diagnostic unit bring idexx more net revenue overall haul year person simply take pet vet be likely result idexx test equipment be used kind diagnostic test be administer time person bring fluffy friend clinic idexx say investor day presentation last august pet owner tend not object fact millennial pet owner be more likely older peer say money be object come pet accord idexx survey work percent year old feel way vs gen xer baby boomer younger person get laser focuse career longer get married have kid go get dog year old say massaro millennial say be prioritize pet other thing maybe person generation hold greater esteem idexx most recent quarter be laud analyst share profit rise share revenue grow top view cent respectively accord zack investment research company have see success sedivue industry first clinic urine sediment analyzer recently launch product catalyst sdma clinic test used vet look kidney disease be adopt north american customer first few month debut idexx chief executive ayer contend amazing amazing accomplishment nothing happen fast veterinary tell analyst call adoption rate be typically very slow context adoption sdma slide have be exceptional so re very very pleased success ve have quarterly beat reinforce piper jaffray bullish call companion animal industry william blair analyst say believe long term investment merit idexx remain very compelling beat single line single reference category say canaccord genuity massaro add get extremely strong commercial execution idexx have most savvy sale organization ve ever see point company unusually large direct sale force sale rep north america more europe particular strength share idexx end trading thursday close barely remain buy point share be marginally friday break sharply cup handle base high volume follow company earning report management also lift full year earning guidance cent organic revenue outlook growth currency neutral basis reaffirm sale outlook adjust exchange rate growth even raymond james ransom have high praise company only reaffirm market perform rating same note client cite high price earning multiple hindrance more positive rating come idexx have more occasion push back launch snap fecal dx allow vet test house presence hookworm whipworm roundworm infection canaccord massaro brushed delay view idexx continue crush number raise guide product launch come tell street re beating number startling idexx consistently trade almost time premium multiple other good health care company say massaro example hologic holx medical imaging company call undisputed leader mammography trade time earning vs idexx time earning idexx consistent beat raise quarters model nearly recur revenue unusually high health care number bolster confidence idexx management team have unbelievable grasp business say william blair analyst ryan daniel believe company be durable business franchise warrant premium multiple write early firm be more aggressive share purchase pullback more broadly raymond james ransom say april investor shouldn expect growth ramp end market companion animal diagnostic mean share company idexx abaxis heska be more likely move individual success share gain new product launch etc move uniformly encompass cyclical dynamic give baseline growth rate animal health diagnostic industry canaccord genuity massaro say mean even worst company space grow year really be spectacular industry say be interested medtech stock break zoetis snag billionstock show improve market leadership idexx laboratory earn rs ratingthis top medical stock break beat raise
8,IDXX,friday idexx laboratory idxx get upgrade ibd smartselect composite rating revise score mean stock currently top other stock term key performance metric technical strength history show top market performer tend have higher score launch major climb idexx laboratory be trading entry consolidation look winning stock try simple stock have ep rating meaning recent quarterly longer term annual earning growth be outpace stock accumulation distribution rating show moderate buy institutional investor last week company report earning share growth revenue growth increase prior report company have now post rise growth last report idexx laboratory hold rank peer medical system equipment industry group cantel medical cmd be rank stock group related company be now outperform stock
9,IDXX,stock market look find renew strength stock watch week be hot stock now buy range apple aapl com wuba paylocity pcty idexx laboratory idxx cheniere energy lng apple have composite rating com lead group paylocity have idexx laboratory have cheniere energy lag composite rating take account variety fundamental technical factor top stock usually have high composite rating launch big run apple paylocity idexx cheniere have relative strength line new high earning fuel upside momentum rs line measure stock price performance vs so new high line be especially bullish apple hit new close high friday breaking double bottom base buy point addition strong rs line heavy volume be bullish indicator apple get newsletter deliver inbox more info product service privacy policy term useapple share gain last week strong earning massive buyback plan news warren buffett berkshire hathaway add share stake tech giant apple stock remain buy zone apple rise monday stock market trading know china craigslist com be hold buy range clear cup handle buy point april volume day be strong have cool com climb monday paylocity stock jump heavy volume friday move put paylocity share flat base buy point payroll human resource software firm top quarterly earning sale estimate thursday enterprise software stock have be market leader fellow hr payroll vendor paycom payc sell last week give line revenue guidance paylocity dip monday idexx lab be move higher big volume report earning share climb friday stock clear cup handle entry process be still buy zone veterinary diagnostic product maker report second straight quarter accelerate earning growth idexx reversed lower fall finally cheniere share be hit highest level half year gain strong volume friday put share buy point month long consolidation cheniere many other oil gas stock be benefit rise commodity price cheniere close flat monday also be interested apple hot stock market rally be key juncturenvidia lead top stock buy earning duethese top software stock industry form new basesstock buy watch top ipos big small cap growth stocksthese hot growth stock have most potential big factor be ray light market look dark
10,IDXX,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
11,IDXX,idexx laboratory idxx see welcome improvement relative strength rs rating monday rise exclusive rating investor business daily track market leadership worst best score rating show stock price behavior last week stack other stock database decade market research show stock go make biggest gain typically have rs rating launch biggest climb look winning stock try simple stock be ibd big cap list be not currently potential buy area see stock go form base spark new run idexx laboratory see earning sale growth rise last quarter earning share increase revenue rise idexx laboratory earn rank peer medical system equipment industry group cantel medical cmd be top rank stock group related stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
12,IDXX,idexx laboratory idxx see welcome improvement relative strength rs rating thursday rise ibd proprietary rating identify share price action worst best score rating show stock price behavior trail week compare other stock database year market history reveal best stock often have rs rating begin biggest climb see idexx laboratory continue rebound hit benchmark idexx laboratory be work flat base entry see break heavy volume idexx laboratory report earning growth latest quarterly report sale growth come company earn rank peer medical system equipment industry group cutera cutr be top rank stock group related stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
13,IDXX,millennial be move needle animal health company idexx laboratory idxx abaxis abax heska hska analyst say monday reiterate buy rating idexx follow firm investor day xover past year pet related spending have rise new millennial pet owner have enter market canaccord analyst mark massaro say millennial be take pet vet higher rate gen baby boomer counterpart believe millennial impact be twofold millennial pet owner be spending more take pet vet higher rate millennial veterinarian appear be more willing order new cut edge diagnostic testing write note client base survey datum idexx present investor day millennial customer age note bring pet vet more once year compare gen owner baby boomer massaro say be likely best benefit idexx make diagnostic test chemistry panel veterinary office massaro see idexx dominant hardly rivale global vet landscape demand remain high least next year accord idexx clinical vet visit year include diagnostic test only visit include chemistry panel practice ranking top idexx client complete time more chemistry panel average client think number be likely increase preventative care visit become more popular millennial continue humanize pet massaro say believe number tick favorable macro trend materialize idexx add additional test chemistry panel ibd take idexx have ibd relative strength rating have lift high best possible earlier month head ibd datum story more go ranking stock massaro keep buy rating price target idexx stock recent slump idexx represent rare buy opportunity say idexx begin form flat base early june buy point share be well day trading average month investor day last week maine idexx reiterate outlook top line growth growth constant currency basis growth be expect be growth international recur revenue recur revenue drive diagnostic now represent total sale idexx say customer retention rate be company also have double sale force north america massaro argue neither key diagnostic rival meaningfully challenge idexx next catalyst be late october idexx report third quarter result likely offer guidance massaro raise adjust earning view share share respectively also see sale adjust income share stock market today idexx be nearly flat lose cent tot related eye be dow component star drug next drugmaker benefit astrazeneca coattailsbiogen teva slip democrat launch ms drug pricing probe
14,IDXX,idexx laboratory idxx have relative strength rs rating upgrade monday ibd unique rating measure market leadership worst best score grade show stock price behavior last week compare other stock database decade market research reveal best perform stock typically have rs rating least launch biggest price move stock be build flat base entry see stock clear price volume least higher normal idexx laboratory report ep growth most recent report sale growth come company earn rank peer medical system equipment industry group cutera cutr be top rank stock group related stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
15,IDXX,ibd stock screen be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap screen be
16,IDXX,ibd stock screen be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap screen be
17,IDXX,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
18,IDXX,tuesday idexx laboratory idxx earn positive adjustment relative strength rs rating ibd unique rating identify share price performance worst best score grade show stock price movement trail week hold other stock database year market history show market biggest winner often have higher rs rating early stage move stock be try complete flat base buy point see break heavy volume company show ep growth latest quarterly report sale rise company earn rank peer medical system equipment industry group fonar fonr be rank stock group related stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
19,IDXX,dow jone industrial average lead market again tuesday extend streak day get more fuel late day apple aapl beat profit expectation rise hour industrial be near mark make record high rise
20,IDXX,disappointing reversal perhaps most significant thing stock market do tuesday be didn do climb new high past midday try clear nearly week span dull horizontal price movement moment later index slide right back flat
21,IDXX,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
22,IDXX,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
23,IDXX,idexx laboratory idxx have relative strength rs rating upgrade wednesday welcome improvement still short higher score prefer see exclusive rating investor business daily identify market leadership worst best score grade show stock price performance last week stack other stock database history reveal stock go make biggest gain typically have rs rating early stage move see idexx laboratory continue show renew price strength clear threshold look best stock buy watch start hereidexx laboratory be still buy zone move past buy point consolidation once stock move higher initial entry consider proper buy zone earning growth decline most recent report sale moved higher look next report feb company earn rank peer medical system equipment industry group intuitive surgical isrg be top rank stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
24,IDXX,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
25,IDXX,stock forget worry trade rule china dodd frank banking regulation inflation apple aapl lead market higher friday nasdaq charge ahead dow jone industrial average large cap add respectively volume fall major exchange bull ve prefer price gain
26,IDXX,here weekly investing action plan need know investor come week chip leader nvidia nvda lead week tech heavy earning chinese tech leader sina sina weibo wb jd com jd follow alibaba baba strong result disney also report launch new stream product prepare close
27,IDXX,idexx laboratory idxx be form base buy point get ready report earning aug current formation be first stage flat base buy stock just ahead earning be risky typically don have enough time build profit cushion latest quarterly number come be sure follow sound buy sell rule minimize exposure idexx laboratory report earning growth last quarter revenue rise consensus analyst estimate call ep growth quarter growth full year idexx laboratory have composite rating hold rank peer medical system equipment industry group hill hrc intuitive surgical isrg be also group highest rate stock note date earning report be estimate subject change check company update related earning calendar analyst estimate stock watchnew option strategy limit risk earning
28,IDXX,much have be written information technology company investing artificial intelligence loup venture manage partner doug clinton note many tech company be capitalize ai technology well clinton have put together portfolio publicly trade tech company be make investment ai improve business recent blog post clinton note assemble portfolio fun exercise way draw attention sweeping nature ai advancement loup venture be early stage venture capital firm clinton select company range industry include health care retail logistic professional service finance transportation energy construction food agriculture year company have be artificial intelligence company win be competitive clinton say company include be ibd stock idexx laboratory idxx idexx make product animal health care sector last earning call company say latest diagnostic product be used machine learn so instrument always have ability learn train new datum such product leverage ai be sedivue dx analyzer clinton say other company loup venture list be accenture acn avis budget group car boee ba caterpillar cat deere domino pizza dpz fedex fdx glaxosmithkline gsk also halliburton hal interpublic group ipg macy nasdaq ndaq northern trust ntrs pioneer natural resource pxd armour ua ibd take cloud compute leader amazon com microsoft google internet giant have track monetize artificial intelligence technology mizuho security say report earlier month venture space clinton say related be drone delivery robotic gofer ready serve be early investing hot spot artificial intelligence shale producer eye drill artificial intelligenceibm rate buy upside potential artificial intelligence move
29,IDXX,ibd be look biggest week second quarter report season more company set file report fortuitous development investor majority name be coil valid basis xmonday roll quiet start name list due report cognex ticker
30,IDXX,veterinary product medical research system manufacturer idexx laboratory idxx hover just buy point flat base wednesday ibd stock spotlight stock also member ibd be year clear base november rebound twice support week move average earning growth
31,IDXX,google parent alphabet googl medtronic mdt other be try challenge dominance intuitive surgical isrg robot assist surgery space so far have fail disrupt market leader maker da vinci surgery system see ibd smartselect composite rating jump tuesday day revise score mean intuitive surgical now top other stock term key performance metric technical strength best stock tend have better grade begin launch significant move intuitive surgical have climb buy point cup handle clear february tuesday moved past follow buy point week tight pattern intuitive pull back session high close positive territory weak spot be company ep rating track quarterly annual earning share growth look improve better show top stock accumulation distribution rating show moderate buy institutional investor last week company report earning share gain prior report revenue growth increase intuitive surgical hold rank peer medical system equipment industry group idexx laboratory idxx be rank stock group related company be now outperform stock
32,IDXX,xwhile february initial public offer varex imaging vrex didn generate anywhere buzz ipo snap snap maker ray imaging component have so far outperformed better know fellow member class tuesday varex get upgrade relative strength rs rating comparison snap have lowly rs rating unique rating identify technical performance used worst best score indicate stock price action trail week match other stock decade market research show stock go make biggest gain typically have rs rating least begin biggest run ipo base fail varex imaging have regroup be try complete flat base buy point see clear price volume least higher normal earning growth come just marked improvement prior report sale growth fall varex imaging hold rank peer medical system equipment industry group idexx laboratory idxx fonar fonr hill hrc be top highly rate stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
33,IDXX,american century ultra fund twcux be roll outperform peer year date past month large cap growth fund be benefit strong showing stock fund fast grow large cap company fund manager have be busy refresh portfolio recent month highly rate stock have advanced new high year ultra be year go thursday vs fund large cap growth peer track morningstar inc past month ultra be vs fund peer fund be outperform newcomer portfolio fund past disclosure include edward lifescience ew idexx laboratory idxx paypal holding pypl happen be member ibd list stock strong relative price strength fundamental additional newcomer include abiom abmd adobe system adbe analog device adi have composite rating ibd composite rating start run combine ibd performance rating stock poise move higher often have comp rating higher think see pattern re right information technology health care be fund first third biggest sector march weighting respectively consumer discretionary stock such amazon com amzn time warner twx fund third ninth biggest position feb constitute fund second biggest sector bet reflect fund overall strategy be long term capital growth investing mainly large company fund manager lee michael li jeff bourke seek high growth investing industry lead firm show sustainable accelerate earning growth positive price momentum edward be leader make replacement heart valf also make cardiac monitoring unit earning grow rate past year sale growth earning share grow past quarters ibd allison gatlin recently report edward sapien valve have relatively low rate deadly paravalvular leak result insufficient sealing site replace valve ibd reader recognize edward be trading buy point large cup handle base pattern often form prior big advance lead stock abiom make device design improve blood flow stock ibd medical product industry group abiom outrank edward abiom ep grow past quarters earning grow rate past year sale growth company be not carry debt ibd take see abiom additional easy understand fundamental technical datum stack rival ibd stock checkup trading share price be extend entry point be buy range alternate entry chipmaker analog device share price be past week way stock also provide income forward annual dividend be share yielding payout have growth rate analog be lead designer maker high performance analog mixed signal digital signal process integrate circuit used signal process application company be slate report second quarter result earning share be expect rise year accord ibd stock checkup paypal show fund latest disclosure stock rank ibd finance credit card payment process industry group share price be year trading share be extend be not currently proper buy point company fundamental continue heat ep grow past quarters american century ultra have expense ratio average large cap growth fund turnover rate be mild related american century ultra fund be poise tech stock reboundtop mutual fund manager have several stock buy zonemarket tailwind be already lift top fidelity mutual fund manager portfolio
34,IDXX,fonar fonr see ibd smartselect composite rating rise friday day revise score mean maker magnetic resonance scanner currently top other stock term key performance metric technical strength history show top market performer tend have higher score launch major climb fonar be currently form consolidation entry stock be sharply week strong earning report wednesday see fona break volume least higher normal note be very thinly trade stock average daily dollar volume stock earn ep rating meaning recent quarterly longer term annual earning growth top stock accumulation distribution rating show heavy buy institutional investor such mutual fund pension fund last week company post ep gain top line growth climb prior report mark quarter increase revenue growth fonar earn rank peer medical system equipment industry group idexx laboratory idxx be top rank stock group related company be now outperform stock
35,IDXX,tuesday steris ste receive upgrade relative strength rs rating ibd proprietary rating track market leadership worst best score score show stock price movement trail week hold other stock database history show market biggest winner often have rs rating early stage move see steris continue rebound clear threshold see ibd help make more money stocksnow be not ideal time jump isn proper buy zone see stock manage establish enter buy zone heavy volume earning growth drop last quarter revenue moved higher keep eye company next round number feb steris hold rank peer medical system equipment industry group cutera cutr idexx laboratory idxx masimo masi be top highly rate stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
36,IDXX,putt together watch list focus stock higher rs rating hill hrc be stock just reach mark now earn score exclusive rating investor business daily track market leadership worst best score grade show stock price performance last week compare other stock database decade market research reveal best stock often have rs rating north launch biggest price move see ibd help make more money hill be not proper buy point right now see go form break proper base company show earning growth latest quarterly report sale growth come hill hold rank peer medical system equipment industry group idexx laboratory idxx masimo masi cantel medical cmd be top highly rate stock group related stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
37,IDXX,relative strength rs rating idexx laboratory idxx enter new percentile wednesday rise ibd unique rating identify market leadership worst best score grade show stock price behavior trail week stack other stock database decade market research reveal market biggest winner often have better rs rating early stage move look winning stock try simple routineidexx laboratory be work flat base buy point see stock break volume least average earning growth decrease most recent report revenue moved higher company hold rank peer medical system equipment industry group cantel medical cmd be rank stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
38,IDXX,blue chip set fast pace friday confirm uptrend marked session dow jone industrial average rise nasdaq add small cap russell tack volume be higher nasdaq preliminary datum show slightly higher nyse
39,IDXX,relative strength rs rating idexx laboratory idxx climb new percentile friday increase exclusive rating investor business daily measure price movement worst best score score show stock price behavior last week stack other stock database year market history show stock go make biggest gain tend have rs rating north early stage move see ibd help make more stocksidexx laboratory be build flat base entry see clear price heavy trading company post earning growth latest quarterly report revenue gain come keep eye company next round number nov company hold rank peer medical system equipment industry group cantel medical cmd be top rank stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
40,IDXX,nation best perform fund past month have continue graze chipmaker sector continue soar market bounce back sharp dip top rate chip stock make new high include nvidia nvda apply material amat lam research lrcx mks instrument mksi advanced energy industry aeis be picked lead fund manager latest report period industry ibd electronic semiconductor equipment group be rank thursday veterinary diagnostic product firm idexx laboratory idxx italian luxury automaker ferrari race see heavy buy top fund handful leisure stock top buy list include china lodging group htht fox factory hold foxf netflix nflx lead fund invest estimate video stream kingpin latest report period ibd spot best perform fund load stamp com stmp investing estimate pioneer select midcap growth fund pgofx add company holding latest report period el segundo calif firm provide internet base mailing shipping solution photostamp product let customer business turn digital photo design corporate logo valid postage earning growth have be robust range past quarters revenue have be strong well notch double digit growth same period stock break quickly give back gain few day later average volume day sell be short live stock have continue steady trek higher read more stamp com last week ibd stock analysis page stock similar stock chart pattern be optical network firm lumemtum lite stock break short fourth stage cup base mid also see day sell follow then have steadily moved higher notch fresh high nation lead fund have be take profit online retail giant amazon com amzn hit share price mark fund owner internet content giant alphabet googl also take money table stock near dollar mark related top mutual fund buy big bank morgan stanley bank americanew stock buy top mutual fund netflix zion bancorp chip stock
41,IDXX,be upside intuitive surgical isrg guidance analyst suggest tuesday investor be already pay downgrade stock likelihood subdue demand asia canaccord analyst jason mill also see medtronic mdt know make heart valve replacement rival edward lifescience ew stout competitor surgery robotic year date intuitive surgical stock be phenomenal year canaccord analyst jason mill write note client intuitive end year sale growth earning growth cash health care sector have be top performer so far intuitive surgical have be lead charge mill say however investor exuberance company strong performance past few year have drive stock unprecedented valuation level mill downgrade intuitive surgical stock hold rating buy year keep price target close stock market today intuitive surgical be expect intuitive surgical deliver solid result believe risk reward setup tilt too much former present say stock hasn trade valuation be now premium own year average ibd take intuitive surgical stock have ibd composite rating best possible rank fourth ibd company medical system equipment industry group idexx laboratory idxx stock lead group cr look group setup head ibd stock checkup guidance have play big role intuitive surgical stock mill say company typically offer conservative guidance easily outperform thus investor expect positive guidance revision balance not be case easter weekend tailwind first quarter become headwind second quarter outside business be slow mill write procedure growth be expect be subdue japan moderate china think be upside current guidance think re already pay write meantime competition be loom say intuitive surgical make robotic assist perform surgery medtronic reiterate earning call last week plan launch surgical robotic outside april fiscal medtronic competitive approach seem be center ability target customer myriad surgical spectrum also deduce conversation management target cost side equation well mill say medtronic not become much competitor late early domestic launch creep closer intuitive surgical investor begin account upcoming competition multiple afford share say related robot surgeon maker launch record high strong
42,IDXX,early stock market weakness quickly abate market rebound head midday trading nasdaq lead way advance tech heavy composite still have lot work do recover yesterday drop moved dow jone industrial average lag nearly loss volume rise modestly nyse fall slightly nasdaq vs tuesday same time dow industrial stock market today apple aapl recoup much yesterday loss rise microsoft msft pace dow advance microsoft be form flat base hold day line potential entry be downside nike nke drop report disappointing revenue late tuesday global apparel maker announce big earning beat revenue fall short today action put dent nike nascent uptrend share crater back day line other earning release healthequity hqy have little left sharp gain open lead provider hsas surpass estimate tuesday close provide mixed fiscal year guidance recent debutante snap snap receive analyst buy rating send share drexel hamilton call snap very unique company snap remain post ipo high make march other analyst action include buy rating alibaba baba american airline aal be downgrade alibaba rise once again test cup handle buy point monday surge faltered yesterday rout american airline fall move day alibaba competitor tencent tcehy miss earning expectation early wednesday soar cost chinese internet giant adr share fall main list be hong kong stock exchange lead growth stock majority leader rebound nicely head midday trading upside idexx laboratory idxx jump arista network anet moved idexx look extend winning streak week arista remain extend week tight add entry downside criteo crto trade mercury system mrcy moved lower related snap alibaba ibm receive buy rating american airline vow halve product cycle week not month stock fall sale marginstencent quarterly earning growth fall short cost soar
43,IDXX,veterinary tech company idexx laboratory idxx be expect report good quarter early thursday canaccord analyst mark massaro say wednesday idexx stock loiter buy zone straight week close bell stock market today idexx share end trading share have linger buy zone nov hit entry point flat base formation consensus analyst poll thomson reuter expect idexx report sale cent diluted earning share respective vs year earlier quarter massaro expect idexx guidance be relatively unchanged idexx see sale adjust ep year year basis figure be respectively midpoint guidance company provide laboratory diagnostic related service veterinarian ibd take company highly technical equipment idexx be roll early last year dive ibd industry snapshot deep dive related unleashed wave pet friendly service innovation
44,IDXX,semiconductor sector pare loss thursday few chip stock make strong move new high thank earning report silicon laboratory slab gain more follow wednesday flat base share chip designer race new high remain buy range
45,IDXX,stock index trade narrow range thursday index close little change volume slow nasdaq ease add less dow jone industrial average be almost flat volume fall major exchange close market get negative news amazon com amzn online retailer
46,IDXX,big week market term earning report economic news open loss general market monday dow jone industrial average fall nasdaq apple aapl exxon mobil xom amazon com amzn facebook fb be company set report quarterly result week economic front friday closely watch december payroll report federal open market committee wrapped day meeting policy announcement wednesday central bank japan england european union be also schedule meet major policy move be expect insight future strategy easily move market major index start week fresh high dow turn last week settle week test support day move average small cap russell rebound fizzle thursday friday leave index dec high monday session open slow roll comparatively small number earning report schedule early report coal miner alliance holding ahgp report revenue earning decline be less be expect single analyst tracking company share rise open alliance be form flat base buy point ironwood pharmaceutical irwd inched fraction company report phase trial constipation treatment linaclotide japan meet primary target stock have pull back mid november high find support last week week move average calabasa calif base ixia xxia pop open market network performance testing module confirm be acquire keysight technology key keysight say deal immediately add earning company achieve annual cost saving month deal be expect close october keysight share be mattress maker tempur sealy tpx get stuff knock announce have terminate contract retail chain mattress firm hold represent total sale company say re orient resource support retailer exhibit long term commitment tempur sealy brand management guide full year revenue analyst consensus raymond james cut stock underperform outperform mattress firm be acquire south africa steinhoff international september fitbit fit take loss cnbc cite tech news site information report company plan announce workforce reduction well guide fourth quarter result analyst expectation announcement later today fitbit share have decline august high relatively tame schedule close stock market today include report packaging corp america pkg cnx coal resource cnxc idex idxx other personal income rise december commerce department say november uptick economist projection advance personal spending jump healthy more double prior month gain line expectation inflation remain check price index month line view core price strip energy food left price more november change performance half gain project economist december pending home sale number arrive national association realtor et dollar be mixed commodity be generally quiet bond trade effectively flat overseas europe market drag lower afternoon session market look bank england policy announcement schedule thursday ftse london drop frankfurt dax trade lower cac paris slump japan tokyo nikkei open week loss bank japan official launch day policy meeting market hong kong shanghai be close lunar new year spring festival holiday related facebook apple amazon fed job report investing action plan
47,IDXX,main index be higher midday monday nasdaq push way new high composite lead gain facebook fb principal component climb more heavy trading rise support day move average social medium company announce add worker britain operation currently show confidence brexit facebook also set stock buyback rise dow jone industrial average volume be tracking lower board small cap be flat russell show fractional gain amazon com amzn big nasdaq stock rise continue bounce post earning sell be stock highest relative volume energy sector be strongest today trading price crude jump highest price end october spdr energy etf xle moved buy point retail chemical internet industry group also be monday best performer ibm ibm inched buy point cup handle base volume be tracking average be good sign still price move be relatively limp handle pattern be short have wedge shape characteristic make suspect ibm fundamental aren exactly sparkling composite rating be idexx laboratory idxx break cup shape base buy point volume be pace more double average company make diagnostic product service veterinary livestock poultry addition water testing have post earning gain past quarters not impressive growth company enough decent ep rating cirrus logic crus rise past buy point flat base stock reversed lower not only be price move disheartening volume also be not strong enough good related record bil pour etfs trump unleash buy frenzybig stock buyback boost come trump tax proposal goldman sachs
48,IDXX,bank financial service firm have dominate recent list new high name citizen financial group cfg charle schwab schw sock big gain so far month turn ibd list more few leader outside banking sector be also thrash new high friday apply material amat
49,IDXX,lead tech stock tumble last week mutual fund sell share like facebook apple amazon google manager franklin dynatech fund ibd best mutual fund award winner isn panic judge dynatech fkdnx lowly portfolio turnover rate comment lead manager matthew moberg power drive growth several key holding fund remain hitch big way market lead stock dynatech have outsized bet technology weighting june accord franklin templeton sort megabet single sector make fund volatile fund performance be consistent well strong fund be so far year oct be dynatech return top peer track morningstar inc averaged gain fund generate average annual return past year fund be ibd best mutual fund award winner have outperformed year period end dec only diversify stock fund meet standard be top category equity large cap growth fund click here see list ibd mutual fund month leadersmoberg year old have be shepherd dynatech talk ibd investment approach office san mateo calif ibd matthew do fund have such large technology weighting moberg fund focus innovation growth name dynatech stand dynamic technology define dynamic force stimulate change progress innovation be bulk wealth creation occur view broad mandate re able look innovation anywhere believe need active management invest innovation part market be often misunderstand person believe be too expensive too unknown so area look mean opportunity get overlooked click here see list mutual fund category performance leadersibd be current tech weighting typical fund moberg be high sector classification change amazon amzn be now classify consumer discretionary stock early be tech visa mastercard be holding re still consider information technology company argue be financial look innovation be find lot place ibd health care be second largest sector weighting hotbed innovation right moberg not great year health care election candidate talk price control yes lot innovation see possibly emerge treatment disease hepatitis cystic fibrosis even cancer ibd be name space moberg celgene celg incyte incy click here see list biggest mutual fund rank performanceibd be fund performance consistent be diversify expose other sector not just tech health care else moberg yes be diversify consistency be also due fundamental research sometimes find stock market doesn appreciate quickly come market best example be facebook fb launch mobile ad first quarter only do revenue be total revenue year month later mobile be do more advertising revenue cbs similar quarter technology adoption be accelerate world be more global investor often don appreciate fast new technology rise so try think long term short term performance be just byproduct think long term ibd take see facebook other highly rate stock be proper buy point visit ibd leaderboard ibd part facebook story do most now moberg first mobile usage mobile ad be more effective other ad argue facebook probably have best set mobile application runway growth second re start monetize instagram person share picture next step be monetize messenger whatsapp usage have be explosive good chance go commerce rather remain solely social activity finally re think monetize year oculus make virtual reality headset be interesting acquisition facebook didn pay much probably monetize year have long runway messenger whatsapp ibd edward lifescience ew seem be benefit new management fiscal discipline key new product transcatheter aortic value replacement tavr moberg yes right now re go very nice product cycle tavr have rough start now tavr be example sensational innovation enable patient avoid need open heart surgery crack open rib cage make giant incision instead put tavr artery small incision patient spend less time hospital go less pain iteration valve get smaller easier insert product cycle last year re also work something mitral valf be harder reach hope expect be leader field well do double addressable market ibd edward have disappointing sale stock plummet have change outlook company stock moberg remain positive edward lifescience edward be still early stage capture transcatheter aortic valve replacement opportunity share so market be only third penetrate stock also fail account potential transcatheter mitral valve replacement opportunity mitral valve disease be twice prevalent aortic valve disease have face misstep new product again world doesn work linearly believe be excellent business ibd ll make wild guess be not investor find amazon product experiment wasteful moberg re incredibly innovative re continually investing new thing ve have big success first be prime get money upfront consumer drive usage amazon significantly second be let third party sell fulfillment amazon require investment inventory generate higher margin addition have amazon web service be increasingly important fastest grow software service company ever amazon continue invest find new idea ve have quite few failure way understand need take risk succeed attitude give confidence continue growth ibd concern amazon miss result sign more weakness come moberg have go many investment cycle past step up investment don always fact rarely work quarterly report cycle understand long term amazon have have very good return invest capital prefer grow organically have culture innovation didn see anything quarter suggest be longer case ibd pioneer natural resource pxd be somewhat new portfolio have straight quarters slow earning thesis moberg invest small position see do try hold long term anything fundamental change right add pioneer be best position oil service be lowest price producer think oil stabilize barrel range ibd do chinese online gaming company netease nte moberg believe gaming space be secular winner netease have game have do well secular trend gaming be better china be very strong see more virtual reality different kind game way person spend leisure time play game ibd do still broadcom avgo much used moberg don believe be innovative used be most accelerate earning share be due consolidation prefer company innovation be first still be do great job buy company rationalize cost raise price ceo be incredibly well thought chipmake industry execute strategy extremely well re pleased someone be take lead start consolidation industry ibd nvidia nvda be relative newcomer portfolio do chipmake moberg be view provider graphic chip pcs then expand make chip game console now re break free prison make central process unit virtual reality re also need car autonomous drive also hyperscale server re used co processor cad cam artificial intelligence total addressable market be explode think lot sustainability company long trajectory earning growth ibd have exposure pet care industry do moberg shocking well treat animal now vs year cancer treatment ct scan be unavailable year so secular trend company most have own longer have largest position be idexx lab idxx idexx be particularly well position business competitively give unique ability single handedly bundle outsourced diagnostic practice diagnostic instrument idexx also offer superior information management capability regard animal diagnostic report record keep relative competitor ibd special aspen technology azpn software firm moberg do supply chain management process industry software be so important even company go bankrupt pay aspen bill be backbone many company have tremendous operate margin profitability competition be serious large company need technology customer be incredibly sticky ibd tell co manager moberg be lead manager fund be founder rupert johnson co manager be fund first manager know be also vice chairman franklin resource ibd matthew person often wonder portfolio manager do hour moberg used run mile week used have hobby now have year old re hobby forget mention avid reader history be history major college find useful look micro trend adoption rate period major minor innovation pattern recognition new technology well macro trend low interest rate federal reserve action period government response related top mutual fund manager capture solid return messy top mutual fund manager win flavor growth hartford growth opportunity fund target stock fidelity contrafund manager play downturn
50,IDXX,abaxis abax heska hska last quarter wrest market share idexx laboratory idxx animal health field accord survey veterinarian canaccord analyst mark massaro be bullish friday idexx customer retention rate customer swap idexx chemistry product abaxis heska product accord canaccord survey massaro write research report indicated plan switch rapid test provider cite cost reason bode well abaxis massaro say survey result earn abaxis stock price target hike massaro keep hold rating stock market today abaxis stock dip fraction idexx stock rise fraction heska stock sank fraction be lightly trade have composite rating idexx touch record high monday ibd take ibd company medical system equipment industry group have topple group track past week biotechs too have flounder keep tab industry theme upswing downswing sector idexx have do good job stabilize rapid test business quarter doesn equal trend massaro say cost continue pressure medical tech maker vet say buy lowest cost rapid test vs prior quarter broad test appeal drop abaxis be now roll fuse app catch idexx software massaro write initial impact likely be limit rollout take time implement september quarter view abaxis report sale cent earning share ex item respective vs last year month massaro expect abaxis complete unit hematology rollout banfield pet hospital abaxis expect banfield add cent ep ex item annually high level hematology testing meanwhile idexx sedivue sdma testing product be well underway massaro say idexx see cumulative sale urinalysis product sedivue massaro see easily beatable survey use sedivue plan order next year assume clinic penetration rate think idexx drive order sedivue end model write believe idexx bolt rev sedivue end respondent say do more urinalysis testing be easier faster say send fresh urine testing diminish quality already survey use idexx sdma test kidney function indicated want start used survey say re willing send sample idexx testing say be likely switch lab provider just get sdma access idexx peg sedivue sdma opportunity respectively massaro say boost price target idexx stock retain buy rating
51,IDXX,medical stock particularly drugmaker play key role buoy challenged market first half year year date tuesday ibd medical sector industry group show average loss biotechs ethical drugmaker be hardest respectively have left medical group rank
52,IDXX,techies often quip internet be make cat love hate proliferation cat video travele social medium reflect important underlie trend american take video cat partly have more time robust consumer spending now person be more willing adopt pet commit long term care animal include health care most human health care be paid pocket patient dote family have work benefit vca woof america lead chain animal hospital company benefit amusing ticker symbol woof interest sector be serious big money be flow defensive area such food beverage tobacco utility stock etf manager matthew tuttle tuttle tactical management say email pet care stock fit mold have catch strong bid recently consumer now consider pet part family even economy slow enter recession consumer continue spend pet be fair big recession be deep enough hit veterinary business include vca last year spending pet have grow average year accord morningstar third quarter vca profit sale growth have be almost continuous drive unceasing increase pet ownership accord pethealth inc lead provider management software animal welfare organization north america year year growth pet adoption animal shelter rise december average growth trail month period credit suisse analyst erin wilson write feb initiation report vca pet euthanasia inversely correlated pet demand drop december consistent recent monthly trend be positive overall pet ownership trend continue first quarter accord vca chief executive robert antin note growth go just hospital number see be contradictory new pet don think question lot more pet be antin say conference call discuss first quarter result analyst april have great vantage point camp bow antin go say most disposable spending level have be doggy day care rise same store growth camp bow site be several hospital service vca offer currently provide revenue most significant be antech diagnostic chain reference laboratory be lab perform specialty test refer hospital clinic vca idexx laboratory idxx hold virtual duopoly market be consider lucrative trade find hefty lab operate margin often north extremely appeal far better quest diagnostic dgx human diagnostic operate margin write morningstar analyst debbie wang april report margin also be higher vca hospital business so even antech provide revenue provide operate profit still company have continue enlarge hospital network see industry ripe consolidation vca north america largest free standing chain privately hold rival banfield have location mostly petsmart retail store own hospital canada total hospital north rio grande accord credit suisse be smaller chain vca see acquisition target most recently acquire interest companion animal practice north america la vegas base chain animal hospital also like buy single site practice provide have annual revenue least employ least full time veterinarian end have permanent selling hospital section say complete transaction day vca also have be willing buy fill reference lab business last year acquire reference lab business abaxis abax help build moat competitor be difficult startup replicate vca reference lab infrastructure analyst wang write report lab compete basis high level service access veterinary specialist consultation accuracy timeliness vca have establish sizable footprint most densely populate metropolitan area density pet ownership relatively high household income support vca efficient lab operation buyout activity lead phil davis ceo psw investment call vca roll play however recent quarters have also show organic growth first quarter same store sale grow outlet hospital side be open more year internal growth lab business be overall vca earning quarter rise year earlier quarter cent share revenue climb beat wall street expectation have fall issue weak fourth quarter report guidance january break stock month consolidation june share touch time high share be little more friday stake new gain monday hit time high intraday same happened tuesday share hit new intraday high settle back new close high overall composite rating vca be ibd list lead growth stock be tough forecast growth acquisition loving company analyst expect earning grow year share represent slight deceleration last year increase revenue be forecast rise highest growth rate analyst wilson estimate single digit organic growth continue not quite robustly first quarter forecast full year growth hospital side growth lab side
53,IDXX,vca massive west los angele animal hospital pet get chemotherapy mri scan receive acupuncture chinese herbal treatment rehab underwater treadmill be enter behavioral counsele well join weight management regimen dog cat rabbit bird prey potbelly pig welcome hospital offer high profile proof thrive pet health
54,IDXX,company provide high end highly technical equipment hospital other care provider have be something roll recently aid pronounce recovery customer spending much medical hardware industry have diversify recent string megamerger small hot group medical system maker have be get more focuse late
55,IDXX,number stock medical equipment industry group be trace bullish pattern make group watch closely group have be market leader rank top ibd group several week investor find attractive mix stock buy range still form basis cantel medical ticker
56,IDXX,lead stock diverse industry marked new high monday broader market post moderate gain food bgs add new high twice normal trade stock be still buy range entry clear friday gap soar massive volume close thursday
57,IDXX,market face shortage challenge buildup distribution day settle back negative territory year nasdaq diving support converge day move average technical challenge be be underscored development vacuum leadership technology industry tech industry group have entirely exit
58,IDXX,hunting best stock put watch list start top rate stock be potential buy point be member top rank industry group cantel medical cmd be name fit bill new jersey base company be stock medical system equipment industry group ahead cynosure ticker
59,IDXX,lead medical device maker cantel medical cmn be testing key line support continue work early stage base new jersey base company be currently stock medical system equipment industry group cynosure cyno ahead intuitive surgical isrg idexx laboratory idxx hill hrc cantel develop device
60,IDXX,stock market erased loss afternoon trading register modest gain nasdaq be apple aapl largest component erased loss be flat trading just buy point climb dow jone industrial average volume be tracking higher nyse lower nasdaq medical stock remain spotlight break stock market today aetna aet rise past buy point flat base health insurer boost full year share earning guidance medical membership grow company top earning expectation first quarter aetna now expect earning share analyst project share centene cnc earning grow cent share cent estimate revenue hmo rise just edge past expectation stock slide be testing week move average however couple other high rate medical stock crater idexx laboratory idxx plunge heavy trading thrash cup shape base be form animal diagnostic health care company earning sale first quarter miss expectation icon iclr clinical research outsource company beat profit estimate sale be line expectation company raise full year profit forecast share decrease revenue guidance prior guidance be share fall dip day line
61,IDXX,nasdaq lead stock market lower monday medical stock be rout
62,IDXX,composite close loss hurt large part biotechs
63,IDXX,top perform industry group slide broadly ishare nasdaq biotechnology ibb exchange trade fund plunge more
64,IDXX,generic drug company mylan myl reject teva teva buyout bid seem have deflate effect health care sector
65,IDXX,akorn akrx make matter generic drug industry share plummet company disclose restate financial have overstate revenue pretax income continue operation
66,IDXX,fall dow jone industrial average give
67,IDXX,small cap loss be even russell slide index close session lows
68,IDXX,volume rise especially nasdaq loser lead winner nyse nasdaq
69,IDXX,medical transportation retail sector be weakest stock market today
70,IDXX,monster beverage mnst clear buy point flat base energy drink stock close entry volume be unimpressive
71,IDXX,several medical company report earning tuesday include pfizer pfe idexx laboratory idxx bristol myer squibb bmy nasdaq lead stock market lower monday medical stock be rout composite close loss hurt large part biotechs top perform industry group slide broadly ishare nasdaq biotechnology ibb exchange trade fund plunge more generic drug company mylan myl reject teva teva buyout bid seem have deflate effect health care sector akorn akrx make matter generic drug industry share plummet company disclose restate financial have overstate revenue pretax income continue operation fall dow jone industrial average give small cap loss be even russell slide index close session lows volume rise especially nasdaq loser lead winner nyse nasdaq medical transportation retail sector be weakest stock market today monster beverage mnst clear buy point flat base energy drink stock close entry volume be unimpressive several medical company report earning tuesday include pfizer pfe idexx laboratory idxx bristol myer squibb bmy
72,IDXX,idexx laboratory idxx provide product service veterinary industry water testing dairy market ibd note dec manage success column idexx allow employee spend time own pet project lead mobile app vet give instant access test result animal
73,IDXX,intuitive surgical isrg stock jump wednesday company say shipment da vinci surgical system rise higher expect growth robotic surgery procedure intuitive be nearly afternoon trading stock market today more month high sunnyvale calif base company late tuesday report
74,IDXX,rough session market tuesday didn stop several semiconductor stock oil gas name score new high chip designer technology avgo jump news be add replace lsi logic lsi company buy acquisition give new exposure enterprise storage
75,IDXX,idexx laboratory longtime worker enjoy pause refresh year company full time salaried employee become eligible week sabbatical spend paid time do want only condition be use professional growth leave full block time year re eligible employee continue earn sabbatical once year anniversary company get mind business come back recharge say jon ayer chairman president chief executive idexx laboratory idxx absence make heart grow fonder sabbatical be many way ayer seek drive innovation maximize contribution company approximately employee base westbrook maine firm provide diagnostic information technology product service improve animal health safety water milk testing dog lyme diseaseayer become ceo early say most important leadership role be articulating vision employee embrace company work closely veterinarian help succeed work involve identify vet need develop test technology use enhance service provide pet owner benefit veterinarian grow practice ayer say re align success grow grow example idexx launch diagnostic test screen dog lyme disease vet be already testing dog heartworm disease idexx new test kit give more valuable tool strengthen diagnostic arsenal have test lyme disease dog develop test ayer say ve now establish very big market preventive testing dog tick bear disease spur innovation ayer say staffer spend job specific project let use other time play idea own freedom pay early employee devise mobile app give vet instant notification test result access pet history diagnostic datum part cloud base solution help vet track patient time anywhere even re office ayer say vet love now offer country ayer decide make mobile app call vetconnectplus free use meet initial resistance colleague seek charge be controversial decision give away free spend million ayer say argue grow usage diagnostic have faster adoption rate re see
76,IDXX,francis pulizzi wouldn think scrimp pet health care even bit pricey new york city native owner chihuahuas figure spend minimum time take dog veterinarian recent visit vet month old puppy sebastian take even bigger bite cash flow cost pulizzi exam various test medication pulizzi isn squawking ll go go dinner make sure pet have proper health care tell ibd be priority have child judge performance high rate idexx laboratory idxx pulizzi have plenty company idexx manufacture develop diagnostic information technology base product service companion animal veterinary livestock poultry water testing dairy market revenue come companion animal group division provide diagnostic product service vet practice say raymond james analyst nichola jansen livestock poultry dairy segment provide diagnostic health monitoring product market product selling company vast lineup include clinic diagnostic solution comprise vetlab suite clinic chemistry hematology analyzer well associate proprietary consumable product test supply chemistry analyzer include product such catalyst dx catalyst be used vet measure level certain enzyme other substance blood urine offer be vetconnect cloud base technology let vet access analyze patient datum idexx diagnostic modality revenue come outside idexx deliver good news investor wednesday pre announce result fourth quarter report jan company say see record total placement premium chemistry hematology analyzer globally fourth quarter america see increase vs year earlier placement catalyst analyzer rise premium hematology analyzer also see record total premium instrument quarterly placement international placement premium analyzer grow fourth quarter result capped year excellent progress reflect full year catalyst placement gain include growth international say ceo ayer press release company also raise guidance full year organic revenue exclude impact distribution change channel inventory related transition direct product distribution model companion animal group diagnostic range prior guidance gain wednesday upbeat report come wake move hybrid direct product distribution model america companion animal group diagnostic product element become fully operational fourth quarter move be announce last july sale go directgo direct mean idexx have drop distributor used past be selling group diagnostic product directly own sale force direct approach idexx take order ship product invoice receive payment recognize revenue rapid assay test kit instrument consumable align direct model instrument reference lab service other companion animal group product ayer add change allow significant expansion direct sale coverage capacity include estimate increase veterinary diagnostic consultant field sale role customer field call frequency ayer say cut distributor also mean idexx keep margin have be pay jansen say be controversy be mixed performance transition idexx lose little share competitor say wednesday announcement allay concern distribution change appear be have very little impact company business momentum seem risk primary concern idexx share write jansen research note follow announcement acknowledge currency headwind only get bigger give recent exchange rate volatility believe underlie fundamental be strengthen guidance reaffirmedalso wednesday company reinforce guidance organic revenue growth outlook reflect expectation organic revenue growth exclude benefit margin capture associate direct sale product distribution strategy company say statement idexx stock hit new high wednesday close give back little thursday company have be enjoy nice run earning have grow double digit past quarters analyst poll thomson reuter expect fourth quarter earning slip cent share report ep be not go be relevant metric fourth quarter company be impact transition direct model weigh report margin say jansen normalizes everything be back normal analyst expect full year earning rise share lift jansen say idexx primary strength be innovation be fuel spending spending represent industry diagnostic product say package strength add be fact idexx offer complete solution diagnostic product service bundle idexx have razor razor blade model say jansen not only sell diagnostic equipment also develop sell test consumable equipment analyze once place system vet animal hospital have highly recur revenue stream say jansen overall landscape business have be improve post great recession say jansen now unemployment consumer confidence translate more spending person pet say jansen diagnostic be faster growth area pet spending idexx be part ibd medical system equipment industry group be strong performer ranking group track idexx get score possible ibd composite rating metric factor thing such earning growth stock gain group also include steris ste cantel medical cmn have composite rating intuitive surgical isrg be group largest firm market cap have composite rating
77,IDXX,dot com bubble burst clobber average large cap growth stock mutual fund term year performance big cap growth stock fund have yet break even end core value mutual fund counterpart have beaten market decent gain investment average large cap growth fund dec
78,IDXX,few lead stock break early tuesday mark new high most pull back session end close buy point idexx laboratory idxx rise clear flat base buy point volume higher usual share animal health product maker be year follow last
79,IDXX,stock market so far call wariness part investor much lead stock break then move sideway fail stock head south
80,IDXX,week edition ibd list do include stock worthy watch list
81,IDXX,ulta beauty ulta persistent winner year recovery be form new base be base week have buy point
82,IDXX,earning most recently report quarter rise analyst be forecasting increase next report
83,IDXX,addition build base stock be find support day move average
84,IDXX,unite therapeutic uthr have poke head buy point flat base volume be miss
85,IDXX,boise cascade bcc have break flat base buy point have pull back buy zone
86,IDXX,build product manufacturer have money lose year have re-cover spectacularly earning previous report quarters rise year analyst expect next report reveal increase growth
87,IDXX,idexx laboratory idxx break flat base tuesday buy point volume be subpar come follow day stock remain buy range bearish reversal high friday call rally question
88,IDXX,earning most recently report quarter rise best number report analyst see decline next report
89,IDXX,parexel international prxl be form base potential buy point base be flaw huge gap heavy volume left side
90,IDXX,perennial winner apple aapl be set new base possible buy point be stock have correct week fall ibd list monday
91,IDXX,quarters decline earning apple be back growth mode ep increase last quarters show earning acceleration analyst expect increase next report due close jan see increase increase
92,IDXX,ibd index lose week vs loss stock market so far call wariness part investor much lead stock break then move sideway fail stock head south week edition ibd list do include stock worthy watch list ulta beauty ulta persistent winner year recovery be form new base be base week have buy point earning most recently report quarter rise analyst be forecasting increase next report addition build base stock be find support day move average unite therapeutic uthr have poke head buy point flat base volume be miss boise cascade bcc have break flat base buy point have pull back buy zone build product manufacturer have money lose year have re-cover spectacularly earning previous report quarters rise year analyst expect next report reveal increase growth idexx laboratory idxx break flat base tuesday buy point volume be subpar come follow day stock remain buy range bearish reversal high friday call rally question earning most recently report quarter rise best number report analyst see decline next report parexel international prxl be form base potential buy point base be flaw huge gap heavy volume left side perennial winner apple aapl be set new base possible buy point be stock have correct week fall ibd list monday quarters decline earning apple be back growth mode ep increase last quarters show earning acceleration analyst expect increase next report due close jan see increase increase ibd index lose week vs loss
93,IDXX,stock market surge tuesday find relief sharp rebound oil price leap nasdaq add dow jone industrial average lead rally oil component other stock rise more volume increase board breadth be strong winner loser
94,IDXX,go flow be well good rise head shoulder crowd be sign solid stock
95,IDXX,today screen day feature company have bolt relative strength line rs line track stock be do incline instance mean company be outperform index
96,IDXX,china base flash sale site vipshop holding vip report earning tuesday be expect report round triple digit earning revenue gain analyst poll thomson reuter see revenue surge ep bump cent share item
97,IDXX,security research firm capital say monday company seem be benefit current chilly weather china share have almost triple start calendar year
98,IDXX,fellow chinese tailer jumei international jmei report wednesday
99,IDXX,chinese search engine baidu bidu recently joined force beij base commerce company lightinthebox litb sell latter product apps lightinthebox retail bargain clothe home good electronic other product online mostly consumer outside china partnership give baidu leg try match pace heavyweight recent ipo alibaba group baba have team costco wholesale cost alibaba conduct wildly successful single day tail holiday last week
100,IDXX,veterinary drugmaker zoetis zts say monday acquire abbott laboratory animal health asset deal worth abbott animal health boost zoetis companion animal product portfolio expand diagnostic business say zoetis release
101,IDXX,small cap stock be spun pfizer pfe be mutual fund manager favorite bill ackman persh square last week disclose stake zoetis
102,IDXX,idexx laboratory idxx pet livestock health care company recently clear stock buy point
103,IDXX,company report result late october share earning rise share top cent sale grow beating analyst forecast
104,IDXX,related
105,IDXX,invest relative strength line confirm power go flow be well good rise head shoulder crowd be sign solid stock today screen day feature company have bolt relative strength line rs line track stock be do incline instance mean company be outperform index china base flash sale site vipshop holding vip report earning tuesday be expect report round triple digit earning revenue gain analyst poll thomson reuter see revenue surge ep bump cent share item security research firm capital say monday company seem be benefit current chilly weather china share have almost triple start calendar year fellow chinese tailer jumei international jmei report wednesday chinese search engine baidu bidu recently joined force beij base commerce company lightinthebox litb sell latter product apps lightinthebox retail bargain clothe home good electronic other product online mostly consumer outside china partnership give baidu leg try match pace heavyweight recent ipo alibaba group baba have team costco wholesale cost alibaba conduct wildly successful single day tail holiday last week veterinary drugmaker zoetis zts say monday acquire abbott laboratory animal health asset deal worth abbott animal health boost zoetis companion animal product portfolio expand diagnostic business say zoetis release small cap stock be spun pfizer pfe be mutual fund manager favorite bill ackman persh square last week disclose stake zoetis idexx laboratory idxx pet livestock health care company recently clear stock buy point company report result late october share earning rise share top cent sale grow beating analyst forecast related invest relative strength line confirm power
106,IDXX,major average end moderate loss tuesday reasonable performance consider european asian bourse fall more overnight higher volume nasdaq result distribution day tech filled index nasdaq fall give dow ease barely avoid distribution day nyse
107,IDXX,major average end week solid foot friday extend gain nasdaq confirm new uptrend oct health care name dominate new high list again common theme recent day edward lifescience ew gap time high rise strong earning late thursday be catalyst third quarter profit
108,IDXX,tough day market number lead stock strengthen chart move new high illinois base drugmaker akorn akrx rally strong trade gain hoist stock buy point stock pop friday news be divest ecr pharmaceutical subsidiary
109,IDXX,dozen stock hit new high good chunk reversed lower friday china distance learn dl example shot much early session slide close flat volume time more average stock seem poise pullback surge support day
110,IDXX,few stock advanced new high major market index re-cover prior session big loss moderate gain michael kor kor gap soar new high clear buy point flat base massive volume open fashion house report fiscal third quarter earning
111,IDXX,few top rate stock break monday highlight day new high list reversed lower tesla motor tsla break cup handle base automaker share climb volume be average suggest ample presence institution buy side tesla base correct steep make
112,IDXX,big pharma pfizer pfe animal health affiliate zoetis zts deliver sharply different earning report early tuesday send stock different direction zoetis bring good news adjust net income be cent share year earlier quarter top analyst estimate cent sale rise slightly consensus company
113,IDXX,just look align technology algn have perfect tech invisible brace company find yet way improve early year san jose calif maker alternative metal brace introduce new material invisalign clear aligner system smarttrack highly elastic material better maintain
114,IDXX,stock be mixed choppy trading midday friday
115,IDXX,nasdaq climb nyse composite slip volume be tracking sharply lower exchange
116,IDXX,athenahealth athn pare gain stock have be much trouncing view late thursday company provide software other service health care provider earn cent share latest quarter cent view sale also beat view grow athenahealth also boost full year outlook earning sale stock be now past buy point handle double bottom base
117,IDXX,idexx laboratory idxx rally record high heavy trading open health care product maker report earning cent share cent view sale grow also top view company also raise full year ep guidance idexx clear buy point cup handle base thursday volume grow average generally turnover be least average day
118,IDXX,downside coinstar cstr pare chunk loss be still huge volume late thursday president redbox dvd rental unit resign coinstar also peg revenue june end quarter vs view also announce stock buyback program stock be much trim loss find support day move average
119,IDXX,bj restaurant bjri give gain fall big volume stock appear have find support day move average late thursday company beat view rise earning gain sale stock be mixed choppy trading midday friday nasdaq climb nyse composite slip volume be tracking sharply lower exchange athenahealth athn pare gain stock have be much trouncing view late thursday company provide software other service health care provider earn cent share latest quarter cent view sale also beat view grow athenahealth also boost full year outlook earning sale stock be now past buy point handle double bottom base idexx laboratory idxx rally record high heavy trading open health care product maker report earning cent share cent view sale grow also top view company also raise full year ep guidance idexx clear buy point cup handle base thursday volume grow average generally turnover be least average day downside coinstar cstr pare chunk loss be still huge volume late thursday president redbox dvd rental unit resign coinstar also peg revenue june end quarter vs view also announce stock buyback program stock be much trim loss find support day move average bj restaurant bjri give gain fall big volume stock appear have find support day move average late thursday company beat view rise earning gain sale
120,IDXX,market get blanket indiscriminate selling thursday highly rate stock make new high understandably suffer reversal stock hold earning share rating higher make new high hailed medical sector perrigo prgo fall end day winning streak volume be just average
121,IDXX,investor drug company insurer other medical related firm seem welcome supreme court uphold key provision pre obama health care overhaul june
122,IDXX,controversial law change extend coverage uninsured american win have do much earning analyst be listen guidance health care chief address shareholder
123,IDXX,johnson johnson jnj kick season pharmaceutical medical firm tuesday morning analyst expect diversify drug medical product maker grow earning share penny revenue be see climb just
124,IDXX,fellow diversify medical firm abbott laboratory report wednesday heart equipment maker st jude medical stj
125,IDXX,thursday come highest ranking stock batch align technology algn maker clear plastic tooth straightener have best possible composite rating athenahealth athn composite rating ibd offer medical record bill software service doctor office related product investor be listen company expect fare push electronic record envision obamacare
126,IDXX,unitedhealth group unh be lower rank composite rating have perhaps most gain group health care overhaul mandate upheld court american buy insurance
127,IDXX,also report thursday be robotic surgery firm intuitive surgical isrg clinical testing provider laboratory corp america lh baxter international bax develop treatment blood disorder
128,IDXX,idexx laboratory idxx cap week report friday company focus medical equipment veterinary use
129,IDXX,overall analyst expectation group be modest consensus estimate call just ep growth accord thomson reuter datum health care group analyst expect earning be flat revenue be expect climb health care group
130,IDXX,challenge analyst note be austerity measure europe sluggish growth expiration key drug patent investor drug company insurer other medical related firm seem welcome supreme court uphold key provision pre obama health care overhaul june controversial law change extend coverage uninsured american win have do much earning analyst be listen guidance health care chief address shareholder johnson johnson jnj kick season pharmaceutical medical firm tuesday morning analyst expect diversify drug medical product maker grow earning share penny revenue be see climb just fellow diversify medical firm abbott laboratory report wednesday heart equipment maker st jude medical stj thursday come highest ranking stock batch align technology algn maker clear plastic tooth straightener have best possible composite rating athenahealth athn composite rating ibd offer medical record bill software service doctor office related product investor be listen company expect fare push electronic record envision obamacare unitedhealth group unh be lower rank composite rating have perhaps most gain group health care overhaul mandate upheld court american buy insurance also report thursday be robotic surgery firm intuitive surgical isrg clinical testing provider laboratory corp america lh baxter international bax develop treatment blood disorder idexx laboratory idxx cap week report friday company focus medical equipment veterinary use overall analyst expectation group be modest consensus estimate call just ep growth accord thomson reuter datum health care group analyst expect earning be flat revenue be expect climb health care group challenge analyst note be austerity measure europe sluggish growth expiration key drug patent
131,IDXX,even st century sound something sci fi film operation perform intuitive surgical isrg da vinci system isn quite same manage sentient droid human doctor still control robotic arm mechanical limb buffer patient surgeon enable more delicate operation risky natural
132,IDXX,medical stock normally hold well even tough market condition fall tuesday afternoon synch broad market retreat slump also come wake warning heart valve maker edward lifescience ew monday expect lower sale current quarter forecast earlier cite weakness europe company say
133,IDXX,dr frederick moll be coaxing surgeon lay scalpel see potential robotic system surgical application moll create intuitive surgical isrg serve first chief executive physician entrepreneur co founder become hansen medical hnsn create small robotic catheter be ceo june moved
134,IDXX,update major index close high trading range strong manufacturing datum soft dollar boost energy commodity lead market
135,IDXX,nyse composite perked swung higher be biggest jump index jan
136,IDXX,dow nasdaq composite climb lower gear respectively
137,IDXX,volume remain soft session provide little fodder bull
138,IDXX,hour rent center rcii rise top consensus sale earning estimate rent own furniture appliance chain report earning sale be still mired quarterly decline
139,IDXX,medical imaging diagnostic equipment maker hologic holx jump close also top analyst sale earning view report decline category fiscal second quarter company offer line earning guidance put revenue consensus company also raise fiscal outlook
140,IDXX,earning schedule tuesday open include american superconductor amsc ctrip com international ctrp dow chemical dow hsy kraft food kft netlogic microsystem netl
141,IDXX,also tuesday december pending home sale be set release january vehicle sale also be
142,IDXX,stock close higher lighter volume
143,IDXX,patrick
144,IDXX,update market start february higher low volume indicated lack conviction
145,IDXX,dow monday add nasdaq nyse composite bolster strong commodity volume fall board
146,IDXX,big winner day be valassis communication vci gap fly big move come news corp nws subsidiary agree pay advertiser settle antitrust suit
147,IDXX,downside idexx laboratory idxx continue sell start release earning friday monday stock fall more time normal trade top fall friday do find support day move average
148,IDXX,stock stay hot light volume
149,IDXX,patrick
150,IDXX,stock hold early session gain volume stay dry
151,IDXX,dow rise nasdaq nyse composite
152,IDXX,ash maker resin adhesive polymer rise high volume action come company recieve upgrade stifel nicolaus analyst boost stock buy rating previous stance hold
153,IDXX,company have wild earning history last quarter profit soar quarter earning be massive turnaround quarter however wall street expect just earning rise
154,IDXX,spanish information technology firm telvent tlvt grow stock be second straight day gain average trade last week stock slip week move average line now trading once again
155,IDXX,cheesecake factory cake restaurant chain add stock be currently consolidate tricky base base pattern first base be september december shallow cup break then settle flat base first rise least
156,IDXX,second base begin week dec be intra week high be higher left side base weekly close high have not surpass close week dec
157,IDXX,stock improve afternoon trade
158,IDXX,vincent mao
159,IDXX,update major index continue push ahead afternoon trading monday
160,IDXX,nyse composite jump dow thank chip stock nasdaq also improve gain philadelphia semiconductor index rally recoup bulk friday loss
161,IDXX,amedisys am reversed morning loss run fast trade last month firm sign deal health insurer humana hum provide home health service
162,IDXX,panera bread pnra erased earlier loss rise nearly heavy trading also erased friday decline operator baker cafe report earning feb analyst see profit rise cent share
163,IDXX,elsewhere pullback dollar lift gold april contract climb ounce
164,IDXX,gold producer also shine
165,IDXX,silver wheaton slw climb erase loss past session
166,IDXX,buenaventura bvn jaguar mining jag gain
167,IDXX,index hold gain commodity strength
168,IDXX,alan elliott
169,IDXX,update commodity industrial issue hold major index high volume remain slower enter afternoon trading
170,IDXX,nyse composite lead gain be dow add nasdaq composite rise warner chilcott wcrx amazon com amzn post big loss
171,IDXX,dow transport be airline railroad fedex fdx grab gain moderate trading dow exxon mobil xom jpmorgan jpm take better gain average trading
172,IDXX,iron ore producer cliff natural resource clf jump strong trade mark biggest advance coal miner massey energy consul energy cnx be close
173,IDXX,seagate technology stx jump heavy trade move put datum storage hardware maker back week move average follow big volume sell last week
174,IDXX,pegasystem pega grab gain very busy trading maker business process software include cloud compute product break cup handle buy point last week then drop mark be now bounce support week move average
175,IDXX,downside arkansa base home bancshare homb tank massive trade announce ron company president chief operate officer die sunday home bancshare be part southwestern bank group accelerate ranking past week
176,IDXX,most index extend gain
177,IDXX,vincent mao
178,IDXX,update most stock index marched new session high brief pullback
179,IDXX,nyse composite climb dow nasdaq rise do not hit new intraday high volume be tracking lower exchange
180,IDXX,seagate technology stx rally regain day move average stock drop friday biggest downside volume year seagate accumulation distribution rating have wane earlier month
181,IDXX,give imaging givn reversed earlier loss turn fractionally higher have be more pace snap session slide
182,IDXX,downside amazon com amzn extend earlier loss tumble lowest level more month
183,IDXX,lubrizol lz fall further south day line share gap drop heavy trading citigroup cut chemical maker sell hold margin concern stock pass buy point cup base jan have now fall more trigger exception sell rule
184,IDXX,stock strengthen morning trade
185,IDXX,vincent mao
186,IDXX,update stock add gain morning mixed economic datum
187,IDXX,thank energy steel gold stock nyse composite lead gain climb dow meanwhile nasdaq gain
188,IDXX,turnover be again tracking lower exchange
189,IDXX,american superconductor amsc rally news win order worth wind turbine control system company report fiscal earning tuesday analyst be expect profit cent share
190,IDXX,baidu bidu rise regain day move average credit suisse raise chinese internet search firm neutral underperform
191,IDXX,downside warner chilcott wcrx gap day move average drop downgrade morgan stanley cut drugmaker equalweight overweight
192,IDXX,stock open higher
193,IDXX,vincent mao
194,IDXX,update stock rushed gate monday make portion friday loss
195,IDXX,nyse composite climb dow nasdaq
196,IDXX,volume be tracking sharply lower board
197,IDXX,economic news ism manufacturing index january come much strong expect read economist expect read
198,IDXX,meanwhile construction spending december drop vs expectation decline
199,IDXX,valassis communication vci gap fly huge volume news corp nws subsidiary agree pay advertiser settle antitrust suit
200,IDXX,akamai akam gap gain upgrade wedbush morgan raise share outperform neutral
201,IDXX,sandisk sndk rise regain day move average bounce back session sell last week flash memory maker report result view sale outlook disappoint
202,IDXX,downside amazon com amzn fall fast trade weekend commerce giant give publisher macmillan concession higher book price
203,IDXX,stock track higher start
204,IDXX,vincent mao
205,IDXX,update future signale higher open monday stock look bounce back last month sell
206,IDXX,future rally point vs fair value nasdaq future gain point dow future climb point
207,IDXX,economic news personal income rise december beating estimate gain personal spending rise third straight month be tad economist estimate future barely budge miss
208,IDXX,datum construction spending ism manufacturing index be
209,IDXX,earning front exxonmobil xom gain pre open trade better expect earning integrate oil giant profit fall year earlier share still top view cent sale rise also view
210,IDXX,humana hum report mixed result health insurer earning rise share match wall street estimate sale edge only view partly due temporary contract extension humana raise profit guidance range share still also consensus estimate share share fall nearly pre market trading
211,IDXX,elsewhere urban outfitter urbn replace affiliated computer system acs index be announce date affiliated computer be be buy xerox xrx urban outfitter climb pre market trade
212,IDXX,fertilizer producer intrepid potash ipi take urban outfitter place midcap also gain pre open activity
213,IDXX,dollar slip month high euro gold oil edge higher
214,IDXX,future point higher open
215,IDXX,vance cariaga
216,IDXX,update stock future point higher open monday wall street look begin february high note finishing january negative territory
217,IDXX,future rise point pre market be fair value dow future gain point nasdaq future add point
218,IDXX,commerce department report personal spending income be due economist project spending rise december rise november income be also expect have rise climb november
219,IDXX,government release datum construction spending december analyst expect spending fall drop november
220,IDXX,also institute supply management january manufacturing index be due economist expect read january december read mean sector be grow
221,IDXX,investor also keep eye nation capital white house send congress budget proposal anticipate record set budget deficit
222,IDXX,earning news exxonmobil xom be most prominent company due report result today
223,IDXX,toyota motor tm unveil plan fix gas pedal more vehicle be recall pedal get stick be slow return release increase risk crash
224,IDXX,elsewhere yield benchmark year treasury note rise early monday late friday yield month bill climb dollar mostly rise other major currency gold price fall
225,IDXX,overseas japan nikkei stock average rise hong kong hang seng add afternoon trade britain ftse gain germany dax index climb france cac update major index close high trading range strong manufacturing datum soft dollar boost energy commodity lead market nyse composite perked swung higher be biggest jump index jan dow nasdaq composite climb lower gear respectively volume remain soft session provide little fodder bull hour rent center rcii rise top consensus sale earning estimate rent own furniture appliance chain report earning sale be still mired quarterly decline medical imaging diagnostic equipment maker hologic holx jump close also top analyst sale earning view report decline category fiscal second quarter company offer line earning guidance put revenue consensus company also raise fiscal outlook earning schedule tuesday open include american superconductor amsc ctrip com international ctrp dow chemical dow hsy kraft food kft netlogic microsystem netl also tuesday december pending home sale be set release january vehicle sale also be stock close higher lighter volumeby patrick update market start february higher low volume indicated lack conviction dow monday add nasdaq nyse composite bolster strong commodity volume fall board big winner day be valassis communication vci gap fly big move come news corp nws subsidiary agree pay advertiser settle antitrust suit downside idexx laboratory idxx continue sell start release earning friday monday stock fall more time normal trade top fall friday do find support day move average stock stay hot light volumeby patrick stock hold early session gain volume stay dry dow rise nasdaq nyse composite ash maker resin adhesive polymer rise high volume action come company recieve upgrade stifel nicolaus analyst boost stock buy rating previous stance hold company have wild earning history last quarter profit soar quarter earning be massive turnaround quarter however wall street expect just earning rise spanish information technology firm telvent tlvt grow stock be second straight day gain average trade last week stock slip week move average line now trading once again cheesecake factory cake restaurant chain add stock be currently consolidate tricky base base pattern first base be september december shallow cup break then settle flat base first rise least second base begin week dec be intra week high be higher left side base weekly close high have not surpass close week dec stock improve afternoon tradeby vincent mao update major index continue push ahead afternoon trading monday nyse composite jump dow thank chip stock nasdaq also improve gain philadelphia semiconductor index rally recoup bulk friday loss amedisys am reversed morning loss run fast trade last month firm sign deal health insurer humana hum provide home health service panera bread pnra erased earlier loss rise nearly heavy trading also erased friday decline operator baker cafe report earning feb analyst see profit rise cent share elsewhere pullback dollar lift gold april contract climb ounce gold producer also shine silver wheaton slw climb erase loss past session buenaventura bvn jaguar mining jag gain index hold gain commodity strengthby alan elliott update commodity industrial issue hold major index high volume remain slower enter afternoon trading nyse composite lead gain be dow add nasdaq composite rise warner chilcott wcrx amazon com amzn post big loss dow transport be airline railroad fedex fdx grab gain moderate trading dow exxon mobil xom jpmorgan jpm take better gain average trading iron ore producer cliff natural resource clf jump strong trade mark biggest advance coal miner massey energy consul energy cnx be close seagate technology stx jump heavy trade move put datum storage hardware maker back week move average follow big volume sell last week pegasystem pega grab gain very busy trading maker business process software include cloud compute product break cup handle buy point last week then drop mark be now bounce support week move average downside arkansa base home bancshare homb tank massive trade announce ron company president chief operate officer die sunday home bancshare be part southwestern bank group accelerate ranking past week most index extend gainsby vincent mao update most stock index marched new session high brief pullback nyse composite climb dow nasdaq rise do not hit new intraday high volume be tracking lower exchange seagate technology stx rally regain day move average stock drop friday biggest downside volume year seagate accumulation distribution rating have wane earlier month give imaging givn reversed earlier loss turn fractionally higher have be more pace snap session slide downside amazon com amzn extend earlier loss tumble lowest level more month lubrizol lz fall further south day line share gap drop heavy trading citigroup cut chemical maker sell hold margin concern stock pass buy point cup base jan have now fall more trigger exception sell rule stock strengthen morning tradeby vincent mao update stock add gain morning mixed economic datum thank energy steel gold stock nyse composite lead gain climb dow meanwhile nasdaq gain turnover be again tracking lower exchange american superconductor amsc rally news win order worth wind turbine control system company report fiscal earning tuesday analyst be expect profit cent share baidu bidu rise regain day move average credit suisse raise chinese internet search firm neutral underperform downside warner chilcott wcrx gap day move average drop downgrade morgan stanley cut drugmaker equalweight overweight stock open higherby vincent mao update stock rushed gate monday make portion friday loss nyse composite climb dow nasdaq volume be tracking sharply lower board economic news ism manufacturing index january come much strong expect read economist expect read meanwhile construction spending december drop vs expectation decline valassis communication vci gap fly huge volume news corp nws subsidiary agree pay advertiser settle antitrust suit akamai akam gap gain upgrade wedbush morgan raise share outperform neutral sandisk sndk rise regain day move average bounce back session sell last week flash memory maker report result view sale outlook disappoint downside amazon com amzn fall fast trade weekend commerce giant give publisher macmillan concession higher book price stock track higher startby vincent mao update future signale higher open monday stock look bounce back last month sell future rally point vs fair value nasdaq future gain point dow future climb point economic news personal income rise december beating estimate gain personal spending rise third straight month be tad economist estimate future barely budge miss datum construction spending ism manufacturing index be earning front exxonmobil xom gain pre open trade better expect earning integrate oil giant profit fall year earlier share still top view cent sale rise also view humana hum report mixed result health insurer earning rise share match wall street estimate sale edge only view partly due temporary contract extension humana raise profit guidance range share still also consensus estimate share share fall nearly pre market trading elsewhere urban outfitter urbn replace affiliated computer system acs index be announce date affiliated computer be be buy xerox xrx urban outfitter climb pre market trade fertilizer producer intrepid potash ipi take urban outfitter place midcap also gain pre open activity dollar slip month high euro gold oil edge higher future point higher openby vance cariaga update stock future point higher open monday wall street look begin february high note finishing january negative territory future rise point pre market be fair value dow future gain point nasdaq future add point commerce department report personal spending income be due economist project spending rise december rise november income be also expect have rise climb november government release datum construction spending december analyst expect spending fall drop november also institute supply management january manufacturing index be due economist expect read january december read mean sector be grow investor also keep eye nation capital white house send congress budget proposal anticipate record set budget deficit earning news exxonmobil xom be most prominent company due report result today toyota motor tm unveil plan fix gas pedal more vehicle be recall pedal get stick be slow return release increase risk crash elsewhere yield benchmark year treasury note rise early monday late friday yield month bill climb dollar mostly rise other major currency gold price fall overseas japan nikkei stock average rise hong kong hang seng add afternoon trade britain ftse gain germany dax index climb france cac
226,IDXX,update thursday blowback session return index back day move average left bank insurer hand tool maker deepest loss day
227,IDXX,loss nyse composite still hold gain week nasdaq head friday ahead week dow also remain higher week
228,IDXX,major index post loss prior week
229,IDXX,close amazon amzn report earning cent share easily expectation cent revenue jump view amazon share vault hour trading
230,IDXX,friday be heavy duty day economic datum commerce department roll gdp figure market open chicago purchasing manager index michigan consumer sentiment index be due
231,IDXX,also be heavy day earning exxon mobil xom chevron cvx be schedule report open arch coal aci honeywell hon idexx lab idxx be also list
232,IDXX,update stock give most wednesday gain
233,IDXX,juan carlos arancibia
234,IDXX,market give back most wednesday big gain most major index close loss
235,IDXX,nyse composite tumble nasdaq dow close session lows
236,IDXX,volume fall however blunting impact sell
237,IDXX,build stock lead way sale new home plunge record low
238,IDXX,financial re-trace gain too spdr financial etf fall
239,IDXX,update market hold loss close enter final hour trade
240,IDXX,alan elliott
241,IDXX,sector moved broadly lower bank insurer fall hardest commodity moved generally higher so do bond price dollar strengthen euro yen gain dollar euro
242,IDXX,nyse composite hold loss just low day nasdaq composite make similar move apiece dow be
243,IDXX,volume hold steady earlier level wednesday average action
244,IDXX,truck builder oshkosh osk financial wb neustar nsr post biggest drop midcap dow transport see slip lead continental airline cal truck fleet operator yrc worldwide yrcw gatx gmt lease logistic operation
245,IDXX,aerospace heavyweight textron txt drilled very fast trade post heaviest loss company report ep cent nickel consensus view revenue fall short company issue downside guidance
246,IDXX,update stock extend loss afternoon trading
247,IDXX,vincent mao
248,IDXX,stock stumble new session lows afternoon trading thursday further downturn essentially wipe gain wednesday follow day
249,IDXX,nyse composite shed nasdaq also drop give day move average meanwhile dow lose
250,IDXX,turnover be tracking lower exchange
251,IDXX,citrix system ctxs gap day move average drop fat trade late wednesday developer application delivery product report smaller expect drop earning company see sale fall citrix slash work force morning credit suisse benchmark downgrade stock
252,IDXX,pss world medical pssi gap slump sale miss expectation late wednesday medical product maker deliver fiscal earning cent share cent view sale grow miss estimate earlier today raymond james cut share market perform outperform
253,IDXX,upside number highly rate stock dwindle
254,IDXX,open text otex vistaprint vprt gain respectively session high
255,IDXX,update bank lead index lower
256,IDXX,alan pull back wednesday rebound haul index new intraday lows afternoon trading
257,IDXX,nyse composite slide nasdaq composite slide dow pull lower bank america bac boee ba citigroup post dow heaviest loss
258,IDXX,volume remain lower time wednesday major exchange decline issue lead advancer better nyse nasdaq
259,IDXX,compass mineral cmp jump solid trading road table salt distributor be try restart right side month base
260,IDXX,downside chattem chtt slump early trade then re-cover loss maker personal care product top analyst view rise ep revenue come just analyst expectation share have be trading rangebound september peak stock be high
261,IDXX,insurer allstate tank big trading miss expectation allstate be laggard rank property casualty title insurance group
262,IDXX,update comeback weaken session halftime
263,IDXX,vincent mao
264,IDXX,stock remain lower midday thursday rebound effort wane major index near morning high
265,IDXX,nyse composite shed nasdaq give dow lose
266,IDXX,volume be again tracking lower board softening today hit
267,IDXX,open text otex gap rally latest quarterly result late wednesday enterprise software maker have deliver fiscal earning cent share beating view cent thursday morning number broker raise price target stock td cut stock hold buy
268,IDXX,vistaprint vprt climb brisk volume earlier week provider online printing service blow away view jump fiscal earning analyst see rise full year profit
269,IDXX,colgate palmolive cl gap day move average gain report sale view help higher price cost cut new product consumer good maker earn share fourth quarter just edge past view
270,IDXX,downside green mountain coffee roaster gmcr fall downgrade late wednesday coffee tea distributor have deliver fiscal earning view raise full year profit outlook thursday morning stifel nicolaus cut share sell hold
271,IDXX,update earning report help pull index lows
272,IDXX,alan elliott
273,IDXX,index take back early loss handful stock moved higher not bad expect earning report
274,IDXX,nyse composite re-trace loss well earlier low nasdaq composite ease dow pull low post lower mmm pull upside remain low
275,IDXX,volume show weaker exchange industry group track ibd moved lower
276,IDXX,gold silver miner see strongest gain
277,IDXX,yen rise broadly vs euro dollar commodity trading be choppy mixed copper take hit pound march crude future backed barrel
278,IDXX,market weak follow wednesday rally follow number stock post healthy gain
279,IDXX,component symantec symc gap gain plush volume report late wednesday earning jump impairment charge quarter left full result loss time loss earning rise cent vs cent year quarter top analyst view wide margin revenue quarter be flat maker security datum backup software be make way steep month correction
280,IDXX,apollo group apol rebound heavy trading private college operator have pull back week move average week powerful gain
281,IDXX,western digital wdc power huge trading computer hard drive maker report wednesday close earning slip cent share clear consensus view least half mile exclude cent share restructure charge share have start right side steep month correction be still june peak
282,IDXX,downside eastman kodak ek take pound miss earning projection company say cut job year work force forecast restructure charge
283,IDXX,hong kong market reopen jump day holiday higher
284,IDXX,japan nikkei tokyo rolled gain financial lead advance shanghai market remain close country new year holiday
285,IDXX,stock slip red zone europe bank retract wednesday rally mining issue see heavy selling london ftse give cac paris shed frankfurt dax swung lower
286,IDXX,update stock big lower volume
287,IDXX,vincent mao
288,IDXX,stock tumble gate thursday heel dismal earning report weak economic datum
289,IDXX,nyse composite drop respectively fall back day move average nasdaq lose hold day line dow lose
290,IDXX,volume be tracking sharply lower nyse slightly lower nasdaq
291,IDXX,economic front new home sale dive annualize rate unit far expect
292,IDXX,corporate news black decker bdk gap tumble weak outlook open power tool maker deliver earning cent share ex item be year earlier cent view sale tumble nearly miss view
293,IDXX,black decker guide profit nickel cent share well wall street estimate cent also peg full year earning far view announce plan slash job
294,IDXX,illinois tool work itw lose lackluster outlook maker fastener post earning cent share year earlier cent view sale fall slightly view first quarter company peg earning range cent cent share vs view cent outlook assume sale fall
295,IDXX,add weakness industrial truck maker oshkosh osk gap dive post bigger expect loss withdraw earning outlook warn potential problem creditor keybanc capital market cut oshkosh hold form buy
296,IDXX,elsewhere qualcomm qcom gap drop wednesday night disappointing earning report wireless firm also slash full year sale outlook
297,IDXX,update stock poise soft open economic datum earning
298,IDXX,vincent mao
299,IDXX,weak economic datum lackluster earning weigh stock future thursday signale lower open
300,IDXX,nasdaq future drop point vs fair value future fall point dow future shed point
301,IDXX,economic front house late wednesday pass economic stimulus package support republican senate vote version package next week
302,IDXX,durable order drop bigger forecast december fifth straight monthly decline demand be weak most big ticket item outside defense related good exclude transportation order fall
303,IDXX,initial jobless claim rise economist expect drop continue claim rise record
304,IDXX,datum december new home sale be economist expect rate unit november
305,IDXX,corporate news astrazeneca azn lose pre market mixed report exclude item drugmaker deliver profit share prior year cent view sale rise only view company lay worker
306,IDXX,starbucks sbux late wednesday report decline fiscal earning miss view coffee chain shed job close more store share fall pre open
307,IDXX,sony sne shed fiscal net profit plunge hurt weakness electronic division
308,IDXX,amazon com amzn slip ahead earning report due close internet retailer be expect earn cent share sale
309,IDXX,dow component mmm rise pre market report mixed result cut outlook fourth quarter maker adhesive office medical supply deliver profit cent share exclude item be year earlier cent ahead view sale fall view
310,IDXX,cut full year earning outlook range share prior guidance analyst estimate be update thursday blowback session return index back day move average left bank insurer hand tool maker deepest loss day loss nyse composite still hold gain week nasdaq head friday ahead week dow also remain higher week major index post loss prior week close amazon amzn report earning cent share easily expectation cent revenue jump view amazon share vault hour trading friday be heavy duty day economic datum commerce department roll gdp figure market open chicago purchasing manager index michigan consumer sentiment index be due also be heavy day earning exxon mobil xom chevron cvx be schedule report open arch coal aci honeywell hon idexx lab idxx be also list update stock give most wednesday gain juan carlos market give back most wednesday big gain most major index close loss nyse composite tumble nasdaq dow close session lows volume fall however blunting impact sell build stock lead way sale new home plunge record low financial re-trace gain too spdr financial etf fall update market hold loss close enter final hour trade alan elliottsector moved broadly lower bank insurer fall hardest commodity moved generally higher so do bond price dollar strengthen euro yen gain dollar euro nyse composite hold loss just low day nasdaq composite make similar move apiece dow be volume hold steady earlier level wednesday average action truck builder oshkosh osk financial wb neustar nsr post biggest drop midcap dow transport see slip lead continental airline cal truck fleet operator yrc worldwide yrcw gatx gmt lease logistic operation aerospace heavyweight textron txt drilled very fast trade post heaviest loss company report ep cent nickel consensus view revenue fall short company issue downside guidance update stock extend loss afternoon tradingby vincent maostock stumble new session lows afternoon trading thursday further downturn essentially wipe gain wednesday follow day nyse composite shed nasdaq also drop give day move average meanwhile dow lose turnover be tracking lower exchange citrix system ctxs gap day move average drop fat trade late wednesday developer application delivery product report smaller expect drop earning company see sale fall citrix slash work force morning credit suisse benchmark downgrade stock pss world medical pssi gap slump sale miss expectation late wednesday medical product maker deliver fiscal earning cent share cent view sale grow miss estimate earlier today raymond james cut share market perform outperform upside number highly rate stock dwindle open text otex vistaprint vprt gain respectively session high update bank lead index lower alan nyse composite slide nasdaq composite slide dow pull lower bank america bac boee ba citigroup post dow heaviest loss volume remain lower time wednesday major exchange decline issue lead advancer better nyse nasdaq compass mineral cmp jump solid trading road table salt distributor be try restart right side month base downside chattem chtt slump early trade then re-cover loss maker personal care product top analyst view rise ep revenue come just analyst expectation share have be trading rangebound september peak stock be high insurer allstate tank big trading miss expectation allstate be laggard rank property casualty title insurance group update comeback weaken session halftimeby vincent maostock remain lower midday thursday rebound effort wane major index near morning high nyse composite shed nasdaq give dow lose volume be again tracking lower board softening today hit open text otex gap rally latest quarterly result late wednesday enterprise software maker have deliver fiscal earning cent share beating view cent thursday morning number broker raise price target stock td cut stock hold buy vistaprint vprt climb brisk volume earlier week provider online printing service blow away view jump fiscal earning analyst see rise full year profit colgate palmolive cl gap day move average gain report sale view help higher price cost cut new product consumer good maker earn share fourth quarter just edge past view downside green mountain coffee roaster gmcr fall downgrade late wednesday coffee tea distributor have deliver fiscal earning view raise full year profit outlook thursday morning stifel nicolaus cut share sell hold update earning report help pull index lows alan elliottindex take back early loss handful stock moved higher not bad expect earning report nyse composite re-trace loss well earlier low nasdaq composite ease dow pull low post lower mmm pull upside remain low volume show weaker exchange industry group track ibd moved lower gold silver miner see strongest gain yen rise broadly vs euro dollar commodity trading be choppy mixed copper take hit pound march crude future backed barrel market weak follow wednesday rally follow number stock post healthy gain component symantec symc gap gain plush volume report late wednesday earning jump impairment charge quarter left full result loss time loss earning rise cent vs cent year quarter top analyst view wide margin revenue quarter be flat maker security datum backup software be make way steep month correction apollo group apol rebound heavy trading private college operator have pull back week move average week powerful gain western digital wdc power huge trading computer hard drive maker report wednesday close earning slip cent share clear consensus view least half mile exclude cent share restructure charge share have start right side steep month correction be still june peak downside eastman kodak ek take pound miss earning projection company say cut job year work force forecast restructure charge hong kong market reopen jump day holiday higher japan nikkei tokyo rolled gain financial lead advance shanghai market remain close country new year holiday stock slip red zone europe bank retract wednesday rally mining issue see heavy selling london ftse give cac paris shed frankfurt dax swung lower update stock big lower volumeby vincent maostock tumble gate thursday heel dismal earning report weak economic datum nyse composite drop respectively fall back day move average nasdaq lose hold day line dow lose volume be tracking sharply lower nyse slightly lower nasdaq economic front new home sale dive annualize rate unit far expect corporate news black decker bdk gap tumble weak outlook open power tool maker deliver earning cent share ex item be year earlier cent view sale tumble nearly miss view black decker guide profit nickel cent share well wall street estimate cent also peg full year earning far view announce plan slash job illinois tool work itw lose lackluster outlook maker fastener post earning cent share year earlier cent view sale fall slightly view first quarter company peg earning range cent cent share vs view cent outlook assume sale fall add weakness industrial truck maker oshkosh osk gap dive post bigger expect loss withdraw earning outlook warn potential problem creditor keybanc capital market cut oshkosh hold form buy elsewhere qualcomm qcom gap drop wednesday night disappointing earning report wireless firm also slash full year sale outlook update stock poise soft open economic datum earningsby vincent maoweak economic datum lackluster earning weigh stock future thursday signale lower open nasdaq future drop point vs fair value future fall point dow future shed point economic front house late wednesday pass economic stimulus package support republican senate vote version package next week durable order drop bigger forecast december fifth straight monthly decline demand be weak most big ticket item outside defense related good exclude transportation order fall initial jobless claim rise economist expect drop continue claim rise record datum december new home sale be economist expect rate unit november corporate news astrazeneca azn lose pre market mixed report exclude item drugmaker deliver profit share prior year cent view sale rise only view company lay worker starbucks sbux late wednesday report decline fiscal earning miss view coffee chain shed job close more store share fall pre open sony sne shed fiscal net profit plunge hurt weakness electronic division amazon com amzn slip ahead earning report due close internet retailer be expect earn cent share sale dow component mmm rise pre market report mixed result cut outlook fourth quarter maker adhesive office medical supply deliver profit cent share exclude item be year earlier cent ahead view sale fall view cut full year earning outlook range share prior guidance analyst estimate be
311,IDXX,update stock have big change heart friday turn lower round upbeat economic datum major index finished week month
312,IDXX,techs lead sell nasdaq shedding philadelphia semiconductor index dive everything computer maker software firm datum storage firm get hit
313,IDXX,meanwhile nyse composite lose dow fall milder gain home depot hd wal mart wmt cushion loss boee ba ibm ibm
314,IDXX,volume jump exchange
315,IDXX,week nasdaq drop nyse composite dow month nyse composite lose dow nasdaq crumble worst monthly loss february
316,IDXX,computer program system cpsi gap day move average swoon huge trade late thursday health care software company report bigger expect drop earning give weak profit outlook stock have be session low
317,IDXX,fellow health care software firm cerner cern quality system qsii drop
318,IDXX,newmarket neu gap dive more time normal trade accord briefing com oppenheimer co note potential decline chemical additive maker quarterly earning stock close just day line
319,IDXX,pegasystem pega reversed morning gain fall fast trade stock clear high handle buy point wednesday trigger sell rule friday
320,IDXX,apple aapl erased earlier gain fall lowest level dec stock also trigger sell rule clear buy point flat base dec
321,IDXX,stock reverse lower
322,IDXX,vincent mao
323,IDXX,update stock fall second straight session friday early rally peter
324,IDXX,nasdaq tumble deficit nyse composite shed dow
325,IDXX,tech related group tumble software datum storage computer maker chip group get hit homebuilder nursing home operator buck trend
326,IDXX,volume climb board
327,IDXX,stock again worsen dow turn red
328,IDXX,vincent mao
329,IDXX,update seller turn heat late trading send major index new session lows even dow turn red
330,IDXX,nasdaq drop pull degree turn nyse composite lose dow be fractionally lower squander gain stock be pace third straight week
331,IDXX,turnover be again tracking sharply higher nyse lower nasdaq
332,IDXX,techs be weak board
333,IDXX,apple aapl erased earlier gain fall lowest level dec stock have now fall buy point flat base
334,IDXX,dell dell fall hewlett packard hpq slip
335,IDXX,qualcomm qcom reversed early gain drop month low microsoft msft also turn tail fall reversed lower report fiscal earning view late thursday
336,IDXX,side berkshire hathaway brkb gap rally month high warren buffett lead conglomerate join index once shareholder approve buyout rail operator burlington northern santa fe bni next month
337,IDXX,stock worsen afternoon trading
338,IDXX,vincent mao
339,IDXX,update stock remain mixed have worsen afternoon trading
340,IDXX,volume be mixed nyse be sharply higher nasdaq be lower
341,IDXX,nasdaq fall new session low chip issue be hardest hit philadelphia semiconductor index shed fresh month low
342,IDXX,meanwhile nyse composite dow fall dow continue buck trend rise
343,IDXX,idexx laboratory idxx shed breach day move average open maker animal health product report result view raise sale outlook
344,IDXX,seagate technology stx drop slice day line fellow hard drive maker western digital wdc lose fall further south day move average
345,IDXX,upside amazon com amzn be session peak still thursday afternoon strong result outlook stock pare most day gain touch resistance day move average
346,IDXX,stock turn mixed early afternoon trade
347,IDXX,vincent mao
348,IDXX,update stock turn mixed tech weakness spil general market
349,IDXX,nasdaq turn gain loss nyse slip fraction also turn slightly lower meanwhile dow edge thank gain caterpillar cat american express axp
350,IDXX,volume be tracking sharply higher nyse lower nasdaq
351,IDXX,computer program system cpsi gap day move average dive huge trade late thursday health care software firm report earning cent share year nickel view also guide profit short analyst estimate stock have be session low
352,IDXX,group mate cerner cern quality system qsii fall
353,IDXX,newmarket neu gap swoon heavy trade accord briefing com oppenheimer co note potential decline chemical additive maker quarterly earning
354,IDXX,sandisk sndk gap tumble just day move average late thursday flash memory maker deliver result top view fail impress full year sale outlook friday morning jpmorgan chase upgrade share neutral underweight
355,IDXX,pegasystem pega reversed morning gain fall fast trade stock be high handle buy point clear wednesday
356,IDXX,market pare gain hot start
357,IDXX,jonah keri
358,IDXX,update major index give back nearly friday morning gain follow hot start trigger bullish gdp result
359,IDXX,dow have trim gain nyse composite nasdaq trade flat volume remain mixed rise nyse fall nasdaq compare same period thursday
360,IDXX,blue nile nile climb nearly twice usual turnover give larger gain online vendor diamond engagement ring find support day move average earlier week
361,IDXX,warner chilcott wcrx gap more double typical trade maker birth control other drug issue fiscal earning projection wall street view company revenue guidance come analyst forecast
362,IDXX,downside apple aapl give close time average volume investor have take sell news approach ipod iphone maker unveil new ipad tablet wednesday
363,IDXX,stock gain accelerate strong econ datum
364,IDXX,jonah keri
365,IDXX,update stock nab brisk gain early trade friday encourage economic datum continue stoke rally
366,IDXX,dow climb nyse composite nasdaq volume be narrowly mixed rise nyse fall nasdaq compare same period thursday
367,IDXX,sorl auto part sorl advanced more twice normal trade auto part maker be several top rate chinese stock mount comeback friday rough past couple week
368,IDXX,cybersource cybs gain time typical turnover maker risk management electronic payment product top fourth quarter earning estimate cybersource stock be try bounce back day move average
369,IDXX,informatica update stock have big change heart friday turn lower round upbeat economic datum major index finished week month techs lead sell nasdaq shedding philadelphia semiconductor index dive everything computer maker software firm datum storage firm get hit meanwhile nyse composite lose dow fall milder gain home depot hd wal mart wmt cushion loss boee ba ibm ibm volume jump exchange week nasdaq drop nyse composite dow month nyse composite lose dow nasdaq crumble worst monthly loss february computer program system cpsi gap day move average swoon huge trade late thursday health care software company report bigger expect drop earning give weak profit outlook stock have be session low fellow health care software firm cerner cern quality system qsii drop newmarket neu gap dive more time normal trade accord briefing com oppenheimer co note potential decline chemical additive maker quarterly earning stock close just day line pegasystem pega reversed morning gain fall fast trade stock clear high handle buy point wednesday trigger sell rule friday apple aapl erased earlier gain fall lowest level dec stock also trigger sell rule clear buy point flat base dec stock reverse lowerby vincent mao update stock fall second straight session friday early rally peter nasdaq tumble deficit nyse composite shed dow tech related group tumble software datum storage computer maker chip group get hit homebuilder nursing home operator buck trend volume climb board stock again worsen dow turn redby vincent mao update seller turn heat late trading send major index new session lows even dow turn red nasdaq drop pull degree turn nyse composite lose dow be fractionally lower squander gain stock be pace third straight week turnover be again tracking sharply higher nyse lower nasdaq techs be weak board apple aapl erased earlier gain fall lowest level dec stock have now fall buy point flat base dell dell fall hewlett packard hpq slip qualcomm qcom reversed early gain drop month low microsoft msft also turn tail fall reversed lower report fiscal earning view late thursday side berkshire hathaway brkb gap rally month high warren buffett lead conglomerate join index once shareholder approve buyout rail operator burlington northern santa fe bni next month stock worsen afternoon tradingby vincent mao update stock remain mixed have worsen afternoon trading volume be mixed nyse be sharply higher nasdaq be lower nasdaq fall new session low chip issue be hardest hit philadelphia semiconductor index shed fresh month low meanwhile nyse composite dow fall dow continue buck trend rise idexx laboratory idxx shed breach day move average open maker animal health product report result view raise sale outlook seagate technology stx drop slice day line fellow hard drive maker western digital wdc lose fall further south day move average upside amazon com amzn be session peak still thursday afternoon strong result outlook stock pare most day gain touch resistance day move average stock turn mixed early afternoon tradeby vincent mao update stock turn mixed tech weakness spil general market nasdaq turn gain loss nyse slip fraction also turn slightly lower meanwhile dow edge thank gain caterpillar cat american express axp volume be tracking sharply higher nyse lower nasdaq computer program system cpsi gap day move average dive huge trade late thursday health care software firm report earning cent share year nickel view also guide profit short analyst estimate stock have be session low group mate cerner cern quality system qsii fall newmarket neu gap swoon heavy trade accord briefing com oppenheimer co note potential decline chemical additive maker quarterly earning sandisk sndk gap tumble just day move average late thursday flash memory maker deliver result top view fail impress full year sale outlook friday morning jpmorgan chase upgrade share neutral underweight pegasystem pega reversed morning gain fall fast trade stock be high handle buy point clear wednesday market pare gain hot startby jonah keri update major index give back nearly friday morning gain follow hot start trigger bullish gdp result dow have trim gain nyse composite nasdaq trade flat volume remain mixed rise nyse fall nasdaq compare same period thursday blue nile nile climb nearly twice usual turnover give larger gain online vendor diamond engagement ring find support day move average earlier week warner chilcott wcrx gap more double typical trade maker birth control other drug issue fiscal earning projection wall street view company revenue guidance come analyst forecast downside apple aapl give close time average volume investor have take sell news approach ipod iphone maker unveil new ipad tablet wednesday stock gain accelerate strong econ databy jonah keri update stock nab brisk gain early trade friday encourage economic datum continue stoke rally dow climb nyse composite nasdaq volume be narrowly mixed rise nyse fall nasdaq compare same period thursday sorl auto part sorl advanced more twice normal trade auto part maker be several top rate chinese stock mount comeback friday rough past couple week cybersource cybs gain time typical turnover maker risk management electronic payment product top fourth quarter earning estimate cybersource stock be try bounce back day move average informatica
370,IDXX,large cap growth opportunity be top echelon portfolio seek resume winning way have hit rough patch
371,IDXX,fund average annual gain year go thursday rank top large cap growth rival track morningstar inc calendar loss meant trail peer
372,IDXX,year fund be vs category
373,IDXX,hal goldstein year old be co lead manager scott mullinix james diedrich be co manager goldstein discuss approach office minneapoli
374,IDXX,ibd be do differently year
375,IDXX,goldstein be challenged particularly fourth quarter be rapid turn stock benefit economic recovery lower quality more cyclical name environment do least well
376,IDXX,year be sort respectable be middle pack
377,IDXX,ibd year
378,IDXX,goldstein win do anything differently stay true process be occasion approach be completely favor even underperform tough quarter long term performance remain strong
379,IDXX,ibd have fish bargain
380,IDXX,goldstein yes favorite growth company earning prospect have stay strong valuation have be compress so ve add repurchase name not have own bit
381,IDXX,ibd such
382,IDXX,goldstein citrix system ctxs re involved desktop virtualization much way vmware vmw provider software virtualization server help client enterprise efficiency cost reduction citrix let enterprise purchase less powerful desktop computer employee manage software more centrally much less expensive maintain software desktop
383,IDXX,sell citrix last year feel cycle desktop virtualization be advance slower pace anticipate growth thesis be not come true even sell company keep monitoring get point want buy back then ve see more evidence desktop virtualization be advance so add back
384,IDXX,ibd example
385,IDXX,goldstein amazon amzn add hold year reason be have not be controversial revenue growth have be strong believe amazon be gain share online sale same time online be gain share brick mortar
386,IDXX,many investor be concern amazon profitability be permanently impair make significant infrastructure investment shipping cost percent sale have go quite bit
387,IDXX,believe be sign margin be least stabilize perhaps show early sign improve
388,IDXX,ibd be bargain bin aspect
389,IDXX,goldstein hard argue amazon be super cheap feel be attractively value growth continue margin stabilize improve example shipping cost percent sale decline first time year
390,IDXX,yes do add more stable company challenge economic environment
391,IDXX,ibd example please
392,IDXX,goldstein consumer space petsmart petm have merchandize initiative allow accelerate growth store same store comp improve already happen degree so earning upside surprise opportunity well sale be better expectation lead profit expectation
393,IDXX,health care idexx laboratory idxx provide veterinary lab testing product benefit rise trend pet adoption
394,IDXX,think rise pet adoption be sign economy be little better employment trend be little better housing be bottom improve residential rental activity be more person be move parent home start household
395,IDXX,ibd general approach
396,IDXX,goldstein first buy subset highly selective universe call exceptional growth company subset be company expectation most exceed consensus expectation
397,IDXX,second develop proprietary growth thesis hold
398,IDXX,hold investment vast majority opportunity opportunity longer exist sell critically important sell be appropriate
399,IDXX,last thing do be construct balanced portfolio objective be dampen volatility
400,IDXX,ibd do diversification right
401,IDXX,goldstein yes diversify sector market capitalization style
402,IDXX,ibd be style diversification
403,IDXX,goldstein have cyclical growth name more stable growth name high growth company
404,IDXX,don own many company domicile outside have meaningful number holding have revenue exposure outside
405,IDXX,way don diversify be relative weighting don allow have more percentage point more less sector weighting russell growth index re typically closer benchmark weighting
406,IDXX,allow much basis point overweight individual security again practice largest overweight tend average basis point
407,IDXX,ibd do diversification sector reflect style diversification
408,IDXX,goldstein right health care holding example be not same type
409,IDXX,own alexion pharmaceutical alxn fast grow high multiple pharmaceutical company company be involved ultrarare disease pharmaceutical also own gilead science gild be involved hepatitis vaccine own vertex vrtx be also involved hepatitis next opportunity be drug kalydeco treatment cystic fibrosis biotech company be develop tomorrow cure
410,IDXX,also own perrigo prgo be more stable company be lead maker store brand counter medicine
411,IDXX,ibd describe diversification sector such consumer discretionary please
412,IDXX,goldstein hand own dollar tree dltr tjx co tjx course benefit reality more person be economically challenged be trading dollar store discount store
413,IDXX,other hand own lululemon athletica lulu coach coh be focuse much higher end demographic more luxury end
414,IDXX,ibd do approach show largest sector technology asset
415,IDXX,goldstein hand have apple aapl lululemon be gain meaningful profitable market share tend sell higher price product more affluent demographic
416,IDXX,other hand own accenture acn be consult outsource company serve global fortune company apple be consumer focuse accenture be enterprise focuse help client cut cost
417,IDXX,also have visa mastercard fall tech sector aren tech do use lot technology do re really increase use plastic globally method payment terrific profitability accrue visa mastercard more person swipe card incremental cost visa mastercard be way incremental revenue terrific margin opportunity
418,IDXX,ibd apple recent quarterly earning report disappoint do see long term problem
419,IDXX,goldstein don believe sign long term crack thesis be gain profitable global market share consumer electronic first buy apple meant be mac computer now have mobile phone new category invented tablet be still intact
420,IDXX,reason be pause apple stock performance be many consumer be wait next iteration iphone update pent demand iphone be large not only exist iphone user also consumer don own iphone so temporary pause sale bigger ramp later year next year
421,IDXX,ibd teradata tdc have quarters higher earning share growth thesis
422,IDXX,goldstein benefit proliferation datum sell hard software combination let very large enterprise collect analyze large amount datum turn use make strategic decision
423,IDXX,demand datum analytic other service be very strong so love top line growth look company top line growth not just margin improvement
424,IDXX,ibd netsuite ep growth jump past quarters take
425,IDXX,goldstein be emerge high growth high valuation company
426,IDXX,re software service so cloud play salesforce com crm benefit enterprise want get business critical software cloud delivery software buy need basis rather own old fashion house suite software
427,IDXX,ibd be cerner cern story basically shift electronic health care record
428,IDXX,goldstein cerner be lead public company health care information technology have strong backlog due government regulatory change merely reflection economic encourage hospital automate digitize be really well run lead health care company
429,IDXX,ibd monster beverage mnst have quarters accelerate ep growth view
430,IDXX,goldstein monster have do well be still attractive be gain share energy drink market international opportunity be sizable mature internationally nice margin improvement opportunity well own reason other get purchase example coke ko re not bet
431,IDXX,ibd whole food wfm have explode recession trough much more specialty market grow
432,IDXX,goldstein believe be still lot room run same store sale tough economy suggest deliver american consumer want comp be fiscal rise store level operate margin show great discipline expect continue grow store base combine same store growth get meaningful profit growth
433,IDXX,ibd gnc gnc ep growth have slow quarters do need shot geritol
434,IDXX,goldstein most recent quarter same store sale be almost be higher most retailer
435,IDXX,secondly opportunity grow internationally attract
436,IDXX,think earning estimate rise rest year most next year collectively factor point attractive opportunity large cap growth opportunity be top echelon portfolio seek resume winning way have hit rough patch fund average annual gain year go thursday rank top large cap growth rival track morningstar inc calendar loss meant trail peer year fund be vs category hal goldstein year old be co lead manager scott mullinix james diedrich be co manager goldstein discuss approach office minneapoli ibd be do differently year goldstein be challenged particularly fourth quarter be rapid turn stock benefit economic recovery lower quality more cyclical name environment do least well year be sort respectable be middle pack ibd year goldstein win do anything differently stay true process be occasion approach be completely favor even underperform tough quarter long term performance remain strong ibd have fish bargain goldstein yes favorite growth company earning prospect have stay strong valuation have be compress so ve add repurchase name not have own bit ibd such goldstein citrix system ctxs re involved desktop virtualization much way vmware vmw provider software virtualization server help client enterprise efficiency cost reduction citrix let enterprise purchase less powerful desktop computer employee manage software more centrally much less expensive maintain software desktop sell citrix last year feel cycle desktop virtualization be advance slower pace anticipate growth thesis be not come true even sell company keep monitoring get point want buy back then ve see more evidence desktop virtualization be advance so add back ibd example goldstein amazon amzn add hold year reason be have not be controversial revenue growth have be strong believe amazon be gain share online sale same time online be gain share brick mortar many investor be concern amazon profitability be permanently impair make significant infrastructure investment shipping cost percent sale have go quite bit believe be sign margin be least stabilize perhaps show early sign improve ibd be bargain bin aspect goldstein hard argue amazon be super cheap feel be attractively value growth continue margin stabilize improve example shipping cost percent sale decline first time year yes do add more stable company challenge economic environment ibd example please goldstein consumer space petsmart petm have merchandize initiative allow accelerate growth store same store comp improve already happen degree so earning upside surprise opportunity well sale be better expectation lead profit expectation health care idexx laboratory idxx provide veterinary lab testing product benefit rise trend pet adoption think rise pet adoption be sign economy be little better employment trend be little better housing be bottom improve residential rental activity be more person be move parent home start household ibd general approach goldstein first buy subset highly selective universe call exceptional growth company subset be company expectation most exceed consensus expectation second develop proprietary growth thesis hold hold investment vast majority opportunity opportunity longer exist sell critically important sell be appropriate last thing do be construct balanced portfolio objective be dampen volatility ibd do diversification right goldstein yes diversify sector market capitalization style ibd be style diversification goldstein have cyclical growth name more stable growth name high growth company don own many company domicile outside have meaningful number holding have revenue exposure outside way don diversify be relative weighting don allow have more percentage point more less sector weighting russell growth index re typically closer benchmark weighting allow much basis point overweight individual security again practice largest overweight tend average basis point ibd do diversification sector reflect style diversification goldstein right health care holding example be not same type own alexion pharmaceutical alxn fast grow high multiple pharmaceutical company company be involved ultrarare disease pharmaceutical also own gilead science gild be involved hepatitis vaccine own vertex vrtx be also involved hepatitis next opportunity be drug kalydeco treatment cystic fibrosis biotech company be develop tomorrow cure also own perrigo prgo be more stable company be lead maker store brand counter medicine ibd describe diversification sector such consumer discretionary please goldstein hand own dollar tree dltr tjx co tjx course benefit reality more person be economically challenged be trading dollar store discount store other hand own lululemon athletica lulu coach coh be focuse much higher end demographic more luxury end ibd do approach show largest sector technology asset goldstein hand have apple aapl lululemon be gain meaningful profitable market share tend sell higher price product more affluent demographic other hand own accenture acn be consult outsource company serve global fortune company apple be consumer focuse accenture be enterprise focuse help client cut cost also have visa mastercard fall tech sector aren tech do use lot technology do re really increase use plastic globally method payment terrific profitability accrue visa mastercard more person swipe card incremental cost visa mastercard be way incremental revenue terrific margin opportunity ibd apple recent quarterly earning report disappoint do see long term problem goldstein don believe sign long term crack thesis be gain profitable global market share consumer electronic first buy apple meant be mac computer now have mobile phone new category invented tablet be still intact reason be pause apple stock performance be many consumer be wait next iteration iphone update pent demand iphone be large not only exist iphone user also consumer don own iphone so temporary pause sale bigger ramp later year next year ibd teradata tdc have quarters higher earning share growth thesis goldstein benefit proliferation datum sell hard software combination let very large enterprise collect analyze large amount datum turn use make strategic decision demand datum analytic other service be very strong so love top line growth look company top line growth not just margin improvement ibd netsuite ep growth jump past quarters take goldstein be emerge high growth high valuation company re software service so cloud play salesforce com crm benefit enterprise want get business critical software cloud delivery software buy need basis rather own old fashion house suite software ibd be cerner cern story basically shift electronic health care record goldstein cerner be lead public company health care information technology have strong backlog due government regulatory change merely reflection economic encourage hospital automate digitize be really well run lead health care company ibd monster beverage mnst have quarters accelerate ep growth view goldstein monster have do well be still attractive be gain share energy drink market international opportunity be sizable mature internationally nice margin improvement opportunity well own reason other get purchase example coke ko re not bet ibd whole food wfm have explode recession trough much more specialty market grow goldstein believe be still lot room run same store sale tough economy suggest deliver american consumer want comp be fiscal rise store level operate margin show great discipline expect continue grow store base combine same store growth get meaningful profit growth ibd gnc gnc ep growth have slow quarters do need shot geritol goldstein most recent quarter same store sale be almost be higher most retailer secondly opportunity grow internationally attract think earning estimate rise rest year most next year collectively factor point attractive opportunity
437,IDXX,update loss be broad base financial pressed back class news regulator delay promise quick fix so call toxic asset hold many bank other institution
438,IDXX,nyse composite end flat nasdaq composite edge ever so slightly lower week dow clip decline
439,IDXX,citigroup lead dow downside juniper network jnpr fall hardest nasdaq juniper be also loss leader worsted only fifth third bancorp fitb
440,IDXX,be tough day someone forget tell amazon com amzn gap gain late thursday online retailer say book earning sale well analyst view other component flowserve fls paccar pcar jump heavy trading
441,IDXX,next week monday promise be busy day economic datum commerce release personal income spending construction spending datum december institute supply management put index general gauge outlook corporate buyer
442,IDXX,monday earning calendar include be aerospace beav corn product international cpo sysco syy prior open independent oil gas heavyweight anadarko apc sandisk sndk athero communication athr check close
443,IDXX,update higher volume loss threaten stock rally
444,IDXX,juan carlos arancibia
445,IDXX,market close session lows friday broad decline
446,IDXX,tumble nasdaq nyse composite dow accord early number
447,IDXX,volume rise give market distribution day come just day market follow selling put market rally serious doubt
448,IDXX,financial slide report plan remove bad asset bank balance sheet be peril
449,IDXX,steel other metal stock also weaken goldman sachs analyst give bearish outlook steel maker downgrade steel other
450,IDXX,update dow head week
451,IDXX,alan elliott
452,IDXX,index be choppy remain session lows late trading
453,IDXX,slump nyse composite nasdaq dow give respectively
454,IDXX,dow slip loss week head final hour trading nyse nasdaq hold fractional gain vs last friday close
455,IDXX,volume be tracking higher loss continue be broad decline issue lead advancer better nyse nearly nasdaq
456,IDXX,commodity continue generally lower oil price remain just barrel hold morning gdp number implication further decline demand
457,IDXX,teleflex international tfx pop provide guidance line analyst consensus diversify engineering service provider put full year ep vs estimate company plan report result feb
458,IDXX,update index dive volume rise
459,IDXX,patrick
460,IDXX,market attempt get back break even end stock take sharp turn downward sink intraday lows
461,IDXX,dow fall nyse composite nasdaq sank
462,IDXX,volume be higher board indicate institutional selling
463,IDXX,financial dove government bad bank rescue idea have hit snag asset valuation problem accord report cnbc
464,IDXX,ruddick rdk supermarket operator gap fall company report earning late thursday show profit fall penny cent share stock pare much loss however
465,IDXX,proctor gamble pg be lower full year outlook add sale quarter possibly rest year fall company be often thought recession resistant
466,IDXX,perkinelmer pki maker genetic screening environmental analysis tool gap lose company say expect profit fall year range midsingle digit midteen stock hit year low
467,IDXX,update index climb lows stick decline
468,IDXX,alan elliotta mixed spate earning report stir choppy trading session
469,IDXX,nyse composite nasdaq dow be lower dip index have trim loss
470,IDXX,only banking financial biotech index nasdaq be sector post deepest loss exchange juniper network jnpr broadcom brcm continue rack heavy loss
471,IDXX,midcaps fall further putt
472,IDXX,volume remain shifty rise nasdaq edge lower nyse
473,IDXX,industry group slide lower machinery farm computer datum storage group draw worst loss
474,IDXX,airgas arg pull back strong trading jpmorgan downgrade distributor industrial medical gase neutral overweight thursday wednesday allentown pa firm report fiscal first quarter earning fall airgas cite severance charge link layoff well souring business condition operate result top consensus estimate
475,IDXX,update loss grow session halftime
476,IDXX,vincent mao
477,IDXX,major stock index extend loss midday friday putt week gain jeopardy
478,IDXX,nasdaq lose dow fall drag loss procter gamble pg mmm caterpillar cat drop also weigh dow mining construction equipment firm cut additional job meanwhile nyse composite lose
479,IDXX,volume be tracking even nasdaq slightly higher nyse
480,IDXX,leader board get hit
481,IDXX,stanley sxe reversed early gain drop slice day day move average late thursday provider service top view jump fiscal earning guide sale range vs view
482,IDXX,quality system qsii also reversed fall slice day line appear be find support day line software maker report earning view late wednesday
483,IDXX,stock have be
484,IDXX,netflix nflx slip downgrade stifel nicolaus cut online movie rental firm sell hold still remain past buy point cup handle pattern
485,IDXX,upside brink cfl rise brisk trade security service firm climb fourth straight session recently find support day line
486,IDXX,update index head lowland volume turn mixed
487,IDXX,alan elliott
488,IDXX,softer expect rise january consumer sentiment be apparently not market be look index groan lower weight downside economic datum
489,IDXX,nyse composite fall hardest nasdaq composite dow ride close carry loss
490,IDXX,amazon amzn kla tencor klac continue pack huge gain nasdaq monster worldwide mww juniper network jnpr clock biggest price loss
491,IDXX,volume eke just shade higher nyse remain few click nasdaq
492,IDXX,decliner lead advance issue nyse not quite nasdaq
493,IDXX,university michigan consumer sentiment index crawl higher january december read consensus view news compound earlier news friday show gdp make sharpest downward jog
494,IDXX,march crude future remain largely unchanged hover just barrel mark natural gas trade dime gold be spot ounce dollar rise euro fall vs yen
495,IDXX,stock compass mineral cmp jump better powerful trading table road salt supplier be get boost foul winter weather harsh shortage road salt supply year share be month correction have be unable top resistance week move average
496,IDXX,idexx laboratory idxx step heavy action earning clear consensus view veterinary animal health supply maker be struggle build upside month consolidation
497,IDXX,downside irrigation system maker lindsay lnn crash massive trading issue downside guidance omaha base company say expect fiscal sale slip prior year result due steep slowdown international order
498,IDXX,lindsay announcement spil valmont industry vmi topple also massive trading maker metal tower other large scale infrastructure component be deep month correction
499,IDXX,overseas hong kong hang seng index edge japan tokyo nikkei tumble yen continue gain strength toshiba nintendo ntdoy rac big loss
500,IDXX,stock post mild late session loss europe commodity drag bank financial attempt pull higher
501,IDXX,update stock fade early gain
502,IDXX,vincent mao
503,IDXX,better expect gdp report give stock early lift friday gain quickly withered
504,IDXX,nasdaq dow be mostly unchanged nyse composite fall shed
505,IDXX,volume be tracking sharply lower board
506,IDXX,exxon mobil xom rise top fourth quarter view oil giant post earning share year earlier cent estimate sale tumble still beat view exxon earn full year largest annual profit ever publicly trade company
507,IDXX,group mate chevron cvx also gain post lower expect sale
508,IDXX,downside juniper network jnpr gap tumble sale miss analyst estimate late thursday company match view rise profit sale grow only view morning piper jaffray cut stock neutral buy lower price target
509,IDXX,genentech dna fall roche make lower hostile bid biotech roche drop buyout bid share take deal directly shareholder
510,IDXX,update stock set mixed open gdp report
511,IDXX,vincent mao
512,IDXX,stock future point mixed open friday follow smaller expect drop gross domestic product
513,IDXX,nasdaq future rise point vs fair value future rise fraction point dow future fall point
514,IDXX,economic front gross domestic product fall final quarter biggest decline almost year better expectation dip future rebound news consumer spending account third gdp fall
515,IDXX,datum chicago pmi consumer sentiment be shortly open
516,IDXX,corporate news amazon com amzn rally pre market follow thursday night stellar quarterly report rough retail environment online retailer earning unexpectedly rise cent share cent view sale also beat view grow
517,IDXX,procter gamble pg report fiscal second quarter profit share cent prior year line view latest result include gain cent stem sale folger coffee business smucker revenue fall view share lose pre market
518,IDXX,honeywell hon slip pre open sale miss estimate thank cost cut maker aircraft equipment chemical control system deliver earning cent share year year line view sale fall view
519,IDXX,caterpillar cat lose goldman sachs place construction mining equipment maker conviction sell list
520,IDXX,citigroup jpmorgan chase jpm well fargo wfc be lower pre open cnbc report problem government lead initiative help bank rid bad asset update loss be broad base financial pressed back class news regulator delay promise quick fix so call toxic asset hold many bank other institution nyse composite end flat nasdaq composite edge ever so slightly lower week dow clip decline citigroup lead dow downside juniper network jnpr fall hardest nasdaq juniper be also loss leader worsted only fifth third bancorp fitb be tough day someone forget tell amazon com amzn gap gain late thursday online retailer say book earning sale well analyst view other component flowserve fls paccar pcar jump heavy trading next week monday promise be busy day economic datum commerce release personal income spending construction spending datum december institute supply management put index general gauge outlook corporate buyer monday earning calendar include be aerospace beav corn product international cpo sysco syy prior open independent oil gas heavyweight anadarko apc sandisk sndk athero communication athr check close update higher volume loss threaten stock rallyby juan carlos market close session lows friday broad decline tumble nasdaq nyse composite dow accord early number volume rise give market distribution day come just day market follow selling put market rally serious doubt financial slide report plan remove bad asset bank balance sheet be peril steel other metal stock also weaken goldman sachs analyst give bearish outlook steel maker downgrade steel other update dow head week alan elliottindex be choppy remain session lows late trading slump nyse composite nasdaq dow give respectively dow slip loss week head final hour trading nyse nasdaq hold fractional gain vs last friday close volume be tracking higher loss continue be broad decline issue lead advancer better nyse nearly nasdaq commodity continue generally lower oil price remain just barrel hold morning gdp number implication further decline demand teleflex international tfx pop provide guidance line analyst consensus diversify engineering service provider put full year ep vs estimate company plan report result feb update index dive volume rise patrick market attempt get back break even end stock take sharp turn downward sink intraday lows dow fall nyse composite nasdaq sank volume be higher board indicate institutional selling financial dove government bad bank rescue idea have hit snag asset valuation problem accord report cnbc ruddick rdk supermarket operator gap fall company report earning late thursday show profit fall penny cent share stock pare much loss however proctor gamble pg be lower full year outlook add sale quarter possibly rest year fall company be often thought recession resistant perkinelmer pki maker genetic screening environmental analysis tool gap lose company say expect profit fall year range midsingle digit midteen stock hit year low update index climb lows stick decline alan nyse composite nasdaq dow be lower dip index have trim loss only banking financial biotech index nasdaq be sector post deepest loss exchange juniper network jnpr broadcom brcm continue rack heavy loss midcaps fall further putt volume remain shifty rise nasdaq edge lower nyse industry group slide lower machinery farm computer datum storage group draw worst loss airgas arg pull back strong trading jpmorgan downgrade distributor industrial medical gase neutral overweight thursday wednesday allentown pa firm report fiscal first quarter earning fall airgas cite severance charge link layoff well souring business condition operate result top consensus estimate update loss grow session halftimeby vincent maomajor stock index extend loss midday friday putt week gain jeopardy nasdaq lose dow fall drag loss procter gamble pg mmm caterpillar cat drop also weigh dow mining construction equipment firm cut additional job meanwhile nyse composite lose volume be tracking even nasdaq slightly higher nyse leader board get hit stanley sxe reversed early gain drop slice day day move average late thursday provider service top view jump fiscal earning guide sale range vs view quality system qsii also reversed fall slice day line appear be find support day line software maker report earning view late wednesday stock have be netflix nflx slip downgrade stifel nicolaus cut online movie rental firm sell hold still remain past buy point cup handle pattern upside brink cfl rise brisk trade security service firm climb fourth straight session recently find support day line update index head lowland volume turn mixed alan elliotta softer expect rise january consumer sentiment be apparently not market be look index groan lower weight downside economic datum nyse composite fall hardest nasdaq composite dow ride close carry loss amazon amzn kla tencor klac continue pack huge gain nasdaq monster worldwide mww juniper network jnpr clock biggest price loss volume eke just shade higher nyse remain few click nasdaq decliner lead advance issue nyse not quite nasdaq university michigan consumer sentiment index crawl higher january december read consensus view news compound earlier news friday show gdp make sharpest downward jog march crude future remain largely unchanged hover just barrel mark natural gas trade dime gold be spot ounce dollar rise euro fall vs yen stock compass mineral cmp jump better powerful trading table road salt supplier be get boost foul winter weather harsh shortage road salt supply year share be month correction have be unable top resistance week move average idexx laboratory idxx step heavy action earning clear consensus view veterinary animal health supply maker be struggle build upside month consolidation downside irrigation system maker lindsay lnn crash massive trading issue downside guidance omaha base company say expect fiscal sale slip prior year result due steep slowdown international order lindsay announcement spil valmont industry vmi topple also massive trading maker metal tower other large scale infrastructure component be deep month correction overseas hong kong hang seng index edge japan tokyo nikkei tumble yen continue gain strength toshiba nintendo ntdoy rac big loss stock post mild late session loss europe commodity drag bank financial attempt pull higher update stock fade early gainsby vincent maoa better expect gdp report give stock early lift friday gain quickly withered nasdaq dow be mostly unchanged nyse composite fall shed volume be tracking sharply lower board exxon mobil xom rise top fourth quarter view oil giant post earning share year earlier cent estimate sale tumble still beat view exxon earn full year largest annual profit ever publicly trade company group mate chevron cvx also gain post lower expect sale downside juniper network jnpr gap tumble sale miss analyst estimate late thursday company match view rise profit sale grow only view morning piper jaffray cut stock neutral buy lower price target genentech dna fall roche make lower hostile bid biotech roche drop buyout bid share take deal directly shareholder update stock set mixed open gdp reportby vincent maostock future point mixed open friday follow smaller expect drop gross domestic product nasdaq future rise point vs fair value future rise fraction point dow future fall point economic front gross domestic product fall final quarter biggest decline almost year better expectation dip future rebound news consumer spending account third gdp fall datum chicago pmi consumer sentiment be shortly open corporate news amazon com amzn rally pre market follow thursday night stellar quarterly report rough retail environment online retailer earning unexpectedly rise cent share cent view sale also beat view grow procter gamble pg report fiscal second quarter profit share cent prior year line view latest result include gain cent stem sale folger coffee business smucker revenue fall view share lose pre market honeywell hon slip pre open sale miss estimate thank cost cut maker aircraft equipment chemical control system deliver earning cent share year year line view sale fall view caterpillar cat lose goldman sachs place construction mining equipment maker conviction sell list citigroup jpmorgan chase jpm well fargo wfc be lower pre open cnbc report problem government lead initiative help bank rid bad asset
521,IDXX,medical device industry trend be reflective extensive discovery innovation life science industry past few year study publish cnbc medical device company have gain importance healthcare world improve research development technology far reach innovation gene therapy newer drug combination patient monitoring help big datum year shape medical fraternity unite state tax suspension fuel medical device market have further gain momentum owing recent year suspension controversial medical device tax excise tax be implement part obamacare medtech manufacturer significantly restrict activity accord article publish xtalk medical device tax be responsible reduction spending decline overall sale however be be see tax be fully eliminate resume year period now deferral encourage activity space bode well medtech company notably past month medical instrument industry have rally index return lead revolution medtechthe medtech space currently offer unprecedented opportunity growth market share expansion solid investment have help manufacturer use benefit big datum artificial intelligence ai medical mechatronic industry be also catch digital datum age enormous size datum be capture technology arrive business insight help healthcare sector provide better care reduce wastage latest trend adopt electronic health record ehr service medtech space have also be gain popularity major hcit healthcare bigwig have carved niche big datum domain be cerner corporation athenahealth inc company be make significant investment boost ehr platform meanwhile medical mechatronic be much await digital evolution global healthcare industry provide innovation healthcare industry reduction size age old medical device development low cost disposable device engineering concern einfochip believe mechatronic be future medical device benefit mechatronic have be see form printing cancer study development better medication deadly disease notably intuitive surgical isrg free report minimally invasive da vinci surgical system stryker corporation syk free report robotic arm assist surgery platform mako deserve mention here choose winning stocksgiven favorable scenario investment medical device stock strong potential seem be wise choice stock strong fundamental solid prospect make reward addition portfolio have take help zack stock screener select favorable stock shortlist stock vast universe medical product have picked one zack rank strong buy buy growth score notably growth score be comprehensive tool come handy screening winning stock broader sector research show stock growth score combine zack rank outperform most stock see complete list today zack rank stock here abiom inc abmd free report sport zack rank stock growth score be indicate outperformance term be underpin fact stock have impressive long term earning growth last day zack consensus estimate abiom current quarter earning share have increase cent abiom inc price consensus abiom inc price consensus abiom inc quotein past month share abiom have sky-rocket industry decline abiom flagship impella world smallest heart pump have continue be growth driver notably fourth quarter fiscal company spend year quarter integer holding corporation itgr free report carry zack rank have growth score long term earning growth be project last day zack consensus estimate integer hold current year earning share have increase integer holding corporation price consensus integer holding corporation price consensus integer holding corporation quotein past month share integer holding have rally fare better industry integer holding have also be enhance profitability area advanced surgical orthopedic power solution focuse sale growth cost structure initiative company plan invest more area cardio vascular neuromodulation accelerate sale market penetration notably first quarter company spend year year basis varian medical system var free report stock have zack rank growth score company long term earning growth be project last day zack consensus estimate varian medical current year earning share have rise varian medical system inc price consensus varian medical system inc price consensus varian medical system inc quotein past month share varian medical have rally significantly beating industry varian medical ride solid growth prospect coveted halcyon radiotherapy treatment system hyperarc platform halcyon be design offer cost effective cancer care hyperarc be high definition radiotherapy technology second quarter fiscal company spend prior year quarter steris plc ste free report have zack rank growth score company current year earning growth be project last day zack consensus estimate steris fiscal earning share have increase steris plc price consensus steris plc price consensus steris plc quotein past month share company have rally considerably better industry company goal be provide infection prevention other procedural product service fourth quarter fiscal company invest year year basis idexx laboratory idxx free report carry zack rank growth score company long term earning growth be project last day zack consensus estimate idexx current year earning share have increase idexx laboratory inc price consensus idexx laboratory inc price consensus idexx laboratory inc quotein past month stock have rally significantly outperform industry company develop manufacture distribute product primarily companion animal veterinary livestock poultry first quarter company spend significant year more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
522,IDXX,jun issue update research report idexx laboratory inc idxx free report company robust worldwide commercial capability best class product include next generation chemistry analyzer catalyst be key growth driver term stock carry zack rank buy past month lead molecular diagnostic company have outperformed industry stock have increase industry decrease notably idexx continue demonstrate strong organic growth drive robust sale companion animal group cag business fuel firm global catalyst uptake international revenue first quarter be organically drive organic gain international cag diagnostic recur revenue reflect continue consumable revenue gain support catalyst instrument base increase average testing utilization sturdy growth european lab revenue companion animal market fundamental remain safe sound tremendous global runway growth additionally be upbeat company expand premium instrument base unite state well international market include growth competitive instrument placement increase utilization consistent customer retention idexx innovation base multus modality global strategy enabled enhance commercial capability accelerate recur cag diagnostic revenue growth report quarter moreover company healthy top line growth be drive considerable contribution rest business segment raise ep guidance be also encourage additionally company boast strong cash balance allow carry share repurchase meanwhile majority idexx consolidated revenue be be derive sale product international market thus strengthen dollar exchange rate relative other currency have negative impact revenue derive currency other money well profit draw product manufacture unite state sell internationally adverse currency translation affected adjust earning share tune cent also company heavy dependence third party distributor be drag other key picksother top rank stock broader medical space include genomic health ghdx free report abiom abmd free report stryker corp syk free report genomic health have expect earning growth rate current quarter stock sport zack rank strong buy see complete list today zack rank stock here abiom have project long term earning growth rate zack rank stryker have project long term earning growth rate stock carry zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
523,IDXX,investor focuse medical space have likely hear idexx laboratory idxx free report be stock perform well comparison rest sector peer let take closer look stock year date performance find idexx laboratory be company medical group medical group currently sit zack sector rank zack sector rank consider different group measure average zack rank individual stock sector gauge strength group zack rank emphasize earning estimate estimate revision find stock improve earning outlook system have long record success stock tend be track beat market next month idxx be currently sporting zack rank buy past month zack consensus estimate idxx full year earning have moved higher signal analyst sentiment be improve stock earning outlook be more positive base most recent datum idxx have return so far year same time medical stock have gain average mean idexx laboratory be outperform sector whole year look more specifically idxx belong medical instrument industry include individual stock currently sit zack industry rank group have lose average so far year so idxx be perform better area idxx likely be look continue solid performance so investor interested medical stock continue pay close attention company
524,IDXX,medical device industry have be benefit favorable consumer behavior grow prevalence minimally invasive surgery demand liquid biopsy test use ensure quick improve patient care shift payment system value base model further consider favorable demographic change market dynamic artificial intelligence ai big datum application increase business investment sector have be go strong broadly speaking latest tax cut job act slash corporate tax rate earlier have also buoy optimism investor additionally senate decision defer implementation industry wide excise tax know medical device couple year have instilled confidence investor tax be effective jan bill also delay cadillac tax tax employer insurance emergo medical device industry be project reach market value boston scientific corporation bsx free report baxter international inc bax free report be close contender space notably stock carry zack rank buy raise investor optimism here make detailed analysis company fundamental determine stock be currently position better medical product space market cap boston scientific be lead manufacturer medical device product used various interventional medical specialty worldwide other hand base deerfield il baxter be lead global medical technology company company have market cap price performancein past year boston scientific share have gain compare industry increase stock have also surpass index increase share baxter have rise period earning zack consensus estimate boston scientific current year earning be peg share reflect year year project growth same baxter be peg indicate year year rise moreover last year datum boston scientific earning share have witness cagr baxter earning be project negative cagr totale hence boston scientific win round sale zack consensus estimate boston scientific current year revenue be peg show year year growth same baxter be pin reflect year year growth boston scientific revenue witness cagr reach baxter revenue depict negative cagr here too boston scientific win baxter factor drive stocksboston scientificover recently report quarters boston scientific demonstrated growth business line geography view also paint bright picture company achieve clinical milestone ranger drug coat balloon watchman left atrial appendage closure device also post suspension lotus valve europe acurate tavr valve platform continue build momentum boston scientific recently announce several acquisition include nxthera nvision urology pelvic health emcision endoscopy securus ep millipede structural heart inorganic expansion plan bode well stock operational growth demand baxter crrt injectable pharmaceutical iv solution peritoneal dialysis therapy be positive buyout recothorm preveleak be noteworthy well recently company get fda approval spectrum iq infusion system baxter surgical portfolio be highly diversify product available more country include exclusive product floseal hemostatic matrix tisseel fibrin sealant coseal surgical sealant vascu guard patch other conclusionour comparative analysis indicate boston scientific be position better baxter consider price performance well earning sale growth other key picksother top rank stock broader medical sector be illumina inc ilmn free report idexx laboratory inc idxx free report illumina sport zack rank strong buy idexx carry zack rank see complete list today zack rank stock here illumina expect long term earning growth idexx have expect long term earning growth rate today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
525,IDXX,launch first trust water etf fiw free report be passively manage exchange trade fund design provide broad exposure industrial water segment equity market passively manage etfs be become increasingly popular institutional well retail investor due low cost transparency flexibility tax efficiency be excellent vehicle long term investor sector etfs be also fund convenience offer many way gain low risk diversify exposure broad group company particular sector industrial water be broad zack sector zack industry classification be currently rank place top index fund be sponsored first trust advisor have amassed asset make average size etfs attempt match performance industrial water segment equity market fiw seek match performance ise clean edge water index fee expense ise clean edge water index be modify market capitalization weight index comprise exchange list company derive substantial portion revenue potable wastewater industry costswhen consider etf total return expense ratio be important factor cheaper fund significantly outperform more expensive counterpart long term other factor remain equal annual operate expense etf be make cheaper product space have month trail dividend yield sector exposure top holdingswhile etfs offer diversify exposure minimize single stock risk deep look fund holding be valuable exercise most etfs be very transparent product disclose holding daily basis etf have heaviest allocation industrial sector portfolio utility healthcare round top look individual holding idexx laboratory inc idxx free report account total asset follow ecolab inc ecl free report corporation dhr free report top holding account total asset management performance etf return be roughly approximately so far year past year respectively fiw have trade last week period etf have beta standard deviation trail year period make medium risk choice space holding have more concentrated exposure peer bottom lineto learn more product other etfs screen product match investment objective read article latest development etf investing universe please visit zack etf center
526,IDXX,idexx laboratory inc idxx free report have be gain investor confidence consistently solid result stock have rally year ahead growth broader industry decline moreover company have market cap year expect growth rate be also favorable compare industry tally dwelling solid prospect zack rank buy player be attractive bet investor moment company estimate revision trend have also be positive last day analyst moved estimate northward movement opposite direction consensus mark current year earning have be raise share style score idexx laboratory sport favorable growth score reflective company strong fundamental research show stock impressive growth style score combine bullish zack rank strong buy offer best upside potential accordingly idexx laboratory have encourage net margin net income sale well industry negative also company sale asset ratio compare industry make sturdy growth pick let find be recent positive momentum be sustainable not company be lead manufacturer product service primarily companion animal veterinary livestock poultry exit first quarter commendable note better expect earning revenue performance stock stellar performance be drive robust sale cag companion animal group business first quarter cag revenue rise organically year year support cag diagnostic recur organic revenue growth moreover idexx vetlab consumable organic revenue growth be firm back expand premium instrument base unite state international market include growth competitive instrument placement increase utilization consistent customer retention notably january company make catalyst sdma test available north america idexx point care customer now be able add sdma essential element routine chemistry panel apart unite state canada idexx expect launch catalyst sdma test other part world next several month continue slew development idexx laboratory enter global agreement january diagnostic company call apply biocode deal idexx laboratory bring reference laboratory customer digital multiplex platform build apply biocode management aim commercially launch technology companion animal market fundamental remain consolidated global runway tremendous growth management innovation base multus modality global strategy accelerate recurrent cag diagnostic revenue growth report quarter moreover substantial top line rise be contribute considerable contribution other business segment furthermore raise guidance bottom line share instill confidence stock be also optimistic company witness double digit organic revenue growth international business upside indicated steady consumable revenue gain ride catalyst instrument base average testing utilization additionally company boast secure cash balance allow carry share repurchase meanwhile idexx laboratory heavy dependence third party distributor raise concern moreover rigid competitive landscape domestic overseas market weigh company margin other key picksa few other top rank stock broader medical space be abiom inc abmd free report genomic health inc ghdx free report intuitive surgical isrg free report abiom have estimate long term earning growth rate stock sport zack rank strong buy see complete list today zack rank stock here genomic health have expect earning growth rate stock have zack rank intuitive surgical have expect long term earning growth rate be zack rank stock make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
527,IDXX,have be month last earning report idexx laboratory inc idxx free report share have add time frame recent positive trend continue lead next earning release be idxx due pullback dive investor analyst have react late let take quick look most recent earning report order get better handle important catalyst recent earningsidexx laboratory report first quarter earning share ep year year report basis comparable constant exchange rate cer basis current zack consensus estimate adjust ep be peg cent company upside report ep be drive revenue growth solid operate margin gain impressive benefit tax reform revenue detailrevenue rise year year organic basis surpass zack consensus estimate upside be drive strong global gain companion animal group cag diagnostic recur revenue include double digit organic revenue gain consumable reference lab well strong acceptance rapid assay veterinary software service diagnostic imaging system further steady overall growth contribute top line segmental analysisidexx derive revenue operate segment cag water livestock poultry dairy lpd other first quarter cag revenue rise organically year year water segment revenue be prior year quarter organically lpd revenue grow organically revenue other segment rise organically marginsgross profit increase report quarter further gross margin expand basis point bps rise cost revenue sale marketing expense rise general administrative expense increase research development expense rise operate margin quarter improve bps financial positionidexx exit first quarter cash cash equivalent compare end net cash provide operate activity report quarter be compare year quarter guidanceidexx have reaffirm revenue outlook company have update revenue organic growth guidance previous however idexx continue expect revenue growth report basis zack consensus estimate revenue be peg guide range management also raise ep guidance earlier support continue operate margin expansion align long term goal update outlook represent ep growth report basis compare state previously zack consensus estimate adjust ep be peg have estimate be move then past month investor have witness downward trend fresh estimate have be revision higher current quarter compare lower idexx laboratory inc price consensus idexx laboratory inc price consensus idexx laboratory inc quotevgm scoresat time idxx have nice growth score be lag bit momentum front charting somewhat similar path stock be allocate grade value side putt bottom investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested style score indicate stock be more suitable growth investor momentum investor outlookestimate have be broadly trend downward stock magnitude revision indicate downward shift interestingly idxx have zack rank buy expect average return stock next few month
528,IDXX,growth stock be most exciting pick market high flyer captivate investor attention produce big gain well however also lead downside growth story be so be important find company be still see strong growth prospect business such company be well position future earning growth be idexx laboratory inc idxx free report firm be medical instrument industry see ep growth last year be look great year too fact current growth estimate year call significant earning share growth furthermore long term growth rate be currently impressive suggest pretty good prospect long haul idexx laboratory inc price consensus idexx laboratory inc price consensus idexx laboratory inc wasn enough stock have actually see estimate rise past month current fiscal year thank rise earning estimate idxx have zack rank buy further underscore potential outperformance company see complete list today zack rank strong buy stock here so be look fast grow stock be still see plenty opportunity horizon make sure consider idxx not only do have double digit earning growth prospect impressive zack rank suggest analyst believe better day be ahead idxx well make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
529,IDXX,issue update research report idexx laboratory inc idxx free report company robust worldwide commercial capability best class product include next generation chemistry analyzer catalyst be key growth driver term stock carry zack rank hold lead molecular diagnostic company have outperformed industry stock have increase industry decrease notably idexx exit first quarter strong note better expect earning revenue improvement solid year year growth organic revenue raise ep guidance be also encourage stellar performance be drive robust sale companion animal group cag business fuel firm global catalyst uptake international revenue first quarter be organically drive organic gain international cag diagnostic recur revenue reflect continue consumable revenue gain support catalyst instrument base increase average testing utilization sturdy growth european lab revenue companion animal market fundamental remain safe sound tremendous global runway growth additionally be upbeat company expand premium instrument base unite state well international market include growth competitive instrument placement increase utilization consistent customer retention idexx innovation base multus modality global strategy enabled enhance commercial capability accelerate recur cag diagnostic revenue growth report quarter moreover company healthy top line growth be drive considerable contribution rest business segment additionally company boast strong cash balance allow carry share repurchase meanwhile majority idexx consolidated revenue be be derive sale product international market thus strengthen dollar exchange rate relative other currency have negative impact revenue derive currency other money well profit draw product manufacture unite state sell internationally adverse currency translation affected adjust earning share tune cent also company heavy dependence third party distributor be drag key picksa few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina have expect long term earning growth rate amedisys have expect long term earning growth rate medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
530,IDXX,re interested broad exposure industrial water segment equity market look further first trust water etf fiw free report passively manage exchange trade fund launch excellent vehicle long term investor passively manage etfs be popular choice institutional retail investor due low cost transparency flexibility tax efficiency sector etfs be also fund convenience offer many way gain low risk diversify exposure broad group company particular sector industrial water be broad zack sector zack industry classification be currently rank place top index fund be sponsored first trust advisor have amassed asset make average size etfs attempt match performance industrial water segment equity market fiw seek match performance ise clean edge water index fee expense ise clean edge water index be modify market capitalization weight index comprise exchange list company derive substantial portion revenue potable wastewater industry costssince cheaper fund tend produce better result more expensive fund assume other factor remain equal be important investor pay attention etf expense ratio annual operate expense etf be make cheaper product space have month trail dividend yield sector exposure top holdingsit be important delve etf holding investing many upside kind fund diversify exposure minimize single stock risk most etfs be very transparent product disclose holding daily basis etf have heaviest allocation industrial sector portfolio utility healthcare round top look individual holding idexx laboratory inc idxx free report account total asset follow ecolab inc ecl free report american water work company inc awk free report top holding account total asset management performance etf have lose be so far year past year respectively fiw have trade last week period etf have beta standard deviation trail year period make medium risk choice space holding have more concentrated exposure peer bottom lineto learn more product other etfs screen product match investment objective read article latest development etf investing universe please visit zack etf center
531,IDXX,have be pay attention share idexx laboratory idxx free report share have be move stock past month idxx hit new week high previous session idexx laboratory have gain start year compare move medical sector year date return peer group drive outperformance stock have great record positive earning surprise have beaten zack consensus estimate last quarters last earning report idexx laboratory report ep versus zack consensus estimate beat consensus revenue estimate current fiscal year idexx laboratory be expect post earning share revenue represent change ep change revenue next fiscal year company be expect earn share revenue represent year year change respectively valuation metricsidexx laboratory be week high right now future hold idxx key aspect question be take look valuation metric order determine company be due pullback level front look zack style score give investor variety way comb stock look zack rank security style be represent grade run category value growth momentum be combine vgm score well idea style score be help investor pick most appropriate zack rank stock base individual investment style idexx laboratory have value score stock growth momentum score be respectively give company vgm score term value breakdown stock currently trade current fiscal year ep estimate trail cash flow basis stock currently trade versus peer group average additionally stock have peg ratio isn enough put company top echelon stock cover value perspective idexx laboratory inc price consensus idexx laboratory inc price consensus idexx laboratory inc quotezack rankwe also need look zack rank stock supersede trend style score front fortunately idexx laboratory currently have zack rank buy thank rise earning estimate recommend investor select stock carry zack rank strong buy style score look idexx laboratory pass test thus seem idxx share have bit more room run term do idexx laboratory stack competition share idexx laboratory have be move higher company still appear be decent choice rest industry industry peer be also look good include iradime irmd free report integer holding itgr free report varian medical system var free report currently have zack rank least vgm score least make well round choice however be worth note zack industry rank group be bottom half ranking so isn good news idexx laboratory still fundamental idxx be promising still have potential be week high
532,IDXX,idexx laboratory inc idxx free report report first quarter earning share ep year year report basis comparable constant exchange rate cer basis current zack consensus estimate adjust ep be peg cent company upside report ep be drive revenue growth solid operate margin gain impressive benefit tax reform revenue detailrevenue rise year year organic basis surpass zack consensus estimate upside be drive strong global gain companion animal group cag diagnostic recur revenue include double digit organic revenue gain consumable reference lab well strong acceptance rapid assay veterinary software service diagnostic imaging system further steady overall growth contribute top line idexx laboratory inc price consensus ep surprise idexx laboratory inc price consensus ep surprise idexx laboratory inc quotesegmental analysisidexx derive revenue operate segment cag water livestock poultry dairy lpd other first quarter cag revenue rise organically year year water segment revenue be prior year quarter organically lpd revenue grow organically revenue other segment rise organically marginsgross profit increase report quarter further gross margin expand basis point bps rise cost revenue sale marketing expense rise general administrative expense increase research development expense rise operate margin quarter improve bps financial positionidexx exit first quarter cash cash equivalent compare end net cash provide operate activity report quarter be compare year quarter guidanceidexx have reaffirm revenue outlook company have update revenue organic growth guidance previous however idexx continue expect revenue growth report basis zack consensus estimate revenue be peg guide range management also raise ep guidance earlier support continue operate margin expansion align long term goal update outlook represent ep growth report basis compare state previously zack consensus estimate adjust ep be peg takeidexx exit first quarter solid note moreover solid year year growth organic revenue raise ep guidance be encourage stellar performance be drive strong sale cag business companion animal market fundamental remain solid tremendous global runway growth management innovation base multus modality global strategy enabled enhance commercial capability accelerate recur cag diagnostic revenue growth moreover strong top line growth quarter be drive considerable contribution rest business segment zack rank other key picksidexx have zack rank buy few other top rank stock broader medical space have report solid result season be intuitive surgical isrg free report cheme corp che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank see complete list today zack rank stock here intuitive surgical report first quarter adjust ep beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust ep surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust ep cent beat zack consensus estimate revenue also edge past zack consensus estimate today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
533,IDXX,headquarter delaware nj idexx laboratory inc idxx free report be developer manufacturer distributer product service primarily companion animal veterinary livestock poultry water testing dairy market company also sell series portable electrolyte blood gas analyzer human point care medical diagnostic market currently idexx have zack rank buy change follow mixed first quarter earning report have just release see complete list today zack rank strong buy stock here have highlighted key detail just release announcement earning current zack consensus estimate be peg cent share idexx first quarter report earning share come increase year year report basis revenue idexx post revenue almost increase year year have beat zack consensus estimate revenue key stat business segment idexx deliver first quarter revenue cag water livestock poultry dairy lpd other segment major factor management growth business first quarter be majorly drive strength cag revenue segment furthermore premium instrument placement include year year increase catalyst placement report quarter have yielded solid return well idexx laboratory inc price ep surprise idexx laboratory inc price ep surprise idexx laboratory inc quotecome guidance company have update revenue organic growth growth guidance previous range however company maintain expect revenue growth report basis idexx also raise full year adjust earning range share previous range stock price follow earning release share price do not show movement pre market trading session check back later full idexx earning report later today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
534,IDXX,growth base debt be unsustainable artificial jose manuel barroso capital be basic requirement production company need exogenous fund finance corporate expense run operation smoothly well expand realm business be depend solely retain earning business growth be next impossible be worth note equity debt most common option used boost company future earning debt be more popular be perhaps due cheap easy availability debt equity financing moreover interest debt be tax deductible make attractive option however debt financing have own drawback problem arise leverage refer amount debt company bear become exorbitant particular company large debt load be more vulnerable economic downturn even go bankrupt worst case scenario course do not mean debt financing be inherent instrument corporation grow earning be taboo corporate financing nevertheless give current macroeconomic scenario unite state favor interest rate hike market seem be not so suitable borrower march federal reserve raise rate sixth time policymaking federal open market committee begin lift rate december therefore be safe side investor try avoid stock bear large debt load empirically several leverage ratio have be construct measure exact amount debt risk company face order safeguard investor debt trap debt equity ratio be such measure perhaps most popular have be used evaluate company credit worthiness potential equity investment analyze debt equitydebt equity ratio total liability shareholder metric be liquidity ratio indicate amount financial risk company bear company lower debt equity ratio indicate improve solvency company first quarter report cycle full swing right now investor be target stock be exhibit solid earning growth stock bear high debt equity ratio time economic downturn so call boom earning picture turn nightmare consider be wise investor select company low leverage be financially more secure immune financial bankruptcy winning aforementioned factor be wise choose stock low debt equity ratio ensure safe return however investment strategy base solely debt equity ratio not fetch desire outcome choose stock have potential give steady return have expand screening criterium include other factor here be other parameter debt equity less industry median stock be less leverage industry peer current price greater equal stock be trading minimum average day volume greater equal substantial trading volume ensure stock be easily tradable percentage change ep greater industry median earning growth add optimism lead stock price appreciation vgm score research show stock vgm score combine zack rank strong buy buy offer best upside potential estimate year ep growth greater show earning growth expectation zack rank irrespective market condition stock zack rank have proven history success exclude stock have negative debt equity ratio here be stock make screen louisiana pacific corporation lpx free report company manufacture build material engineer wood product unite state canada chile brazil pull average positive earning surprise trail quarters currently sport zack rank idexx laboratory inc idxx free report be developer manufacturer distributer product service primarily companion animal veterinary livestock poultry water testing dairy market company carry zack rank deliver average positive earning surprise trail quarters solaredge technology inc sedg free report company provide innovative solar power harvesting monitoring solution residential commercial utility scale solar pv installation pull average positive earning surprise trail quarters currently carry zack rank see complete list today zack rank stock here curtiss corporation cw free report be innovative engineering company provide high tech critical function product system service commercial industrial defense power market company carry zack rank pull average positive earning surprise trail quarters inc athm free report offer online destination automobile consumer primarily person republic china company currently sport zack rank deliver average positive earning surprise trail quarters get rest stock list start putt other idea test be do research wizard stock pick back testing software research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performance zack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
535,IDXX,idexx laboratory inc idxx free report be schedule report first quarter result open bell last quarter company deliver positive earning surprise notably stock have outperformed zack consensus estimate precede quarters average beat be let take look thing be shape prior announcement key catalyst idexx be expect continue gain momentum first quarter courtesy strong global rise companion animal group cag diagnostic revenue last time upside be drive consistent strong double digit growth reference lab consumable owing high single digit increase register rapid assay sale management vouch trend be retain further idexx laboratory inc price ep surprise idexx laboratory inc price ep surprise idexx laboratory inc quote be also upbeat idexx enhance commercial capability unite state maintain recur revenue growth cag diagnostic expect first quarter result reflect rise productivity new sale representative establish fresh customer relationship also anticipate company report exceptional customer retention rate reference lab well instrument consumable unite state worldwide zack consensus estimate cag diagnostic revenue represent improvement last report quarter notably idexx revenue growth projection quarter be report highlight organic gain overall zack consensus estimate total quarterly revenue be peg other factor predict influence idexx first quarter result be pin considerable hope progress water business lie growth trajectory late backed encourage test result unite state well benefit draw global go direct initiative moreover business witness organic growth last quarter management also eye gain favorable regulatory development pertain wastewater unite state drink water europe company earlier state be perfectly track continue high single digit organic revenue boost business consensus mark water revenue stand yet be report quarter idexx carry expand global footprint have be significantly draw advantage bountiful opportunity emerge companion animal diagnostic market further management consistent share buyback underscore robust free cash flow reserve believe outcome endeavor bear reflection first quarter conference call flip side foreign currency fluctuation be major headwind concern be company heavy reliance third party distributor purchasing dynamic distributor leave significant impact company sale instrument consumable well rapid assay product moreover idexx have be witness rise operate expense due increase head count higher investment portfolio development expansion unite state internationally additionally competitive landscape domestic overseas market weigh idexx performance thus struggle gain market traction be drag first quarter result here quantitative model predict proven zack model company favorable zack rank strong buy buy hold have higher chance beating estimate also have positive earning esp idexx have zack rank increase predictive power esp however company earning esp leave surprise prediction inconclusive caution sell rate stock go earning announcement especially company be see negative estimate revision uncover best stock buy sell re report earning esp filter stock worth lookhere be few medical stock worth consider right combination element surpass estimate time baxter international inc bax free report have earning esp be zack rank player laboratory corporation america holding lh free report have earning esp zack rank stryker corporation syk free report have earning esp be rank player see complete list today zack rank stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
536,IDXX,petm express inc pet free report have be gain investor confidence consistently positive result past year company share price have outperformed broader industry stock have gain broader industry decline also company have outperformed gain company have market cap petm have deliver average earning beat trail quarters solid prospect zack rank strong buy stock be attractive pick investor moment company estimate revision trend current year have be positive past day analyst revise estimate upward movement opposite direction resultantly earning estimate rise zack style score system petm have growth score reflect company solid prospect research show stock growth style score combine zack rank buy offer best upside potential regard petm have favorable price earning growth peg ratio compare broader industry attractive annualize project earning growth rate petm score higher industry let find recent positive trend be sustainable petm have be successfully deliver solid quarterly result second quarter fiscal company top zack consensus estimate revenue earning be upbeat stellar increase reorder new order sale quarter encouragingly note company be strive implement several strategy revitalize top line include increase focus advertising efficiency boost new order sale shift sale higher margin item also expand product offering moreover company be work resolve issue limit consumer spending be also optimistic petm focus improve effectiveness campaign have be quite successful drive sale commerce petm boast comprehensive range product be market primarily well know brand medication such frontline advantix advantage heartgard sentinel interceptor other believe improve economic condition conjunction petm broad portfolio provide boost top line additionally company have strong cash balance allow carry share repurchase flip side escalate advertising expense quarter have be dent bottom line also competitive threat raise concern other key picksother top rank medical stock be align technology inc algn free report myriad genetic inc mygn free report idexx laboratory inc idxx free report notably align technology myriad genetic sport zack rank idexx laboratory carry zack rank see complete list today zack rank stock here align technology have long term expect earning growth rate stock have gain year myriad genetic have long term expect earning growth rate stock have gain year idexx laboratory have long term expect earning growth rate stock have rally year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
537,IDXX,dec issue update research report idexx laboratory inc idxx free report stock currently have zack rank buy lead molecular diagnostic company have be trading broader industry stock have gain last year comparison broader industry idexx derive large share revenue companion animal group cag segment third quarter cag organic revenue rise high single digit cag diagnostic recur organic revenue growth vetlab consumable impressive organic revenue growth be upbeat company expand premium instrument base unite state international market include growth competitive instrument placement increase utilization continue customer retention moreover believe management innovation base global strategy be lead growth cag diagnostic notably idexx widen cloud technology portfolio addition rvetlink expect company demonstrate solid global growth day ahead international revenue second quarter grow high single digit drive rise recur organic revenue cag diagnostic gain water business additionally company have strong cash balance allow carry share repurchase flip side idexx high dependence third party distributor intense competition be major deterrent moreover cag business be likely suffer adverse currency fluctuation owing expand international operation company estimate revision trend current year have be positive last day analyst revise estimate upward movement opposite direction magnitude estimate revision earning increase share other key picksother top rank medical stock be petm express inc pet free report align technology inc algn free report myriad genetic inc mygn free report notably petm align technology myriad genetic sport zack rank strong buy see complete list today zack rank stock here petm have long term expect earning growth rate stock have rally roughly year align technology have long term expect earning growth rate stock have gain year myriad genetic have long term expect earning growth rate stock have gain year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
538,IDXX,ecolab inc ecl free report recently announce acquisition pest service company provide specialize capability food storage transaction be worth be close dec acquire company be food protection service llc royal pest solution inc research company llc latest development expand ecolab pest elimination solution food beverage industry food protection operate pacific northwest great lake midwest mississippi delta royal pest solution function mid atlantic region new jersey south carolina research company serve gulf coast state texas louisiana mississippi alabama florida acquisition be expect boost ecolab offering food beverage market strengthen global service specialty business segment other term deal have be keep wrapped acquisition boost growthecolab continue focus investment key growth business bolt acquisition gain market traction boost profit inorganic growth september company sign agreement acquire paper chemical business georgia pacific deal enhance ecolab position grow tissue towel well packaging board segment paper industry earlier ecolab trucost microsoft have initiate strategic collaboration introduce water risk monetizer industry first publicly available financial modele tool allow business understand impact water risk sustainability water other notable tie up recent past ecolab take jianghai environmental protection co ltd industrial water treatment company headquarter changzhou china share shine brightyear date ecolab have return almost higher broader industry company continue see improvement underlie sale volume pricing most business segment solid portfolio product launch expand customer base drive organic sale realization target synergy associate acquisition drive margin furthermore solid performance global institutional segment be encourage sale increase segment last quarter lead strong growth specialty healthcare business line zack rank key picksecolab have zack rank hold few better rank stock broader medical sector be petm express pet free report luminex corporation lmnx free report idexx laboratory idxx free report notably petm express sport zack rank strong buy company have long term expect earning growth rate see complete list today zack rank stock hereluminex yielded return last year stock have zack rank idexx laboratory have long term expect earning growth rate stock have climb year time have zack rank buy look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
539,IDXX,company favorable efficiency level be likely be investor radar irrespective market condition be company favorable efficiency level be expect provide impressive return be believe be positively correlated price performance key ratio identify become difficult measure efficiency level company be reason consider popular efficiency ratio select stock efficiency ratio be inventory turnover ratio month cost good sell cog quarter average inventory be consider most popular efficiency ratio indicate company ability maintain suitable inventory position high value indicate company have relatively low level inventory compare cog low value indicate company be face decline sale result excess inventory receivables turnover be ratio month sale quarter average receivables show company potential extend credit collect debt term credit high receivables turnover ratio account receivable turnover ratio debtor turnover ratio be desirable show company be capable collect account receivables have quality customer asset utilization ratio indicate company capability convert asset output be thus widely know measure efficiency level be calculate divide total sale past month last quarter average total asset ratio high asset utilization indicate company be efficient operate margin efficiency measure be ratio operate income past month sale same period measure company ability control operate expense hence high value ratio indicate company manage operate expense more efficiently peer screening parametersin addition mentioned ratio have add favorable zack rank buy screen objective make strategy more profitable see complete list today zack rank strong buy stock here inventory turnover receivables turnover asset utilization operate margin greater industry average value ratio higher industry average indicate efficiency level company be higher peer use few criterium have narrow universe stock only here be stock make screen cheme corporation che free report provide hospice palliative care service unite state operate segment vita roto rooter company have average quarter positive earning surprise baxter international inc bax free report provide portfolio renal hospital product company operate segment hospital product renal company have average quarter positive earning surprise idexx laboratory inc idxx free report develop manufacture distribute product service primarily companion animal veterinary livestock poultry dairy water testing market worldwide company have average quarter positive earning surprise advanced energy industry inc aeis free report design manufacture sell support power conversion control product transform power various usable form company have average quarter positive earning surprise pioneer natural resource company pxd free report operate independent oil gas exploration production company unite state company have average quarter positive earning surprise get rest stock list signing now week free trial research wizard start used screen own trading further also create own strategy test first take investment plunge research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performancezack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
540,IDXX,have be pay attention share lemaitre vascular lmat free report share have be move stock past month lmat hit new week high previous session lemaitre vascular have gain start year compare move medical sector year date return peer group drive outperformance stock have impressive record positive earning surprise have beaten zack consensus estimate last quarters last earning report february lemaitre vascular report ep versus zack consensus estimate miss consensus revenue estimate current fiscal year lemaitre vascular be expect post earning share revenue represent change ep change revenue next fiscal year company be expect earn share revenue represent year year change respectively valuation metricslemaitre vascular be week high right now future hold lmat key aspect question be take look valuation metric order determine company be due pullback level front look zack style score provide investor additional way sort stock look zack rank security style be represent grade run category value growth momentum be combine vgm score well idea style score be help investor pick most appropriate zack rank stock base individual investment style lemaitre vascular have value score stock growth momentum score be respectively give company vgm score term value breakdown stock currently trade current fiscal year ep estimate trail cash flow basis stock currently trade versus peer group average additionally stock have peg ratio isn enough put company top echelon stock cover value perspective lemaitre vascular inc price consensus lemaitre vascular inc price consensus lemaitre vascular inc quotezack rankwe also need look zack rank stock supersede trend style score front fortunately lemaitre vascular currently have zack rank buy thank rise earning estimate recommend investor select stock carry zack rank strong buy style score look lemaitre vascular fit bill thus seem lmat share have potential week month come do lemaitre vascular stack competition share lemaitre vascular have be soar company still appear be decent choice rest industry industry peer be also look good include stryker corporation syk free report icu medical icui free report idexx laboratory idxx free report currently have zack rank least vgm score least make well round choice however be worth note zack industry rank group be bottom half ranking so isn good news lemaitre vascular still fundamental lmat be promising still have potential be week high
541,IDXX,have more triple mar gruel spell follow great recession be now second longest second highest bull market run history bull run have be longest stock scale new high republican tax cut robust economic growth home abroad recent trade war tension uproar white house higher interest rate half dollar loss tech stock just week span have push index back critical support day move average fact fall correction territory volatility have more double so far year not stock be however face tumultuous have be able dish impressive year date gain have remain unperturbed higher bout gyration backed rally start positive note trump police include tax cut repeal regulation increase infrastructure outlay restore expectation pro growth agenda help move north latest tax law give company massive tax relief now be pay instead earlier bring back money hold overseas mean foreign profit company be hoard be bring back turn be used create job reward shareholder something trump administration have be aim campaign day trump economy be also good shape jobless rate year low initial jobless claim remain lowest level number person collect unemployment benefit tank fresh year low be major factor strong american growth global economic growth major country china europe latin america japan expand healthy pace accord international monetary fund global economy expand rate last year fastest end sour noteselling stock intensified trump administration announce levy tariff ten billion dollar chinese import top impose duty foreign steel aluminum response trump tariff beij say target product import value investor panic full blow trade war deal heavy blow economy result widespread unemployment number high profile departure trump administration meantime push political risk highest level invasion iraq such event threaten upset trump administration business friendly policy fedha tighten monetary policy conclusion fomc meeting mar jerome powell lead federal reserve hike interest rate quarter percentage point project steeper path rate hike hasn go well investor know have pile stock notion quantitative ease help domestic economy grow better rate emerge economy china add downbeat tone be also sharp selloff technology sector investor remain concern tighter regulation large tech company sector take beating follow backlash facebook inc fb free report handle user datum everyone raise question cambridge analytica work trump election campaign have gain access personal datum roughly facebook user knowledge tech sector be most crowd trade year peaked mar putt market cap however market cap be currently nearly decline wsj market datum group best stock now have fall more peak january average number stock index be almost week high average stock sector be already bear market territory defined decline bespoke investment group brutal selloff past few week stock have manage give encourage return thank great story maybe little luck here be rundown best stock stock also flaunt zack rank strong buy buy seagate technology plc stx free report provide datum storage technology solution unite state internationally even company be part larger tech sector trader have be plough back stx stock stock have zack rank zack consensus estimate current year earning rise last day company be expect give solid return year seagate technology have outperformed broader industry year date period vs consider seagate technology have do so well come surprise close cousin micron technology inc mu free report performance have be pretty encourage provider semiconductor system have zack rank zack consensus estimate current year earning rise last day micron technology be expect give staggering return year stock have already give steady return year date period idexx laboratory inc idxx free report develop manufacture distribute product service primarily companion animal veterinary livestock poultry dairy water testing market stock have zack rank zack consensus estimate current year earning rise last day company be expect give promising return year idexx laboratory have outperformed broader industry year date period vs see complete list today zack rank stock here kohl corporation kss free report operate department store unite state company have zack rank zack consensus estimate current year earning climb last day stock be expect give solid return year kohl have outperformed broader industry year date period vs motorola solution inc msi free report provide mission critical communication infrastructure device accessory software service company have zack rank zack consensus estimate current year earning rise last day stock be expect give encourage return year motorola solution have outperformed broader industry year date period vs investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
542,IDXX,baxter international inc bax free report have have impressive run bourse late last year company have add outperform broader industry gain current level be also higher return recur revenue stream expand product portfolio strong presence international market be key positive stock have zack rank buy here take sneak peek major factor drive growth baxter moment year have be favorable baxter regulatory front recently management confirm fda have grant new approval temporary importation certain drug facility canada mexico development baxter now have operational site approve meet demand market furthermore fda approval new premixed injectable be key catalyst company new product home peritoneal dialysis pd technology also receive fda nod platform leverage baxter flagship amia automate peritoneal dialysis apd system recent past baxter achieve regulatory milestone advanced dialysis technology company receive approval fda home pd solution system improve patient access home dialysis baxter have strong presence foreign market make international diversification core component strategy bid fortify overseas presence company have launch oxiris set continuous renal replacement therapy crrt sepsis management protocol select market europe middle east africa notably oxiris leverage company flagship prismaflex system be expect lend baxter competitive edge global market large proportion sale come overseas market baxter benefit develop country incremental investment health care system recent acquisition position company well revenue growth rapidly expand asian latin american market other key picksa few other top rank stock broader medical sector be petm express pet free report luminex corporation lmnx free report idexx laboratory idxx free report notably petm express sport zack rank strong buy company have long term expect earning growth rate see complete list today zack rank stock here luminex represent return last year stock have zack rank idexx laboratory have long term expect earning growth rate stock have climb year time have zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
543,IDXX,idexx laboratory inc idxx free report have be gain investor confidence consistently positive result stock have surge year ahead gain broader industry rally moreover company have market cap year historical growth rate be also favorable compare industry dwelling solid prospect zack rank buy stock be attractive bet investor moment company estimate revision trend have be positive last day analyst revise estimate upward movement opposite direction consensus mark earning increase share style score idexx laboratory sport growth score reflective company strong fundamental research show stock impressive growth style score combine favorable zack rank strong buy offer best upside potential idexx laboratory inc price idexx laboratory inc price idexx laboratory inc quote regard idexx laboratory have favorable net margin net income sale industry negative also company sale asset ratio compare industry signify sturdy growth pick let find recent positive momentum be sustainable company be lead manufacturer product service primarily companion animal veterinary livestock poultry exit fourth quarter promising note stable year year growth organic revenue be also encourage stock stellar performance be drive robust sale cag companion animal group business fourth quarter cag organic revenue rise low double digit back strong cag diagnostic recur organic revenue growth vetlab consumable organic revenue growth additionally be upbeat company expand premium instrument base unite state international market include improve competitive instrument placement increase utilization continue customer retention regard be also optimistic gain commercial launch catalyst sdma test north america january breakthrough company point care customer be able add sdma essential element routine chemistry panel continue slew development idexx laboratory enter global agreement january diagnostic company apply biocode agreement idexx laboratory bring reference laboratory customer digital multiplex platform build apply biocode management aim commercially launch technology companion animal market fundamental remain consolidated tremendous global runway growth management innovation base multus modality global strategy accelerate recur cag diagnostic revenue growth report quarter moreover substantial top line growth quarter be drive considerable contribution other business segment furthermore raise guidance earning share instill confidence stock be also upbeat company witness double digit organic revenue growth international business upside reflect consistent consumable revenue gain support catalyst instrument base average testing utilization additionally company have secure cash balance allow carry share repurchase meanwhile idexx laboratory heavy reliance third party distributor raise concern moreover tough competitive landscape domestic overseas market weigh company margin other key pickssome other top rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report varian medical system inc var free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate varian medical have long term expect earning growth rate stock carry zack rank hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
544,IDXX,mar issue update research report idexx laboratory inc idxx free report company witness strong organic revenue growth international business additionally companion animal market fundamental remain solid tremendous global runway growth stock carry zack rank buy also lead molecular diagnostic company have be outperform industry past month stock have rally compare gain industry meanwhile idexx continue demonstrate solid growth globally strong international expansion fourth quarter company witness double digit organic revenue growth international business upside be owing continue consumable revenue gain support catalyst instrument base average testing utilization international market company witness considerable organic lab revenue gain support positive customer response sdma well significant growth rapid assay sale addition management experience steady growth reference lab lead consistent gain europe furthermore cag organic revenue growth low double digit strong vetlab consumable cag diagnostic recur organic revenue growth be impressive be also optimistic company expand premium instrument base unite state international market include growth competitive instrument placement increase utilization continue customer retention move ahead expect company gain commercial launch catalyst sdma test north america january idexx too enter global agreement diagnostic company apply biocode same month moreover idexx have strong cash balance allow carry share repurchase nevertheless high dependence third party distributor intense competition continue threat other stock considersome other top rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report athenahealth inc athn free report perkinelmer have long term expect earning growth rate stock carry zack rank bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
545,IDXX,varian medical var free report recently announce partnership penn medicine develop launch comprehensive proton therapy training education program management varian confirm training online course be available january latest development be likely enhance knowledge skill clinician therapist global proton therapy space fact continue education training be likely boost availability proton therapy product niche market proton therapy space glanceproton therapy proton beam therapy be type particle therapy used beam proton treat diseased tissue most often case cancer research report cision pr newswire suggest global proton therapy system market be expect reach favorable reimbursement policy unite state europe rise awareness cancer related healthcare policy expenditure emerge nation be likely propel proton therapy space long haul fact various report suggest proton therapy space be dominate unite state thank massive investment development therapy center now come lead player space hitachi ion beam application mevion medical system sumitomo also deserve mention meanwhile proton therapy market be grow manifold expect witness stellar demand come day varian strong footholdapart enjoy dominant market share conventional radiotherapy believe proton therapy also hold significant promise varian be company flagship probeam compact proton therapy system be superior other external beam radiotherapy available market probeam precisely locate cancerous tumor thereby cause lesser side effect surround tissue regard varian proton therapy portfolio have product probeam proton therapy system probeam compact single room proton therapy solution probeam multus room proton therapy solution however company have see lackluster performance proton therapy segment recently last quarter revenue segment be year year basis quarter varian book order include concord medical proton center guangzhou china hcg india yet proton therapy order grow same period year year basis believe such development help varian gain traction niche space share shine brightover past month varian outperformed broader industry term price performance company return compare favorably broader industry gain just also current return be higher gain same time frame zack rank stock considervarian have zack rank sell few other top rank stock broader medical sector be petm express pet free report luminex corporation lmnx free report idexx laboratory idxx free report notably petm express sport zack rank strong buy company have long term expect earning growth rate see complete list today zack rank stock here luminex represent return last year stock have zack rank idexx laboratory have long term expect earning growth rate stock have climb year time have zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
546,IDXX,nov issue update research report stryker corporation syk free report company acquisition drive strategy be expect boost growth expand exist product offering business segment however challenge global economic condition supply side issue fluctuation foreign currency exchange rate strengthen dollar be likely dent top line growth term stryker currently carry zack rank hold stryker add almost last year much higher broader industry return stryker wide range product shield company significant sale shortfall economic downturn company pipeline include product hip knee mako robotic arm assist surgery fact solid performance mako robotic platform have be boost revenue long end last report third quarter stryker sell total robot continue update robot field total knee application stryker have be follow acquisition drive strategy boost inorganic growth profile recently company announce plan acquire france base vexim vexim portfolio be highly complementary interventional spine business stryker instrument division key product segment include extensive platform vertebral augmentation vertebroplasty radiofrequency ablation procedure september stryker complete buyout novadaq net purchase price boost visualization platform flipside stryker recently announce voluntary product recall oral care lineup sage product unit recall pertain cross contamination issue oral care solution be manufacture stryker sage unit third party supplier notably solution be distribute market july august foreign exchange fluctuation be expect affect net sale nominally adjust earning be expect be impact cent share net sale fourth quarter be expect be impact positively however stryker expect negative impact adjust net earning diluted share fourth quarter approximately cent share share price movement estimate revision trendstryker share price movement past year have be favorable company yielded return almost better broader industry current level be also higher return meanwhile company recent earning estimate have be impressive current quarter have see estimate go higher past day compare lower meanwhile full year estimate have see same time period have nominal impact consensus estimate consensus estimate current quarter rise past month full year estimate inched key picksa few better rank stock broader medical sector be petm express pet free report luminex corporation lmnx free report idexx laboratory idxx free report notably petm express sport zack rank strong buy company have long term expect earning growth rate see complete list today zack rank stock here luminex represent return last year stock have zack rank idexx laboratory have long term expect earning growth rate stock have climb year time have zack rank buy investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
547,IDXX,growth stock be most exciting pick market high flyer captivate investor attention produce big gain well however also lead downside growth story be so be important find company be still see strong growth prospect business such company be well position future earning growth be idexx laboratory inc idxx free report firm be medical instrument industry see ep growth last year be look great year too fact current growth estimate year call earning share growth furthermore long term growth rate be currently impressive suggest pretty good prospect long haul idexx laboratory inc price consensus idexx laboratory inc price consensus idexx laboratory inc wasn enough stock have actually see estimate rise past month current fiscal year thank rise earning estimate idxx have zack rank buy further underscore potential outperformance company see complete list today zack rank strong buy stock here so be look fast grow stock be still see plenty opportunity horizon make sure consider idxx not only do have double digit earning growth prospect impressive zack rank suggest analyst believe better day be ahead idxx well investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
548,IDXX,idexx laboratory inc idxx free report have be gain investor confidence consistently positive result stock have rally last year ahead gain broader industry rise moreover lead manufacturer product service primarily companion animal veterinary livestock poultry have market cap company year historical growth rate be also favorable compare industry solid prospect zack rank buy stock be attractive pick investor moment company estimate revision trend current year have be positive last day analyst revise estimate upward movement opposite direction estimate revision earning increase share same time frame style score idexx laboratory sport growth score be reflective company strong prospect research show stock growth style score combine zack rank strong buy offer best upside potential regard idexx laboratory have favorable net margin net income sale industry negative company sale asset ratio versus industry signify be solid growth pick let find recent positive trend be sustainable idexx exit fourth quarter promising note strong year year growth organic revenue be encourage stellar performance be drive strong sale cag business fourth quarter cag organic revenue rise low double digit strong cag diagnostic recur organic revenue growth vetlab consumable organic revenue growth be upbeat company expand premium instrument base unite state international market include growth competitive instrument placement increase utilization continue customer retention regard be optimistic gain commercial launch catalyst sdma test north america january company point care customer be able add sdma essential element routine chemistry panel continue slew development january idexx enter global agreement diagnostic company apply biocode agreement idexx bring reference laboratory customer digital multiplex platform build apply biocode management aim commercial launch technology companion animal market fundamental remain solid tremendous global runway growth management innovation base multus modality global strategy accelerate recur cag diagnostic revenue growth report quarter moreover strong top line growth quarter be drive considerable contribution rest business segment furthermore raise guidance earning share instill confidence stock be also upbeat company witness double digit organic revenue growth international business reflect continue consumable revenue gain support catalyst instrument base average testing utilization additionally company have strong cash balance allow carry share repurchase meanwhile idexx high reliance third party distributor be concern moreover competitive landscape domestic overseas market weigh company other key picksother top rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank see complete list today zack rank stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson company have zack rank company have long term expect earning growth rate hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
549,IDXX,company favorable efficiency level be likely be investor radar irrespective market condition price performance be believe be positively correlated efficiency efficiency company ability transform input output be potential indicator company financial health key ratio identify become difficult measure efficiency level company be reason consider popular efficiency ratio select stock efficiency ratio be inventory turnover ratio month cost good sell cog quarter average inventory be consider most popular efficiency ratio indicate company ability maintain suitable inventory position high value indicate company have relatively low level inventory compare cog low value indicate company be face decline sale result excess inventory receivables turnover be ratio month sale quarter average receivables show company potential extend credit collect debt term credit high receivables turnover ratio account receivable turnover ratio debtor turnover ratio be desirable show company be capable collect account receivables have quality customer asset utilization ratio indicate company capability convert asset output be thus widely know measure efficiency level be calculate divide total sale past month last quarter average total asset ratio high asset utilization indicate company be efficient operate margin efficiency measure be ratio operate income past month sale same period measure company ability control operate expense hence high value ratio indicate company manage operate expense more efficiently peer screening parametersin addition mentioned ratio have add favorable zack rank strong buy buy screen objective make strategy more profitable inventory turnover receivables turnover asset utilization operate margin greater industry average value ratio higher industry average indicate efficiency level company be higher peer use few criterium have narrow universe stock only here be stock make screen lululemon athletica lulu free report athletic apparel company together subsidiary design distribute retail athletic apparel accessory woman man female youth company have average quarter positive earning surprise stock have zack rank exelixis exel free report company engage discovery development new medicine potential enhance care outcome person cancer company have average quarter positive earning surprise stock carry zack rank idexx laboratory idxx free report develop manufacture distribute product service primarily companion animal veterinary livestock poultry dairy water testing market worldwide company have average quarter positive earning surprise stock have zack rank see complete list today zack rank stock here teradyne ter free report design develop manufacture sell support automatic test equipment worldwide company have average quarter positive earning surprise stock flaunt zack rank pioneer natural resource pxd free report operate independent oil gas exploration production company unite state company have average quarter positive earning surprise stock have zack rank get rest stock list signing now week free trial research wizard start used screen own trading further also create own strategy test first take investment plunge research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performancezack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
550,IDXX,second sight medical product inc eye free report be big mover last session company see share rise nearly day move come solid volume too far more share change hand normal session break recent trend company stock be now trading volatile price range past month time frame stock gain company announce key milestone achievement include first human implant orion record number argus ii retinal prosthesis system implant company expect momentum continue company have see change come estimate revision past few week zack consensus estimate current quarter have also remain unchanged recent price action be encourage so make sure keep close watch firm future second sight currently have zack rank hold earning esp be second sight medical product inc price second sight medical product inc price second sight medical product inc quotea better rank stock medical instrument industry be idexx laboratory inc idxx free report hold zack rank buy see complete list today zack rank strong buy stock here be eye go predict see other think stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
551,IDXX,feb issue update research report idexx laboratory inc idxx free report stock carry zack rank buy lead molecular diagnostic company have be trading broader industry stock have gain past month compare broader industry idexx exit fourth quarter solid note moreover strong year year growth organic revenue raise guidance earning share be encourage stellar performance be drive strong sale cag business fourth quarter cag organic revenue rise low double digit strong cag diagnostic recur organic revenue growth vetlab consumable organic revenue growth be upbeat company expand premium instrument base unite state international market include growth competitive instrument placement increase utilization continue customer retention companion animal market fundamental remain solid tremendous global runway growth management innovation base multus modality global strategy accelerate recur cag diagnostic revenue growth report quarter moreover strong top line growth quarter be drive considerable contribution rest business segment be also upbeat company witness double digit organic revenue growth international business reflect continue consumable revenue gain support catalyst instrument base average testing utilization additionally company have strong cash balance allow carry share repurchase meanwhile majority idexx consolidated revenue have be derive sale product international market thus strengthen rate exchange dollar relative other currency have negative impact revenue derive currency other dollar profit product manufacture unite state sell internationally also company high dependence third party distributor be concern other key picksother top rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report resm rmd free report bio rad laboratory have zack rank see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock have zack rank resm have long term expect earning growth rate stock carry zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
552,IDXX,idexx laboratory inc idxx free report report fourth quarter adjust earning share ep cent exclude negative impact cent share due tax reform adjust ep figure surpass zack consensus estimate cent report ep come cent full year report ep come share moreover report earning figure be comparable constant currency basis revenue detailrevenue rise year year organic basis surpass zack consensus estimate worldwide sale year come year year report basis figure also surpass zack consensus estimate year year upside be drive strong global gain companion animal group cag diagnostic recur revenue include double digit organic revenue gain consumable reference lab well strong acceptance rapid assay veterinary software service diagnostic imaging system idexx laboratory inc price consensus ep surprise idexx laboratory inc price consensus ep surprise idexx laboratory inc quote segmental analysisidexx derive revenue operate segment cag water livestock poultry dairy lpd other fourth quarter cag revenue rise organically year year water segment revenue be prior year quarter organically lpd revenue grow organically revenue other segment rise organically marginsgross profit increase report quarter however gross margin contract basis point bps rise cost revenue sale marketing expense rise general administrative expense increase research development expense rise operate margin quarter improve bps financial positionidexx exit fiscal cash cash equivalent end net cash provide operate activity be compare year period guidanceidexx raise revenue outlook previous reflect organic revenue growth expectation compare state previously zack consensus estimate revenue be peg guide range management also raise ep guidance earlier support continue operate margin expansion align long term goal update outlook represent ep growth report basis compare state previously zack consensus estimate ep be peg guide range takeidexx exit fourth quarter solid note moreover solid year year growth organic revenue raise ep guidance be encourage stellar performance be drive strong sale cag business companion animal market fundamental remain solid tremendous global runway growth management innovation base multus modality global strategy enabled enhance commercial capability accelerate recur cag diagnostic revenue growth moreover strong top line growth quarter be drive considerable contribution rest business segment zack rank other key picksidexx have zack rank buy few other top rank stock report solid result earning season be petm express pet free report perkinelmer pki free report accuray aray free report petm sport zack rank strong buy perkinelmer accuray carry zack rank see complete list today zack rank stock here petm report third quarter fiscal result adjust ep cent improve prior year quarter revenue rise year year basis perkinelmer report fourth quarter adjust ep cent adjust revenue be approximately year quarter accuray report loss cent share second quarter fiscal cent narrower year figure total revenue improve year year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
553,IDXX,latest tax reform plan have be landmark achievement president trump usual initial stage nation give mixed reaction controversial bill few american slam new plan job killer other find be excellent opportunity fix break tax code bill claim primarily focus ease tax wo middle class american massive cut corporate taxe tell different story altogether fact research report cnbc reveal frank clemente executive director american tax fairness slam new tax code big giveaway millionaire corporation neglect one be real need now be be see bill be fated meet overall failure get fulfill promise inclusive economic growth medtech be cut taxe wealthy take health care away million senate democratic minority leader chuck schumer customer base reduction corporate taxe encourage development expensive cut edge medtech product question profitability loom large be higher number uninsured lesser deduction healthcare cost industry be likely witness shrink customer base indicate decline demand expensive medical procedure device tax decision medtech device medtech community have be hopeful trump propose policy entail abolition infamous medical device sale tax such high taxe force company lay employee limit research development activity reduce capital investment furthermore advame lead american medical device trade association have refer medical device tax significant drag medical innovation notably small device company suffer most such worry repeal tax paradigm be expect resume aggressive pace hire investment america base medical device manufacturer instilling investor confidence stock datum provide medical device trade group ken blackwell article publish daily caller partial year repeal medtech tax have result roughly rise research development investment medtech player comeback tax lead rise taxe largely discourage activity undoubtedly future medtech industry depend republican decision medical device tax key picksper trump democrat have establish lousy healthcare model however complete medical device tax renovation be be widely believe new set streamline rule benefit medical device space meanwhile stock strong fundamental give assured return tax conundrum have zero stock sport zack rank strong buy buy boast strong fundamental notably stock promise long term expect earning growth rate more idexx laboratory inc idxx free report headquarter delaware nj idexx be developer manufacturer distributer product service primarily companion animal veterinary livestock poultry water testing dairy market company also sell series portable electrolyte blood gas analyzer human point care medical diagnostic market company continue demonstrate solid growth globally strong international expansion management innovation base global strategy be lead cag diagnostic growth notably idexx expand cloud technology portfolio addition rvetlink solid organic revenue growth raise guidance buoy optimism stock have long term expect earning growth rate idexx have zack rank last year idexx have add higher broader industry gain luminex corporation lmnx free report luminex develop manufacture market proprietary biological testing technology application life science diagnostic industry company open architecture multiplexing xmap multus analyte profile technology be sell worldwide be used lead research laboratory well major pharmaceutical diagnostic biotechnology company conduct biological test luminex assay business be likely be key growth driver long term company also witness favorable tiding regulatory front third quarter regard recent ce ivd mark ary norovirus assay fda approval ary assay reimbursement approval verigene assay japan be noteworthy luminex be verge complete clinical study group strep be close submit same fda review stock have long term expect earning growth rate luminex have zack rank last month luminex have return much higher broader industry see complete list today zack rank stock here masimo corporation masi free report irvine base masimo develop manufacture market family invasive monitoring system company flagship product signal extraction set pulse oximetry be used monitor blood oxygen saturation level protect hypoxemia hyperoxemia believe company expand product portfolio be key catalyst wider adoption invasive patient monitoring technology help company gain traction masimo set pulse oximetry business represent considerable growth opportunity international market moreover fda approval radius wearable regional oximetry device be significant positive masimo have zack rank promise long term expect earning growth rate last month masimo have return higher broader industry align technology inc algn free report base california align manufacture market system clear aligner therapy intra oral scanner cad cam computer aid design computer aid manufacturing digital service used dentistry orthodontic dental record storage be encourage company solid invisalign technology prospect growth north america internationally particularly asia pacific region strong summer season performance drive invisalign growth global market be also upbeat company signing distribution agreement patterson dental company receipt patent smarttrack invisalign aligner material buoy optimism well align have zack rank promise long term expect earning growth last month stock have return way higher broader industry cooper company inc coo free report cooper base pleasanton be specialty medical device company operate global basis company be poise gain expand product portfolio increase penetration international market accretive acquisition be also key catalyst long term company have be see strong growth coopervision business segment late notably segment bank myday clariti biofinity silicone hydrogel lense platform coopersurgical segment also deliver strong sale quarter strong guidance fiscal instill confidence stock cooper recently complete acquisition procornea add lead ortho technology cooper lens portfolio marked foray emerge myopia controlled market stock have zack rank expect earning growth rate last year stock have add much higher broader industry make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
554,IDXX,idexx laboratory inc idxx free report be expect beat earning report fourth quarter result feb open bell last quarter company deliver positive earning surprise be worth note idexx have outperformed zack consensus estimate precede quarters average be let take look thing be shape prior announcement key catalystsimilar prior quarter idexx be expect gain strong global growth companion animal group cag diagnostic recur revenue upside be drive double digit organic revenue gain consumable reference lab strong acceptance rapid assay veterinary software service diagnostic imaging system well continue expansion idexx premium instrument install base management expect solid performance reflect fourth quarter result well be also upbeat idexx enhance commercial capability unite state maintain recur revenue growth cag diagnostic management expect fourth quarter result show rise productivity new sale representative establish new customer relationship switch commission base compensation instrument placement also expect company report exceptional customer retention rate reference lab instrument consumable unite state worldwide fourth quarter zack consensus estimate cag diagnostic revenue reflect increase year quarter overall zack consensus estimate fourth quarter total revenue be project prior year quarter notably idexx expect revenue range reflect organic revenue growth idexx laboratory inc price ep surprise idexx laboratory inc price ep surprise idexx laboratory inc quote here be other factor influence idexx fourth quarter result be upbeat growth water business have be growth trajectory late encourage test result unite state benefit global go direct initiative moreover last report quarter business witness organic growth management be also look forward benefit favorable regulatory development pertain wastewater unite state drink water europe accordingly zack consensus estimate water revenue reflect increase year quarter idexx continue expand globally have be significantly benefitting bountiful opportunity companion animal diagnostic market emerge nation further management consistent share buyback reflect strong free cash flow reserve believe outcome endeavor be reflect fourth quarter performance management also estimate ep band support continue operate margin expansion align long term goal outlook represent year year ep growth report basis zack consensus estimate earning cent show increase year flip side foreign currency fluctuation be major headwind concern be company high reliance third party distributor purchasing dynamic distributor have significant impact company sale instrument consumable rapid assay product also idexx have be see rise operate expense owing increase head count higher investment portfolio development expansion unite state internationally also competitive landscape domestic overseas market weigh idexx performance struggle gain market traction prove be drag fourth quarter result here be quantitative model predict idexx have right combination main ingredient positive earning esp zack rank hold higher need increase odd earning beat zack esp earning esp idexx be uncover best stock buy sell re report earning esp filter zack rank idexx carry zack rank buy other stock worth lookhere be few other medical stock worth consider have right combination element post earning beat quarter bio rad laboratory bio free report have earning esp zack rank stron buy see complete list today zack rank stock here myriad genetic mygn free report have earning esp zack rank henry schein hsic free report have earning esp zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
555,IDXX,baxter international inc bax free report be currently top perform stock medtech space improvement price performance strong fundamental reflect stock bullish run therefore haven take advantage share price appreciation yet time add stock portfolio company have perform impressively have potential carry momentum upcoming period long term expect earning growth rate be positive attractive pick share price appreciationa glimpse company price trend reveal stock have have impressive run bourse year date baxter return whopping compare favorably index rally current return be also greater industry gain northward estimate revisionsnine estimate current year moved north past day versus southward revision reflect analyst optimism company same period zack consensus estimate adjust earning increase current year positive trend signify analyst bullish sentiment company hold zack rank buy indicate robust fundamental expectation outperformance term strong growth company zack consensus estimate earning reflect year year growth moreover earning be expect register growth zack consensus estimate revenue reflect year year improvement moreover revenue be expect witness growth baxter estimate sale growth approximately compound annual basis notably adjust operate margin full year be expect be approximately revenue previous guidance baxter expect full year adjust diluted earning band share positive earning surprise historybaxter have impressive earning surprise history company outpaced zack consensus estimate trail quarters deliver positive average earning surprise year have be favorable baxter regulatory front recently management confirm fda have grant new approval temporary importation certain drug facility canada mexico development baxter have operational site approve help address demand market further fda approval new premixed injectable be key catalyst baxter launch oxiris set continuous renal replacement therapy crrt sepsis management protocol select market europe middle east africa recently further recent launch devicevue comprehensive asset tracking solution available exclusively hospital bolster company product portfolio company operate life sustain critical care product category be cushion economic downturn baxter product be not commodity nature provide strong recur revenue base baxter have be experience burgeon demand dialyzer globe more person be inflict end stage renal disease esrd due grow incidence diabetes blood pressure other kidney related disease other picksother top rank stock broader medical sector be petm express pet free report luminex corporation lmnx free report idexx laboratory idxx free report petm express flaunt zack rank strong buy company have long term expect earning growth rate see complete list today zack rank stock here luminex have long term expect earning growth rate stock flaunt zack rank idexx laboratory have long term expect earning growth rate stock carry zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
556,IDXX,dec issue update research report intuitive surgical inc isrg free report grow adoption company da vinci system increase procedure volume strategic acquisition continuous innovation solid recur revenue base be key catalyst stock have zack rank hold intuitive surgical be manufacturer da vinci surgical system advanced robot assist surgical system related instrument accessory system enable minimally invasive surgery help avoid trauma associate open surgery last quarter intuitive surgical launch additional instrument accessory da vinci xi platform country notably company initiate limit launch refine vessel sealer europe quarter management announce plan file first fda approval da vinci sp program submission additional indication thereafter intuitive surgical have strong opportunity general surgery market particularly drive procedure hernia repair colorectal surgery internationally company have significant opportunity japan south korea china flip side foreign exchange movement be affect company result intuitive surgical generate major portion revenue domestic market continue investment international business be widening company exposure international market hence unfavorable foreign exchange be major concern further medical product space have be precarious game republican day courtesy president trump repeat failure repeal replace obamacare however major medtech player intuitive surgical have be pin hope trump promise abolish infamous medical device sale tax elimination be far be achieve regard let not forget massive chaos medtech space trigger failure first republican healthcare bill be propose summer so call american health care act ahca fail garner support house owing solid opposition conservative moderate lawmaker persistent uncertainty have give rise concern regard sustainability medtech company include intuitive surgical investor optimism have be grow thank president trump promise enactment new tax reform however market have not benefit due lack favorable development regulatory front notably tax have be suspend year be likely be put effect again jan share shine surgical price movement have be robust last month company represent solid return almost compare favorably industry rally just current level be bit lower index gain key picksa few better rank stock broader medical sector be petm express pet free report luminex corporation lmnx free report idexx laboratory idxx free report petm express flaunt zack rank strong buy company have long term expect earning growth rate see complete list today zack rank stock here luminex yielded return last year stock flaunt zack rank idexx laboratory have long term expect earning growth rate stock rise year time carry zack rank buy zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
557,IDXX,first trust water etf fiw free report be launch be passively manage exchange trade fund design offer broad exposure industrial water segment equity market excellent vehicle long term investor passively manage etfs be popular choice institutional retail investor due low cost transparency flexibility tax efficiency investor friendly sector etfs provide many option gain low risk diversify exposure broad group company particular sector industrial water be broad zack sector zack industry classification be currently rank place bottom index fund be sponsored first trust advisor have amassed asset make average size etfs attempt match performance industrial water segment equity market fiw seek match performance ise clean edge water index fee expense ise clean edge water index be modify market capitalization weight index comprise exchange list company derive substantial portion revenue potable wastewater industry costsexpense ratio be important factor return etf long term cheaper fund significantly outperform more expensive counterpart other thing remain same annual operate expense etf be make cheaper product space have month trail dividend yield sector exposure top holdingsit be important delve etf holding investing many upside kind fund diversify exposure minimize single stock risk most etfs be very transparent product disclose holding daily basis etf have heaviest allocation industrial sector portfolio utility healthcare round top look individual holding idexx laboratory inc idxx free report account total asset follow american water work company inc awk free report ecolab inc ecl free report top holding account total asset management performance riskyear date first trust water etf have add roughly so far be last month fiw have trade past week period etf have beta standard deviation trail year period make medium risk choice space holding have more concentrated exposure peer bottom lineto learn more product other etfs screen product match investment objective read article latest development etf investing universe please visit zack etf center
558,IDXX,medtronic plc mdt free report report second quarter fiscal adjust earning share ep beating zack consensus estimate earning however decline year year adjustment quarter primarily include impact restructure charge intangible asset amortization divestiture related item adverse effect hurricane marium acquisition related item adjust unfavorable foreign exchange impact penny adjust ep be adjustment company report ep be year year total revenue report quarter gross constant exchange rate cer basis report basis top line miss zack consensus estimate foreign currency fluctuation affected medtronic second quarter revenue quarter review sale total revenue decline year year develop market revenue totale total revenue reflect increase cer report emerge market revenue total revenue amount cer report medtronic plc price consensus ep surprise medtronic plc price consensus ep surprise medtronic plc quote segment company currently generate revenue major group viz cardiac vascular group cvg minimally invasive therapy group mitg restorative therapy group rtg diabetes group cvg comprise cardiac rhythm heart failure crhf coronary structural heart csh aortic peripheral vascular division apv mitg now include surgical innovation si respiratory renal rgr division divestiture patient care deep vein thrombosis compression nutritional insufficiency enteral fee business rtg comprise spine brain therapy specialty therapy pain therapy segment diabetes group incorporate intensive insulin management iim intensive diabetes therapy ndt diabetes service solution dss division cvg revenue improve cer report drive strong balanced growth division crhf sale totale year year cer report come back growth arrhythmia management lead high teen growth atrial fibrillation solution low double digit rise diagnostic cer amplify penetration micra transcatheter pace system strong uptake tyrx absorbable antibacterial envelope apart strong demand company suite quadripolar cardiac therapy pacemaker crt growth mechanical circulatory support drive heart failure division revenue csh revenue be cer report back high constant currency growth transcatheter aortic valf result strong customer uptake corevalve evolut pro platform moreover company recent launch resolute onyx drug eluting stent unite state japan revive coronary business apv revenue register growth cer report drive continue adoption valiant stent graft system strength heli fx endoanchor system peripheral be drive double digit growth percutaneous transluminal angioplasty drug coat balloon moreover recently launch concerto detachable coil system drive mid single digit growth endovenous mitg worldwide sale reach mark year year increase cer report basis mid single digit growth si be affected hurricane marium partially offset low single digit decline rgr rtg worldwide revenue be year year cer same report low double digit growth brain therapy offset decline spine specialty therapy pain therapy moreover spine pain therapy division pelvic health business specialty therapy division unite state be affected hurricane marium however revenue diabetes group decline cer flat report marginsgross margin report quarter expand basis point bps decline gross profit adjust operate margin contract bps year year owing rise research development expense uptick selling general administrative expense other expense report quarter totale compare year quarter reiterate fiscal constant currency revenue ep guidance company maintain full year revenue growth projection range cer however company revise foreign currency fluctuation estimation be now project have positive impact fiscal result compare estimate earlier zack consensus estimate revenue remain fiscal adjust earning share growth be still expect range cer currency translation be expect have adverse impact cent compare earlier expectation negative effect cent positive impact penny zack consensus estimate fiscal earning be peg third quarter fiscal medtronic expect currency translation have favorable impact revenue currency translation be expect contribute penny third quarter earning share takemedtronic exit fiscal second quarter mixed note company demonstrated improve segmental performance cer escalate cost expense continue weigh bottom line unfavorable currency translation also act dampener bright side major business group contribute solid top line growth cer highlighted sustainability group region addition display successful integration achievement synergy target be also encourage company solid growth trend unite state well healthy global acceptance advanced therapy apart product innovation company be focuse geographical diversification business moreover company recent receipt fda approval commercial launch azure pacemaker bluesync technology buoy optimism zack rank peer currently have zack rank sell few better rank stock broader medical sector be petm express pet free report luminex corporation lmnx free report idexx laboratory idxx free report notably petm express sport zack rank strong buy company have long term expect earning growth rate see complete list today zack rank stock here luminex represent return year stock have zack rank idexx laboratory have long term expect earning growth rate stock have climb year time have zack rank buy zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
559,IDXX,patterson company inc pdco free report report adjust earning cent share second quarter fiscal miss zack consensus estimate cent earning be also lower year figure cent hurricane hurt patterson company earning share approximately penny quarter net sale fall year quarter also miss zack consensus estimate adjust effect foreign currency exchange sale decline year year basis include negative impact approximately basis point bps hurricane patterson company have zack rank sell patterson company inc price consensus patterson company inc price consensus patterson company inc quote segmental analysisanimal health segment segment be lead distributor product service technology production companion animal health market north america come second quarter performance platform total sale sale increase almost constant currency cc year year basis companion animal sale decline production animal sale increase reflect strong performance segment especially swine business dental segment segment provide virtually complete range consumable dental product equipment software turnkey digital solution value add service dentist dental laboratory north america second quarter dental sale total sale decline cc year year approximately decline be lead decrease sale cerec digital technology product equipment sale dental segment fall consumable dental supply decrease however other service product primarily comprise technical service part labor software support service office supply increase share repurchase updatepatterson approximately share outstanding common stock report quarter company also paid cash dividend shareholder guidance company expect adjust earning share fiscal range way previously issue band patterson company expect deal amortization expense cent share company estimate integration business restructure expense cent share takepatterson company exit second quarter tepid note miss zack consensus estimate count furthermore downbeat guidance indicate loom concern lackluster performance dental segment be concern management expect headwind technology base equipment business persist fiscal however be upbeat company animal health segment witness strong sale last quarter patterson company provide wide range consumable supply equipment software value add service company broad spectrum product cushion economic downturn medtech space believe diversify product portfolio strong veterinary business prospect accretive acquisition strategic partnership be key growth catalyst stock considera few better rank stock broader medical sector be petm express pet free report luminex corporation lmnx free report idexx laboratory idxx free report notably petm express sport zack rank strong buy company have long term expect earning growth rate see complete list today zack rank stock here luminex represent return last year stock have zack rank idexx laboratory have long term expect earning growth rate stock have climb year time have zack rank buy zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
560,IDXX,accelerate diagnostic inc axdx free report be big mover last session company see share rise nearly day move come solid volume too far more share change hand normal session break recent trend company stock be now trading volatile price range past month time frame company have see negative estimate revision past few week zack consensus estimate current quarter have also moved lower past few week suggest be trouble road so make sure keep eye stock go forward see recent move higher last accelerate diagnostic currently have zack rank sell earning esp be positive accelerate diagnostic inc price accelerate diagnostic inc price accelerate diagnostic inc quotea better rank stock medical sector be idexx laboratory inc idxx free report currently carry zack rank buy see complete list today zack rank strong buy stock here be axdx go predict see other think downzack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
561,IDXX,astute investor be always lookout plan be likely yield high return regardless market circumstance efficiency level measure company capability transform available input output be often consider important parameter used gauge company potential rake handsome return company promising efficiency level be likely deliver stellar return be assume be positively correlated price performance measure efficiency have consider popular ratio order find efficient company have potential provide impressive return inventory level be key indicator company business health high inventory level indicate company be go rough patch term sale dwindle level indicate company run stock favorable sale condition be inventory turnover come play be ratio month cost good sell cog quarter average inventory thus high value ratio indicate low level inventory relative cog low ratio signal company have excess inventory receivables ratio be used measure company capability extend credit collect debt basis credit receivables turnover ratio account receivable turnover ratio debtor turnover ratio be calculate divide month sale quarter average receivables high ratio indicate company efficiently collect account receivables have quality customer low ratio signal company have inefficient collection procedure have low quality customer inefficient credit policy asset be widely used measure company efficiency asset utilization indicate company potential utilize asset be ratio total sale past month last quarter average total asset so higher ratio greater be chance company be utilize asset efficiently contrary low value ratio signal be fail use asset effectively operate marginanother popular efficiency ratio be operate margin operate profit margin be simply operate income past month divide sale same period indicate well company be control operate expense company have high operate profit margin relation competitor be do better job control operate expense ratio be consider effective measure compare different company particular sector industry be reason have consider only company have higher ratio respective industry average screening parametersin addition mentioned ratio have add favorable zack rank strong buy buy screen objective make strategy more profitable inventory turnover receivables turnover asset utilization operate margin greater industry average value ratio higher industry average indicate efficiency level company be higher peer zack rank better equal buy only zack rank strong buy buy rate stock get use few criterium have narrow universe stock only here be stock pass screen home depot inc hd free report operate home improvement retailer company have zack rank have average quarter positive earning surprise baxter international inc bax free report provide portfolio renal hospital product company operate segment hospital product renal company have zack rank have average quarter positive earning surprise idexx laboratory inc idxx free report develop manufacture distribute product service primarily companion animal veterinary livestock poultry dairy water testing market worldwide company have zack rank have average quarter positive earning surprise see complete list today zack rank stock here nvr inc nvr free report operate homebuilder unite state company have zack rank have average quarter positive earning surprise mam software group inc mam free report provide software information commerce related service business engage automotive aftermarket unite state canada ireland company have zack rank have average quarter positive earning surprise get rest stock list signing now week free trial research wizard start used screen own trading further also create own strategy test first take investment plunge research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performancezack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
562,IDXX,nov issue update research report davita healthcare partner inc dva free report company recently conclude third quarter mixed note slash guidance full year hint trouble road stock have zack rank sell hurricane harvey irma dealt heavy blow davita operate income third quarter company incur loss owing higher production cost approximately disruption bill process third quarter adjust operate earning cent share miss zack consensus estimate cent further earning decline year year basis management hurricane affected davita inorganic growth approximately basis point report quarter fourth quarter management davita expect hurricane impact revenue management tepid forecast full year add concern davita expect adjust consolidated operate income range lower previously issue range full year company expect adjust consolidated operate income band significantly lower previous guidance lower forecast fail instill confidence investor result decline share earning release yesterday close davita share price movement have be also unfavorable year date basis company have lose wider broader industry decline however davita announce plan restructure davita medical group elimination clinical position company expect result annualize saving be approximately year start stock considera few better rank stock broader medical sector be petm express pet free report luminex corporation lmnx free report idexx laboratory idxx free report notably petm express sport zack rank strong buy company have long term expect earning growth rate see complete list today zack rank stock here luminex represent return last year stock have zack rank idexx laboratory have long term expect earning growth rate stock have climb year time have zack rank buy hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
563,IDXX,headquarter delaware nj idexx laboratory inc idxx free report be developer manufacturer distributer product service primarily companion animal veterinary livestock poultry water testing dairy market company also sell series portable electrolyte blood gas analyzer human point care medical diagnostic market currently idexx have zack rank buy change follow mixed fourth quarter earning report whichha just release see complete list today zack rank strong buy stock here have highlighted key detail just release announcement earning current zack consensus estimate be peg cent share idexx fourth quarter report earning share come cent decrease year year moreover exclude negative impact cent share due tax reform cent share benefit other tax item adjust earning come cent adjust figure miss zack consensus estimate cent revenue idexx post revenue almost increase year year have beat zack consensus estimate revenue key stat business segment idexx deliver fourth quarter revenue cag water livestock poultry dairy lpd other segment major factor management growth business fourth quarter be majorly drive strength cag revenue segment furthermore premium instrument placement include year year increase catalyst placement report quarter have yielded solid return well idexx laboratory inc price ep surprise idexx laboratory inc price ep surprise idexx laboratory inc quote come guidance company have update revenue growth guidance report basis organic basis company raise full year adjust earning range stock price follow earning release share price do not show movement pre market trading session check back later full idexx earning report later wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
564,IDXX,headquarter delaware nj idexx laboratory inc idxx free report be developer manufacturer distributer product service primarily companion animal veterinary livestock poultry water testing dairy market company also sell series portable electrolyte blood gas analyzer human point care medical diagnostic market currently idexx have zack rank buy change follow mixed third quarter earning report whichha just release see complete list today zack rank strong buy stock here have highlighted key detail just release announcement earning current zack consensus estimate be peg cent share idexx third quarter earning share come cent increase year year report basis constant currency basis revenue idexx post revenue almost increase year year have miss zack consensus estimate revenue idexx laboratory inc price ep surprise idexx laboratory inc price ep surprise idexx laboratory inc quote key stat business segment idexx deliver third quarter revenue cag water livestock poultry dairy lpd other segment major factor management growth business third quarter be majorly drive strength cag revenue segment furthermore premium instrument placement include year year increase catalyst placement report quarter have yielded solid return well come guidance company have update revenue growth guidance report basis organic basis company expect full year adjust earning range stock price follow earning release share price do not show movement pre market trading session check back later full idexx earning report later wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
565,IDXX,investor be always look stock be poise beat earning season idexx laboratory inc idxx free report be such company firm have earning come pretty soon event be shape quite nicely report be idexx laboratory be see favorable earning estimate revision activity late be generally precursor earning beat analyst raise estimate right earning most date information possible be pretty good indicator favorable trend surface idxx report fact most accurate estimate current quarter be currently cent share idxx compare broader zack consensus estimate cent share suggest analyst have very recently bump estimate idxx give stock zack earning esp head earning season be important positive read zack earning esp have proven be very powerful produce positive surprise outperform market recent year backtest show stock have positive earning esp zack rank hold better show positive surprise nearly time have return average annual return see more top earning esp stock here give idxx have zack rank buy esp positive territory investor want consider stock ahead earning see complete list today zack rank strong buy stock here clearly recent earning estimate revision suggest good thing be ahead idexx laboratory beat be card upcoming report wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
566,IDXX,petm express inc pet free report announce earning share ep cent second quarter fiscal year quarter cent also earning surpass zack consensus estimate year year rise earning be drive increase sale improve margin net sale report quarter rise year year outpace zack consensus estimate petm express inc price consensus ep surprise petm express inc price consensus ep surprise petm express inc quote lead pet pharmacy americas upside sale be result increase new order reorder quarter report quarter reorder sale increase year year basis new order sale rise average order value be approximately quarter compare year quarter note variation average order value be mainly drive shift sale higher price item company seasonality business be mainly proportion flea tick heartworm medication product mix spring summer be consider peak season fall winter represent season quarter review petm acquire new customer year roughly order be generate versus prior year quarter gross margin expand basis point bps year year report quarter general administrative expense be year year also advertising expense rise lead increase adjust operate expense depreciation expense amount nevertheless adjust operate margin quarter rise bps year quarter petm exit fiscal second quarter cash cash equivalent compare end first quarter fiscal company also announce quarterly dividend cent share payable shareholder record nov takepetm successfully deliver yet quarter solid result fiscal second quarter company once again top zack consensus estimate revenue earning be also encourage note stellar increase reorder new order sale quarter company be also strive implement several strategy revitalize top line include increase focus advertising efficiency boost new order sale shift sale higher margin item also expand product offering petm currently offer wide range product cater dog cat horse work upgrading exist portfolio zack rank key pickspetm currently have zack rank hold few better rank stock medical sector be abbott free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report carry zack rank buy see complete list today zack rank strong buy stock here abbott have long term expect earning growth rate stock rally roughly last year idexx laboratory have long term expect earning growth rate stock surge last year thermo fisher have long term expect earning growth rate stock gain last year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
567,IDXX,expect idexx laboratory inc idxx free report beat expectation report third quarter result oct open bell last quarter company deliver positive earning surprise be worth note idexx have outperformed zack consensus estimate precede quarters average let take look thing be shape prior announcement key catalystsimilar prior quarter idexx be expect gain strong global growth companion animal group cag diagnostic recur revenue growth cag diagnostic be lead double digit organic revenue gain consumable reference lab rapid assay revenue well continue expansion idexx premium instrument install base be upbeat year year rise uptake snap pro unit north america last quarter management expect solid performance continue be report quarter well zack consensus estimate cag diagnostic revenue reflect increase year quarter here be other factor influence idexx third quarter result idexx laboratory inc price ep surprise idexx laboratory inc price ep surprise idexx laboratory inc quoteidexx expect livestock poultry dairy lpd business witness flat modest growth second half segment have be see continue strength china also expansion recur pregnancy testing franchise buoy optimism zack consensus estimate lpd business third quarter reflect increase year quarter company continue expand globally have be significantly benefitting bountiful opportunity companion animal market emerge nation further management consistent share buyback reflect strong free cash flow reserve believe outcome endeavor be reflect company third quarter performance encourage factor idexx expect revenue range reflect organic revenue growth expectation zack consensus estimate third quarter total revenue be project prior year also estimate ep guidance band share support continue operate margin expansion align long term goal outlook represent ep growth report basis zack consensus estimate earning reflect increase year quarter moreover management be upbeat rise sale force market other area third quarter flip side foreign currency fluctuation be major headwind concern company be high reliance third party distributor purchasing dynamic distributor have significant impact company sale instrument consumable rapid assay product also company be expose higher operate expense pertain increase head count higher investment target portfolio development geographic expansion unite state internationally also competitive landscape domestic overseas market weigh idexx performance struggle gain market traction prove be drag third quarter result here be quantitative model predict idexx do not have right combination main ingredient positive earning esp zack rank hold higher need increase odd earning beat zack esp earning esp idexx be uncover best stock buy sell re report earning esp filter zack rank idexx carry zack rank increase predictive power esp however also need have positive esp be confident positive earning surprise zack consensus estimate earning cent reflect improvement year year basis stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter cooper company inc coo free report have earning esp zack rank buy see complete list today zack rank strong buy stock here thermo fisher scientific inc tmo free report have earning esp zack rank align technology inc algn free report have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
568,IDXX,america have best doctor best nurse best hospital best medical technology best medical breakthrough medicine world rep bill fristin term market size health care market be largest world report health access suggest america unparalleled purchasing power massive demand medical service equipment opportunity innovation have lend competitive edge further market get boost president donald trump ardent proponent live big live large come power constant effort boost american lifestyle focus middle class incorporate best health care america have be create stir trump effort eliminate country jobless stature be remarkable report unemployment rate be peg november lowest february undoubtedly trump america first pitch have be drive employment growth never factor drive medtech increase consolidation latest trend increase consolidation healthcare space have lead reduction number player greater market concentration reduce competition well increase barrier entry industry company benefit higher market cap put position negotiate supplier consumer recent deal aetna inc aet free report cvs health cvs free report be significant example qualify vertical integration enable newly form entity sell range service product drug insurance cover president trump focus emerge marketsper recent bcg report share emerge market revenue be less quarter medtech global revenue be likely increase nearly third thus unite state trade plan emerge country be likely favor domestic company regard investor find president trump day asia trip last month interesting visit be aim boost country trade relation particularly emerge nation trump promise augment bilateral trade agreement indo pacific nation instill confidence apac policy also emphasize free open indo pacific trade focus nation japan australia india ivd pbm market thrive research report evaluatemedtech world preview indicate global medtech sale be expect witness cagr ivd diagnosis rake annual sale cagr increase investment government private player form reimbursement coverage speedy patent approval be drive demand role pharmacy benefit manager pbm healthcare sector have be evolve pbms manage pharmaceutical spending enhance health benefit end user report market research report biz global pbm market see cagr investing pbm stock be prudent move register solid gain look best stock be first see top stock portfolio here robot base application boost medtechthe ai base application have be enhance healthcare space clinical application diagnostic support operational efficiency electronic health record system practice workflow supply chain management grow prevalence minimally invasive robot assist surgery self automate home base care use quick improve patient care shift payment system value base model example medtech major intuitive surgical design manufacture market da vinci surgical system advanced robot assist surgical platform ai platform enable minimally invasive surgery help avoid trauma associate open surgery company plan expand usage da vinci general thoracic surgery colorectal surgery hernia repair day come pick right stocksbased certain parameter have select medtech growth stock be poise impressive return stock carry solid zack rank strong buy buy growth style score note growth style score encompass essential metric company financial statement get true sense quality sustainability growth research show stock growth style score combine zack rank offer best investment opportunity growth investing space growth pickscheme corp che free report stock have zack rank growth score zack consensus estimate cheme sale be peg next year reflect growth year year basis stock have market cap long term expect earning growth rate cheme raise guidance banking roto rooter business strength buoy optimism moment roto rooter be currently nation lead provider plumbing drain clean service network company own branch independent contractor franchise roto rooter offer plumbing drain clean service population cheme corp price consensus cheme corp price consensus cheme corp quote athenahealth inc athn free report stock flaunt zack rank growth score zack consensus estimate athenahealth sale be peg signify growth year year basis stock have market cap long term expect earning growth rate moment athenahealth strong product portfolio solid network expansion strategy unique business model be key tailwind athenahealth portfolio comprise wide array product include electronic health record revenue cycle management medical bill patient engagement care coordination population health management epocrate notably company launch athenainsight online news hub report healthcare activity trend healthcare provider identify patient athenahealth inc price consensus athenahealth inc price consensus athenahealth inc quote align technology inc algn free report stock have zack rank growth score zack consensus estimate align technology sale be peg next year signify growth year year basis stock have market cap long term expect earning growth rate now align technology consistent effort boost product development balanced growth channel focus international market bolster confidence stock be encourage company strong invisalign technology prospect growth north america international region be also upbeat company signing distribution agreement patterson company recently align technology inc price consensus align technology inc price consensus align technology inc quote idexx laboratory inc idxx free report stock have zack rank growth score zack consensus estimate idexx laboratory sale peg next year reflect growth year year basis stock have market cap long term expect earning growth rate idexx laboratory continue depict solid growth globally strong international expansion management innovation base global strategy be lead cag diagnostic growth notably idexx widen cloud technology portfolio add rvetlink solid organic revenue growth raise guidance buoy optimism idexx laboratory inc price consensus idexx laboratory inc price consensus idexx laboratory inc quotestraumann hold ag stock have zack rank growth score zack consensus estimate straumann hold sale peg next year signify growth year year basis stock have market cap long term expect earning growth rate now see complete list today zack rank stock here straumann hold be global leader implant restorative dentistry oral tissue regeneration company collaborate lead clinic research institutes university research develop manufacture dental implant instrument prosthetic tissue regeneration product use tooth replacement restoration solution prevent tooth loss straumann hold ag price consensus straumann hold ag price consensus straumann hold ag quotepra health science inc prah free report stock have zack rank growth score zack consensus estimate straumann hold sale be peg next year signify growth year year basis stock have market cap long term expect earning growth rate now company operate global contract research organization provide outsourced clinical development service biotechnology pharmaceutical industry offer therapeutic service area cardio metabolic biosimilar infectious disease immunology neurology psychiatry oncology hematology rare disease respiratory need pra health science inc price consensus pra health science inc price consensus pra health science inc quote medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
569,IDXX,ecolab inc ecl free report techstar world largest private agricultural company recently announce launch accelerator program minnesota program be call farm fork accelerator month program aim integrate innovative idea other company be focuse agriculture food base digital technology food process food safety notably high potential company be select program receive monetary investment mentoring ecolab expert next year company also leverage techstar global network notably application process program open january program begin july market global population have quadruple century report world require more food current period farm fork accelerator enable company upgrade technology meet grow demand factor include climate change urbanization lack investment production have be major concern food company program introduce ecolab techstar be expect improve current situation ecolab inc price ecolab inc price ecolab inc quote acquisition latest development closely follow ecolab acquisition scotland base arpal group arpal provide clean sanitizing product service unite kingdom middle east medtech major announce acquisition pest service company provide specialize service food storage transaction be worth be close dec acquire company be food protection service llc royal pest solution inc research company llc development expand ecolab pest elimination solution food beverage industry september company sign agreement acquire paper chemical business georgia pacific deal enhance ecolab position grow tissue towel well packaging board segment paper industry price performanceyear date ecolab stock have trade industry company have return almost compare industry rally ecolab continue witness improvement underlie sale volume pricing most business segment robust product portfolio launch expand customer base be likely drive organic sale realization target synergy associate acquisition expand margin further solid performance company global institutional segment be positive sale increase segment last quarter courtesy strong growth specialty healthcare business line zack rank key stock have zack rank hold few better rank stock broader medical sector be petm express pet free report luminex corporation lmnx free report idexx laboratory idxx free report notably petm express flaunt zack rank strong buy company have long term expect earning growth rate see complete list today zack rank stock here luminex yielded return last year stock sport zack rank idexx laboratory have long term expect earning growth rate stock rise year time carry zack rank buy zack editor chief go stock full disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
570,IDXX,medical device company be regard globally innovation company have competitive advantage player other industry courtesy big datum analytic biotechnology software development medical device fraternity be likely gain recent deferral medical device tax company plan hike spending provide competitive edge long haul article emergo industry be project attain masimo corp masi free report steris plc ste free report be close contender medical instrument space notably stock carry zack rank buy see complete list today zack rank strong buy stock here masimo have growth score same steris be instill investor optimism stock research show stock growth score combine zack rank be profitable pick here make detailed analysis company fundamental determine be currently better position market cap masimo develop manufacture market family invasive monitoring system base ohio steris develop manufacture andmarket infection prevention well assurgical support product service factor drive stocksmasimo have strong international presence recently california base company technology be integrate uae ministry health prevention mohap hospital raise guidance also buoy optimism steris focus inorganic expansion have be positive company acquisition base outsourced sterilization service provider synergy health plc be significant move november company sell synergy health healthcare consumable solution hcs business vernacare price performancein past year steris share have gain significantly masimo rise medical instrument industry have decline same time frame estimate zack consensus estimate masimo current year earning share be peg reflect growth previous year same steris be project indicate growth masimo corporation price consensus masimo corporation price consensus masimo corporation zack consensus estimate masimo current year revenue be peg show growth previous year steris be expect reflect growth steris plc price consensus steris plc price consensus steris plc quotethus masimo have competitive advantage steris consider current year earning revenue estimate fundamental growth storysince masimo revenue totale cagr company earning reach cagr same period steris sale amount cagr company earning have increase cagr here too masimo beat steris conclusionour comparative analysis indicate masimo be position better steris consider current year projection fundamental want more industry few other top rank stock themedical instrument space be integer holding corporation itgr free report idexx laboratory inc idxx free report integer holding carry zack rank company have stable foothold cardiac neuromodulation space medical power solution market idexx carry zack rank company have be gain solid performance core companion animal group segment today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
571,IDXX,president trump latest tax bill repeal significant part affordable care act be again reject house republican nov accord washington post article only modest change be make legislation president aim give bill final attempt stress importance tax cut reform economic growth vote tax cut bill slate nov let see medtech industry be gear accord report business insider republican tax plan repeal itemize deduction apply healthcare expense new bill get implement family high healthcare expenditure be impact expense longer be deduct taxe hence mass longer be interested expensive healthcare medtech procedure report hill say section republican tax bill plan impose excise tax good manufacture overseas subsidiary company tax code puerto rico be consider foreign land imply parent company have pay excise taxe purchase subsidiary island regard fda recently find puerto rico gross domestic product be drive pharmaceutical medical device undoubtedly latest tax plan have create uproar medtech player witness huge reduction turnover approval bill doubt latest political development have result widespread volatility medtech space growth stock focusin such tumultuous scenario have used zack stock screener pick stock significant gain let take look medtech stock be expect gain long haul apart flaunt strong zack rank strong buy buy stock boast growth style score growth style score highlight vital metric company financial obtain clearer picture quality sustainability growth research show stock style score combine zack rank offer best investment opportunity idexx laboratory inc idxx free report be lead provider diagnostic detection information product animal health industry well quality assurance product service food water industry zack rank company have long term expect earning growth rate growth score stock project ep growth rate year stand compare broader industry estimate stock have gain last year higher broader industry company have vgm score anda growth score see complete list today zack rank stock here vwr corporation be global laboratory supply distribution company company carry zack rank vgm score project sale growth rate year stand compare broader industry projection stock have gain last year better broader industry seaspine holding corporation spne free report be medical technology company focuse design development surgical solution treatment spinal disorder company boast zack rank stock have growth score vgm score have gain last year compare broader industry project ep growth rate year stand compare broader industry livanova plc livn free report be medical technology company focus provide treatment cardiovascular disease neuromodulation zack rank stock promise long term expect earning growth notably livanova have growth score vgm score stock have gain last year higher broader industry gain today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
572,IDXX,fourth quarter earning season be gain momentum participant have already release financial number jan latest earning preview report cycle be encourage start average proportion company edge past top bottom line expectation total earning member have improve increase revenue result roughly member slate be announce week zack datum estimate period be gradually trend upward board zack sector medical bracket be expect witness earning rise fourth quarter revenue growth projection store medical device industry medical device space broader medical sector somewhat display mixed bag sort part tax overhaul corporate tax rate have be slash previous thus lend huge relief medtech mammoth however ahead industry fourth quarter earning release section analyst expect new tax law negatively impact industry due possible cut overall medicare spending certain criterium be not fulfilled specific date congressional budget office apprehend absence alternative meet fiscal deficit huge tax reduction automatic cut back worth include medicare cut mandatory budget spending be trigger tax reform related concern news congress delay medical device tax year come huge boost industry player investor tax be earlier delay congress couple year deferral once again largely propel activity space let take sneak peek performance major medical device company wait report earning feb boston scientific corporation bsx free report be optimistic company gradually improve performance interventional cardiology lead innovative portfolio robust commercial team globally more specifically watchman platform be expect experience excellent quarter consistent global momentum boston scientific multiple market development effort continue push growth company have positive earning esp zack rank hold favorable zack esp indicate likely positive surprise bullish zack rank strong buy buy increase predictive power esp conversely sell rate stock never be consider go earning announcement especially company be see negative estimate revision read more watchman boost boston scientific earning boston scientific corporation price ep surprise boston scientific corporation price ep surprise boston scientific corporation quotebaxter international inc bax free report fourth quarter baxter international be anticipate gain strong hospital product drive solid sale fluid system business well robust demand injectable pharmaceutical hospital product segment expect fluid system maintain momentum evident zack consensus estimate be report quarter reflect improvement year period banking solid prospect quantitative model also show beat company give combination zack rank earning esp uncover best stock buy sell re report earning esp filter read more baxter beat earning hospital product baxter international inc price ep surprise baxter international inc price ep surprise baxter international inc quotemckesson corporation mck free report major player pharmaceutical medical supply distribution market expect witness solid performance canadian business third quarter fiscal also mckesson specialty health unit be likely drive company top line same time frame unit be likely benefit close intrafusion acquisition recent bdi pharma buyout be unable conclude mckesson be likely beat earning quarter stock carry zack rank increase predictive power esp earning esp however need have positive esp be confident earning surprise see complete list today zack rank stock here read more mckesson report earning beat card mckesson corporation price ep surprise mckesson corporation price ep surprise mckesson corporation quoteedward lifescience corporation ew free report lead cardiovascular product maker be expect grow robust transcatheter heart valve therapy segment fourth quarter back continue therapy adoption geography notable strength unite state company be likely retain bullish run period be report edward lifescience be zack rank player have earning esp positive zack esp denote likely earning surprise favorable zack rank company raise predictive power esp read more edward lifescience thvt likely drive earning edward lifescience corporation price ep surprise edward lifescience corporation price ep surprise edward lifescience corporation quoteidexx laboratory inc idxx free report repeating precede quarter success idexx be estimate gain strong global footprint companion animal group diagnostic recur revenue fourth quarter be also upbeat idexx enhance commercial capability unite state maintain recur revenue growth cag diagnostic company be rank player have earning esp therefore be unable conclude idexx be likely beat earning quarter however idexx trail month average beat be read more idexx post beat earning cag strength idexx laboratory inc price ep surprise idexx laboratory inc price ep surprise idexx laboratory inc hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
573,IDXX,abbott lab free report report third quarter adjust earning continue operation cent share ahead zack consensus estimate penny year year adjust quarterly number also remain upper end company guidance range cent cent report earning quarter come cent share compare year loss cent share third quarter worldwide sale come year year report basis quarterly figure also remain slightly ahead zack consensus estimate abbott laboratory price consensus ep surprise abbott laboratory price consensus ep surprise chart abbott laboratory quoteon comparable operational basis adjust impact foreign exchange certain acquisition divestment sale increase year year report quarter quarter detailabbott operate segment establish pharmaceutical division epd medical device nutrition diagnostic epd sale be report basis comparable operational basis be positive impact back currency fluctuation sale key emerge market increase drive double digit growth brazil russia india china expect sale india be positively impact purchasing pattern follow implementation new good service tax system lower second quarter sale country medical device business sale spiked report basis comparable operational basis sale increase cardiovascular neuromodulation sale soar report basis comparable operational basis double digit growth structural heart heart failure neuromodulation vascular product sale growth however be sluggish comparable operational basis rhythm management company register loss comparable operational basis sale be impact continue competitive dynamic magnetic resonance mr conditional category product diabetes care sale improve comparable operational basis drive double digit international sale growth lead continue consumer uptake freestyle libre revolutionary continuous glucose monitoring system abbott nutrition sale be year year report basis same comparable operational basis foreign exchange favorably affected sale marginal pediatric nutrition sale increase comparable operational basis adult nutrition sale be comparable operational basis diagnostic sale rise year year report basis comparable operational basis core laboratory point care diagnostic sale grow comparable operational basis molecular diagnostic sale be strong growth infectious disease testing business be partially offset plan scale genetic business guidanceabbott have narrow full year guidance adjust certain net specify item full year adjust earning share continue operation be now expect stay band earlier guidance be current zack consensus estimate be peg midpoint project range company have also provide fourth quarter adjust earning share guidance expect report adjust earning continue operation range cent cent quarter current zack consensus estimate cent fall midpoint project range takeone more time abbott have successfully exceed zack consensus estimate earning sale front be optimistic company strong consistent epd medical device performance however strong performance be extent offset sluggish nutrition business company continue benefit recently complete acquisition st jude medical have start offer industry lead pipeline cardiovascular neuromodulation diabetes vision care company be effectively execute exist operate model focus selling portfolio core therapeutic area also emerge market performance remain extremely promising several new strategic development abbott currently carry zack rank buy stock considera few other top rank stock medical sector be integra lifescience holding corp iart free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report integra lifescience sport zack rank strong buy idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank strong buy stock here integra lifescience have long term expect earning growth rate stock rally roughly last month idexx laboratory have long term expect earning growth rate stock gain last year thermo fisher have long term expect earning growth rate stock gain last year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
574,IDXX,oct issue update research report phibro animal health corporation pahc free report nj base company be lead global diversify animal health mineral nutrition company last month phibro have be trading broader industry currently stock have gain compare broader industry animal health be key contributor deliver positive growth last few quarters accord phibro animal health product be excellent prevent control treat disease animal well improve nutrition improve health believe diverse portfolio allow company address distinct grow condition livestock different region world outside unite state phibro have extend reach brazil other country south america china india asia pacific russia africa feel help company counter competition company continue invest far east asia poultry dairy industry be expect grow exponentially currently company be expand dairy business market australia brazil mexico believe turmoil economy russia greece brazil china phibro have perform quite well have potential maintain performance flip side phibro operate highly competitive industry respect major product face threat substantial number global regional player furthermore withdrawal approval mecadox carbadox fda be concern additionally phibro conduct operation globally entail transaction variety currency result currency fluctuation be major issue company zack rank key picksphibro carry zack rank hold few better rank stock medical sector be abbott free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report abbott idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank strong buy stock here abbott have long term expect earning growth rate stock rally roughly last year idexx laboratory have long term expect earning growth rate stock gain last year thermo fisher have long term expect earning growth rate stock gain last year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
575,IDXX,henry schein medical subsidiary henry schein inc hsic free report announce exclusive distribution agreement terason distribute latter usmart nexgen development remain part henry schein medical emergency medical service em business terason division teratech corporation be manufacturer portable ultrasound machine usmart be portable ultrasound device allow emergency responder carry exam emergency medical transport vehicle aircraft reduce need speculate em professional usmart nexgen be portable light weight ultrasound tablet easy transport operate terason usmart feature many advanced feature include customize preset fast boot grab go portability wi fi capability responder recognize issue point care transportation also alert emergency room staff important vital usmart accord company access patient vital help emergency responder make more inform decision treatment also help emergency room staff prepare ahead patient arrival henry schein be consistently work boost medical segment notably worldwide medical revenue rise year year last report second quarter henry schein medical recently inked agreement cerebral assessment system cas distribute cognivue be first computerize cognitive assessment screening device clear fda detection early sign dementia moreover henry schein announce partnership simplifeye create mobile platform health care provider use practice management electronic health record software micromd accord report market market ultrasound market be expect reach value cagr consider substantial potential market believe latest development be strategic past year henry schein have underperform broader industry stock have gain compare gain broader industry estimate revision estimate revision trend have be favorable company current quarter estimate moved north compare movement opposite direction last month result zack consensus estimate current quarter earning share have increase cent cent zack rank key pickshenry schein have zack rank hold few better rank stock medical sector be abbott free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report abbott idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank strong buy stock here abbott have long term expect earning growth rate stock rally roughly last year idexx laboratory have long term expect earning growth rate stock gain last year thermo fisher have long term expect earning growth rate stock gain last year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
576,IDXX,thermo fisher scientific inc tmo free report have be gain investor confidence consistently positive result stock have rally last month ahead gain broader industry rise moreover massachusett base medical instrument manufacturer have market cap company year historical growth rate be favorable compare industry solid prospect zack rank buy stock be attractive pick investor moment company have impressive earning surprise history have surpass zack consensus estimate trail quarters average beat company estimate revision trend current year have be positive last day analyst revise estimate upward movement opposite direction magnitude estimate revision earning increase share same time frame let find recent positive trend be sustainable company have be steadily add capacity enhance exist one acquisition regard acquisition fei have already start generate synergy contribute largely company analytical instrument portfolio have turn boost market optimism surround stock moreover be look forward company latest patheon buyout thermo fisher forayed high potential contract development manufacturing organization cdmo space moreover company plan continue strengthen foothold emerge market such china india translate success other high priority opportunity region such south korea russia brazil second quarter company record solid contribution china india middle east be also upbeat company recent open center excellence electron microscopy saudi arabia additionally company have strong cash balance enable carry share repurchase program turn provide solid return investor moreover believe company strong cash balance enable carry strategy inorganic expansion flip side thermo fisher derive majority revenue international market expose fluctuation foreign currency management currently estimate unfavorable foreign exchange have negative impact top line also tough competitive landscape continue challenge company other key picksother top rank stock medical sector be abbott free report idexx laboratory inc idxx free report integra lifescience holding corporation iart free report abbott idexx laboratory thermo fisher carry zack rank see complete list today zack rank strong buy stock here abbott have long term expect earning growth rate stock rally roughly last year idexx laboratory have long term expect earning growth rate stock gain last year integra lifescience have long term expect earning growth rate stock gain last year trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
577,IDXX,oct issue update research report abbott free report global healthcare company dedicate improve life development product technology stock carry zack rank hold last month abbott have be trading broader industry stock have gain industry decline market be upbeat several new initiative adopt abbott latest buyout company be alere oct abbott have also announce receipt fda approval freestyle libre flash glucose monitoring system unite state moreover company announce receipt fda approval magnetic resonance mr conditional labele ellipse implantable cardioverter defibrillator icd apart fda approval buyout be upbeat abbott freestyle libre flash glucose monitoring system prospect post receipt full partial reimbursement french health ministry platform company announce health canada license freestyle libre june abbott also announce freestyle libre system be now available reimbursement flip side abbott sluggish pediatric business china continue mar growth management be concern economic problem venezuela be expect remain unresolved time also foreign exchange be major headwind abbott considerable portion revenue come outside unite state key stocksa few better rank stock medical sector be qiagen qgen free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report qiagen idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank strong buy stock here qiagen have long term expect earning growth rate stock rally roughly last year idexx laboratory have long term expect earning growth rate stock gain last year thermo fisher have long term expect earning growth rate stock gain last year stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
578,IDXX,integra lifescience holding corporation iart free report develop manufacture market medical device implant biomaterial primarily used treatment burn skin defect spinal cranial disorder orthopedic other surgical application company have rally last month better gain broader industry stock have market cap company year historical growth rate be also favorable compare index solid prospect zack rank buy stock be attractive pick present let find recent positive trend be sustainable integra lifescience have positive earning surprise last quarters also have long term expect earning growth rate market be upbeat integra lifescience latest development most recent be launch collagen matrix revize revize plastic reconstructive surgery expand tissue technology portfolio also follow ce mark approval integra lifescience recently announce launch mesh acellular dermal tissue matrix adm surgimend prs mesh pre sub pectoral breast reconstruction europe moreover integra lifescience have finally complete codman neurosurgery business acquisition johnson johnson expand neurosurgery business latest development indicate company have capability sustain momentum other key picksother top rank stock medical sector be abbott free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report abbott idexx laboratory thermo fisher carry zack rank see complete list today zack rank strong buy stock here abbott have long term expect earning growth rate stock rally roughly last year idexx laboratory have long term expect earning growth rate stock gain last year thermo fisher have long term expect earning growth rate stock gain last year trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
579,IDXX,transenterix inc trxc free report announce receipt fda clearance senhance surgical robotic system senhance be multiport surgical robotic system help perform minimally invasive surgery be first fda approve entrant field abdominal surgical robotic development be go fortify transenterix medical device robotic segment business accord company senhance surgical robotic system help surgeon direct small surgical instrument camera robotic precision also offer security haptic feedback eye sense camera control first time robotic surgery platform minimize procedural cost senhance enable hospital surgeon leverage technology investment operate room ecosystem system make robotic surgery cost effective procedure basis used fully reusable instrument recently transenterix sell senhance robotic surgery system japanese customer be sell saitama medical university international medical center locate saitama prefecture greater tokyo region moreover system get install imperial college london notably senhance be ce marked use general gynecology urology thoracic surgery accord report market market minimally invasive surgical instrument market be forecast reach value cagr consider substantial potential market believe latest development be strategic transenterix share have outperformed industry past month stock have sky-rocket compare industry gain same period current level be better return estimate revision trend estimate revision trend have be favorable company current year estimate moved north compare movement opposite direction last month result zack consensus estimate current year have narrow loss cent share loss cent zack rank key have zack rank hold few better rank stock medical sector be abbott free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report abbott idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank strong buy stock here abbott have long term expect earning growth rate stock rally roughly last year idexx laboratory have long term expect earning growth rate stock gain last year thermo fisher have long term expect earning growth rate stock gain last year trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
580,IDXX,oct issue update research report henry schein inc hsic free report lead distributor health care product service globe company carry zack rank hold term price return performance past month stock remain line broader industry expect trend improve balanced growth operate segment henry schein be also encourage company effort grow internationally apart north america europe have presence australia new well emerge nation china brazil israel czech republic poland also company continue ride high dental business majorly accretive strategic merger integration colossal merger field be poland base dental cremer henry schein animal health revenue growth have be consistently support niche acquisition begin company have make foray brazilian animal health market investment tecnew same time company announce decision acquire southern sas turn benefit dental business controlled controlled pharmaceutical well surgical supply also henry schein gain several trend end market customer demographic increase number life cover follow healthcare reform unite state be likely boost company additionally henry schein gain traction animal health business back tailwind north america well overseas market burgeon demand animal health product unite state further drive company growth flip side escalate cost expense continue be drag company margin bottom line tough competitive landscape pricing pressure also weigh henry schein stock key better rank stock medical sector be qiagen qgen free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report carry zack rank buy see complete list today zack rank strong buy stock here qiagen have long term expect earning growth rate stock have rally roughly last year idexx laboratory have long term expect earning growth rate stock have surge last year thermo fisher have long term expect earning growth rate stock have gain last year stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
581,IDXX,nuvasive inc nuva free report have be news late receipt expand fda approval advanced magnetic invasive limb lengthen technology precice fall nuvasive specialize orthopedic nso precice now be used treat open close fracture fixation pseudoarthrosis malunion nonunion bone transport notably product be earlier allow use limb lengthen procedure elongate femur tibia approval be expect considerably drive nuvasive customer base precice platform comprise intramedullary device be implanted used external remote controller order invasively compress distract long bone company key precice platform be magnetic interaction external remote control precice intramedullary nail notably nso operate wholly own subsidiary nuvasive acquisition ellipse technology nuvasive continue gain share nso portfolio include magnetic external control magec early onset scoliosis precice technology build magec technology platform latest development nuvasive expect gain traction fast grow limb reconstruction trauma market report ally market research publish ortho spine news global extremity reconstruction market substantiate view report global extremity reconstruction market be expect reach value cagr believe unhealthy lifestyle result several joint disorder rapidly agee population rise awareness technological advancement increase spending healthcare government individual continue drive limb reconstruction trauma market thus nuvasive latest fda approval likely help cash bountiful opportunity niche market share price have be trading broader industry last stock have lose comparison broader industry decline believe latest development help company boost investor sentiment reverse downtrend zack rank key picksnuvasive currently carry zack rank sell few better rank stock medical sector be qiagen qgen free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report qiagen idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank strong buy stock here qiagen have long term expect earning growth rate stock rally roughly last year idexx laboratory have long term expect earning growth rate stock gain last year thermo fisher have long term expect earning growth rate stock gain last year stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
582,IDXX,major setback company investor medtronic mdt free report recently foresee significant impact hurricane marium second quarter fiscal sale have acquire category status hurricane marium have be place top most intense atlantic hurricane record thus hit company business puerto rico quite hard add wo company have level manufacturing setup business group viz cardiac vascular group cvg minimally invasive therapy group mitg restorative therapy group rtg diabetes group puerto rico facility be gradually get operative oct site be only partially active present power supply back generator considerable repair do company expect normal manufacturing process get fully restore come week financial have provide statement company financial health badly hurt marium further affect overall business notably line business continuity protocol company be utilize exist inventory level increase manufacturing process location outside puerto rico multiple product medtronic project fiscal second quarter revenue adjust net earning show impact extent more specifically mitg rtg group be expect be worst hit notably quarter close oct significantly company forecast recur expense directly related recovery effort puerto rico be exclude adjust earning however expense related effect outside puerto rico be consider operate expense incidentally medtronic be lack enough visibility impact marium post second quarter however forecasting strong new product demand particularly cvg diabetes group company continue expect mid single digit revenue growth comparable constant currency basis second half fiscal marium related impact company reaffirm fiscal second quarter full year fiscal guidance company many support disaster management medtronic foundation have direct disaster relief date be match employee contribution authorize agency price performance last month medtronic have be observed underperform broader industry stock have decline versus broader industry gain period sad true gloomy scenario be likely continue company latest financial prediction due marium zack rank key picksmedtronic currently carry zack rank sell few better rank stock medical sector be orthofix international ofix free report thermo fisher scientific inc tmo free report idexx laboratory inc idxx free report orthofix international sport zack rank strong buy idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank stock here orthofix international have long term expect earning growth rate stock have rally roughly last month thermo fisher have long term expect earning growth rate stock have gain last year idexx laboratory have long term expect earning growth rate stock have surge last year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
583,IDXX,idexx laboratory inc idxx free report record third quarter earning share ep cent same constant exchange rate cer year year report basis further report figure surpass zack consensus estimate cent strong top line growth third quarter drive earning revenue detailidexx third quarter revenue rise year year organic basis however miss zack consensus estimate year year increase be drive strong global gain companion animal group cag diagnostic recur revenue include double digit organic revenue gain consumable reference lab well strong acceptance rapid assay veterinary software service diagnostic imaging system idexx laboratory inc price consensus ep surprise idexx laboratory inc price consensus ep surprise idexx laboratory inc quote segmental analysisidexx derive revenue operate segment cag water livestock poultry dairy lpd other third quarter cag revenue rise organically year year water segment revenue be prior year quarter organically lpd revenue meanwhile decline organically revenue other segment rise organically marginsgross profit increase report quarter gross margin expand basis point bps rise cost revenue sale marketing expense rise general administrative expense increase research development expense increase overall operate margin quarter improve bps financial positionidexx exit third quarter cash cash equivalent end second quarter year date net cash provide operate activity be compare year period guidanceidexx narrow revenue outlook previously provide range reflect organic revenue growth expectation zack consensus estimate revenue be peg peg lower end guide range management also raise ep guidance earlier support continue operate margin expansion align long term goal update outlook represent ep growth report basis zack consensus estimate ep be peg guide range takeidexx exit third quarter mixed note earning beating revenue miss zack consensus estimate however solid year year growth organic revenue buoy optimism company raise ep guidance be also encourage stellar quarterly performance be drive strong sale company companion animal business companion animal market fundamental remain solid tremendous global runway growth management innovation base multus modality global strategy enabled enhance commercial capability accelerate recur cag diagnostic revenue growth moreover strong top line growth quarter be drive considerable contribution rest business segment however foreign currency fluctuation be expect continue hurt company operate result lower extent expect earlier zack rank other key picksidexx currently have zack rank buy other top rank stock broader medical sector be petm express inc pet free report thermo fisher scientific inc tmo free report intuitive surgical inc isrg free report notably petm sport zack rank strong buy thermo fisher scientific intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report ep cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter thermo fisher scientific report adjust earning share third quarter year year also company revenue grow year year intuitive surgical post adjust earning share third quarter year year basis further revenue increase year year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
584,IDXX,ecolab inc ecl free report have have dismal run bourse late last month company have return intensify competition foreign exchange volatility higher raw material cost integration risk be primary headwind company now let take look other major factor have be impede ecolab growth trajectory ecolab grapple issueshurricane deal blow various report suggest hurricane dealt heavy blow medtech major ecolab be exception regard force shut down manufacturing plant houston area management ecolab estimate third quarter adjust diluted earning share low end slightly previously forecast band full year ecolab expect adjust earning low end previously issue range divestiture yielding stellar return last year august management ecolab announce last quarter have be quiet equipment care business register just growth year year basis add wo segment run short manpower recent past result ecolab announce plan divest equipment care audax private equity grow upper single digit segment witness strong sale almost net sale diversify offering equipment care have lend ecolab competitive edge global market so far divestiture plan enhance company focus core business be also likely mar net revenue read more ecolab divest equipment care segment share fall fall estimate estimate revision trend ecolab have be unfavorable full year analyst moved north compare movement opposite direction last month result full year estimate decline share current quarter analyst moved north compare movement opposite direction same time frame result zack consensus estimate current quarter earning drop share stock have zack rank sell ecolab inc price consensus ecolab inc price consensus ecolab inc quote stock look expensive ecolab stock look bit overvalue moment comparative analysis company forward basis ratio reflect relatively gloomy picture be cause investor concern ratio currently stand significantly stretched compare ratio furthermore stock be overvalue compare peer be current ratio basis broader industry be key picksa few better rank stock broader medical sector be sonova hold sonvy free report idexx laboratory inc idxx free report luminex corporation lmnx free report sonova luminex sport zack rank strong buy idexx laboratory have zack rank buy see complete list today zack rank stock here sonova represent solid return last year company have long term expect earning growth rate idexx laboratory have average earning beat trail quarters have long term expect earning growth rate luminex come positive earning surprise last quarter stock have long term expect earning growth rate stock watch massive equifax hack cybersecurity stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
585,IDXX,bruker corporation brkr free report scale new week high oct eventually close bit lower zack rank hold stock have market cap comparison broader majority last month company share price have considerably outperformed broader industry stock have rally last month outshine industry return company have also outperformed gain last month company year historical growth rate be also favorable compare broader industry index take stable stock performance consideration expect bruker gain ground come quarters growth week high come back several new development most recent be introduction new ce ivd marked fungiplex candida fast diagnostic assay multiplex real time pcr test rapid identification most common pathogen associate invasive candidiasis company also introduce ce ivd marked micronaut be antimycotic test plate automate manual antifungal susceptibility testing afst yeast culture recently bruker introduce timstof pro system pasef mass spectrometry annual world congress human proteome organization hupo also bruker announce new ray diffraction xrd system japan analytical scientific instrument show jasis bruker recently complete buyout merlin gmbh locate germany merlin have specialize skill product service consult field antibiotic resistance testing art antibiotic susceptibility testing ast acquisition have also play pivotal role drive company share price new week high key stocksa few better rank stock medical sector be qiagen qgen free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report qiagen idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank strong buy stock here qiagen have long term expect earning growth rate stock rally roughly last year idexx laboratory have long term expect earning growth rate stock gain last year thermo fisher have long term expect earning growth rate stock gain last year stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
586,IDXX,share price abbott free report scale new week high oct eventually close lower company have gain past month much higher gain abbott have also outperformed broader industry gain last month stock have market cap further abbott estimate revision trend current year have be favorable past day estimate moved moved estimate be share same time frame company also have trail quarter average positive earning surprise positive long term growth hold promise abbott carry zack rank hold company have impressive growth style score growth style score highlight vital metric company financial obtain clearer picture quality sustainability growth research show stock style score combine zack rank strong buy buy offer best investment opportunity growth market be upbeat abbott acquisition alere get complete oct face several regulatory hurdle buyout help company gain access new channel geography include entry fast grow outlet such doctor office clinic pharmacy home testing major upside company be recent fda approval freestyle libre flash glucose monitoring system unite state market be also optimistic abbott gain national reimbursement freestylelibre glucose monitoring system national health service nhs business service authority have be major breakthrough company diabetic business also be worth mention abbott ellipse implantable cardioverter defibrillator icd recently gain fda approval magnetic resonance mr conditional labele factor be expect drive company share price further key picksa few better rank stock medical sector be orthofix international ofix free report luminex corporation lmnx free report idexx laboratory inc idxx free report orthofix international luminex sport zack rank strong buy idexx laboratory carry zack rank buy see complete list today zack rank stock here orthofix international have long term expect earning growth rate stock have rally roughly last month luminex have long term estimate earning growth rate stock gain last month idexx laboratoriesha long term expect earning growth rate stock have gain last year trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
587,IDXX,oct issue update research report new york base dentsply sirona inc xray free report global leader design development manufacture marketing dental consumable dental laboratory product dentsply recently announce renewal exist distribution agreement henry schein canada inc continue dec henry schein agreement dentsply be initiate august feel deal extension be smart move dentsply preexist agreement do not include cerec cad cam restoration system schick line imaging sensor include aforementioned line product company benefit henry schein distribution network canada recent development dentsply announce renewal partnership pacific dental service duo latest agreement extend period year be sign move be also strategic pacific dental network consist center state tenure present agreement management expect number such office utilize dentsply technology exceed dentsply dual brand strategy product innovation growth opportunity emerge market especially asia pacific middle east africa diversify product portfolio recur revenue base be key catalyst company expect solid guidance full year project adjust ep range flip side apart series macroeconomic headwind currency fluctuation continue be major dampener fact strengthen dollar euro other emerge market currency have dent company growth trajectory furthermore higher capital expenditure product development be expect keep margin pressure share price estimate revision lack lusterdentsply estimate revision trend look unfavorable moment third quarter analyst moved south compare upward revision last month notably current quarter estimate drop cent share last day dentsply share price movement have be unfavorable last month company shed much higher industry decline zack rank key picksdentsply currently carry zack rank hold few better rank stock broader medical sector be abbott free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report abbott idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank strong buy stock here abbott have long term expect earning growth rate stock have rally roughly year idexx laboratory have long term expect earning growth rate stock have gain year thermo fisher have long term expect earning growth rate stock have gain last year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
588,IDXX,oct issue update research report veeva system inc veev free report be upbeat veeva commercial cloud platform clinch multiple contract world company have many core crm project track large pharma company veeva currently carry zack rank buy headquarter pleasanton veeva offer cloud base software application datum solution life science industry life science industry have be quite slow adopt cloud base software compare other industry however believe industry be gradually realize benefit cloud base application particularly due rise regulation budgetary constraint cost effectiveness cloud base application premise application be attract life science company moreover uncertain regulatory environment have drive demand software vendor be well acquaint industry trend company industry specific focus lend significant leverage view be aptly demonstrated strong sale growth aid new business gain better pricing product innovation company knowledge different component life science industry be help build target product notably product veeva opendata provide customer datum healthcare professional hcp healthcare organization hco affiliation major life science market veeva be optimistic product pipeline include exclusive range product flagship vault commercial cloud platform product include vault ctms vault promomat dam crm engage meeting crm engage webinar share price estimate revisionveeva share price movement continue be robust company have gain year date surpass broader industry current level be also higher return zack consensus estimate full year inched close cent share last month key picksa few better rank stock broader medical sector be sonova hold sonvy free report idexx laboratory inc idxx free report luminex corporation lmnx free report sonova luminex have zack rank strong buy idexx laboratory have zack rank buy see complete list today zack rank stock here sonova represent solid return last year company have long term expect earning growth rate idexx laboratory have average earning beat trail quarters have long term expect earning growth rate luminex come positive earning surprise last quarter stock have long term expect earning growth rate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
589,IDXX,henry schein inc hsic free report recently complete earlier announce buyout merritt veterinary supply certain undisclosed financial term merritt be part veterinary business henry schein namely henry schein animal health merritt be independent family own supplier animal health product merritt have veterinary clinic eastern unite state strong presence southeastern part nation company offer comprehensive line product include pharmaceutical diagnostic equipment merritt generate revenue approximately accord henry schein acquisition drive earning share henry schein have be consistently try expand animal health business company global animal health segment witness improvement revenue last report second quarter recently henry schein animal health announce open new national distribution service center columbus brookhollow neighborhood expand presence central ohio begin henry schein have enter brazilian animal health market investment tecnew privately hold distributor animal health product prior company have acquire rxwork lead provider veterinary practice management software primarily customer australia new netherlands other country accord report grand view research global animal health market be expect reach value consider huge potential market believe latest development be strategic past year henry schein have underperform broader industry stock have gain compare broader industry rise estimate revision trend estimate revision trend have be favorable company current quarter estimate moved north compare movement opposite direction last month result zack consensus estimate current quarter have increase cent share cent zack rank key pickshenry schein currently carry zack rank hold few better rank stock medical sector be qiagen qgen free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report qiagen idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank strong buy stock here qiagen have long term expect earning growth rate stock have rally roughly last year idexx laboratory have long term expect earning growth rate stock have gain last year thermo fisher have long term expect earning growth rate stock have gain last year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
590,IDXX,share teleflex incorporate tfx free report rally new week high oct close tad lower represent strong return approximately last month better same time frame teleflex design develop manufacture supply single use medical device common diagnostic therapeutic procedure critical care surgical application worldwide company currently have zack rank hold year date company share price have considerably outperformed broader industry stock have rally higher industry gain just notably teleflex have market cap take stable performance stock consideration expect teleflex scale higher come quarters company long term growth also hold promise neotract october teleflex complete acquisition neotract inc term deal teleflex promise upfront cash payment neotract deal closure furthermore teleflex have agree pay additional end management buyout be expect generate mid single digit constant currency revenue growth next several year also drive teleflex margin introduction cleansweep technology teleflex recently introduce cleansweep close suction system css innovative close suction catheter boost broad portfolio respiratory care platform have be showcased anniversary american association respiratory care aarc congress indianapoli management cleansweep platform provide enhance secretion removal dual operation balloon sweeping technology focus high flow nasal cannula therapy high flow nasal cannula therapy hfnct be new standard care patient acute hypoxemic respiratory failure teleflex have gain prominence aarc congress introduction highly exclusive suite hfnct solution well estimate revision trend solid estimate revision trend teleflex be favorable moment full year analyst moved north compare movement opposite direction last month result full year estimate inched share current quarter analyst moved north compare movement opposite direction last month zack consensus estimate current quarter earning rise share same time frame teleflex incorporate price consensus teleflex incorporate price consensus teleflex incorporate quotekey picksa few better rank stock broader medical sector be sonova hold sonvy free report idexx laboratory inc idxx free report luminex corporation lmnx free report sonova luminex sport zack rank strong buy idexx laboratory have zack rank buy see complete list today zack rank stock here sonova represent solid return last year company have long term expect earning growth rate idexx laboratory have average earning beat trail quarters have long term expect earning growth rate luminex come positive earning surprise last quarter stock have long term expect earning growth rate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
591,IDXX,diversify healthcare company opko health inc opk free report recently sign exclusive agreement japan tobacco inc development kidney drug rayaldee japan tobacco be responsible regulatory approval commercial activity pertain rayaldee japan glimpse opko health price trend reveal stock have have unimpressive run bourse year date opko health register negative return almost versus approximate positive gain industry bearish price trend estimate revision stock have be dismal estimate full year decline last day move opposite direction result zack consensus estimate full year currently stand loss cent notably stock have zack rank sell come back news japan tobacco make upfront payment opko health worth payment be make initiation opko health plan phase study rayaldee dialysis patient unite state addition opko health be eligible receive additional development regulatory milestone sale base milestone opko health be medical company focuse diagnostic pharmaceutical develop treatment secondary company operate unite state chile israel mexico uruguay spain diagnostic business consist bio reference laboratory be nation third largest clinical laboratory core genetic testing business person sale force key picksa few better rank stock broader medical sector be sonova hold sonvy free report idexx laboratory inc idxx free report luminex corporation lmnx free report sonova luminex have zack rank strong buy idexx laboratory have zack rank buy see complete list today zack rank stock here sonova represent solid return last year company have long term expect earning growth rate idexx laboratory have average earning beat trail quarters have long term expect earning growth rate luminex come positive earning surprise last quarter stock have long term expect earning growth rate stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
592,IDXX,oct issue update research report laboratory corporation america holding lh free report popularly know labcorp stock currently carry zack rank buy last month burlington nc base healthcare diagnostic company provide comprehensive clinical laboratory service end end drug development support have be outperform broader industry stock have lose compare industry decline period market seem be upbeat diagnostic business have deliver promising performance recent past spite persistent softness company covance drug development business be also encourage successful closure acquisition chiltern international group specialty contract research organization chiltern be major partner serve top biopharma segment help company focus high growth emerge mid market biopharma segment notably labcorp be steadily progress prong strategy drive growth first company be focuse research development collaboration academic institution order gain traction grow lab testing market second labcorp be increasingly deploy integrate testing capability industry lead science innovative technology offering establish strategic partnership provider moreover investor be look forward long standing strategic collaboration andme have already demonstrated impressive growth trajectory third labcorp core diagnostic strategy be base innovation datum integration tool support enhance connectivity report decision support company be also focuse extend core testing capability traditional health care set flip side unfavorable foreign exchange be threat moreover company operate tough competitive landscape meanwhile apprehension tough reimbursement scenario intensify concern company other key picksother top rank stock medical sector be qiagen qgen free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report qiagen idexx laboratory thermo fisher carry zack rank see complete list today zack rank strong buy stock here qiagen have long term expect earning growth rate stock have rally roughly last year idexx laboratory have long term expect earning growth rate stock have gain last year thermo fisher have long term expect earning growth rate stock have gain last year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
593,IDXX,cryolife inc cry free report recently enter definitive agreement buy german base jotec ag jotec privately hold maker technologically advanced endovascular stent graft cardiac vascular surgical graft focuse aortic repair company have be record revenue cagr last year financial term agreement cryolife pay aggregate deal cash share cryolife common stock issue jotec shareholder buyout be slate complete later subject customary close condition deal cryolife aim expand exist portfolio product focuse aortic surgery thereby solidify footprint fast grow endovascular surgical market management deal help cryolife diversify business gain access global market stent graft used endovascular open repair aortic disease market be project value interestingly cryolife aim deliver consistent high single digit revenue growth deal deal be also line company strategy directly sell eliminate distributor europe create cross selling opportunity company product portfolio last report quarter cryolife begin process direct selling canada belgium netherlands luxembourg expand direct operation europe same time management expect newly add product continue post double digit growth outside unite state least next year moreover deal be expect prove accretive company gaap ep cagr not less next year contribute gross operate margin cryolife expect gain access stent graft market be project value roughly newly gain highly competitive product portfolio advanced research development platform thus company expect deal drive growth well cryolife also provide sneak peek preliminary third quarter result company have record revenue consider negative impact hurricane delay receipt re certification ascend aortic prosthesis reversal record revenue repurchase inventory third party distributor order sell directly believe unhealthy lifestyle favorable demographic rise expenditure healthcare government technological development continue drive growth aortic aneurysm market fact be further substantiated research market report publish nasdaq report global aortic aneurysm market be estimate witness cagr thus acquisition deal be expect boost top line cryolife share price performanceover last month cryolife have be trading broader industry stock have gain compare broader industry rise zack rank key pickscryolife currently carry zack rank hold few better rank stock medical sector be qiagen qgen free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report qiagen idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank strong buy stock here qiagen have long term expect earning growth rate stock have rally roughly last year idexx laboratory have long term expect earning growth rate stock have gain last year thermo fisher have long term expect earning growth rate stock have gain last year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
594,IDXX,oct issue update research report netherlands base molecular diagnostic provider qiagen qgen free report company offer innovative technology product pre analytical sample preparation molecular diagnostic solution be upbeat qiagen partnership co marketing agreement centogene ag boost bioinformatic portfolio also be encourage note post receipt fda approval june qiagen announce complete launch fourth generation blood test tuberculosis tb infection quantiferon tb gold qft unite state moreover company strategic focus drive growth sample insight offering buoy optimism qiagen be form collaboration personalize homecare space well qiagen currently market product more country last report second quarter company witness growth international region include top emerge market flip side last month qiagen have be trading broader industry latest share price company have gain compare gain broader industry moreover adverse currency translation continue be drag overall sale furthermore decline hpv sale unite state continue be drag competitive landscape heavy dependence collaboration continue be concern zack rank other key picksqiagen currently carry zack rank buy other top rank stock medical sector be abbott free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report abbott idexx laboratory thermo fisher carry zack rank see complete list today zack rank stock here abbott have long term expect earning growth rate stock have rally roughly last year idexx laboratory have long term expect earning growth rate stock have gain last year thermo fisher have long term expect earning growth rate stock have gain last year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
595,IDXX,express script hold company esrx free report recently inked agreement acquire privately hold evicore healthcare investor include general atlantic ta associate ridgemont equity partner transaction be expect close fourth quarter evicore provide evidence base integrate medical benefit management service mbm solution drive cost reduction quality care outcome notably evicore operate standalone business unit express script express script pharmacy benefit management couple evicore complementary medical benefit management be likely build comprehensive patient benefit management pbm solution buyout provide express cross sell client basis financial acquisition be expect prove accretive express script adjust diluted earning share first full year operation exclude transaction related expense amortization intangible accord company deal be likely take care be spend healthcare annually industry pbm be highly competitive industry report market research project pharmacy benefit management market see cagr accord market market report global healthcare provider network management market value cagr period take account express script have be consistently try expand core pbm business company recently announce plan expand customize worker compensation pharmacy solution acquisition mymatrixx pharmacy benefit solution provider worker compensation industry furthermore company anticipate compound annual ebitda growth rate core pbm business however express script announce biggest customer lead health insurer anthem inc antm be not likely extend pharmacy benefit management agreement be slate expiration end price script stock have underperform broader industry last year specifically stock have lose period industry gain zack rank key picksexpress script currently carry zack rank hold few better rank stock medical sector be abbott free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report abbott idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank strong buy stock here abbott have long term expect earning growth rate stock have rally roughly last year idexx laboratory have long term expect earning growth rate stock have gain last year thermo fisher have long term expect earning growth rate stock have gain last year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
596,IDXX,expand tissue technology portfolio integra lifescience holding corporation iart free report recently announce launch collagen matrix revize revize plastic reconstructive surgery available solid mesh configuration revize revize collagen matrix be derive fetal bovine dermis contain high level type iii collagen company revize revize aid implant strengthen weak soft tissue surgical repair damage rupture soft tissue membrane solidify footprint plastic reconstructive surgery global medical technology company recently announce launch collagen matrix surgimend prs mesh feature meshing pattern parallel release integra announce launch surgimend prs mesh pre sub pectoral breast reconstruction europe company launch surgimend mp collagen matrix complex abdominal hernia repair feature highly macroporous design enable fluid drainage same month company announce european launch dermal regeneration template single layer thin dermal repair defect reconstruction step procedure interestingly company orthopedic tissue technology segment account company total revenue last report quarter latest launch be expect boost segment scontribution integra effort grow plastic reconstructive surgery market seem be strategic technavio datum publish business wire report global plastic surgery product market be expect reach value cagr believe grow consciousness appearance individual increase awareness rise expenditure healthcare technological advancement be likely drive demand cosmetic surgery thus latest launch help integra cash opportunity niche market share price performancein last month integra have be consistently trading broader industry date stock have rally higher gain broader industry zack rank key picksintegra currently carry zack rank hold few better rank stock medical sector be orthofix international ofix free report thermo fisher scientific inc tmo free report idexx laboratory inc idxx free report orthofix international sport zack rank strong buy idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank stock here orthofix international have long term expect earning growth rate stock have rally roughly last month idexx laboratory have long term expect earning growth rate stock have gain last year thermo fisher have long term expect earning growth rate stock have gain last year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
597,IDXX,oct issue update research report latham ny base angiodynamic inc ango free report company recently report dismal first quarter fiscal adjust earning revenue miss zack consensus estimate angiodynamic have zack rank buy moment company ride market solid response solero microwave tissue ablation mta system especially microwave ablation space platform be intend be used ablation soft tissue open procedure research report micro market monitor suggest global microwave ablation be expect reach worth end first quarter tepid note company reaffirm guidance fiscal angiodynamic expect adjust earning share band cent cent revenue be project range furthermore free cash flow be expect be more be important note foreign exchange do not have impact report quarter however continue softness vascular access venous business affected revenue first quarter growth core angiographic catheter business be also likely fortify company footprint global space angiographic business fall company peripheral vascular pv segment believe angiovac be key growth driver pv segment management expect thrombus management platform pv product line lend competitive advantage open significant long term opportunity however angiodynamic end first quarter outstanding debt be likely impose certain operate financial restriction impede company core business initiative come stock price performance angiodynamic see negative return almost last year significantly underperform gain same time frame furthermore current level be lower broader industry gain other key picksa few other top rank stock broader medical sector be sonova hold sonvy free report idexx laboratory inc idxx free report luminex corporation lmnx free report sonova luminex have zack rank strong buy idexx laboratory have zack rank see complete list today zack rank stock here sonova represent solid return last year company have long term expect earning growth rate idexx laboratory have average earning beat trail quarters have long term expect earning growth rate luminex come positive earning surprise last quarter stock have long term expect earning growth rate hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
598,IDXX,integra lifescience holding corporation iart free report have finally come news complete codman neurosurgery business acquisition johnson johnson jnj free report development be expect heel last month major asset divestment initiative company whopping purchase have be consider major breakthrough integra provide company global reach neurosurgery thus connote core expertise company specialty surgical solution integra expect complete say asset divestment soon form part certain close condition codman acquisition notably integra have sign definitive agreement sell company certain neurosurgery asset healthcare product service provider natus medical incorporate baby free report total deal value company have also decide sell global camino icp monitoring product line include san diego manufacturing facility natus medical additionally natus get hold right related integra fix pressure shunt well right codman duraform dural graft implant standard evd catheter csf collection system earlier announce set divestiture natus integra have discuss imminent financial impact company approximately revenue be earn neurosurgery product line associate divestiture take net divestiture codman acquisition account company preliminary basis estimate fourth quarter revenue contribution approximately full year integra expect codman neurosurgery contribute revenue net divestiture overall codman neurosurgery business be anticipate remain accretive integra adjust earning share contribute least cent however full year integra expect minimal contribution codman neurosurgery adjust earning share integra lifescience holding corporation price consensus integra lifescience holding corporation price consensus integra lifescience holding corporation quoteper integra codman neurosurgery exist portfolio new product pipeline advanced hydrocephalus neuro critical care be go complement acquirer lead product pipeline tissue ablation dural repair cranial stabilization post closure buyout consolidated portfolio offer complete solution neurosurgery scale invest well bring new technology table patient worldwide notably report radiant insight global neurosurgery market be project witness estimate cagr take consideration huge growth prospect believe integra initiative strengthen foothold particular niche area be well time overall integra have be consistently trading broader industry last month stock have rally year date thus substantially outperform industry gain period zack rank other key pickintegra currently carry zack rank buy top rank medical stock be idexx laboratory inc idxx free report also carry same bullish zack rank see complete list today zack rank strong buy stock here idexx laboratory have positive earning surprise last quarters stock have roughly surge year make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
599,IDXX,keep pace expect timeline completion amedisys inc am free report recently announce subsidiary associate home care have close purchase intercity home care massachusett base personal care provider notably intercity home care entire asset base have be take associate home care acquisition renown home health hospice service provider have more widespread presence massachusett intercity home care have location greater boston north shore merrimack valley community also amedisys gain access extend customer base health heal service provider intercity home care expect serve client mentioned state company have be make encourage move respect recently integrate personal care business latest report quarter net service revenue personal care witness rise year year additionally amedisys look forward huge growth prospect personal care segment segment fact perform sync management expectation integration recent tuck acquisition follow amedisys inc price consensus amedisys inc price consensus amedisys inc quoteearlier march company have decide buy personal care provider east tennessee personal care service believe buyout expand personal care footprint massachusett notably company management expect be well stock enough cash balance manoeuvre plenty such acquisition future amedisys be currently explore opportunity home health hospice segment too company favorable demographic trend strategic acquisition be impressive well past month company share price have outperformed broader industry stock have gain versus broader industry loss zack rank other key picksamedisys currently carry zack rank hold better rank medical stock be idexx laboratory inc idxx free report luminex corporation lmnx free report masimo corporation masi free report carry zack rank buy see complete list today zack rank strong buy stock here idexx laboratory have positive earning surprise last quarters stock have roughly surge last year luminex corporation have long term expect earning growth rate more stock have gain last month masimo have long term historical adjust earning growth stock have rally nearly year date make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
600,IDXX,ecolab inc ecl free report recently announce plan divest equipment care segment audax private equity grow upper single digit segment witness strong sale almost net sale transaction be subject regulatory clearance be expect close fourth quarter other term agreement have be keep wrapped be important note ecolab program service help promote safe food maintain clean environment optimize water energy use improve operational efficiency customer food energy healthcare industrial hospitality market more country share price fallsshare ecolab decline close follow news release fact last year ecolab have be trading market large stock have return return current level be also bit lower broader industry return same time frame fact zack consensus estimate full year drop share last month result ecolab have zack rank sell signify probability term equipment care segment equipment care segment have be offer commercial kitchen equipment maintenance ecolab last year yielding stellar return last year august management ecolab announce equipment care business have be witness quiet period lately register just growth year year basis last quarter add wo segment run short manpower recent past apart be lead player chemical specialty space comprehensive diversify offering equipment care have lend ecolab competitive edge global market believe divestiture enhance ecolab strategic focus core segment global industrial global institutional global energy however be difficult gauge impact divestiture ecolab full year result least now regard ecolab have provide full year guidance adjust diluted earning share band earlier key picksa few better rank stock broader medical sector be sonova hold sonvy free report idexx laboratory inc idxx free report luminex corporation lmnx free report sonova luminex have zack rank strong buy idexx laboratory have zack rank buy see complete list today zack rank stock here sonova represent solid return last year company have long term expect earning growth rate idexx laboratory have average earning beat trail quarters have long term expect earning growth rate luminex come positive earning surprise last quarter stock have long term expect earning growth rate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
601,IDXX,post receipt fda approval june qiagen qgen free report recently announce complete launch fourth generation blood test tuberculosis tb infection quantiferon tb gold qft unite state advanced test kit be available oct build quantiferon tb gold qft platform qft provide enhance analysis tb infection advanced kit make tb testing innovative antigen possible measure cell mediate immune response tb cd cd cell company roughly disease unite state originate person reservoir latent tb infection highlight significance availability testing kit qft launch be likely widen qiagen customer base huge tb testing market morbidity mortality weekly report mmwr publish center disease control prevention total new tb case be diagnosed unite state accord research market datum publish business wire tb market be expect see cagr qft test kit fall company molecular diagnostic segment be highest revenue grosser last report quarter notably segment contribute total revenue back substantial growth quantiferon latent tb test qiasymphony automation system consumable portfolio personalize healthcare share price have be gain investor confidence consistently encourage result last month company share price have outperformed broader industry stock have gain compare broader industry gain company have also surpass gain market same time frame zack rank key carry zack rank hold few better rank stock medical sector be orthofix international ofix free report luminex corporation lmnx free report idexx laboratory inc idxx free report orthofix international luminex sport zack rank strong buy idexx laboratory carry zack rank buy see complete list today zack rank stock here orthofix international have long term expect earning growth rate stock have rally roughly last month luminex have long term expect earning growth rate stock gain last month idexx laboratoriesha long term expect earning growth rate stock have gain last year trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
602,IDXX,hologic inc holx free report announce receipt clearance fda panther fusion flu rsv assay run new panther fusion system follow ce mark approval earlier year latest fda clearance be treat major breakthrough company molecular diagnostic arm panther fusion module be lab upgrade original panther instrument add flexibility pcr polymerase chain reaction proven performance transcription mediate amplification tma be used panther system panther fusion system have benefit panther platform include full sample result automation ability run multiple test single sample random access sample process continuous load stat capability moreover feature provide higher throughput panther fusion test hour fusion aptima test be also incorporate unite state panther fusion be available full system testing capability be extend attach panther fusion module exist panther system apart panther fusion flu rsv assay additional respiratory panel panther fusion paraflu assay panther fusion adv hmpv rv adenovirus human metapneumovirus rhinovirus assay be presently fda review accord company panther fusion respiratory assay offer modular approach testing ability run assay single patient specimen panther fusion assay also use ready use reagent offer day board stability panther fusion system cut hand time laboratory provide random continuous access rapid turnaround time panther fusion system be only instrument combine tma transcription mediate amplification real time tma real time pcr full sample result automation hologic be consistently try expand diagnostic segment notably segment generate total revenue last report third quarter face year year decline accord cision molecular diagnostic market be project reach worth cagr consider huge potential market believe company latest development be quite strategic past month hologicha underperform broader industry stock have lose gain broader industry zack rank key pickshologic currently carry zack rank hold few better rank stock medical sector be orthofix international ofix free report luminex corporation lmnx free report idexx laboratory inc idxx free report orthofix international luminex sport zack rank strong buy idexx laboratory carry zack rank buy see complete list today zack rank stock here orthofix international have long term expect earning growth rate stock have rally roughly last month luminex have long term estimate earning growth rate stock gain last month idexx laboratory have long term expect earning growth rate stock have gain last year trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
603,IDXX,share perkinelmer inc pki free report rally new week high oct close tad lower represent strong year date return approximately better same time frame perkinelmer provide scientific instrument consumable service pharmaceutical biomedical environmental testing chemical general industrial market worldwide company currently have zack rank hold majority last month company share price have considerably outperformed broader industry stock have rally month slightly higher industry gain just notably perkinelmer have market cap take stable performance stock consideration expect perkinelmer scale higher come quarters company long term growth also hold promise spectrum broad perkinelmer expand product portfolio be help market share boost organic growth first half year organic growth have be company year year basis short span time perkinelmer new product gain significant traction consumer believe product continue boost company market share area diagnostic research environment estimate revision trend solid estimate revision trend perkinelmer be favorable moment full year analyst moved north compare movement opposite direction last month result full year estimate inched share current quarter analyst moved north compare movement opposite direction last month zack consensus estimate current quarter earning rise cent share same time frame perkinelmer inc price consensus perkinelmer inc price consensus perkinelmer inc drive growth acquisition strategic partnership have be key catalyst perkinelmer year earlier year company announce plan acquire euroimmun medical laboratory diagnostic ag approximately cash deal be expect close fourth quarter buyout expand perkinelmer reach autoimmune allergy diagnostic market acquisition also reinforce company capability pertain new infectious disease chinese market management acquisition be expect add cent cent adjust earning guidance raise perkinelmer revise adjust earning guidance full year company now expect adjust earning share band previously provide range key picksa few better rank stock broader medical sector be sonova hold sonvy free report idexx laboratory inc idxx free report luminex corporation lmnx free report sonova luminex have zack rank strong buy idexx laboratory have zack rank buy see complete list today zack rank stock here sonova represent solid return last year company have long term expect earning growth rate idexx laboratory have average earning beat trail quarters have long term expect earning growth rate luminex come positive earning surprise last quarter stock have long term expect earning growth rate trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
604,IDXX,boston scientific corporation bsx free report recently announce plan acquire campbell base privately hold company apama medical inc total value be line company strategy gain traction market be poise reach value more datum article factory deal be slate close fourth quarter subject customary close condition acquisition agreement subject attainment certain clinical regulatory target boston scientific be schedule pay maximum contingent payment cash immediate basis however company do not expect buyout prove accretive adjust earning even apama medical be involved research development apama radiofrequency rf balloon catheter system treatment atrial fibrillation af management af be heart rhythm disorder have affected roughly globally deal boston scientific aim expand suite arrhythmia solution fall sub segment company company also intend integrate rhythmia hdx mapping system apama rf balloon system order enhance visualization heart ablation process apama rf balloon be expect receive ce mark approval late af ficient study result present af symposium annual meeting january have be favorable interestingly boston scientific revenue improve last report quarter higher uptake new rhythmia hdx platform management continue roll hdx platform europe recently initiate same unite state japan overall company continue expand toolkit support rhythmia hdx provide ablation technology match excellence mapping system add tool expand reach utility rhythmia hdx different procedure type context company plan launch intellanav mifi open irrigate therapeutic catheter europe unite state third quarter moreover boston scientific strategy gain traction sub segment seem be align datum provide ally market research report global cardiac monitoring cardiac rhythm management market be expect see cagr reach value believe unhealthy lifestyle rise agee population continue result high incidence cardiovascular disease be further support datum provide gbi research report global cardiovascular disease market see cagr space market be expect witness highest momentum cagr share price scientific have be gain investor confidence consistently positive result last month company share price have outperformed broader industry stock have gain compare broader industry gain zack rank key picksboston scientific currently carry zack rank hold few better rank stock medical sector be orthofix international ofix free report luminex corporation lmnx free report idexx laboratory inc idxx free report orthofix international luminex corporation sport zack rank strong buy idexx laboratory carry zack rank buy see complete list today zack rank stock here orthofix international have long term expect earning growth rate stock have rally roughly last month luminex corporation have long term expect earning growth rate stock gain last month idexx laboratory have long term expect earning growth rate stock gain last year make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
605,IDXX,masimo corporation masi free report recently announce release proprietary patient datum visualization report software trace unite state be specifically design masimo root radical monitor trace communicate masimo device high speed wire wireless connection ability download hour patient datum second aid efficiency provide analytic determination minimum maximum mean value measurement percentage time spend defined parameter threshold threshold cross count duration desaturation event trace also support visual tool such trend graph histogram event annotation year date masimo have outperformed industry term price company have return compare sub industry increase also current return be higher gain same time frame consider bountiful opportunity advanced monitoring technology global market launch instill investor confidence stock research report market market reveal niche market be expect reach worth globally cagr additionally masimo long term growth fundamental be strong company base irvine record year cagr revenue adjust earning share masimo have particularly witness improvement earning last year masimo develop manufacture market family invasive monitoring system latest development significantly fortify company position niche market zack rank key picksmasimo carry zack rank hold better rank stock medical sector be orthofix international ofix free report luminex corporation lmnx free report idexx laboratory inc idxx free report orthofix international luminex corporation sport zack rank strong buy idexx laboratory carry zack rank buy see complete list today zack rank stock here orthofix international have long term expect earning growth rate stock have surge roughly last month luminex corporation have long term expect earning growth rate stock have rally last month idexx laboratory have long term expect earning growth rate stock have climb year time trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
606,IDXX,quest diagnostic dgx free report recently announce completion buyout outreach laboratory service operation hartford healthcare hospital william backus hospital hospital central connecticut however financial term transaction have be keep wrapped now laboratory operation hospital be shift quest diagnostic advanced full service clinical laboratory marlborough rapid response laboratory wallingford torrington stratford hartford norwich base connecticut buyout have be approve state connecticut office health care access give care provider direct access quest diagnostic broader menu service wider network patient service center company deal strengthen business relationship hartford healthcare context quest diagnostic have acquire outreach laboratory service business clinical laboratory partner wholly own subsidiary hartford healthcare be also highly optimistic company focus point strategy accord quest diagnostic plan divestiture focus diagnostic product business be part strategy refocu diagnostic information service additionally several new collaboration hospital integrate delivery network have turn be major growth driver regard be look forward company deal walmart particularly company be positive recent agreement peacehealth pacific northwest be expect bolster growth also management be upbeat latest acquisition med fusion clearpoint advance diagnostic space be also encourage company plan acquire outreach laboratory service business cape cod healthcare company tuck acquisition fit well ambit guideline quest diagnostic takeover plan be consistent goal contribute revenue annually accretive acquisition thus believe latest buyout widen customer base lead diagnostic service information provider share price diagnostic have be gain investor confidence consistently positive result last year company share price have outperformed broader industry stock have gain contrast broader industry decline zack rank key picksquest diagnostic currently carry zack rank sell few better rank stock medical sector be orthofix international ofix free report luminex corporation lmnx free report idexx laboratory inc idxx free report orthofix international luminex corporation sport zack rank strong buy idexx laboratory carry zack rank buy see complete list today zack rank stock here orthofix international have long term expect earning growth rate stock have rally roughly last month luminex corporation have long term expect earning growth rate stock gain last month idexx laboratory have long term expect earning growth rate stock gain last year make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
607,IDXX,oct issue update research report bad homburg germany base fresenius medical care fms free report largest integrate provider product service individual undergo dialysis follow chronic kidney failure fresenius medical have chalk long term plan call growth strategy formulate few initiative gain solid market traction long haul postulate growth strategy fresenius medical aim increase revenue reflect average annual growth rate full year revenue increase year year basis courtesy strong growth health care service revenue furthermore management forecast increase revenue organic inorganic growth addition stock strong performance core dialysis business fresenius medical intend achieve target expand care coordination dialysis segment well come product line fresenius medical manufacture variety durable medical device used treatment end stage renal disease esrd device hemodialysis machine peritoneal dialysis machine granuflo concentrate mix tank monitoring device crit line platform be part portfolio fresenius medical provide wide range dialysis product clinic third party include modular machine component dialyzer bloodline system hd hemodialysis solution concentrate water treatment system acquisition have be drive company growth trajectory long major one buyout cura group xenio ag renal care group renal solution liberty dialysis sparsh nephrocare deserve special mention company make acquisition worth flipside fresenius medical have have unimpressive run bourse year date stock have gain lower industry addition almost zack rank key picksfresenius medical currently carry zack rank hold better rank stock medical sector be orthofix international ofix free report luminex corporation lmnx free report idexx laboratory inc idxx free report orthofix international luminex corporation sport zack rank strong buy idexx laboratory carry zack rank buy see complete list today zack rank stock here orthofix international have long term expect earning growth rate stock have surge roughly last month luminex corporation have long term expect earning growth rate stock have rally last month idexx laboratory have long term expect earning growth rate stock have climb year time today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
608,IDXX,oct issue update research report lead medical device company boston scientific corporation bsx free report past month boston scientific have be trading broader industry stock have improve compare broader industry gain period recent upside worth mention be company acquisition symetis bid fortify european structural heart business be also encourage company secure multiple product approval domestic well overseas market notably company receive fda approval resonate family icd crt system additionally market hold optimism stock follow company recent release outline sustain growth strategy focuse plan expansion new market consolidate product line business segment company particularly plan launch product high growth adjacent market strong potential reap incremental market opportunity boston scientific corporation price consensus boston scientific corporation price consensus boston scientific corporation quotewhile adverse foreign exchange continue challenge be concern company recall prime product lotus range heart device be important note last quarter foreign exchange headwind affected company top line adjust gross margin basis point also dull defibrillator sale core cardiac rhythm management crm continue remain drag overall growth wo challenge economy competitive landscape persistently burden stock however give company bullish second quarter result several recent development find quite few positive factor rely company be leave stone unturned reinforce core business invest more global market zack rank key picksboston scientific carry zack rank hold few better rank stock medical sector be orthofix international ofix free report thermo fisher scientific inc tmo free report idexx laboratory inc idxx free report orthofix international sport zack rank strong buy idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank stock here orthofix international have long term expect earning growth rate stock have rally roughly last month thermo fisher have long term expect earning growth rate stock have gain last year idexx laboratory have long term expect earning growth rate stock have surge last year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
609,IDXX,oct issue update research report genomic health inc ghdx free report global cancer research company focus advanced molecular diagnostic past month share company have be trading broader industry stock have decline contrast broader industry gain redwood city base company sole reliance profitability breast oncotype dx test remain concern rise operate expense continue be major headwind create bottom line pressure genomic health inc price consensus genomic health inc price consensus genomic health inc quoteabove management decision issue guidance have be discourage thus turn fail provide clear cut visibility company upcoming performance positive note genomic health continue experience strong growth breast cancer score late company have witness rise invasive breast cancer revenue have see growth global breast cancer business recently report second quarter well company also recently announce expand medicare coverage oncotype dx genomic prostate score test fact continue be market leader low risk intermediate risk prostate cancer back test volume performance last several quarters company be currently focuse partnership epic science launch oncotype dx ar prostate cancer end additionally company colon cancer test help attain global identity more oncotype dx test major cancer type namely breast colon prostate result have establish strong foothold unite state genomic health be now make considerable expansion international arena zack rank key picksgenomic health currently carry zack rank sell better rank stock medical sector be orthofix international ofix free report luminex corporation lmnx free report idexx laboratory inc idxx free report orthofix international luminex corporation sport zack rank strong buy idexx laboratory carry zack rank buy see complete list today zack rank stock here orthofix international have long term expect earning growth rate stock have surge roughly last month luminex corporation have long term expect earning growth rate stock have rally last month idexx laboratory have long term expect earning growth rate stock have climb year time stock watch massive equifax hack cybersecurity stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
610,IDXX,oct issue update research report integra lifescience holding corporation iart free report stock currently have zack rank buy last month integra have be consistently trading broader industry date stock have gain higher gain broader industry consistently strong performance orthopedic tissue technology segment buoy optimism believe company recent product diversification bolster investor confidence thereby boost stock price further integra regenerative technology be largest franchise orthopedic tissue technology portfolio company latest launch new size surgimend primatrix omnigraft well continue growth private label product be encourage company expect launch several other regenerative product third quarter well be also optimistic fact integra have successfully see certain key development overseas face foreign exchange fluctuation international business also integra have adopt several term objective pillar strategy management also expect gain market traction strategic partnership acquisition flip side foreign exchange stiff competition be potent headwind also many integra manufacturing development research facility be vulnerable natural disaster unprecedented event depend severity force company cease development manufacturing product key picksa few better rank stock medical sector be orthofix international ofix free report luminex corporation lmnx free report idexx laboratory inc idxx free report orthofix international luminex sport zack rank strong buy idexx laboratory carry zack rank buy see complete list today zack rank stock here orthofix international have long term expect earning growth rate stock have rally roughly last month luminex have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last year stock watch massive equifax hack cybersecurity stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
611,IDXX,henry schein medical subsidiary henry schein inc hsic free report recently inked agreement cerebral assessment system cas distribute cognivue be first computerize cognitive assessment screening device clear fda detection early sign dementia believe development bolster growth company field mental cognitive disease cas be medical device company engage research commercialize automate solution routine measurement monitoring brain health accord company cognivue be fully automate solution display visual stimuli computer screen physician conduct quantitative analysis brain health get single score overall brain functional integrity result be store cloud enable doctor observe current brain health identify potential issue be address problem worsen henry schein be consistently work boost medical segment notably worldwide medical revenue rise year year last report second quarter recently henry schein announce partnership simplifeye create mobile platform health care provider use practice management electronic health record software micromd accord report research market global treatment syndrome dementia movement disorder market be anticipate reach value cagr consider huge potential market believe latest development be strategic past year henry schein have underperform broader industry stock have gain compare gain broader industry estimate revision trend estimate revision trend have be favorable company current quarter estimate moved north compare movement opposite direction last month result zack consensus estimate current quarter earning share have increase cent cent same period zack rank key pickshenry schein currently carry zack rank hold few better rank stock medical sector be orthofix international ofix free report luminex corporation lmnx free report idexx laboratory inc idxx free report orthofix international luminex sport zack rank strong buy idexx laboratory carry zack rank buy see complete list today zack rank stock here orthofix international have long term expect earning growth rate stock have rally roughly last month luminex have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last year stock watch massive equifax hack cybersecurity stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
612,IDXX,oct issue update research report hill holding inc hrc free report stock currently have zack rank hold hill have underperform broader industry last month stock have lose compare industry decline foreign exchange stiff competition be potent headwind company lower full year revenue earning guidance be indicative persistently sluggish trend positive note hill be focuse product innovation research development also product launch slate fourth quarter be boost investor confidence commercial launch centrella med surg platform regard be worth mention also hill announce introduction line safety surgical instrument include bard parker safeswitch disposable scalpel handle scalpel handle cover bard parker blade remover additionally hill merger acquisition pipeline be strong company aggressively pursue acquisition accelerate growth key clinical focus area advance patient mobility wound care prevention surgical safety efficiency clinical solution respiratory help meanwhile order focus core operation hill recently sign agreement divest volker business affiliate cobe capital notably volker business primarily serve long term care bed market europe key picksa few better rank stock medical sector be orthofix international ofix free report luminex corporation lmnx free report idexx laboratory inc idxx free report orthofix international luminex corporation sport zack rank strong buy idexx laboratory carry zack rank buy see complete list today zack rank stock here orthofix international have long term expect earning growth rate stock have rally roughly last month luminex have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last year hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
613,IDXX,follow ce mark approval earlier month integra lifescience holding corporation iart free report recently announce launch mesh acellular dermal tissue matrix adm surgimend prs mesh pre sub pectoral breast reconstruction europe surgimend prs mesh solution allow patient opt just single stage implant breast reconstruction post mastectomy instead multiple stage surgery launch be expect widen company portfolio acellular dermal tissue matrix plastic reconstructive surgery include breast reconstruction announcement global medical technology company announce collagen matrix surgimend prs mesh feature meshing pattern be available centimeter cms cms configuration expand roughly cms cms hydrated fully expand interestingly adm product line fall company orthopedic tissue technology segment contribute company total revenue last report quarter latest launch be expect further boost top line contribution segment company launch surgimend mp collagen matrix complex abdominal hernia repair feature highly macroporous design enable fluid drainage also company announce european launch dermal regeneration template single layer thin dermal repair defect reconstruction step procedure same month integra lifescience effort grow plastic reconstructive surgery market seem be strategic technavio datum publish business wire report global plastic surgery product market be expect reach value cagr grow consciousness appearance woman increase awareness rise expenditure healthcare technological advancement be likely drive demand cosmetic surgery time fact be further substantiated datum provide global market insight project global breast implant market be set reach worth roughly cagr period believe latest launch help integra lifescience cash bountiful opportunity niche market share price performancein last month integra lifescience have be consistently trading broader industry date stock have gain higher gain broader industry zack rank other key picksintegra lifescience currently carry zack rank buy other top rank stock medical sector be orthofix international ofix free report luminex corporation lmnx free report idexx laboratory inc idxx free report orthofix international luminex corporation sport zack rank strong buy idexx laboratory carry zack rank see complete list today zack rank stock here orthofix international have long term expect earning growth rate stock have rally roughly last month luminex have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last year hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
614,IDXX,oct issue update research report chesterbrook pa base corporation abc free report world largest pharmaceutical service company company focus provide drug distribution related service reduce health care cost improve patient outcome company currently have zack rank sell have unimpressive run bourse last month trading industry term price performance glimpse price movement reveal share have lose compare unfavorably gain industry belong unfavorable performance be lead pricing pressure generic drug space lackluster guidance full year expect fiscal revenue growth range significantly lower previous range band company expect brand drug inflation range take pharmedium healthcare holding back believe temporary slowdown pharmedium growth mar bottom line come quarters notably company aim boost investment enhance pharmedium quality assurance qa quality control qc system term product quality patient safety lend company competitive advantage long haul result bottom line headwind business fiscal lackluster performance hepatitis revenue segment be concern witness negative revenue impact decline sale segment last report second quarter revenue improve only quarter have be adverse impact hepatitis segment cutthroat competition niche space be additional concern operate highly competitive pharmaceutical distribution related health care service market company primary competitor be national generic regional distributor generic industry be witness consolidation customer manufacturer globalization increase quality regulatory challenge company also face competition manufacturer chain drugstore specialty distributor packaging health care technology company key picksa few better rank medical stock be idexx laboratory inc idxx free report luminex corporation lmnx free report masimo corporation masi free report carry zack rank buy see complete list today zack rank strong buy stock here idexx laboratory have positive earning surprise last quarters stock have roughly surge last year luminex corporation have long term expect earning growth rate more stock have gain last month masimo have long term historical adjust earning growth stock have rally nearly year date hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
615,IDXX,oct issue update research report co base davita healthcare partner inc dva free report lead provider dialysis service unite state patient suffering chronic kidney failure be also know end stage renal disease esrd past month share company have be trading broader industry stock have lose compare broader industry decline acquire dialysis center business own operate similar center other ancillary service have be davita prefer business strategy long strategy have boost company top line large extent major acquisition recent past everett clinic medical group davita medical group division acquire totem lake family medicine be renown medical group further davita announce healthcare partner have enter strategic partnership cigna global health insurance service company agreement duo offer hmo health maintenance organization health plan integrate health care option employer los angele steady expansion overseas market strategic alliance acquisition dialysis center have play key role boost growth davita past few year company have strengthen position emerge develop market columbia portugal malaysia taiwan saudi arabia china india germany be expect help davita deliver more efficient patient care however company expect hike dialysis related lab service general administrative expense upcoming quarters davita plan undertake initiative improve information technology infrastructure be likely result higher cost investment support regulatory compliance legal matter well effort tap new business opportunity drive expense zack rank key picksdavita healthcare currently carry zack rank hold better rank stock medical sector be orthofix international ofix free report luminex corporation lmnx free report idexx laboratory inc idxx free report orthofix international luminex corporation sport zack rank strong buy idexx laboratory carry zack rank buy see complete list today zack rank stock here orthofix international have long term expect earning growth rate stock have surge roughly last month luminex corporation have long term expect earning growth rate stock have rally last month idexx laboratory have long term expect earning growth rate stock have climb year time look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
616,IDXX,cardiovascular system inc csii free report expect fiscal first quarter revenue be affected devastate harvey irma hurricane earlier company have estimate revenue range quarter however take effect hurricane account company anticipate drop first quarter revenue previously guide range accord cardiovascular system more company revenue be generate houston florida hurricane have dent procedure volume greater houston area florida moreover fiscal first quarter revenue be more heavily weight september procedure volume start pick summer level thus company be not confident meeting previously guide range first quarter revenue management expect short term performance be affected long term prospect be likely be untarnished majority last year cardiovascular system have be trading broader industry currently stock have gain higher gain broader industry however stock lose announcement sep estimate revision estimate revision trend have be unfavorable company current quarter estimate moved north compare movement opposite direction last month result zack consensus estimate full year have fall cent loss cent share same period zack rank key systemscarry zack rank hold few better rank medical stock be edward lifescience corporation ew free report amedisys inc am free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy amedisys idexx carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month amedisys have long term expect earning growth rate stock have gain last year idexx have long term expect earning growth rate stock have gain last year promising stock pick keep eye news story computer hacking identity theft become increasingly commonplace cybersecurity industry look promising investment opportunity stock buy zack just release cybersecurity investor guide locking profit help answer question new special report give information need make well inform investment choice space more importantly also highlight cybersecurity pick strong profit potential get new investing guide now
617,IDXX,sep issue update research report lead manufacturer proprietary life science material research system bruker corporation brkr free report last month billerica base company have gain compare industry company impressive second quarter earning revenue growth have bolster market confidence lead further rally share price late company have be witness growth nano surface business restructure cost reduction action portfolio also get boost acquisition hysitron nano indent product begin improve result axs business moreover be upbeat thecompany recent launch venture biotool laboratory macromolecular crystallography be part axs segment bruker nano additionally company gain traction semiconductor metrology market certain industrial apply end market segment zack rank hold company have be consistently introduce product portfolio company recently unveil ray diffraction xrd system japan analytical scientific instrument show jasis be also encourage launch eiger latest generation hybrid photon count hpc pixel detector bruker dectris notably build dectris eiger detector have be integrate bruker advance instrument platform enhance several ray diffraction xrd application be also impressed bruker latest product developmental activity nuclear magnetic resonance nmr spectroscopy business company line launch include neo platform next generation nmr console tiger series spectrometer management also claim have make technical quality progress high temperature superconduct ht tape management expect ht boost ultra high field gigahertz nmr business be also upbeat company receipt fda approval add new species maldi biotyper system efficient microbial identification notably maldi biotyper be company latest revolutionary approach analysis microorganism late bruker have be work chalk strategy improve financial performance initiative include divestiture certain core business outsource various manufacturing activity transfer cease operation certain facility meanwhile company raise revenue guidance raise optimism flip side bruker conduct business international market result adverse currency fluctuation continue result loss company moreover headwind such unfavorable economic condition intense competition continue threat key picksa few better rank medical stock be edward lifescience corporation ew free report amedisys inc am free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy amedisys idexx carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month amedisys have long term expect earning growth rate stock have gain last month idexx have long term expect earning growth rate stock have gain last year promising stock pick keep eye news story computer hacking identity theft become increasingly commonplace cybersecurity industry look promising investment opportunity stock buy zack just release cybersecurity investor guide locking profit help answer question new special report give information need make well inform investment choice space more importantly also highlight cybersecurity pick strong profit potential get new investing guide now
618,IDXX,developer robotic technology product mazor robotic ltd mzor free report recently announce expect report third quarter revenue approximately compare year quarter bullishness come strength mazor system sale increase procedure volume stock price performance israel base company have be encourage last month stock have return outperform industry gain roughly stock current return be higher return same time frame bullish price trend estimate revision stock have be quite disappointing full year see estimate move south last month compare movement opposite direction result estimate contract loss cent share loss cent aforementioned period factor mazor strengthdure third quarter company receive purchase order mazor system unite state addition mazor receive purchase order renaissance system chinese market mazor be guidance system simplify spine surgery advanced feature sophisticated integrative ability strong demand mazor system third quarter reach backlog introduction second half company be slate report financial result third quarter end sep november bottom linewe be hopeful encourage global spine surgery market research report market market suggest niche market be estimate reach cagr fact increase utilization rate mazor be quite compelling company believe cycle mazor platform be progress plan grow customer base zack rank other key pickscurrently mazor have zack rank strong buy few other top rank stock broader medical sector be abbott free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report abbott idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank stock here abbott have long term expect earning growth rate stock have rally roughly last year idexx laboratory have long term expect earning growth rate stock have gain last year thermo fisher have long term expect earning growth rate stock have gain last year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
619,IDXX,wall street be gear third quarter release republican have lose battle pertain repeal affordable care act aca obamacare recent graham cassidy bill defeat sometimes lose battle find new way war president trump however recent development suggest table turn again president latest executive order aim exempt certain association health plan buy health insurance core obamacare schedule take shape serious threat healthcare community large also rep lindsey graham promise revisit graham cassidy legislation deserve mention here issue medtech industry have so far have bullish run notwithstanding third quarter be likely take hit policy debacle fact latest gop defeat dampen probability new republican healthcare reform better tax paradigm time soon here take sneak peek other burn issue be likely impact quarterly number medtech fraternity tax wo present point focus capitol hill seem be tax cut medtech community have be quite hopeful change presidential power trump propose policy have be favor abolition infamous medical device sale tax undoubtedly abolition tax paradigm be far be achieve add stronger dollar pricing shipping related issue well core market challenge be likely affect quarterly number medtech major season hurricane deal blow various report suggest unfortunate occurrence hurricane end third quarter be likely mar revenue earning several medtech company primarily florida texas puerto rico medtech major medtronic mdt free report acknowledge impact hurricane marium quarterly metric company expect almost impact revenue earning apart natural calamity rise unemployment short live decline consumer income couple increase aggregate spending be likely deal heavy blow medtech number stock buy solid return have take help zack stock screener shortlist medtech stock zack rank strong buy buy be expect yield solid result third quarter have zero stock andhave favorable growth style score research show stock style score combine zack rank offer best investment opportunity furthermore estimate revision trend stock have be solid current quarter idexx laboratory inc idxx free report zack rank company have growth score idexx laboratory be developer manufacturer distributer product service primarily companion animal veterinary livestock poultry water testing dairy market company expect livestock poultry dairy revenue witness stellar growth quarter strong growth china last month analyst moved north compare movement opposite direction zack consensus estimate increase current quarter same time frame company be expect see sale growth quarter be report furthermore earning be expect increase year year basis idexx laboratory inc price consensus idexx laboratory inc price consensus idexx laboratory inc quotesteris corp ste free report zack rank company have growth score recent past steris have be strategically pursue expansion adjacent market acquisition dilution earlier year company sell uk linen business have late complete divestment linen business come estimate revision trend current quarter analyst moved north compare movement opposite direction completion synergy health deal steris combine business be expect gain market traction overseas additionally strong cash balance position be encourage steris be expect witness growth earning quarter be report year year basis steris plc price consensus steris plc price consensus steris plc quotek group holding inc free report zack rank company have growth score estimate revision trend stock have be solid upward estimate revision last month zack consensus estimate current quarter increase same time frame solid operational execution group be expect enjoy edge spinal fusion market quarter furthermore significant progress product development print product portfolio be positive company be expect witness growth sale rise earning third quarter group holding inc price consensus group holding inc price consensus group holding inc quotetandem diabetes care inc tndm free report zack rank company have growth score demand tandem next generation slim pump be expect stay high add stellar growth insulin pump sale be expect drive company third quarter number estimate revision trend stock have be solid estimate move upward compare downward last month zack consensus estimate current quarter rise same time frame company be expect witness growth sale rise earning third quarter tandem diabetes care inc price consensus tandem diabetes care inc price consensus tandem diabetes care inc quoteintersect ent inc xent free report zack rank stock have growth score successful launch past propel contour be expect be key driver third quarter sale company initial product propel propel mini be drug eluting implant use patient chronic sinusitis offer product therapy ear nose throat surgeon improve treatment patient chronic disease intersect be expect witness year year growth sale rise earning quarter be report intersect ent inc price consensus intersect ent inc price consensus intersect ent inc quotetoday stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
620,IDXX,irvine base masimo corporation masi free report recently announce clearance full market release proprietary rad pulse co oximeter launch rad offer masimo noninvasive continuous monitoring measure motion low perfusion set pulse oximetry upgradeable rainbow technology be include compact standalone monitor incorporate advanced customizability connectivity device integration capability masimo pulse oximetry prodcut aim give accurate oxygen saturation pulse rate measurement wider adoption invasive patient monitoring technology be help company gain market share also masimo set pulse oximetry business have considerable growth opportunity international market believe masimo innovative product line drive top line growth consider bountiful opportunity advanced monitoring technology global market launch instill investor confidence stock research report market market reveal niche market be expect reach worth globally cagr additionally masimo long term growth fundamental be strong company record year cagr revenue adjust earning share masimo have particularly witness improvement earning last year masimo develop manufacture market family invasive monitoring system latest development significantly fortify company position niche market masimo carry zack rank buy year date masimo have outperformed industry term price company have return compare sub industry gain also current return be higher gain same time frame other key picksa few other top rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc notably edward lifescience sport zack rank strong buy idexx laboratory cogentix medical hold zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat last quarters company have long term expect earning growth rate idexx laboratory deliver average earning beat trail quarters have long term expect earning growth rate cogentix medical come positive earning surprise last quarter stock represent stellar return last year promising stock pick keep eye news story computer hacking identity theft become increasingly commonplace cybersecurity industry look promising investment opportunity stock buy zack just release cybersecurity investor guide locking profit help answer question new special report give information need make well inform investment choice space more importantly also highlight cybersecurity pick strong profit potential get new investing guide now
621,IDXX,sep issue update research report san francisco base mckesson corporation mck free report health care service information technology company stock currently carry zack rank hold past month mckesson have be trading broader industry last trading price stock have gain higher broader market gain company continue witness strong growth pharma biotech backed solid market fundamental plan growth strategy raise guidance be also encourage mckesson deliver disappointing result recently report first quarter fiscal adjust earning revenue miss zack consensus estimate quarter see strong performance distribution solution segment segment be expect remain consistent performance fiscal weak pricing trend customer consolidation boost growth company recently acquire covermymed approximately come guidance distribution solution business revenue growth be expect witness robust growth year year basis upside be expect be drive market growth acquisition mckesson expect gaap earning diluted share fiscal end mar adjust earning same period be expect range diluted share flipside pricing pressure independent retail pharmacy channel be headwind mckesson enter fiscal assumption brand inflation mid single digit first quarter slightly surpass expectation mckesson have be witness increase price competition independent retail pharmacy channel eventually result reduce volume company continue witness competitive market selling generic pharmaceutical unite state however expect overcome independent pharmacy sell side pricing impact end second quarter fiscal cutthroat competition niche market currency headwind reimbursement issue remain challenge estimate revision estimate revision trend mckesson have be unfavorable moment current quarter analyst moved south compare movement opposite direction last month result magnitude full year estimate fall key picksa few better rank medical stock medical sector be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx have long term expect earning growth rate stock have gain last year new report investor guide have become more frequent destructive ever fact re expect cause year damage cybersecurity industry be expand quickly response threat fact project year be spend protect consumer corporate asset zack have just release cybersecurity investor guide locking profit reveal promising investment candidate download new report now
622,IDXX,several fail effort repeal replace obamacare trump government come graham cassidy heller johnson gchj bill graham cassidy bill however bill also fail materialize believe be boon space congressional budget office cbo latest warning report project health coverage loss million american due reduction federal spending medicaid meanwhile market be abuzz rumor signing impending executive order trump fortnight believe threat healthcare player be believe draft be pass industry see contraction customer base trump obamacare replacement saga have compel investor keep eye medtech sector accord report today medical development report global medical device market be position impressive growth term revenue international trade value be expect reach respectively due age population increase healthcare cost technological advancement growth stock focuslet take look medtech stock be expect gain long haul apart flaunt strong zack rank strong buy buy stock boast growth style score growth style score highlight vital metric company financial obtain clearer picture quality sustainability growth research show stock style score combine zack rank offer best investment opportunity straumann hold ag straumann group be global leader implant restorative dentistry oral tissue regeneration company sport zack rank have long term expect earning growth rate project ep growth rate stock year stand compare broader industry projection company have growth score see complete list today zack rank stock here stock have gain last year better broader industry idexx laboratory inc idxx free report idexx laboratory be world leader provide diagnostic detection information product animal health industry well quality assurance product service food water industry zack rank company have long term expect earning growth rate growth score project ep growth rate stock year stand compare broader industry estimation stock have gain last year higher broader industry company have growth score vgm score steris plc ste free report steris provide infection prevention contamination control microbial reduction procedural support product service healthcare pharmaceutical scientific research industrial governmental customer company boast zack rank growth score vgm score stock have gain last year compare broader industry gain historical ep growth rate stock year stand compare broader industry tandem diabetes care inc tndm free report tandem diabetes care design develop commercialize product person insulin dependent diabetes zack rank stock promise long term expect earning growth notably tandem diabetes care have growth style score project ep growth rate stock year stand compare broader industry projection stock have gain last month higher broader industry gain today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
623,IDXX,pacific bioscience california inc pacb free report recently form alliance genomic datum drive medicine company bluebee develop advanced assembly pipeline integrate company technology combine solution be introduce american society human genetic ashg annual meeting be hold next week orlando fl announcement menlo park base pacific bioscience assembly pipeline now be integrate bluebee genomic analysis platform integration offer simplified fully automate end end datum analysis solution allow assembly genome size include human variety also include guarantee turn time enable better plan improve productivity grow demand single molecule real time smrt sequence genomic community company expect huge customer adoption new cloud base analysis option pacific bioscience end end solution integrate downstream datum analysis bluebee high security regulatory compliant compute center pacific bioscience global customer notably smrt sequence provide complete accurate picture genome courtesy superior performance sequence accuracy uniformity coverage extremely long read length ability characterize dna base modification be perfect tool investigate high sequence genetic complexity otherwise difficult resolve used short read technology industry prospect significantly prospect long read sequence market pacific bioscience be lead name be grow leap bound recent report decisive bio insight next generation sequence ngs manufacturer market size reach grow annum rate touch primarily drive adoption worldwide clinical customer believe pacific bioscience slew latest development be well time industry price performance past month stock have surge more compare favorably broader industry gain roughly zack rank key pickspacific bioscience currently carry zack rank hold few better rank stock medical sector be abbott free report thermo fisher scientific inc tmo free report idexx laboratory inc idxx free report stock carry zack rank buy see complete list today zack rank stock here abbott have long term expect earning growth rate stock have rally roughly last month thermo fisher have long term expect earning growth rate stock have gain last year idexx laboratory have long term expect earning growth rate stock have surge last year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
624,IDXX,initiative boost customer base algerium lead medical device software manufacturer varian medical system inc var free report recently announce conduction day workshop radiotherapy practitioner country varian have system operate algerium moment latest development signify company long term goal serve cancer patient year workshop demonstrate advanced prostate head neck treatment technique be attend clinical team regional hospital latest development be collaboration algerian ministry health help clinician use varian technology deliver advanced radiotherapy cancer patient algerium fact first varian linear accelerator be install year country varian also inked deal algerian ministry equip country cancer treatment center company technology radiotherapy radio surgery meanwhile varian solid performance radiotherapy business improve margin launch halcyon radiotherapy treatment system be key highlight furthermore strong revenue opportunity several oncology imaging component product grow adoption proton therapy strong overseas presence particularly emerge country new partnership be key positive varian have be consistently expand internationally long fact company have receive order australia belgium india morocco romania russia turkey unite kingdom last quarter regard varian proton therapy unit have seal deal bangkok base king chulalongkorn memorial hospital earlier year march brazil base moinhos hospital initiate cancer treatment country used varian technology precisely moinhos used company flagship product calypso tumor tracking system cancer treatment varian have zack rank hold past month varian medical have outperformed broader industry term price company have return compare sub industry also current return be higher gain same time frame key picksa few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc notably edward lifescience sport zack rank strong buy idexx laboratory cogentix medical have zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat last quarters company have long term expect earning growth rate idexx laboratory deliver average earning beat trail quarters have long term expect earning growth rate cogentix medical come positive earning surprise last quarter stock represent stellar return last year new report investor guide have become more frequent destructive ever fact re expect cause year damage cybersecurity industry be expand quickly response threat fact project year be spend protect consumer corporate asset zack have just release cybersecurity investor guide locking profit reveal promising investment candidate download new report now
625,IDXX,sep issue update research report north kansa city mo base cerner corporation cern free report lead global provider healthcare information technology solution hcit stock currently carry zack rank hold believe cerner have solid growth opportunity revenue cycle management rcm suite solution fact segment have be strong contributor recent time revwork service deliver solid performance fact booking second quarter be time high year year basis secondary growth driver cerner be population health ph management platform notably company clinch high number large contract ph platform last report quarter cerner offer exposure worldwide healthcare automation international operation provide more diversify revenue stream past company win contract well middle east furthermore cerner constantly pursue complementary business acquisition enable expand solution device offering service flipside company operate hcit space be intensely competitive fast evolve subject rapid technological change share price estimate revisioncerner have impressive run bourse last month trading industry term price performance glimpse price movement reveal cerner share have gain compare favorably rise industry belong cerner corporation price cerner corporation price cerner corporation quoteon flip side estimate revision trend current year remain unfavorable estimate move south last month compare only movement opposite direction company current estimate slip past month key picksa few better rank medical stock be edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc edward lifescience sport zack rank strong buy idexx laboratory cogentix medical hold zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat last quarters company have long term expect earning growth rate idexx laboratory have average earning beat trail quarters have long term expect earning growth rate cogentix medical come positive earning surprise last quarter stock represent stellar return last year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
626,IDXX,sep issue update research report petm express inc pet free report petm currently carry zack rank hold last month petm have be trading broader industry last trading price company have gain stupendous compare growth broader industry fiscal first quarter petm post better expect result mark solid start fiscal be encourage significant increase reorder sale new order sale quarter expect same continue year petm be strive implement several strategy revitalize top line include focuse advertising efficiency boost new order sale shift sale higher margin item expand product offering however be apprehensive escalate advertising expense incur quarter company market product primarily well know brand medication such frontline advantix advantage heartgard sentinel interceptor other flip side petm operate highly competitive fragmented pet medication market competitor include veterinarian traditional retailer other mail order online retailer pet medication other health product also acquisition novartis animal health division eli lilly company have give rise more challenge petm key pickssome better rank medical stock be edward lifescience corporation ew free report idexx laboratory inc idxx free report amedisys inc am free report edward lifescience sport zack rank strong buy idexx amedisys carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month amedisys have long term expect earning growth rate stock have gain last month idexx have long term expect earning growth rate last month stock have return look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
627,IDXX,investor keen consolidation abbott lab free report alere expect much await good news arrive soon abbott latest update necessary regulatory clearance get fulfilled closure company finally plan complete hugely contentious acquisition alere inc oct notably year rollercoaster ride overcome regulatory hurdle abbott alere have progressed merger process base certain amend term original agreement amend agreement clause announce earlier april abbott have agree pay common share acquire alere reduction earlier deal common share cash transaction conclusion result expect new equity value approximately lower originally estimate equity value almost takeabbott have state successful wrap transaction total diagnostic sale be company also anticipate emerge lead player point care diagnostic space broader diagnostic market takeover combine entity be expect generate approximately point care testing sale worldwide buyout also enable company gain access new channel geography include entry fast grow outlet such doctor office clinic pharmacy home testing more alere complementary portfolio diagnostic product comprise test infection such hiv tuberculosis malaria dengue be add abbott portfolio significantly alere develop simple rapid test include alere molecular test flu strep deliver report less minute hence share business offer several option test broad array instance infectious disease molecular cardiometabolic toxicology testing also union definitely expand abbott lab platform include benchtop rapid strep test alere hitherto generate half total sale unite state alone company have grow presence key international market potential strengthen abbott footprint ahead territory price performanceover past month abbott share price have outperformed broader industry belong stock have gain versus industry loss zack rank other key picksabbott currently carry zack rank hold better rank medical stock be idexx laboratory inc idxx free report luminex corp lmnx free report masimo corp masi free report carry zack rank buy see complete list today zack rank strong buy stock here idexx laboratory have positive earning surprise last quarters stock have roughly surge last year luminex corp have long term expect earning growth rate stock have gain last month masimo have expect long term adjust earning growth almost stock have rally nearly year date today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
628,IDXX,masimo corporation masi free report have be healthy growth trajectory late have rally last month ahead gain stock have market cap irvine base masimo develop manufacture market family invasive monitoring system stock have long term expect earning growth solid estimate revision estimate revision trend current year have be favorable masimo past day estimate moved north movement opposite direction result zack consensus estimate current year moved notably positive trend signify bullish analyst sentiment masimo boast zack rank buy indicate robust fundamental expectation outperformance term let find recent positive trend be sustainable growth tide regulatory front masimo announce clearance full market release proprietary rad pulse co oximeter earlier month launch rad offer masimo noninvasive continuous monitoring measure motion low perfusion set pulse oximetry upgradeable rainbow technology consider substantial demand advanced monitoring technology global market launch reinstate investor confidence stock research report market market reveal global niche market be expect reach worth cagr compelling fundamental growth story masimo long term growth fundamental be strong company record year cagr revenue adjust earning share company have particularly witness improvement earning last year positive study result august india base study masimo sphb platform demonstrated encourage result study conclude masimo sphb allow physician exclusively focus haemoglobin trend oncosurgery earlier month netherland base study analyze performance masimo ispo rx screening newborn critical congenital heart disease also demonstrated positive result other stock consider few other top rank stock broader medical sector include edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc edward lifescience sport zack rank strong buy idexx laboratory cogentix medical hold zack rank see complete list today zack rank stock here edward lifescience deliver average earning beat last quarters company have long term expect earning growth rate idexx laboratory have average earning beat trail quarters have long term expect earning growth rate cogentix medical come positive earning surprise last quarter stock represent stellar return last year trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
629,IDXX,initiative eradicate ambiguity determine medicinal cost discount allscript healthcare solution inc mdrx free report recently launch allscript real time health system exclusive work flow solution optimize clinical financial impact medical prescription enhance prescription price transparency latest launch allscript aim provide clinician patient complete information include medication price cost alternative therapy competitive price prescribe therapy different pharmacy notably allscript be first major healthcare information technology player come such solution undoubtedly allscript real time health system boost consumer knowledge satisfaction management company emb prescription pricing information work flow system help lead pharmacy benefit manager technology partner nation regard management allscript be hopeful company partnership drfirst goodrx surescript deliver real time benefit price information earlier month allscript announce dbmotion solution platform have be select south western sydney phn swsphn deliver integrate care notably dbmotion solution be allscript proprietary community platform dbmotion solution support swsphn goal improve clinical excellence promote quality care also help swsphn collaborate internationally recognize dbmotion site unite state canada israel stock performance lack lusterallscript have zack rank hold company have have discourage run bourse last year stock represent return just compare unfavorably gain further current level be lower broader industry return same time frame notably allscript expect modest increase operate expense second half support business growth company product have long sale cycle involve decision make different managerial level increase company operate expense even result cancellation order takeallscript management be focuse various restructure initiative research development plan launch exclusive product management have also be try streamline operational efficiency cater client need introduction product believe favorable demographic trend reinforce supportive regulatory environment be expect sustain growth demand company higher client demand company population health management solution drive long term growth long term expect earning growth rate instill confidence investor regard key picksa few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc notably edward lifescience sport zack rank strong buy idexx laboratory cogentix medical have zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat last quarters company have long term expect earning growth rate idexx laboratory deliver average earning beat trail quarters have long term expect earning growth rate cogentix medical come positive earning surprise last quarter stock represent stellar return last year look stock skyrocket upside zack have just release special report boom investment opportunity legal new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
630,IDXX,sep issue update research report thermo fisher scientific inc tmo free report lead scientific instrument maker stock currently carry zack rank buy past month thermo fisher have be trading broader industry last trading price stock have gain higher broader market gain time frame company continue see strong growth pharma biotech backed solid market fundamental plan growth strategy raise guidance be also encourage company acquisition activity drive growth inorganically also raise hope be particularly upbeat company foray high potential contract development manufacturing organization cdmo space recent acquisition patheon moreover takeover fei company have start contribute thermo fisher analytical instrument portfolio few company other strategic purchase be finesse solution alfa aesar meanwhile waltham base company plan continue strengthen foothold emerge market such china india translate success other high priority opportunity region such south korea russia brazil second quarter company record solid contribution china india middle east be also upbeat company recent open center excellence electron microscopy saudi arabia additionally thermo fisher have strong cash balance enable adopt attractive share repurchase program turn provide solid return investor flip side thermo fisher derive majority revenue international market expose fluctuation foreign currency management currently estimate unfavorable foreign exchange have negative impact top line landscape have become intensely competitive thank change technology customer demand require continual research development other key picksa few other top rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx carry zack rank see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx have long term expect earning growth rate stock have gain last year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
631,IDXX,surmodic inc srdx free report recently announce promising clinical trial presentation datum preveil early feasibility study ef company surveil drug coat balloon dcb vascular interventional advance conference accord company preveil be multus center single arm trial design evaluate safety feasibility paclitaxel dcb surveil be used treat subject symptomatic peripheral artery disease pad due lesion femoral popliteal artery surmodic share have outperformed broader industry past month stock have gain period compare industry current level be also better return positive surveil result closely follow regulatory approval same platform reflect surmodic solid surface technology muscular device particularly drug delivery space come back news month datum be base patient be treat clinical site study show subject secure positive outcome demonstrate trial acute success measure safety company aim use lower drug dosage enhance drug transfer impact arterial wall reduce amount drug reach tissue outside area treatment surveil dcb meanwhile company anticipate increase expense second half fiscal be increase investment related surveil dcbtrial other proprietary product estimate revision latest estimate revision trend have be favorable company current year estimate moved north compare movement opposite direction last month result zack consensus estimate full year earning have increase cent share takeaccording report market research future global peripheral artery disease market be expect reach worth cagr period consider huge potential market believe latest development be strategic fit zack rank key zack rank hold few better rank medical stock medical sector be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx have long term expect earning growth rate stock have gain last year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
632,IDXX,qiagen qgen free report have be hog limelight recent partnership co marketing agreement centogene ag partnership aim deliver complete sample insight research clinical testing solution end user field rare genetic condition collaboration agreement qiagen integrate bioinformatic suite centogene highly develop centomd rare disease variant database goal improvise test understand notably integration centomd phenotype genotype database be expect considerably enhance qiagen knowledge base qiagen clinical insight qci bioinformatic solution co marketing agreement qiagen now act authorize exclusive international commercial distribution partner centomd also qiagen bioinformatic solution be license centogene support latter extensive rare disease diagnostic testing service bid grow bioinformatic portfolio offer valuable observation complex biological datum qiagen announce acquisition omicsoft corporation january acquisition qiagen gain access omicsoft powerful multus omic datum management infrastructure solution well omic datum bank believe company latest partnership centogene be strategic take consideration huge prospect bioinformatic globally accord market market report global bioinformatic market be project reach worth cagr believe increase spending healthcare government private organization rise awareness trigger need nucleic acid protein sequence technological innovation development back successful partnership company research institutes continue drive growth bioinformatic market thus latest development help qiagen cash bountiful opportunity niche market share price have be gain investor confidence consistently encourage result last month company share price have outperformed broader industry stock have gain compare broader industry gain company have also surpass gain market same time frame zack rank other key picksqiagen currently carry zack rank buy other top rank stock medical sector be abbott free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report abbott idexx laboratory thermo fisher carry zack rank see complete list today zack rank strong buy stock here abbott have long term expect earning growth rate stock have rally roughly last month idexx laboratory have long term expect earning growth rate stock have gain last year thermo fisher have long term expect earning growth rate stock have gain last year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
633,IDXX,nuvasive inc nuva free report successfully continue make way company strategy strengthen footprint fast grow spine market follow last week announcement vertera spine buyout company be once again news courtesy commercial launch lessray software technology system nuvasive lessray system be base propriety software algorithm hardware component particularly work help address overexposure radiation hospital operate room mostly case minimally invasive spine surgery mis study result provide company spine orthopedic surgeon receive lifetime occupational radiation limit first year career statistic reveal cancer rate contraction cataract associate radiation exposure be nearly double compare other surgery practice nuvasive claim lessray system proprietary image enhancement technology improve low dose low radiation fluoroscopy image derive similar diagnostic capability conventional full dose fluoroscopy accordingly reduce radiation emission exposure retain high resolution full radiation dose shot nuvasive consider breakthrough important milestone healthcare facility begin sell capital equipment bring technology advancement hospital apart curb radiation exposure lessray system enhance imaging capability improve spine surgery productivity eventually predictability take consideration healthy pipeline interest customer nuvasive expect huge customer adoption rate follow launch lessray system notably nuvasive be leave stone unturned capture rapidly evolve spine market recently report second quarter company core spinal hardware business maintain bullish trend report growth upside be drive strong consistent adoption reline posterior fixation system company iga platform company also witness steady uptake recently launch expandable interbody cage base ti interfixated alif procedure latest acquisition vertera spine nuvasive aim market distribute vetera spine fda approve cohere cervical coalescetm lumbar interbody fusion device unite state deal also lend company dimensional porous interbody technology peek titanium material past month nuvasive have underperform broader industry stock have sunk contrast gain broader industry period expect company bounce back slew latest development spine space zack rank key picksnuvasive currently carry zack rank hold better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have surge last month idexx have long term expect earning growth rate stock have soar last year trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
634,IDXX,genomic health inc ghdx free report biocartis group nv bcart sign agreement develop diagnostic ivd version oncotype dx breast recurrence scoretest biocartis proprietary idylla platform be perform locally laboratory partner well hospital globally biocartis be innovative molecular diagnostic company provide next generation diagnostic solution accord genomic health oncotype dx breast recurrence score test evaluate activity gene patient breast tumor tissue provide customize treatment option base biology patient individual disease company claim be only proven test predict chemotherapy benefit consequently be include major cancer guideline worldwide further test be consider standard care early stage breast cancer biocartis idylla platform provide unique solution be unparalleled localization complex molecular diagnostic base advanced feature idylla platform genomic health expect local pathology lab generate oncotype dx breast recurrence score result minimal labor efficient turnaround time company also look forward maintain high quality clinical utility physician patient expect oncotype dx agreement provide genomic health right develop commercialize oncotype dx breast recurrence score test idylla platform development oncotype dx ivd test be expect initiate late genomic health be anticipate pay biocartis third quarter rest payment be make biocartis achieve few commercial milestone exclude transaction cost partnership genomic health continue anticipate earn profit full year agreement company make royalty payment base net sale ivd test develop biocartis idylla platform post september genomic health announce new datum show additional evidence unmatched value oncotype dx breast recurrence scoretest predict outcome early stage breast cancer patient accurately july majority panelist st gallen international breast cancer conference expert panel support oncotype dx be only test provide information aid physician take decision omit chemotherapy patient positive node panel also publish update guideline endorse oncotype dx guide chemotherapy treatment decision node negative node positive breast cancer patient june study breast cancer be present american society clinical oncology asco annual meeting include new analysis tie up surveillance epidemiology end result seer registry program study focuse outcome more woman have receive oncotype dx breast recurrence score test analysis examine risk breast cancer specific mortality full range recurrence score result be consistent previous validation study accord report gbi research global breast cancer therapeutic market be estimate reach cagr consider huge potential market believe latest agreement be strategical fit past year genomic health have be trading broader industry stock have gain comparison broader industry gain zack rank key picksgenomic health carry zack rank hold few better rank medical stock medical sector be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx have long term expect earning growth rate stock have gain last year trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
635,IDXX,angiodynamic inc ango free report report adjust earning cent share first quarter fiscal earning miss zack consensus estimate cent decrease year year meanwhile net sale fall almost year year basis miss zack consensus estimate be important note foreign exchange do not have impact report quarter however continue softness vascular access venous business affected revenue first quarter internationally angiodynamic register revenue year quarter international growth be strengthen solid sale oncology surgery business however company register revenue unite state year year basis lackluster performance be lead softness venous business be more less muted growth oncology portfolio angiodynamic inc price consensus ep surprise angiodynamic inc price consensus ep surprise angiodynamic inc quotesegment vascular pv business sale segment totale report quarter lower year quarter quarter see slow growth venous core business be offset stellar performance fluid management thrombus management product line disappointing performance pv segment management expect thrombus management platform lend company competitive edge open significant long term opportunity note angiodynamic be lead player thrombolytic catheter space catheter direct thrombolysis company boast highly unique catheter uni fuse speedlyser pulse spray thrombus portfolio vascular access va business sale segment be year year basis however be offset solid growth bioflo midline dialysis bioflo line product segment be expect be key catalyst oncology surgery business angiodynamic witness sale first quarter year year basis segment perform impressively recent launch solero microwave tissue ablation system meanwhile angiodynamic announce market withdrawal flagship acculis microwave tissue ablation system last quarter margin detailsadjust gross margin decrease basis point bps quarter decline gross margin be primarily voluntary market withdrawal acculis microwave tissue ablation system recent past solero direct impact gross margin be approximately bps adjust ebitda first quarter fiscal exclude item show attach reconciliation table be compare first quarter fiscal financial have strong cash flow balance first quarter management company generate operate cash flow free cash flow additionally angiodynamic end quarter cash cash equivalent outstanding debt reaffirm guidance fiscal fiscal company expect adjust earning share band cent cent company project fiscal revenue range furthermore free cash flow be expect be more report dismal first quarter fiscal adjust earning revenue miss zack consensus estimate company also reaffirm guidance fiscal angiodynamicis ride market solid response solero especially microwave ablation space growth core angiographic catheter business be also likely fortify company footprint global space flipside angiodynamic recall acculis microwave tissue ablation system oncology surgery segment last quarter company also have high outstanding debt level end first quarter higher debt impose certain operate financial restriction limit execution company core business strategy zack rank key have zack rank hold few better rank stock broader medical sector be sonova hold sonvy free report idexx laboratory inc idxx free report cogentix medical inc company hold zack rank buy see complete list today zack rank strong buy stock here sonova represent solid return last year company have long term expect earning growth rate idexx laboratory have average earning beat trail quarters have long term expect earning growth rate cogentix medical come positive earning surprise last quarter stock represent stellar return last year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
636,IDXX,change political power unite state have be quite rough phase medtech thing start get president trump start proceed plan repeal obamacare series futile attempt republican re-sort skinny repeal obamacare fail well now republican be back latest graham cassidy bill target termination obamacare investor be busy gauge extent impact latest graham cassidy legislation medical device space have be few encourage development sub industry meanwhile company zack outpatient healthcare industry integral part medical device space currently have better prospect be evident zack industry rank place sub industry top zack industry back testing show top zack rank industry outperform bottom factor more thus be prudent investor pick stock fundamentally strong sub industry moment have choose amedisys inc am free report cheme corporation che free report base favorable zack rank buy amedisys market cap be lead provider healthcare service unite state company operate segment home health hospice personal care meanwhile cheme market cap be lead provider hospice palliative care service nation company operate segment vita roto rooter let now do comparative analysis stock make final call amedisys have vgm score compare cheme zack style score system stand value growth momentum vgm score be simply weight combination parameter be comprehensive tool allow investor filter standard score system pick winning stock amedisys also have favorable price earning growth peg ratio compare cheme amedisys also stand strong compare broader industry amedisys inc peg ratio ttm amedisys inc peg ratio ttm amedisys inc quotecheme corp peg ratio ttm cheme corp peg ratio ttm cheme corp attractive year project earning growth rate amedisys again score higher cheme industry amedisys also boast better leverage ratio compare cheme broader industry amedisys have favorable debt equity ratio compare cheme industry again long term debt capital ratio metric stand favor amedisys come comparison cheme broader industry amedisys estimate revision trend current year have also be attractive compare cheme past day estimate moved north movement opposite direction amedisys magnitude estimate revision earning increase same time frame cheme estimate moved north movement opposite direction past day magnitude estimate revision earning increase only same time frame base detailed analysis safely conclude amedisys make superior pick portfolio moment other key picksother top rank medical stock be edward lifescience corporation ew free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy idexx carry zack rank see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month idexx laboratory have long term expect earning growth rate stock have gain last year trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
637,IDXX,oct issue update research report illumina inc ilmn free report stock currently carry zack rank hold last month san diego base company provide tool integrate system analysis genetic variation function have be trading broader industry stock have gain period higher broader industry gain past few quarters company have deliver promising top line performance primarily banking strong product launch latest list include launch veriseq nipt solution europe also overall strong uptake novaseq be encourage moreover rate nipt adoption be rise outside unite state be also upbeat illumina partnership telegraph hill partner set independent company verogen inc independent company be expect boost illumina next generation sequence ngs business forensic genomic market have global commercial right product illumina be only provider miseq fgx forensic genomic system include miseq fgx sequencer forenseq dna signature prep kit forenseq universal analysis software be encourage development clinical market demand customer undergo oncology test remain robust moreover investor be await response extend ra panel be slate launch third quarter june company announce receipt fda approval extend ra companion diagnostic kit class iii pma be also look forward grail illumina own develop company focuse cancer screening market flip side weak margin due novaseq launch higher array service revenue product mix sequence consumable continue raise concern also national institutes health nih funding issue tough competitive landscape be few challenge deal key picksa few better rank stock medical sector be abbott free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report zack rank buy see complete list today zack strong buy rank stock here abbott have long term expect earning growth rate stock have rally roughly last month idexx laboratory have long term expect earning growth rate stock have gain last year thermo fisher have long term expect earning growth rate stock have gain last year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
638,IDXX,masimo corporation masi free report recently announce full market release ra single use adhesive respiration sensor rainbow acoustic monitoring ram respiration rate launch be expect strengthen company foothold grow global respiratory care market notably ram be flagship noninvasive technology masimo continuously measure respiration rate prospective patient used adhesive sensor acoustic transducer ra exclusively operate post surgical patient undergo patient controlled analgesia self administer pain management here note ra ra be notable adhesive sensor ram management ra go ahead highlight exclusivity product include smaller adhesive profile usage transparent adhesive flexibility compare like be available market product be also likely empower company flagship signal extraction set rainbow mx technology consider bountiful opportunity advanced monitoring technology global market launch instill investor confidence stock research report market market reveal niche market be expect reach worth globally cagr additionally masimo long term growth fundamental be strong irvine base company record year cagr revenue adjust earning share masimo have particularly witness improvement earning last year masimo develop manufacture market family invasive monitoring system latest development significantly fortify company position niche market masimo carry zack rank buy year date masimo have outperformed industry term price company have return compare sub industry increase also current return be higher gain same time frame other key picksa few other top rank stock broader medical sector be sonova hold sonvy free report idexx laboratory inc idxx free report cogentix medical inc company hold zack rank buy see complete list today zack rank strong buy stock here sonova yeilded solid return year company have long term expect earning growth rate idexx laboratory have average earning beat trail quarters have long term expect earning growth rate cogentix medical come positive earning surprise last quarter stock represent stellar return last year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
639,IDXX,amedisys inc am free report lead home health hospice service company be healthy growth trajectory late have rally year date ahead gain broader industry decline stock have market cap company long term expect growth rate be also favorable compare gain broader industry solid growth prospect zack rank buy stock be attractive pick present let find recent positive trend be sustainable company estimate revision trend current year have be positive past day analyst moved upward movement opposite direction magnitude estimate revision increase share same time frame late amedisys have be ride high solid potential new opportunity home health hospice service segment be also encourage company long term strategy evolve traditional home health hospice care company focuse unit bring home continuum care serve patient better service diversify source payment become less reliant medicare company have be witness growth personal care segment back synergy acquisition recently make slew strategic acquisition recent be intercity home care massachusett slate close oct home health industry be poise substantial growth long term drive positive demographic trend unite state company be expect continue benefit agee demographic population higher acuity patient home nursing environment notably company be track fortify footprint market place lately announce completion national readmission prevention collaborative certification program clinical program team handle home healthcare program additionally company strong cash balance position bolster confidence stock flip side anticipate synergy tenet healthcare acquisition escalate cost operate expense weigh company margin also intense competitive landscape regulatory concern continue challenge home health hospice industry other key picksother top rank medical stock be edward lifescience corp ew free report cheme corp che free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy cheme idexx carry zack rank see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month cheme have expect earning growth rate current year stock have gain last month idexx have long term expect earning growth rate stock have gain last month make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
640,IDXX,idexx laboratory inc idxx free report have be gain investor confidence consistent positive result stock have rally last year ahead gain broader industry rise moreover lead manufacturer product service primarily companion animal veterinary livestock poultry have market cap company year historical growth rate be also favorable compare industry solid prospect zack rank buy stock be attractive pick investor moment company estimate revision trend current year have be positive past day analyst revise estimate upward movement opposite direction magnitude estimate revision earning increase share same time frame also zack style score system idexx laboratory sport growth score suggest company strong growth prospect research show stock growth style score combine zack rank strong buy buy offer best upside potential regard idexx laboratory have favorable net margin net income sale industry negative company sale asset ratio compare industry ratio signify solid growth stock moreover project sale growth rate surpass industry rate let find recent positive trend be sustainable idexx laboratory continue display strong growth respect international expansion company have be significantly benefitting companion animal market emerge nation demonstrate bountiful opportunity stellar topline performance past few quarters be drive company companion animal business companion animal market fundamental remain solid tremendous global runway growth last report second quarter management unique innovation base multus modality global strategy enabled enhance commercial capability accelerate recur cag diagnostic revenue growth moreover strong top line growth quarter be drive considerable contribution other business segment also idexx laboratory recently announce addition rvetlink portfolio technology application additionally company have strong cash balance enable carry share repurchase program turn provide solid return investor flip side foreign currency fluctuation be major headwind company concern be company high reliance third party distributor idexx laboratory face higher operate expense pertain increase head count portfolio expansion higher investment target geographical expansion unite state internationally moreover competitive landscape domestic overseas market weigh company performance other key picksother top rank medical stock be edward lifescience corp ew free report cheme corp che free report amedisys inc am free report edward lifescience sport zack rank strong buy cheme amedisys carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month amedisys have long term expect earning growth rate stock have gain last month cheme have long term expect earning growth rate stock have gain last month make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
641,IDXX,edward lifescience corporation ew free report specialize player advanced cardiovascular disease be healthy growth trajectory late stock have rally last month ahead gain broader industry stock have market cap company year historical growth rate be also favorable compare increase broader industry gain solid prospect zack rank strong buy stock be attractive pick headquarter irvine company estimate revision trend current year have also be positive past couple month analyst moved north movement opposite direction magnitude estimate revision increase share same time frame let find recent positive trend be sustainable edward lifescience recently report second quarter performance be quite promising company beating zack consensus estimate revenue earning also raise guidance hint brighter prospect fact outlook increase be backed strong performance company product line market be also upbeat edward lifescience recent fda approval inspiris resilium aortic valve be first class resilient heart valf company also announce receipt fda approval aortic mitral valve valve procedure used sapien transcatheter heart valve believe recent fda approval several product have be boost investor confidence stock be encourage edward lifescience focus build strong pipeline further firm foothold operate business company have also witness growth emerge portfolio mitral tricuspid repair therapy latest plan company new ultra system include balloon delivery system next generation sheath technology be expect be available europe second half edward lifescience be also track initiate launch acumen hpi software suite new flotrac iq smart disposable inspiris resilium aortic valve europe japan end however stiff competition currency headwind reimbursement issue be challenge stock ahead other key picksother top rank medical stock be cheme corporation che free report amedisys inc am free report idexx laboratory inc idxx free report carry zack rank buy see complete list today zack rank stock here cheme have expect earning growth rate current year stock have gain last month amedisys have long term expect earning growth rate stock have gain last month idexx have long term expect earning growth rate stock have gain last month make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
642,IDXX,cheme corporation che free report have be gain investor confidence back consistent performance positive result stock have rally last year ahead gain industry rise lead manufacturer product service primarily companion animal veterinary have market cap company year historical growth rate be also favorable compare market solid prospect zack rank buy stock be attractive pick investor moment company estimate revision trend current year have also be positive past day estimate moved north movement opposite direction magnitude estimate revision earning share increase same time frame also zack style score system cheme sport growth score suggest company strong growth prospect research show stock growth style score combine zack rank strong buy offer best upside potential regard cheme have favorable net margin net income sale better industry sale asset ratio support company solid growth stock comparison industry moreover debt capital ratio be attractively place comparison industry let find recent positive trend be sustainable cheme second quarter performance be quite promising bottom line significantly improve year year basis stellar performance be drive company increase average net medicare reimbursement rate average daily census continue momentum raise outlook roto rooter segment earning share be indicative company anticipate improve operate result upcoming quarters turn boost investor optimism stock fact raise view be backed cheme expectation significant gain roto rooter business cheme vita business management note recent admission trend have be positive be expect continue come quarters second quarter vita perform well financially operationally thereby surpass company estimate additionally company strong cash balance enable carry share repurchase program provide solid return investor however headwind reimbursement related issue seasonality business competitive landscape dependence government mandate challenge cheme also tweak guidance medicare cap bill limitation be matter concern other key picksother top rank medical stock be edward lifescience corporation ew free report idexx laboratory inc idxx free report amedisys inc am free report edward lifescience sport zack rank idexx amedisys carry zack rank see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month idexx have long term expect earning growth rate stock have gain last month amedisys have long term expect earning growth rate stock have gain last month make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
643,IDXX,baxter international inc bax free report recently announce launch comprehensive asset tracking solution devicevue solution be used company proprietary pump system sigma spectrum infusion system aid clinician biomedical engineer quickly find unused pump view location status datum pc ipad iphone be bullish development provide edge sigma spectrum compare other smart pump market stock performance solidover past month baxter have gain compare favorably broader industry increase moreover current level be higher gain same time frame baxter be poise gain expand product portfolio increase penetration international market accretive acquisition be also key catalyst long haul company long term expect earning growth rate hold promise regard baxter have diverse portfolio improve exist product new product development namely more convenient kidney dialysis solution regenerative tissue product next generation sigma spectrum infusion pump recently notably deerfield il base company launch new version ak hd system platform offer way connectivity capability meet need potential patient baxter be medical technology company engage principally development manufacture sale medical device instrument system reagent company focus product launch be significant catalyst view additionally expansion plan especially emerge overseas market acquisition drive strategy hold considerable promise flipside lower demand healthcare product intense competition significant exposure foreign exchange volatility higher debt level major headwind zack rank stock considerbaxter have zack rank hold better rank medical stock include sonova hold sonvy free report idexx laboratory inc idxx free report cogentix medical inc company hold zack rank buy see complete list today zack rank strong buy stock here sonova represent solid return last year company have long term expect earning growth rate idexx laboratory have average earning beat trail quarters have long term expect earning growth rate cogentix medical come positive earning surprise last quarter stock represent stellar return last year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
644,IDXX,share mazor robotic ltd mzor free report have moved last month ahead gain broader industry rally stock have market cap solid prospect zack rank buy stock be attractive pick present company have deliver positive average earning surprise last quarters let find positive trend be sustainable company estimate revision have be encourage past day estimate moved north movement opposite direction current year accordingly zack consensus estimate have narrow loss cent share loss cent mazor robotic ltd price mazor robotic ltd price mazor robotic ltd market be upbeat company recent ce mark approval mazor surgical assurance platform approval allow mazor robotic partner medtronic commercialize co promote market mazor platformin country recognize ce mark mazor robotic solid performance last report second quarter have instilled confidence investor notably revenue marked increase year year basis company be also expand globally capitalize untapped market regard note mazor robotic end second quarter install system worldwide other key picksother top rank medical stock be biotelemetry inc beat free report idexx laboratory inc idxx free report amedisys inc am free report biotelemetry idexx laboratory amedisys carry zack rank see complete list today zack rank strong buy stock here biotelemetry have long term expect earning growth rate stock have rally roughly last month idexx laboratory have long term expect earning growth rate stock have gain last year amedisys have long term expect earning growth rate stock have gain last year hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
645,IDXX,luminex corporation lmnx free report have be healthy growth trajectory late have rally month time ahead gain stock have market cap solid prospect zack rank buy stock be attractive pick now company estimate revision trend current year have also be positive past day estimate have go upward luminex none move downward same time period zack consensus estimate moved cent cent same time frame let find recent positive trend be sustainable luminex second quarter witness strong top line performance solid cash flow soar profit company assay business be likely be key growth driver long term notably revenue quarter increase high year year further luminex reiterate annual revenue guidance band depict year year growth follow strong revenue performance second quarter luminex recently announce plan collaborate sutter health bid bolster molecular diagnostic testing portfolio collaboration be anticipate enhance company patient care technique especially case cystic fibrosis illness respiratory tract infection also late july luminex receive fda clearance ary assay be moderate complexity sample answer test rapid detection however stiff competition life science industry stretched valuation reimbursement issue be challenge stock other key picksother top rank stock medical sector be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain month time idexx have long term expect earning growth rate stock have gain last year trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
646,IDXX,davita inc dva free report subsidiary davita medical group recently announce receipt leadership energy environmental design leed gold certification green build council usgbc award have be confer davita base facility also know casa pacifica build notably leed gold certification be exclusively grant building situate sustainable site strong water energy atmosphere material resource efficiency additionally building operate superior indoor environment show innovation design regional priority credit undoubtedly davita casa pacifica build be solid choice base aforementioned criterium initiative bolster davita environmental goal company operation be conduct healthy environment davita be solely commit improve health care unite state violate basic environmental norm regard casa pacifica construction waste be divert landfill share lack lusterdavita have have unfavorable run bourse last month stock have lose almost much wider broader industry decline just current level also substantially underperform gain roughly deterioration be largely due ongoing political conundrum medical world have initiate presidential election high debt level adverse effect healthcare reform escalate expense be other major stock dampener favorable estimate revision estimate revision trend have be favorable company current quarter estimate moved north compare movement opposite direction last month result zack consensus estimate ongoing quarter have inched cent share same time frame davita carry zack rank hold full year estimate moved upward compare downward movement result zack consensus estimate full year have increase share same period takedavita environment friendly operation be likely enhance company sustainable growth long haul fact davita base headquarters be award leed platinum certification usgbc operation maintenance efficiency only last year davita significant growth recent time be reflect back strong patient service last quarter company see solid improvement kidney care davita also make crucial effort control expense company strength basically lie enhance service offering compelling inorganic growth story support strong financial position be key development catalyst moment key picksa few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc notably edward lifescience sport zack rank strong buy idexx laboratory cogentix medical have zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat trail quarters company have long term expect earning growth rate idexx laboratory deliver average earning beat trail quarters have long term expect earning growth rate cogentix medical come positive earning surprise last quarter stock represent stellar return last year trade profit big league trump policy stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
647,IDXX,share price deerfield il base baxter international inc bax free report scale new week high share sep then close bit lower company have gain past month much better rise past month zack rank hold stock have steadily outshined broader industry stock price have climb substantially higher broader industry gain stock have market cap almost also company estimate revision trend current quarter be favorable past month estimate have moved downward revision magnitude estimate revision same time period increase cent share company also have quarter average positive earning surprise baxter international inc price consensus baxter international inc price consensus baxter international inc quotegrowth catalystslong term outlook upbeat buoy stellar growth earning sale second quarter company raise long term outlook baxter estimate sale growth approximately compound annual basis notably adjust operate margin full year be expect be approximately revenue much previously issue guidance baxter expect full year adjust diluted earning band share fact baxter raise full year expectation sale growth approximately cc constant currency adjust earning share continue operation be forecast range third quarter baxter estimate sale rise cc adjust earning share be project cent bracket broad product spectrum latest week high come back company impressive product line baxter have exciting product portfolio improve exist product new product development namely more convenient kidney dialysis solution regenerative tissue product next generation sigma spectrum infusion pump last quarter baxter launch new version ak hd system platform offer way connectivity capability meet need potential patient favorable tiding regulatory front be well regulatory front baxter last quarter company receive clearance regulatory authority regard propose acquisition claris injectable additionally fda approval new premixed injectable be key catalyst company new product home pd technology also get fda nod second quarter platform leverage baxter flagship amia automate peritoneal dialysis apd system sharesource telehealth platform recently baxter achieve regulatory milestone advanced dialysis technology good news be company receive significant guidance fda clarify regulatory pathway home peritoneal dialysis pd solution system improve patient access same key picksa few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc notably edward lifescience sport zack rank strong buy idexx laboratory cogentix medical have zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat trail quarters company have long term expect earning growth rate idexx laboratory deliver average earning beat trail quarters have long term expect earning growth rate cogentix medical register positive earning surprise last quarter stock represent stellar return last year trade profit big league trump policy stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
648,IDXX,sep issue update research report steris plc ste free report manufacturer marketer infection prevention decontamination microbial reduction surgical support product service company currently carry zack rank hold last month ohio base company have be trading broader industry stock have gain contrast slip broader industry period be impressed company persistently strong organic growth performance segment also gross operate margin expand year year recently company make couple organizational change serve customer better way expect move enhance company cost structure well further growth free cash flow reserve be indicative company strong cash balance steris plc price steris plc price steris plc quotehowever note government insurance company consistent effort curb healthcare cost have be putt pressure stock quite time be also concern current customer consolidation scenario continue affect company checked immediately competitive landscape weak cost reduction initiative be other overhang key pickssome better rank medical stock be cheme corporation che free report idexx laboratory inc idxx free report amedisys inc am free report carry zack rank buy see complete list today zack rank strong buy stock here cheme have long term expect earning growth rate stock have gain roughly last month idexx laboratory have long term expect earning growth rate stock have surge last year amedisys have long term expect earning growth rate stock have rally last year hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
649,IDXX,orthofix international ofix free report have be gain investor confidence consistently positive result stock have rally year date ahead gain broader industry rise moreover medical device company provide reconstructive regenerative orthopedic spine solution physician globally have market cap company also deliver positive earning surprise prevailing quarters average beat banking solid prospect zack rank strong buy stock be attractive investment pick moment company estimate revision trend current year have be positive past day analyst revise estimate upward movement opposite direction magnitude estimate revision earning be share let find recent positive trend be sustainable orthofix deliver promising performance last report second quarter company strategic business unit sbu deliver better expect performance significant contribution biologic spine fixation management strength biologic spine fixation business be expect continue back improve performance sale partner expand distributorship network introduction product moreover orthofix seem be upbeat encourage response receive spinal stim cervical stim bone growth therapy device launch earlier moreover company cetra anterior cervical plate have witness strong market adoption result sale more first month launch continue slew product development launch company recently present rival full line foot ankle internal fixation system also extremity fixation space company recently launch juniortho new brand orthopedic product currently account roughly third extremity fixation sale also believe raise full year guidance be indicative brighter prospect orthofix have strong cash balance enable carry share repurchase program turn provide solid return investor flip side currency fluctuation competitive landscape macroeconomic headwind continue challenge company moreover higher operate expense be matter concern also increase dependence third party distribution product expose company risk other key picksother top rank medical stock be biotelemetry inc beat free report idexx laboratory inc idxx free report amedisys inc am free report biotelemetry idexx laboratory amedisys carry zack rank buy see complete list today zack rank stock here biotelemetry have long term expect earning growth rate stock have rally roughly last month idexx laboratory have long term expect earning growth rate stock have gain last year amedisys have long term expect earning growth rate stock have gain last year hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
650,IDXX,medtech industry have be grapple multiple issue president donald trump start work remove obamacare series futile attempt republican settle skinny repeal only meet failure again political scenario worsen republican vote favor exist healthcare act blessing disguise have be able delay cadillac tax also medtech industry be hopeful trump government do away medical device tax soon late trump have be strive implement regulatory change notably trump sign fda reauthorization act fdara law extend fiscal revise fda user fee medical device also center medicare medicaid service cms recently issue propose rule begin october medicaid share hospital dsh allotment be slash more period year stock pick right now such mixed scenario have used zack stock screener pick stock significant gain have narrow stock carry strong zack rank strong buy buy long term expect growth higher sale growth more have also take growth style score consideration growth style score highlight vital metric company financial obtain clearer picture quality sustainability growth research show stock style score combine zack rank offer best investment opportunity idexx laboratory inc idxx free report idexx laboratory be developer manufacturer distributer product service primarily companion animal veterinary livestock poultry water testing dairy market zack rank company have long term expect earning growth rate growth score see complete list today zack rank stock here idexx laboratory boast annual sale growth stock have gain past year compare industry lemaitre vascular inc lmat free report company market sell service support medical device implant treatment peripheral vascular disease worldwide lemaitre have zack rank promise long term expect earning growth rate growth score company annual sale growth be stock have gain last year compare broader industry gain veracyte inc vcyt free report veracyte be diagnostic company be focuse discover develop commercialize molecular cytology solution stock carry zack rank growth score company have long term expect earning growth rate annual sale growth stock have gain past year higher broader industry amedisys inc am free report company be lead multus regional provider home health care nursing service zack rank company have long term expect earning growth rate growth score annual sale growth be stock have gain last year compare broader industry decline straumann hold ag company be global leader implant restorative dentistry oral tissue regeneration sport zack rank promise long term expect earning growth rate annual sale growth be estimate stock have gain last year compare broader industry new report investor guide have become more frequent destructive ever fact re expect cause year damage cybersecurity industry be expand quickly response threat fact project year be spend protect consumer corporate asset zack have just release cybersecurity investor guide locking profit reveal promising investment candidate download new report now
651,IDXX,share biotelemetry inc beat free report have moved last month ahead gain broader industry rally stock have market cap company have long term growth solid prospect zack rank buy stock be attractive pick present company have deliver positive average earning surprise last quarters let find recent positive trend be sustainable one company estimate revision trend be positive past day analyst estimate moved north movement opposite direction current year zack consensus estimate have increase share cent say time frame current quarter analyst estimate moved north compare southward movement last day magnitude estimate revision current quarter rise cent cent same time frame market be upbeat biotelemetry strong top line performance past few quarters notably last report second quarter marked consecutive quarter year year revenue growth company also register growth segment expansion adjust operate margin be also encourage company consistent effort product innovation research development buoy optimism regard note research development expense increase second quarter furthermore biotelemetry acquire lifewatch ag deal value july buyout biotelemetry enhance position wireless medicine space expand product profile customer base cardiac monitoring diagnostic service space management expect acquisition yield significant synergy next month company manufacture product monitoring cardiac care patient precision raise full year revenue guidance be also encourage post acquisition lifewatch biotelemetry expect full year revenue range guidance be way higher full year report revenue be other key pickssome other top rank medical stock be edward lifescience corporation ew free report amedisys inc am free report idexx laboratory inc idxx free report edward lifescience sport zack rank amedisys idexx carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month amedisys have long term expect earning growth rate stock have gain last month idexx have long term expect earning growth rate stock have gain last month make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
652,IDXX,sep issue update research report allscript healthcare solution inc mdrx free report company have be healthy growth trajectory late have rally last year ahead gain zack rank hold stock have market cap allscript healthcare provide information technology solution service healthcare organization higher adoption company ehr solution particularly sunrise ehr platform consistently drive company top line help counter stiff competition long run initiative eradicate ambiguity determine medicinal cost discount allscript recently launch allscript real time health system exclusive work flow solution optimize clinical financial impact medical prescription enhance prescription price transparency latest launch allscript aim provide clinician patient complete information medication price cost alternative therapy competitive price prescribe therapy different pharmacy notably allscript be first major healthcare information technology player come such solution allscript healthcare solution inc price allscript healthcare solution inc price allscript healthcare solution inc quoteon flipside company expect modest increase operate expense second half allscript product have long sale cycle involve decision make different managerial level increase company operate expense add linger global economic weakness present substantial risk allscript manufacturer life save device demand software company product be closely tie budgetary process client result company have see significant decline system sale due decline customer order key picksa few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc notably edward lifescience sport zack rank strong buy idexx laboratory cogentix medical have zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat last quarters company have long term expect earning growth rate idexx laboratory deliver average earning beat trail quarters have long term expect earning growth rate cogentix medical come positive earning surprise last quarter stock represent stellar return last year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
653,IDXX,sep issue update research report omnicell inc omcl free report stock currently have zack rank hold market be upbeat company recently launch xt series automate supply dispense cabinet next generation supply solution have feature provide additional flexibility modular design increase storage capacity advanced technology omnicell have also launch software xt hardware allow aesynt customer fully benefit xt further omnicell recent partnership completerx provide comprehensive medication distribution management solution commonwealth massachusett state office pharmacy service sop be encourage omnicell inc price omnicell inc price omnicell inc quotemoreover company be expand footprint globally omnicell have establish footprint sweden germany singapore middle east south africa china also company witness strong business trend europe healthy acceptance medication adherence product flip side omnicell face intense competition medication management supply chain solution market further company have adopt several strategy drive top line include portfolio expansion acquisition further penetration medication adherence market thus company continue battle escalate cost also stretched valuation add concern last month omnicell have be trading industry latest share price movement stock have gain significantly industry addition key picksa few top rank medical stock be edward lifescience corporation ew free report idexx laboratory inc idxx free report amedisys inc am free report edward lifescience sport zack rank strong buy idexx laboratory amedisys carry zack rank see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month idexx laboratory have long term expect earning growth rate stock have gain last year amedisys have long term expect earning growth rate stock have gain last year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
654,IDXX,sep issue update research report align technology inc algn free report stock currently have zack rank hold align technology manufacture market system clear aligner therapy intra oral scanner cad cam computer aid design manufacturing digital service used dentistry orthodontic dental record storage have be trading industry past month stock have gain period compare growth industry company strong invisalign technology prospect growth north america international region look encourage align technology witness balanced sale growth channel recent past primarily drive continue strong invisalign technology case volume customer channel geography align technology inc price align technology inc price align technology inc quotemoreover align technology have be ride high back strong growth internationally reflect continue strong performance emea apac region company also reach new benchmark patient have adopt invisalign treatment encourage development company recently sign distribution agreement patterson dental exclusive agreement effective september align technology itero element intraoral scanning system be available part patterson dental cad cam portfolio unite state canada be also upbeat company sopening new invisalign technology treatment plan facility china company receipt patent smarttrack aligner material also buoy optimism contrary foreign exchange headwind continue raise concern align technology international operation also escalate cost expense be weigh margin moreover tough competitive landscape other macroeconomic headwind pose concern key picksa few top rank medical stock be edward lifescience corporation ew free report idexx laboratory inc idxx free report amedisys inc am free report edward lifescience sport zack rank strong buy idexx laboratory amedisys carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month idexx laboratory have long term expect earning growth rate stock have gain last year amedisys have long term expect earning growth rate stock have gain last year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
655,IDXX,sep issue update research report latham ny base angiodynamic inc ango free report company be expect maintain focus exclusive technology offer superior outcome economic value healthcare system company currently have zack rank hold strong demand company bioflo platform continue drive sale angiodynamic angiodynamic expand product portfolio international market expansion cost save initiative represent considerable growth opportunity company design manufacture sell wide range medical surgical diagnostic device exclusive endexo technology bioflo be expect enhance company growth trajectory fact new bioflo midline catheter feature have gain significant traction short span time owing easy insertion procedure ability effectively draw blood apart bioflo angiodynamic be lead player thrombolytic catheter space catheter direct thrombolysis well company boast unique catheter uni fuse speedlyser pulse spray thrombus portfolio flipside angiodynamic have high debt level be likely impose certain operate financial restriction impede company core business initiative company end fourth quarter fiscal debt notably company operate result capital resource prove inadequate face substantial liquidity problem be force dispose material asset operation meet debt obligation additionally company also be require reduce delay plan expansion capital expenditure sell asset restructure refinance debt seek additional equity capital sluggish capital spending environment third party risk pricing headwind due aggressive competition regulatory setback be also expect dent top line growth company yielded return almost last year current level be significantly same time frame furthermore current level be lower broader industry gain notably angiodynamic be expose pricing headwind stem lower selling price peripheral vascular product due aggressive price competition key picksa few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc notably edward lifescience sport zack rank strong buy idexx laboratory cogentix medical have zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat last quarters company have long term expect earning growth rate idexx laboratory deliver average earning beat trail quarters have long term expect earning growth rate cogentix medical come positive earning surprise last quarter stock represent stellar return last year new report investor guide have become more frequent destructive ever fact re expect cause year damage cybersecurity industry be expand quickly response threat fact project year be spend protect consumer corporate asset zack have just release cybersecurity investor guide locking profit reveal promising investment candidate download new report now
656,IDXX,sep issue update research report phibro animal health corporation pahc free report nj base company be lead global diversify animal health mineral nutrition company last month phibro have be trading broader industry currently stock have gain compare broader industry be encourage note outside unite state phibro have extend reach brazil other country south america china india asia pacific russia africa feel help company counter competition company continue invest far east asia poultry dairy industry be expect grow exponentially currently company be expand dairy business market australia brazil mexico believe turmoil economy russia greece brazil china phibro have perform quite well have potential maintain performance meanwhile phibro end fiscal fourth quarter solid note net sale adjust earning beating zack consensus estimate also year year increase count be encourage further company witness year year improvement segment be also encourage expansion gross operate margin report quarter moreover full year basis adjust earning net sale surpass zack consensus estimate well year year increase meanwhile company have provide fiscal guidance net sale adjust earning flip side phibro operate highly competitive industry respect major product face threat substantial number global regional player phibro competitive position be principally base product registration customer service support breadth product line product quality manufacturing technology facility location product price furthermore withdrawal approval mecadox carbadox fda continue be concern additionally phibro conduct operation globally entail transaction variety currency result currency fluctuation be major issue company zack rank key picksphibro carry zack rank hold few better rank medical stock medical sector be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx have long term expect earning growth rate stock have gain last year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
657,IDXX,aug issue update research report radnor pa base vwr corporation offer laboratory product service solution company currently carry zack rank buy be eagerly wait close vwr acquisition avantor global supplier ultra high purity material life science advanced technology industry post close expect fourth quarter consolidated entity create major consumable focuse solution service provider high growth life science advanced technology industry buyout build avantor strength include cgmp current good manufacturing practice process significant exposure emerge market vwr vital position americas well europe combine company therefore be serve global customer base area activity research production thus reflect unique advantage fast grow marketplace shareholder point view potential merger avantor seem beneficial move moment consolidation deal have be fix share cash vwr common stock represent enterprise value approximately purchase price represent approximate premium unaffected close stock price day market speculation potential sale vwr start vwr corporation price consensus vwr corporation price consensus vwr corporation quotenotably stock price have already inched closer avantor offer price investor merger closure hence short term upside potential vwr be limit now other key picksa few other top rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank cansee complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have surge last month idexx laboratory have long term expect earning growth rate stock have gain last month simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
658,IDXX,aug issue update research report pleasanton base cooper company coo free report company currently carry zack rank buy share cooper have outperformed industry year date share company have increase compare industry gain additionally company earning estimate have moved north current year reflect analyst optimism past month current next earning estimate have increase respectively moreover cooper report earning have beaten zack consensus estimate trail quarters average surprise company lead position market specialty lense be also support highly exclusive product biofinity clariti fact flagship silicone hydrogel lense be expect deliver strong sale come quarters company have also initiate process introduce myday lense domestic market be already available europe have gain significant traction short span time clariti lense also hold significant growth prospect company outlook contact lens industry be favorable fall dropout rate contact lens wearer further market penetration especially develop nation be expect continuous improvisation technology growth international market be something contact lens manufacturer be banking furthermore user preference be shift low feature commodity lense more expensive single use specialty lense such lense aspherical optical property higher oxygen permeable lense silicone hydrogel believe cooper be well position address shift customer preference base expansive product portfolio company recently introduce biofinity energys contact lense be target group user frequently complain discomfort arise prolong usage smartphone tablet laptop car display other device company be leader high margin toric lens market offer multiple design toric lense wide range parameter competitor offer same lense limit design be expect further boost top line growth go forward flip side macroeconomic concern several international market spell trouble company additionally slowdown chinese economy continue dent discretionary spending also give significant international presence cooper remain highly vulnerable fluctuation exchange rate other key picksother top rank medical stock include idexx laboratory inc idxx free report lantheus holding inc lnth free report edward lifescience corporation ew free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank see complete list today zack rank stock here idexx laboratory have long term expect earning growth rate stock have gain last month lantheus holding have long term expect earning growth rate stock have surge last month edward lifescience have long term expect earning growth rate stock have rally roughly last month simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
659,IDXX,thermo fisher scientific inc tmo free report recently complete buyout patheon notably patheon be lead contract development manufacturing organization cdmo serve pharmaceutical biotechnology sector close deal patheon be part thermo fisher laboratory product service segment thermo fisher initial tender offer patheon expire close deal share cash patheon generate approximately revenue fiscal thermo fisher collaboration significantly strengthen unique value proposition pharmaceutical biotech customer add highly complementary service thermo fisher revenue laboratory product service segment account total revenue grow second quarter company be make consistent effort drive revenue growth segment management expect realize total synergy approximately year follow close acquisition consist approximately cost synergy adjust operate income benefit revenue related synergy accord report market market global laboratory equipment service market be estimate reach cagr look bountiful opportunity niche space believe development be strategic fit be upbeat other takeover thermo fisher recent time regard note thermo fisher buyout fei company close late have help thermo fisher access fei industry lead high performance electron microscopy platform used protein study facilitate life science research company latest takeover affymetrix also deserve mention here genetic analysis affymetrix technology perfectly complement thermo fisher product target clinical apply market also take consideration other strategic purchase thermo fisher finesse solution alfa aesar advanced scientific lambda doe ingall past month thermo fisher have be trading broader industry last trading price stock have gain better broader market decline period zack rank key picksthermo fisher carry zack rank hold few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last month surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
660,IDXX,sep issue update research report lead molecular diagnostic company amedisys inc am free report stock currently carry zack rank buy last month amedisys have gain industry decline company impressive result second quarter earning revenue significantly improve year year have bolster market confidence lead further rally share price be encourage company long term strategy evolve traditional home health hospice care company focuse bring home continuum care serve patient better diversify source payment become less reliant medicare moreover company have be witness growth personal care segment synergy acquisition company recently make number strategic acquisition recent be intercity home carein massachusett be slate close oct home health industry be poise substantial growth long term drive positive demographic trend unite state company be expect continue benefit age demographic population higher acuity patient home nursing environment notably company be track fortify footprint market place recently announce completion national readmission prevention collaborative nrpc certification program clinical program team handle home healthcare program additionally company strong cash balance position bolster confidence stock flip side expect synergy tenet healthcare acquisition escalate cost operate expense weigh company margin also intense competitive landscape regulatory concern continue challenge home health hospice industry other key picksa few other top rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx carry zack rank see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx have long term expect earning growth rate stock have gain last year trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
661,IDXX,sep issue update research report cincinnatus base cheme corporation che free report stock currently carry zack rank buy last month cheme have be trading broader industry stock have gain industry decline improvement average net medicare reimbursement rate increase average daily census recently report second quarter be encourage raise outlook roto rooter segment earning share be indicative company anticipate improve operate result upcoming quarters turn boost investor optimism stock notably cheme vita business have be trouble past few quarters due certain admission coding change initiate center medicare medicaid service cms however management note recent admission trend be positive continue come quarters well term roto rooter business company continue display robust performance strength core plumbing drain clean service segment also prompt solid rise water restoration management increase expectation achieve roto rooter full year revenue growth much higher earlier project range revenue estimate be base increase job pricing approximately continue growth water restoration service however headwind reimbursement related issue seasonality business competitive landscape dependence government mandate challenge cheme also tweak guidance medicare cap bill limitation be matter concern other key picksa few other top rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have surge last month idexx laboratory have long term expect earning growth rate stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
662,IDXX,aug issue update research report burlington nc base laboratory corporation america holding lh free report popularly know labcorp company be major player healthcare diagnostic space provide comprehensive clinical laboratory service end end drug development support last month labcorp have be trading broader industry stock have surge industry loss period continue dull performance company covance drug development business market be upbeat diagnostic business have successfully demonstrated solid show recent past covance drug development financial performance be year year recently report second quarter company be currently track achieve target cost synergy year period end have also complete remain consolidation central lab facility europe unite state notably company strategic focus woman health reproductive genetic acquisition sequenom leader invasive prenatal testing have reenergize larger genetic testing portfolio diagnostic also market be look forward long standing strategic collaboration andme have already demonstrated impressive growth trajectory provide further strategic collaboration opportunity flip side unfavorable foreign exchange remain drag late reduce guidance also fail indicate chance respite soon be also apprehension tough reimbursement scenario company be already face degree zack rank key pickslabcorp carry zack rank hold few better rank medical stock be idexx laboratory inc idxx free report lantheus holding inc lnth free report edward lifescience corporation ew free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy cansee complete list today zack rank stock here idexx laboratory have long term expect earning growth rate stock have gain last month lantheus holding have long term expect earning growth rate stock have surge last month edward lifescience have long term expect earning growth rate stock have rally roughly last month zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
663,IDXX,sep issue update research report pleasanton base cooper company coo free report share cooper have outperformed industry year date share company have increase compare industry gain additionally company earning estimate have moved north current year reflect analyst optimism past month current next quarter earning estimate have increase respectively moreover cooper report earning have surpass zack consensus estimate trail quarters average surprise company lead position market specialty lense be also support highly exclusive product biofinity clariti fact flagship silicone hydrogel lense be expect deliver strong sale come quarters company have also initiate process introduce myday lense domestic market be already available europe have gain significant traction short span time clariti lense hold significant growth prospect company outlook contact lens industry be favorable fall dropout rate contact lens user further market penetration especially develop nation be expect continuous improvisation technology growth international market be something contact lens manufacturer be banking furthermore user preference be shift low feature commodity lense expensive single use specialty lense such lense aspherical optical property higher oxygen permeable lense silicone hydrogel believe cooper be well position address shift customer preference base expansive product portfolio company recently introduce biofinity energys contact lense be target group user frequently complain discomfort arise prolong usage smartphone tablet laptop car display other device company be leader high margin toric lens market offer multiple design toric lense wide range parameter competitor offer same lense limit design be expect further boost company top line growth go forward flip side macroeconomic concern several international market spell trouble company additionally slowdown chinese economy continue dent discretionary spending also give significant international presence cooper remain highly vulnerable fluctuation exchange rate zack rank key pickscooper carry zack rank hold few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have surge roughly last month lantheus holding have long term expect earning growth rate stock have rally last month idexx laboratory have long term expect earning growth rate stock have gain last month simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
664,IDXX,aug issue update research report medtronic plc mdt free report medtronic exit fiscal first quarter mixed note earning exceed zack consensus estimate revenue miss same last month medtronic have underperform broader industry company have witness decline share price release quarterly result last share price movement company have lose broader industry gain last month moreover escalate cost expense be weigh margin also unfavorable foreign exchange continue remain drag positive note apart display successful integration achievement synergy target medtronic major business group continue contribute top line growth highlighted sustainability segment geography recently company announce receipt ce mark attain stability quad mri active fixation heart lead be also encourage solid growth trend continue unite state well healthy global acceptance advanced therapy moreover consistent gradually stabilize movement global cardiac rhythm heart failure crhf market be observed improve further come quarters be also look forward medtronic receive cash patient monitoring recovery pmr division divestment strengthen company position make further developmental investment meanwhile post covidien acquisition consolidated company have so far successfully demonstrated strong segmental performance reflect successful integration achievement synergy target apart note face severe macroeconomic pressure medtronic see growth emerge market last report quarter contribute nearly company overall revenue strong growth figure be line company double digit growth projection long term company be currently resort possible mean boost growth include penetrating emerge market expansion portfolio restructure initiative benefit medtronic long term be also encourage foray rapidly grow transcatheter mitral valve replacement market acquisition california base medical device start inc present medtronic carry zack rank sell key picksa few better rank medical stock be edward lifescience corporation ew free report idexx laboratory inc idxx free report lantheus holding inc lnth free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last month zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
665,IDXX,aug issue update research report petm express inc pet free report operate petmed company be lead nationwide pet pharmacy petm currently sport zack rank strong buy last month petm have be trading broader industry last trading price company have gain stupendous compare gain broader industry petm post better expect result first quarter mark solid start fiscal be encourage significant increase reorder sale new order sale quarter well expect company impressive first quarter performance maintain momentum petm be strive implement several strategy revitalize top line include focuse advertising efficiency boost new order sale shift sale higher margin item also expand product offering however be apprehensive escalate advertising expense incur quarter company market product primarily well know brand medication such frontline advantix advantage heartgard sentinel interceptor other flip side petm operate highly competitive fragmented pet medication market competitor include veterinarian traditional retailer other mail order online retailer pet medication other health product also acquisition novartis animal health division eli lilly company have give rise more challenge petm other key picksa few other top rank medical stock be idexx laboratory inc idxx free report lantheus holding inc lnth free report edward lifescience corporation ew free report edward lifescience sport zack rank lantheus holding idexx laboratory carry zack rank buy cansee complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last month zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
666,IDXX,lead veterinary product distributor henry schein inc hsic free report continue expand global footprint successfully several partnership acquisition latest list be company agreement buy merritt veterinary supply inc independent family own supplier animal health product financial term deal have be keep wrapped company declare expect transaction get complete third quarter headquarter columbia south carolina merritt have veterinary clinic eastern unite state strong presence southeastern part nation company offer comprehensive line product include pharmaceutical diagnostic equipment lead independent regional veterinary supplier have total sale approximately post close transaction merritt become part henry schein animal health company acquisition meaningfully strengthen exist animal health business also benefit animal health diagnostic equipment surgical instrument business include scil kruuse veterinary instrumentation henry schein henry schein inc price henry schein inc price henry schein inc quotenotably henry schein revenue growth animal health business have be consistently support niche acquisition robust buyout strategy help pursue target provide access additional product line begin henry schein enter brazilian animal health market investment tecnew privately hold distributor animal health product prior company acquire rxwork lead provider veterinary practice management software primarily customer australia new uk netherlands other world wide country business impending merritt buyout be set fortify global animal health operation go forward henry schein have outperformed broader industry year stock have gain compare broader industry rise zack rank key pickshenry schein currently carry zack rank hold few better rank medical stock be idexx laboratory inc idxx free report lantheus holding inc lnth free report edward lifescience corporation ew free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here idexx laboratory have long term expect earning growth rate stock have gain last month lantheus holding have long term expect earning growth rate stock have surge last month edward lifescience have long term expect earning growth rate stock have rally roughly last month zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
667,IDXX,lead diagnostic testing company laboratory corporation america holding lh free report agreement interpace diagnostic group inc idxg have be renew extend extend deal agreement be deem valid january successful initial phase press release interpace diagnostic be fully integrate commercial company provide clinically useful molecular diagnostic test pathology service evaluate risk cancer leverage latest technology personalize medicine better patient diagnosis management labcorp have originally enter agreement january offer interpace diagnostic molecular test thygenx thyramir thygenx thyramir reflex testing yield high predictive value determine presence absence cancer thyroid nodule simpler word test provide latest technology diagnosis thyroid cancer indeterminate thyroid nodule patient accord report market datum forecast thyroid cancer market be estimate reach worth cagr consider bountiful opportunity niche space believe be strategic move company late labcorp have be take strategic initiative specialize test recently start offer new proprietary adamts test distinguish disease characterize life threaten acute thrombotic microangiopathy tma notably tma be relatively rare serious syndrome tma small blood vessel develop blood clot result mechanical destruction red blood cell company also announce availability pretrm test unite state pretrm test be develop sera prognostic inc be only validate blood test offer early individualized prediction preterm birth risk pregnant woman further labcorp announce significant enhancement proprietary vistaseq hereditary cancer portfolio new test panel focuse risk specific hereditary cancer syndrome majority last month labcorp have be trading broader industry period stock have gain industry decline zack rank key pickslabcorp carry zack rank hold few better rank medical stock be idexx laboratory inc idxx free report lantheus holding inc lnth free report edward lifescience corporation ew free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy cansee complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last month zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
668,IDXX,varian medical system var free report recently announce release fda approve treatment plan software eclipse help clinician treat more accuracy efficiency eclipse also provide treatment plan support varian hyperarc oncology system hdrt efficient automate delivery complex stereotactic radiosurgery hyperarc hdrt be new type radiosurgery treatment eclipse offer graphic process unit gpu support help physician optimize speedily calculate dose eclipse feature multus criterium optimization mco allow clinician explore application different clinical criterium accord company accord company mco focus find optimal plan faster give patient minimal trial error iteration last report third quarter varian medical revenue decline oncology system company be consistently try turn oncology system business apart latest development company recently announce fda clearance revolutionary halcyon product company receive order country system north america company sign agreement petcure oncology bring unprecedented level care pet suffering cancer accord report market market global oncology information system market be expect reach worth cagr consider huge potential market believe latest development be strategic fit past month varian medical have outperformed broader industry term price company have return compare favorably sub industry gain estimate revision estimate revision trend have be favorable company current year estimate moved north compare movement opposite direction last month result zack consensus estimate full year have increase share same period zack rank key picksvarian medicalcarry zack rank hold few better rank medical stock be edward lifescience corporation ew free report amedisys inc am free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy amedisys idexx carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month amedisys have long term expect earning growth rate stock have gain last year idexx have long term expect earning growth rate stock have gain last year promising stock pick keep eye news story computer hacking identity theft become increasingly commonplace cybersecurity industry look promising investment opportunity stock buy zack just release cybersecurity investor guide locking profit help answer question new special report give information need make well inform investment choice space more importantly also highlight cybersecurity pick strong profit potential get new investing guide now
669,IDXX,lately medtech space have be face brunt frequent regulatory change trump administration be face socio economic upheaval investor be apprehensive impact stock historic trend suggest investor sentiment have always be partially incline fancy brand name volatile economic backdrop result company solid brand value robust fundamental generally enjoy sail even political turbulence such bigwig medtech space be abbott laboratory free report have greatly evolved recent year company have pursue slew merger divestment have also see solid growth diabetic business strategic buyout acquisition cfr pharmaceutical tendyne holding st jude medical be worth mentioningafter spin proprietary pharmaceutical product division form abbvie inc abbv free report abbott have gain traction establish pharmaceutical division then revenue have see cagr last year period company have more less report strong quarterly number indicate fundamental strength share lack lusterhowever share price performance abbott have be disappointing same time frame company represent meager return just lower broader industry gain return same time frame main issue plague abbott foreign exchange be major headwind strengthen euro other develop market currency have constantly hampered company performance international market abbott currently expect currency exchange have negative impact sale apart business environment continue be challenge globe slow growth nutrition business china economic problem venezuela be expect remain unresolved time dampening company top line growth bleak prospectswhile abbott boast solid fundamental company prospect be dull note company promise long term earning growth just lower broader industry estimate growth rate furthermore abbott revenue have decline last year compare broader industry revenue growth secondly abbott historical cash flow growth have be extremely low compare unfavorably broader industry positive growth unfavorable growth metric be indicative fact solid brand value abbott not prove be lucrative pick long haul growth stock long term growth parameter be not favor abbott hold zack rank hold now so instead opt brand value let take look follow not so fancy medtech stock be expect gain long haul apart flaunt strong zack rank strong buy buy stock promise long term expect growth rate higher compare favorably broader industry also have take growth style score consideration growth style score highlight vital metric company financial obtain clearer picture quality sustainability growth research show stock style score combine zack rank offer best investment opportunity lonza group ltd lzagy free report lonza group sport zack rank have long term expect earning growth rate company have growth score see complete list today zack rank stock here lonza group supply product service pharmaceutical biotech specialty ingredient market worldwide outstanding first half year lonza group continue expect strong performance pharma biotech specialty ingredient segment company strategic initiative improve customer relationship management process innovation operational improvement program area automation streamline instill investor confidence stock have gain last year orasure technology inc osur free report zack rank stock promise long term expect earning growth notably orasure have growth style score company develop manufacture market sell oral fluid diagnostic product specimen collection device unite state europe internationally orasure bank solid growth infectious disease business unit higher sale company molecular product oraquick hcv product be primary growth driver company have also be banking flagship oragene product line orasure have have impressive run last year company have return significantly higher broader industry same time frame idexx laboratory inc idxx free report zack rank company continue demonstrate solid growth globally strong international expansion long term expect earning growth rate growth score idexx laboratory exit second quarter solid note beating zack consensus estimate count headquarter delaware nj idexx laboratory be developer manufacturer distributer product service primarily companion animal veterinary livestock poultry water testing dairy market major fraction idexx laboratory revenue be derive companion animal group segment drive expand premium instrument base unite state international market company be expect grow extensively long haul idexx laboratory boast stellar return last year furthermore estimate revision trend next year be promising notably analyst moved north last month zack consensus estimate next year increase share same time framee lemaitre vascular inc lmat free report lemaitre have zack rank promise long term expect earning growth rate growth score company xenosure platform be key catalyst moment stock have gain last year headquarter burlington company market sell service support medical device implant treatment peripheral vascular disease worldwide company expect sale rise almost organically next quarter strong margin expansion lemaitre estimate revision trend next year be quite encourage notably analyst moved north compare movement opposite direction result zack consensus estimate increase almost same time frame surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
670,IDXX,aug issue update research report hill holding inc hrc free report stock currently have zack rank sell hill exit last report third quarter mixed note earning ahead estimate revenue miss same company disappoint decline patient support system revenue due impact watchchild architectural product divestiture lower rental revenue hill have underperform broader industry last month stock have now lose versus industry gain foreign exchange stiff competition remain headwind company lower full year revenue earning guidance be indicative persistent sluggish trend go ahead positive note hill see solid year year increase revenue strong international growth hill currently aim gain traction untapped international market successful execution company be focuse product innovation research development also product launch slate fourth quarter be pump investor confidence commercial launch centrella med surg platform regard be worth mention additionally hill merger acquisition pipeline remain robust company aggressively pursue acquisition accelerate growth key clinical focus area namely advance patient mobility wound care prevention surgical safety efficiency clinical solution respiratory help key pick few better rank medical stock be idexx laboratory inc idxx free report lantheus holding inc lnth free report edward lifescience corporation ew free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy cansee complete list today zack rank stock here idexx laboratory have long term expect earning growth rate stock have gain last month lantheus holding have long term expect earning growth rate stock have surge last month edward lifescience have long term expect earning growth rate stock have rally roughly last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
671,IDXX,healthcare diagnostic company laboratory corporation america holding lh free report labcorp continue expand inorganic mean apart huge buyout covance company be steady spree add complementary capability strategic merger follow company announcement acquire analytical testing service business chromadex corp cdxc free report last week labcorp be again headline earlier announce impending acquisition chiltern international group limit specialty cro contract research organization company source federal trade commission ftc have grant request early termination wait period chiltern buyout hart scott rodino antitrust improvement act hsr act close acquisition be expect sep be still subject other customary close condition notably last month labcorp have enter definitive agreement chiltern shareholder purchase company cash transaction value approximate labcorp consolidation strengthen position innovative diagnostic drug development solution buyout covance have already demonstrated value combine diagnostic cro capability labcorp cro business have grow nearly annual revenue chiltern addition be expect further promote development also provide labcorp enhance capability broader client base combine entity have approximately employee americas europe middle east africa asia pacific closure transaction chiltern become part labcorp covance segment former integration enhance latter offering chiltern be major partner serve top biopharma segment assist labcorp focus high growth emerge mid market biopharma segment last month labcorp have be trading broader industry period stock have rally industry loss zack rank key pick labcorp carry zack rank hold better rank medical stock be idexx laboratory inc idxx free report edward lifescience corporation ew free report edward lifescience sport zack rank strong buy idexx laboratory carry zack rank buy cansee complete list today zack rank stock here idexx laboratory have long term expect earning growth rate stock have gain last month lantheus holding have long term expect earning growth rate stock have surge last month edward lifescience have long term expect earning growth rate stock have rally roughly last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
672,IDXX,cooper company inc coo free report recently sign asset purchase agreement acquire flagship contraception platform israel base teva pharmaceutical industry teva free report paragard intrauterine device cash transaction bolster cooper company coopersurgical csi business contraceptive device market share price cooper company inched close follow news however acquire business line be exclusively operated teva pharmaceutical manufacturing facility buffalo ny cooper company expect acquisition prove accretive earning share cent first year deal furthermore exclude acquisition related cost transaction be expect boost cooper company gross operate margin well management intrauterine device market be worth be expect multiply mid single digit paragard be only approve hormonal intrauterine device space robust csi product portfoliocooper company be well position benefit expand csi product portfolio management believe long term growth csi be drive fertility segment company have gain strong foothold courtesy reprogenetic genesis recombine buyout moreover purchase expand company international presence open opportunity market spain japan peru south america uae south africa jordan taiwan last report quarter csi revenue jump constant currency cc year year basis fiscal management trim revenue guidance csi segment csi revenue be now project range significantly lower previous range stock performance solidover past month cooper company have gain compare favorably broader industry addition moreover current level be higher gain same time frame cooper company be poise gain expand product portfolio increase penetration international market accretive acquisition be also key catalyst long haul furthermore outlook contact lens industry be favorable be likely boost stock price long haul company long term expect earning growth rate hold promise regard zack rank other key pickscooper company currently carry zack rank buy couple other top rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report notably edward lifescience sport zack rank strong buy idexx laboratory have zack rank see complete list today zack rank stock here edward lifescience deliver average earning beat trail quarters company have long term expect earning growth rate idexx laboratory deliver average earning beat trail quarters have long term expect earning growth rate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
673,IDXX,third year row st paul mn base ecolab inc ecl free report have be select member dow jone sustainability index djsi global indicator tracking financial performance lead sustainability drive company launch djsi be consider benchmark area index be draw dow jone collaboration investment management firm strategic asset management sam ecolab have be select leader corporate sustainability djsi company claim be recognition world class service product program well successful integration corporate responsibility sustainability overall business practice be third consecutive year company have be select company fourth list ecolab be lead provider water hygiene energy technology service protect person vital resource company program service help promote safe food maintain clean environment optimize water energy use improve operational efficiency customer food energy healthcare industrial hospitality market more country ecolab have impressive run bourse last month trading industry term price performance glimpse price movement reveal ecolab share have gain industry decline company prospect global industrial global institutional business segment reflect positivity last report quarter sale segment scale year year basis furthermore ecolab boast compelling fundamental revenue adjust earning multiply rate last year however flip side unfavorable foreign currency impact venezuelan deconsolidation be expect hurt earning term also escalate cost expense be weigh margin last month comparative study ecolab forward forward month basis multiple reflect stock have be quite overvalue zack rank key picksecolab currently carry zack rank hold few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have surge roughly last month lantheus holding have long term expect earning growth rate stock have rally last month idexx laboratory have long term expect earning growth rate stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
674,IDXX,becton dickinson company bdx free report commonly know bd recently announce agreement italy base euroclone development global distribution molecular assay molecular assay be exclusively formulate detect sexually transmit pathogen fact bd have be lead player provide solution woman health sexually transmit infection sti notably company latest development closely follow recent launch bd ultra fine micro pen needle mm use pen injection device needle offer comfortable injection experience enhance customer satisfaction device be slate distribution month come back news bd euroclone plan launch molecular assay outside unite state molecular assay leverage company flagship platform bd max system detect infectious genital mycoplasmas include mycoplasma ureaplasma species be generally unidentifiable conventional method however assay be currently not available sale unite state management addition assay exist bd max portfolio company other assay bd surepath bd onclarity hpv assay be likely fortify company foothold clinical laboratory testing sti impressive stock price bd inched close follow news release last year company have outperformed broader industry stock be broader industry gain just nonetheless current return be relatively lower addition same time frame also zack rank hold company focus expand overseas market particular emerge market follow new product launch acquisition drive strategy be significant growth catalyst takebd have diversify product portfolio reduce risk exposure specific product additionally diverse revenue base increase adoption company new exist product be expect drive top line growth meanwhile latest development be likely maintain company international footprint evidently bd witness increase revenue outside unite state comparable currency neutral basis last quarter accord report ally market research global sexually transmit disease testing market be anticipate reach cagr markedly consider huge potential market believe latest development be strategic fit stock consider few better rank stock broader medical sector include edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc edward lifescience sport zack rank strong buy idexx laboratory cogentix medical hold zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat last quarters company have long term expect earning growth rate idexx laboratory pull average earning beat trail quarters have long term expect earning growth rate cogentix medical come positive earning surprise last quarter stock represent stellar return last year make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
675,IDXX,boston scientific bsx free report announce positive clinical trial datum multisensor chronic evaluation ambulatory heart failure patient multisense study study base patient be conduct examine performance heartlogic heart failure diagnostic predict impending heart failure hf decompensation study demonstrated heartlogic diagnostic iincrease ability classify patient high low risk experience future hf event presently physician recommend blood test diagnose hf determine disease severity however method be less reliable assessment lose relevance patient condition change multisense trial datum show heartlogic diagnostic expand ability baseline blood test identify patient high risk hf event notably heartlogic diagnostic be already ce marked fda approve be available commercially later year rhythm management segment last report second quarter rhythm management be second largest contributor boston scientific top line include cardiac rhythm management crm crm reflect year year increase sale report quarter accord report globaldata heart failure market be estimate reach value cagr consider huge potential market believe latest development be strategic fit past year boston scientific have be trading broader industry stock have rise period gain broader industry estimate revision estimate revision trend have be favorable company current year estimate moved north compare movement opposite direction last month result zack consensus estimate full year have increase share same period zack rank key picksboston scientificcarry zack rank hold few better rank medical stock be edward lifescience corporation ew free report amedisys inc am free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy amedisys idexx carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month amedisys have long term expect earning growth rate stock have gain last month idexx have long term expect earning growth rate stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
676,IDXX,sep issue update research report lead medical device company boston scientific corporation bsx free report past month boston scientific have be trading broader industry several issue stock have improve compare broader industry gain period adverse foreign exchange continue challenge be concern company recall prime product lotus range heart device be important note last quarter foreign exchange headwind affected company top line adjust gross margin basis point also dull defibrillator sale core cardiac rhythm management crm continue remain drag overall growth wo challenge economy competitive landscape persistently burden stock boston scientific corporation price consensus boston scientific corporation price consensus boston scientific corporation quotehowever give company bullish second quarter result several recent development find quite few positive factor rely company be leave stone unturned strengthen core business invest more global market recent upside worth mention be company acquisition symetis bid fortify european structural heart business be also encourage company secure multiple product approval domestic overseas market notably company receive fda approval resonate family icd crt system additionally market hold optimism stock follow company recent release outline sustain growth strategy focuse plan expansion new market consolidate product line business segment company particularly plan launch product high growth adjacent market strong potential reap incremental market opportunity zack rank key picksboston scientific carry zack rank hold few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy cansee complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have surge roughly last month lantheus holding have long term expect earning growth rate stock have rally last month idexx laboratory have long term expect earning growth rate stock have gain last month surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
677,IDXX,becton dickinson company bdx free report commonly know bd recently launch bd ultra fine micro pen needle mm use pen injection device needle offer comfortable injection experience enhance customer satisfaction notably device be slate distribution month bd have widen needle length option diabetic person interestingly most insurance plan include medicare part cover bd ultra fine micro mm pen needle person diabetes require inject insulin subcutaneous fat abdomen thigh upper arm buttock bd latest needle diabetic person be less likely inject insulin dose muscle accidently accord company needle be rigorously test ensure performance maintain high quality standard medical technology company be consistently try improve performance diabetes care unit bd medical segment bd see diabetes care revenue growth last report third quarter expect bd see higher growth segment day ahead accord report bccresearch global diabetes market reach worth cagr also report market market global human insulin market be expect value grow cagr consider huge potential market believe latest development be strategic fit last year bd have outperformed broader industry term share price company have return compare favorably broader industry gain estimate revision estimate revision trend have be favorable company current year estimate moved north compare movement opposite direction last month result zack consensus estimate full year have increase share zack rank key picksbd carry zack rank hold few better rank medical stock be edward lifescience corporation ew free report amedisys inc am free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy amedisys idexx carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month amedisys have long term expect earning growth rate stock have gain last month idexx have long term expect earning growth rate stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
678,IDXX,neogen corporation neog free report report adjust earning cent share first quarter fiscal figure beat zack consensus estimate increase year quarter revenue increase year year basis beating zack consensus estimate revenue detailsfood safety segment revenue neogen food safety segment totale notably revenue segment jump first quarter overall organic growth growth be majorly fuel strength number exist product line recent acquisition furthermore increase testing toxin buoy sale segment also note sale segment be drive surge sale allergen test food such gluten peanut courtesy global food allergen regulatory effort animal safety segment animal safety segment record revenue reflect increase year quarter growth segment be mainly drive increase sale company insect control product line rise sale veterinary instrument particularly needle syringe product line flipside neogen witness decline sale cleaner disinfectant thank termination distribution agreement third quarter fiscal genomic unit genomic business unit record increase year year basis management growth business unit be fuel expansion company testing facility scotland development new genomic testing product acquisition brazil base deoxi early neogen corporation price consensus ep surprise neogen corporation price consensus ep surprise neogen corporation quotemargin detailsadjust gross margin contract basis point bps quarter largely due mixed impact acquisition quat rogama operate income be sale first quarter compare year takewe believe neogen be steadily progress back prong strategy also be encourage accretive acquisition expand international footprint drive neogen overall result fiscal moreover company have broad portfolio innovative disinfectant product more epa fda register product strengthen company global market position zack rank key pickswe note neogen carry zack rank hold few better rank medical stock be edward lifescience corporation ew free report idexx laboratory inc idxx free report amedisys inc am free report edward lifescience sport zack rank strong buy idexx amedisys carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate company deliver positive earning surprise last report quarter idexx have long term expect earning growth rate company deliver positive earning surprise last report quarter amedisys have long term expect earning growth rate company deliver positive earning surprise last report quarter more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
679,IDXX,company favorable efficiency level be poise be investor radar irrespective market condition be company favorable efficiency level be expect provide impressive return be believe be positively correlated company price performance efficiency company ability transform input output be important measure determine financial condition key ratio identify become difficult measure efficiency level company be reason consider popular efficiency ratio select stock efficiency ratio be inventory turnover ratio month cost good sell cog quarter average inventory be consider be most popular efficiency ratio indicate company ability maintain suitable inventory position high value indicate company have relatively low level inventory compare cog low value indicate company be face decline weak sale result excess inventory receivables turnover be ratio month sale quarter average receivables show company potential extend credit collect debt term credit high receivables turnover ratio account receivable turnover ratio debtor turnover ratio be desirable signal company be capable collect account receivables have quality customer asset utilization ratio indicate company capability convert asset output be thus widely know measure efficiency level be calculate divide total sale past month last quarter average total asset ratio high asset utilization also indicate company be efficient operate margin efficiency measure be ratio operate income past month sale same period measure company ability control operate expense hence high value ratio indicate company manage operate expense more efficiently peer screening parametersin addition mentioned ratio have add favorable zack rank strong buy buy screen objective make strategy more profitable inventory turnover receivables turnover asset utilization operate margin greater industry average value ratio higher industry average indicate efficiency level company be higher peer use few criterium narrow universe stock only here be stock make screen lululemon athletica inc lulu free report be designer distributor retailer athletic apparel company operate segment company operated store direct consumer zack rank company have average quarter positive earning surprise sanderson farm inc safm free report be integrate poultry process company produce process market distribute fresh frozen prepared chicken product unite state zack rank company have average quarter positive earning surprise idexx laboratory inc idxx free report develop manufacture distribute product provide service companion animal veterinary livestock poultry dairy water testing market zack rank company have average quarter positive earning surprise see complete list today zack rank stock here nvr inc nvr free report be engage construction sale single family detach home townhome condominium building zack rank company have average quarter positive earning surprise get rest stock list signing now week free trial research wizard start used screen own trading further also create own strategy test first take investment plunge research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performancezack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
680,IDXX,aug issue update research report austin tx base luminex corp lmnx free report manufacturer marketer proprietary biological testing technology application life science diagnostic industry company currently sport zack rank strong buy luminex second quarter see strong top line performance solid cash flow soar profit company assay business be likely be key growth driver long term luminex report earning cent share second quarter revenue quarter increase almost year year company reiterate annual revenue guidance have project third quarter revenue range previously issue band luminex expect revenue segment be impact funding challenge related multus year bulk bead contract life science customer company also witness favorable tiding regulatory front second quarter regard recent ce ivd mark ary norovirus assay fda approval ary assay reimbursement approval verigene assay japan be noteworthy luminex be verge complete clinical study group strep be close submit same fda review company have broad product portfolio comprise advanced xmap xtag multicode technology moreover luminex have collaborative agreement several company help expand use product technology regard note luminex have earlier announce signing new supply distribution agreement bio techne corp tech luminex also enter similar deal affymetrix affx term agreement ebioscience business division affymetrix commercialize magpix luminex flexmap multiplexed assay platform select country americas asia europe flipside reimbursement landscape cutthroat competition continue be major challenge also share price movement luminex have be unfavorable last year notably stock lose broader industry gain roughly further luminex stock look little overvalue moment comparative analysis company ttm basis multiple reflect relatively gloomy picture be cause investor concern zack rank key picksluminex sport zack rank strong buy few other top rank medical stock be idexx laboratory inc idxx free report lantheus holding inc lnth free report edward lifescience corporation ew free report edward lifescience sport zack rank lantheus holding idexx laboratory carry zack rank buy cansee complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last month surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
681,IDXX,aug issue update research report cincinnatus base cheme corporation che free report company currently operate wholly own subsidiary vita healthcare roto rooter last month cheme have be trading broader industry term price stock have gain higher industry loss improvement average net medicare reimbursement rate increase average daily census recently report second quarter be encourage raise outlook roto rooter segment earning share be indicative company anticipate improve operate result upcoming quarters boost investor optimism stock notably cheme vita business have be trouble past few quarters due certain admission coding change initiate center medicare medicaid service cms however management note recent admission trend be positive continue come quarters well cheme corp price consensus cheme corp price consensus cheme corp quotedure second quarter vita perform well financially operationally surpass company expectation business experience net revenue growth compare prior year quarter vita also generate admission growth quarter term roto rooter business display robust performance core plumbing drain clean service segment second quarter well prompt solid rise water restoration management increase expectation achieve roto rooter full year revenue growth higher earlier expect range revenue estimate be base increase job pricing approximately continue growth water restoration service however headwind reimbursement related issue seasonality business competitive landscape dependence government mandate challenge cheme also tweak guidance medicare cap bill limitation be matter concern zack rank key pickscheme currently have zack rank buy few other top rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally last month lantheus holding have long term expect earning growth rate stock have surge last month idexx laboratory have long term expect earning growth rate stock have gain roughly last month surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
682,IDXX,global leader field dna sequence array base technology illumina inc ilmn free report telegraph hill partner thp announce plan set independent company verogen inc thp be life science focuse venture capital growth equity firm base san francisco verogen headquarter san diego area have right provide illumina forensic sequence technology forensic customer include criminal casework other human nonhuman forensic application independent company be expect strengthen illumina next generation sequence ngs business forensic genomic market be sole provider miseq fgx forensic genomic system include miseq fgx sequencer forenseq dna signature prep kit forenseq universal analysis software also have global commercial right product miseq fgx forensic genomic system be used operational crime laboratory private service lab forensic research institutes worldwide company also be offer other illumina product forensic lab operationalize ngs routine forensic genomic illumina continue manufacture miseq fgx instrument core sequence consumable management believe miseq fgx forensic genomic system continue lead transition ngs genomic forensic market improve justice public safety remove barrier adopt ngs crime laboratory company be hopeful illumina ngs technology together thp forensic expert help verogen provide long term success customer kirk malloy have be name ceo verogen cydne holt serve general manager chief scientific officer accord bcc research report major forensic product service market reach worth nearly cagr period thus company clearly have bountiful opportunity space illumina be strive expand ngs technology base line illumina have announce launch solution noninvasive prenatal testing nipt kit europe product veriseq nipt solution be ce ivd marked next generation sequence ngs base approach nipt also illumina announce extend ra panel fda approve next generation sequence ngs kit meet newly publish guideline evaluation colorectal cancer company have also launch bio rad single cell sequence solution first next generation sequence ngs single cell analysis collaboration bio rad laboratory inc bio free report last month illumina have be trading broader industry stock have gain past month compare broader industry zack rank key picksillumina carry zack rank hold few better rank medical stock be idexx laboratory inc idxx free report lantheus holding inc lnth free report lantheus holding idexx laboratory carry zack rank buy cansee complete list today zack rank strong bu stock here lantheus holding have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have rally last month surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
683,IDXX,solid prospect lantheus holding inc lnth free report be attractive pick present stock have rally last month ahead gain also better broader industry stock have market cap diagnostic medical imaging agent product provider estimate revision trend current year have also be positive past day analyst moved north be movement opposite direction magnitude estimate revision increase share cent same time frame company report stellar quarter positive average earning surprise earning surprise last report second quarter let find recent positive trend be sustainable headquarter north billerica lantheus holding post solid second quarter result year year increase earning revenue earning share increase year year revenue improve globally back approximately growth definity growth technelite sale globally also raise revenue guidance full year indicate possibility continuation bullish trend full year worldwide revenue guidance have be raise worldwide revenue third quarter be project gross margin exclude impact ge healthcare payment be approximately reflect increase basis point last year improvement be drive increase contribution higher margin product impact xenon cost saving generate addition process finishing capability billerica facility market be also upbeat zack rank buy company consistent effort expand globally company be also look forward receipt chinese regulatory approval necessary start confirmatory study partner double crane definity china program notably first patient cardiac study have already enrolled company have also receive regulatory approval taiwan other key picksa few other better rank medical stock be edward lifescience corporation ew free report petm express inc pet free report idexx laboratory inc idxx free report edward lifescience petm express sport zack rank strong buy idexx laboratory carry zack rank cansee complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month petm express have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last month surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
684,IDXX,henry schein inc hsic free report have recently team integrate medical foundation imf lugpa association independent urology group practice raise awareness prostate cancer more specifically henry schein global corporate social responsibility program henry schein care work matter henry schein support imf lugpa series communication effort increase awareness practitioner public importance early detection prostate cancer accord have be widely accept early detection prostate cancer greatly enhance patient chance recover disease believe company move be well time take consideration frequency rate prostate cancer be grow national cancer institute estimate approximately man be diagnosed disease lifetime american cancer society more man be expect be diagnosed prostate cancer more man succumb disease henry schein be yet make foray world cancer research have already come several awareness drife late only last month company announce offer dental animal health medical customer opportunity join fight cancer proposal be open september december purchasing range pink product customer support company practice pink program initiative design increase awareness back cure breast cancer well other cancer therapy past month henry schein have underperform broader industry stock have lose compare broader industry decline zack rank key pickshenry schein carry zack rank hold few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have surge last month idexx laboratory have long term expect earning growth rate stock have gain last month be reissue article correct mistake original article issue september longer be rely zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
685,IDXX,trump fail effort repeal replace obamacare trump introduce skinny repeal call do away part affordable care act aca obamacare individual mandate employer mandate cadillac taxe last month republican lose debate skinny repeal unite state witness political dilemma republican vote favor exist healthcare act probably decide support exist healthcare act base datum provide congressional budget office cbo joint committee taxation jct report abolition obamacare person be uninsured more count be expect increase cancellation withdrawal individual employer mandate have make health insurance contract health insurance coverage expensive significantly dent demand healthcare service impact medical device industry whole however medtech industry be look forward abolishment major healthcare taxe include cadillac tax medtech tax republican fail pass skinny repeal have be able delay cadillac tax thank postponement cadillac tax medical device industry be hopeful medical device tax be eradicate soon such mixed scenario feel investor place bet large cap stock deliver positive average earning surprise last report quarters be witness upward revision earning estimate stock pickwe have select medical device stock help zack stock screener hyperlink shortlist medical device stock be poise impressive return next year stock boast zack rank strong buy buy have market cap more edward lifescience corporation ew free report edward lifescience promise long term expect earning growth rate stock sport zack rank see complete list today zack rank stock here look estimate revision trend current quarter last month estimate increase cent share stock have deliver positive earning surprise last quarters average come price performance last month edward stellar return much higher broader industry gain roughly idexx laboratory inc idxx free report stock have zack rank stock have long term earning growth rate last quarters company deliver positive earning surprise average fact estimate revision trend current quarter seem favorable last month estimate increase cent share last year idexx represent return beating broader industry gain cooper company inc coo free report stock carry zack rank promise long term earning growth last quarters company deliver positive earning surprise average regard current quarter estimate increase share last month last month company represent stellar return much better broader industry rally roughly icon plc iclr free report stock carry zack rank long term earning growth estimate revision trend current quarter look promising estimate increase share last month stock have deliver positive earning surprise last quarters average come price performance last month icon represent stellar return much higher broader industry increase roughly zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
686,IDXX,healthcare diagnostic company laboratory corporation america holding lh free report labcorp successfully continue expand acquisition strategy apart huge buyout covance company continue add complementary capability target tuck merger latest list be company agreement purchase analytical testing service business chromadex corp cdxc transaction be expect complete early september newly acquire entity become part labcorp covance food solution business notably chromadex be natural product company work health wellness nutritional ingredient create science base solution dietary supplement food beverage skin care sport nutrition pharmaceutical product company haven disclose deal financial term press release report american city business journal deal value have be fix report covance buy analytical testing business agreement chromadex be also able receive earnout payment accord filing security exchange commission be important make note labcorp mega buyout covance virtue company be full force expand range diagnostic offering create new industry leader laboratory testing cro contract research organization space slate act lead provider medical testing operate premier full service drug development organization company covance drug development be only cro provide full spectrum drug development capability research real world evidence study create commercial scientific advantage labcorp partner apart covance recent significant buyout be sequenom prominent player field invasive prenatal testing nipt reproductive health sequenom nipt genetic testing capability have further add impetus labcorp extensive woman health test menu inclusion have also expand company geographic reach domestically internationally particularly eu asia pacific region company acquire pathology associate medical laboratory paml former owner providence health service providence catholic health initiative chi paml be nation premier medical reference laboratory healthcare solution company acquisition be consistent company effort strengthen foothold personalize diagnostic testing market last month labcorp have be trading broader industry period stock have gain industry loss zack rank key pickslabcorp currently have zack rank hold few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally last month lantheus holding have long term expect earning growth rate stock have surge last month idexx laboratory have long term expect earning growth rate stock have gain roughly last month simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
687,IDXX,kalamazoo mi base stryker corporation syk free report largest medical device company global orthopedic market recently announce voluntary product recall oral care lineup be offer company sage product unit add voluntary recall stryker have place temporary hold certain cloth base product decision follow complaint minor irritation allergic reaction consumer however management expect reinitiate product shipment september expect begin full supply capacity end year share price stryker slip close follow news release lead recall recall pertain cross contamination issue oral care solution be manufacture sage third party supplier notably solution be distribute market july august however stryker affirm have close business third party supplier fact sage have resume production oral care solution come temporary hold decision cloth base product fda expressed concern regard ongoing microbiological testing method product sage platform now fda have instruct stryker product be verify used new compendial microbiological method undoubtedly new method be more time consume complex previously used sage notably fda have warn stryker issue july product recall hurt recall be likely adversely impact company sale operate income full year stryker now expect organic sale growth low end previously issue guidance band add company announce net earning diluted share be expect low end range third quarter stryker estimate adjust net earning diluted share low end previously issue band stryker have be grapple supply issue spine business long prove be major drawback quarters ahead fact international growth company spine segment second quarter be partially affected supply headwind stock performance glancestryker share price movement past year have be favorable company yielded return almost better broader industry only solid performance medsurg neurotech segment last report quarter hold promise strength international segment strong momentum europe china also buoy optimism zack rank key picksstryker have zack rank hold few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc notably edward lifescience sport zack rank strong buy idexx laboratory cogentix medical have zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat trail quarters company have long term expect earning growth rate cogentix medical register positive earning surprise last report quarter stock represent stellar return last year idexx laboratory deliver average earning beat trail quarters have long term expect earning growth rate simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
688,IDXX,invacare corporation ivc free report recently announce global launch proprietary invacare tdx sp power wheelchair brand wheelchair come equip linx technology motion concept ultra low maxx position system new linx technology allow high end complex rehabilitation need be meet exceptional functionality ease use linx electronic system include touch screen display wireless programming remote monitoring help better clinical evaluation easy intuitive programming seamless connect functionality provider invacare produce aforementioned series wheelchair north american market taylor street manufacturing facility elyrium european customer product be assemble germany tdx sp power wheelchair base be build several invacare core patented technology include surestep suspension stability lock trac tracking technology go forward believe tdx sp wheelchair linx technology help enable long term revenue growth company share invacare have gain last month industry decline invacare be lead manufacturer distributor medical equipment used acute care setting company design manufacture distribute medical device help person move breathe rest perform essential hygiene provide medical device solution congenital acquire degenerative ailment company sell product principally home medical equipment provider retail commerce channel residential care operator distributor government health service north america europe asia pacific zack rank key pickscurrently invacare have zack rank hold few better rank stock broader medical sector be edward lifescience corporation ew free report fresenius medical care corporation fms free report idexx laboratory inc idxx free report notably edward lifescience fresenius medical sport zack rank strong buy idexx laboratory have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock have return last month fresenius medical have yielded strong return year date stock have long term expect earning growth rate idexx laboratory have long term expect earning growth rate additionally stock represent impressive year return hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
689,IDXX,halyard health inc lead medical technology company recently announce positive clinical datum support use coolief treatment chronic osteoarthritis knee pain coolief be invasive patient treatment used cool radiofrequency technology safely treat chronic pain be also know cool radiofrequency therapy lead dr timothy davis founder medical director orthopedic pain specialist santa monica california randomize multus center study include examination patient month primary effectiveness month month study coolief provide significantly greater longer last pain relief improve physical function higher patient satisfaction intra articular steroid injection positive datum be present last week european society regional anaesthesia pain therapy annual congress lugano switzerland april halyard health receive clearance food drug administration fda marketing coolief relief chronic moderate severe knee pain cause osteoarthritis halyard health share have outperformed industry past month stock have gain period industry decline current level be also better return zack consensus estimate halyard health fiscal increase couple cent share last day similarly fiscal estimate increase cent share same time frame halyard health be alpharetta ga base medical technology company advance health healthcare deliver clinically superior solution prevent infection eliminate pain expedite recovery company offer surgical infection prevention product operate room portfolio innovative medical device focuse pain management respiratory digestive health zack rank other stock considerhalyard health carry zack rank buy few well rank medical stock medical sector be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx have long term expect earning growth rate stock have gain last year more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
690,IDXX,late healthcare sector have be bumpy ride obamacare saga dominate headline industry have be grapple multiple issue fail repeal replace obamacare trump major skinny repeal also lose ground report congressional budget office cbo joint committee taxation jct abolishment obamacare result more uninsured person count be expect rise medtech sector be expect witness decline customer base elimination obamacare indicate weaker demand expensive medical procedure device however obamacare stay dreadful medical device tax impose selling price be likely take away quarter profit medtech player also reduce capital intensive research development activity medtech space addition cadillac tax make sustainability difficult small player competitive medtech industry hurricane worsen scenariotension escalate devastate hurricane harvey irma impact economy datum american automobile association inc suggest national price gallon gas hit sep month further bank america estimate loss crop worth approximately florida due irma turn lead higher price grocery statistic provide labor department official federal government initial jobless claim have increase highest believe rise unemployment short live decline consumer income couple increase aggregate spending be likely deal heavy blow medtech industry medtech growth stock focusthese stock carry strong zack rank strong buy buy promise long term expect growth higher compare favorably broader industry also have take growth style score consideration growth style score highlight vital metric company financial obtain clearer picture quality sustainability growth research show stock style score combine zack rank offer best investment opportunity lonza group ltd lzagy free report lonza group supply product service pharmaceutical biotech specialty ingredient market worldwide company sport zack rank have long term expect earning growth rate project ep growth rate stock year stand compare broader industry projection company have growth score vgm score stock have gain last year higher broader industry orasure technology inc osur free report company develop manufacture market sell oral fluid diagnostic product specimen collection device unite state europe internationally zack rank stock promise long term expect earning growth notably orasure have growth style score project ep growth rate stock year stand compare broader industry projection orasure have have impressive run last year company have return significantly higher broader industry same time frame lemaitre vascular inc lmat free report company market sell service support medical device implant treatment peripheral vascular disease worldwide lemaitre have zack rank promise long term expect earning growth rate growth score stock have gain last year project ep growth rate stock year stand compare broader industry projection idexx laboratory inc idxx free report idexx laboratory be developer manufacturer distributer product service primarily companion animal veterinary livestock poultry water testing dairy market zack rank company have long term expect earning growth rate growth score see complete list today zack rank stock here idexx laboratory boast stellar return last year project ep growth rate stock year stand compare broader industry projection veracyte inc vcyt free report veracyte be diagnostic company be focuse discover develop commercialize molecular cytology solution stock carry zack rank growth score company have long term expect earning growth rate project ep growth rate year higher broader industry stock have gain past year compare industry more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
691,IDXX,share inogen inc ingn free report rally new week high sep close tad lower represent strong year date return approximately higher same time frame stock have zack rank hold take stable stock performance consideration expect inogen scale higher come quarters also company long term expect earning growth rate be higher broader industry majority last month company share price have considerably outperformed broader industry stock have rally last month beating industry gain just same time frame factor drive stockguidance upbeat banking solid performance last quarter inogen raise revenue adjust net income guidance moreover company narrow full year adjust ebitda guidance inogen project revenue range higher previous range represent year year growth previous range adjust ebitda be project band compare estimate earlier represent increase compare year quarter inogen expect adjust net income range previous band unique direct customer business model notably inogen have market cap company direct customer business model have lend lead position oxygen therapy market direct consumer model give company opportunity build unique brand relationship directly customer initiative support growth direct consumer line business company have announce have secure additional facility cleveland area solid result inogen report stellar second quarter beating zack consensus estimate count solid domestic international business business sale drive revenue fact company expect direct consumer sale be fastest grow channel follow domestic business business sale come quarters solid focus europe bright prospect ltot space inogen develop manufacture market portable oxygen concentrator poc company recently announce receipt ec certificate inogen platform be available sale select international country believe expand long term oxygen therapy ltot market advantage pocs traditional delivery model direct customer business model underpenetrated international market expand product portfolio be key growth catalyst favorable estimate revision trend inogen estimate revision trend have be promising full year last month estimate moved north compare movement opposite direction full year estimate rise almost share same time frame current quarter estimate moved compare downward revision last month result zack consensus estimate current quarter increase cent share same time frame inogen inc price consensus inogen inc price consensus inogen inc quotekey picksa few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc notably edward lifescience sport zack rank strong buy idexx laboratory cogentix medical have zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat trail quarters company have long term expect earning growth rate cogentix medical register positive earning surprise last report quarter stock represent stellar return last year idexx laboratory deliver average earning beat trail quarters have long term expect earning growth rate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
692,IDXX,share mazor robotic ltd mzor free report rally new week high sep eventually close little lower stock currently carry zack rank buy israel base developer robotic technology product have market cap roughly average volume share trade last month be company have expect long term earning share growth mazor robotic have outperformed industry past year company share have moved period compare industry gain strategic partnership medtroniclast wednesday mazor robotic announce have amend strategic partnership medtronic plc mdt free report amendment duo enter next phase agreement earlier be expect medtronic assume exclusive worldwide distribution mazor system make third tranche investment mazor robotic grow installation mazor systemsin last report quarter company have receive purchase order surgical guidance system include mazor system renaissance system be mazor customer primarily major hospital corporation renaissance system order receive be sell internationally distribution partner australia thailand mazor robotic system backlog end second quarter reach global basis company end second quarter system install worldwide unite state solid revenue growth second quartermazor robotic report total revenue beating zack consensus estimate notably revenue marked increase year year basis solid performance be drive positive factor strong sale order pipeline new mazor system continue utilization renaissance install base favorable regulatory year company announce receipt fda clearance mazor align software software be design assist surgeon plan spinal deformity correction spinal alignment procedure perform mazor surgical assurance platform consider development be encourage opportunity global spine surgery market research report market market suggest niche market reach worth cagr other key pickssome other medical stock worth consider be lantheus holding inc lnth free report idexx laboratory inc idxx free report stock carry zack rank see complete list today zack rank strong buy stock here lantheus holding have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last month zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
693,IDXX,aug issue update research report sunnyvale base intuitive surgical inc isrg free report manufacturer da vinci surgical system advanced robot assist surgical system related instrument accessory company currently carry zack rank hold major positive intuitive surgical have have impressive run bourse late glimpse recent price performance reveal favorable return past year compare favorably industry increase company have solid track characterize consecutive earning beat trail quarters recent time intuitive surgical report stellar performance mainly due grow adoption da vinci system physician overall growth global procedure da vinci surgical system enable minimally invasive surgery help avoid trauma associate open surgery performance be also aid grow volume courtesy general surgery oncology urology gynecology procedure intuitive surgical continuously introduce technology surgical system company also plan launch upgrade da vinci flagship vinci xi technology regard management confirm submission document ce mark approval vinci furthermore company expect availability device europe end long haul extensive expenditure product pipeline expansion international market europe drive growth company flipside company expect procedure growth rate slow bit outside unite state come quarters long sale purchase order cycle da vinci system have add wo also expense research development increase significantly first half reflect high spending advanced imaging advanced instrumentation next generation robotic key picksa few better rank medical stock be idexx laboratory inc idxx free report lantheus holding inc lnth free report edward lifescience corporation ew free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here idexx laboratory have long term expect earning growth rate stock have gain last month lantheus holding have long term expect earning growth rate stock have surge last month edward lifescience have long term expect earning growth rate stock have rally roughly last month surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
694,IDXX,initiative boost illumigene platform cincinnatus base meridian bioscience inc vivo free report recently initiate clinical trial illumigene cmv molecular amplification test simple saliva base test detect congenital cytomegalovirus cmv infection newborn infection result developmental disability even death share merdian jump close follow news release believe latest development further buoy company stock performance term follow encourage outcome clinical trial meridian be expect submit test fda review notably be fda approve clinical trial cmv screening newborn date latest development be significant move company diagnostic segment note illumigene be flagship platform segment include isothermal dna amplification be molecular platform be suitable laboratory size centralize decentralize illumigene comprise commercialize test illumigene illumigene group streptococcus illumigene group streptococcus illumigene mycoplasma more apart enhance illumigene platform company announce expansion immunocard stat profile recently addition immunocard stat flu product platform deserve mention regard meridian reaffirm fiscal guidance be key highlight moment company expect adjust diluted earning share range cent cent however company have have unimpressive performance last month stock lose much wider broader industry decline same time frame current level be also lower return almost same time frame stock have zack rank sell key picksa few better rank stock broader medical sector be edward lifescience corporation ew free report fresenius medical care corporation fms free report idexx laboratory inc idxx free report notably edward lifescience fresenius medical sport zack rank strong buy idexx laboratory have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock have return last month fresenius medical yielded strong return year date stock have long term expect earning growth rate idexx laboratory have long term expect earning growth rate additionally stock represent impressive year return simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
695,IDXX,initiative boost long term strategy growth strategy fresenius medical care fms free report recently sign agreement acquire outstanding share nxstage medical nxtm free report share transaction have be value be subject close approval nxstage stockholder other customary condition fresenius expect acquisition prove accretive earning year deal closure furthermore deal be expect provide annual pretax cost saving next year fresenius also expect integration cost next year time announcement management takeover boost revenue care coordination segment regard last quarter margin care coordination decline substantially year year basis owing lower profit vascular service higher cost pharmacy service believe latest development help company counter pressure margin growth strategy glanceper management latest development be significant step boost company grand long term goal fresenius have set strong long term objective growth strategy formulate few initiative attain solid market traction postulate growth strategy fresenius aim boost revenue corresponding average annual growth rate enhance core business care coordination unit meanwhile full year fresenius estimate revenue growth cc net income attributable shareholder company be likely increase share shine brightmeanwhile stock represent solid return compare favorably broader industry gain just last month furthermore fresenius promise long term expect earning growth rate almost indicate chance outperformance long haul note fresenius sport zack rank strong buy courtesy solid estimate revision trend estimate move north last month full year notably current year estimate stock rise share same time frame takefresenius provide wide range dialysis product own dialysis clinic third party clinic company offer wide array hemodyalisis peritoneal dialysis acute dialysis product well however latest development be expect fortify company foothold home dialysis market particularly renal care space datum news long island global renal dialysis market be expect see cagr reach worth key picksa few other top rank stock broader medical sector be edward lifescience corporation ew free report idexx laboratory inc idxx free report notably edward lifescience sport zack rank idexx laboratory have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock have return last month idexx laboratory have long term expect earning growth rate additionally stock represent impressive year return more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
696,IDXX,transenterix inc trxc free report global medical technology company recently announce have file response fda related senhance surgical robotic system submission company expect receive fda approval system fiscal transenterix share have outperformed industry past month stock have skyrockect compare industry gain same period current level be better return estimate revision trend stock have be dismal estimate move south last month estimate move north notably current year estimate stock decrease cent loss cent share same time frame come back news be bullish company progress fda approval senhance robotic surgery system senhance be multiport surgical robotic system help perform minimally invasive surgery patient recently system get install imperial college london notably senhance be ce marked use general surgery gynecology urology thoracic surgery be not available sale unite state company acquire senhance italy sofar be upbeat global market trend show minimally invasive surgical instrument market be forecast reach total cagr market market follow submission clearance senhance system fda company be able tap bountiful prospect domestic market zack rank key carry zack rank hold few better rank medical stock medical sector be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx have long term expect earning growth rate stock have gain last year more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
697,IDXX,surmodic inc srdx free report recently announce have receive food drug administration fda ce mark clearance low profile percutaneous transluminal angioplasty pta balloon dilation catheter aforementioned product be design peripheral angioplasty procedure surmodic share have outperformed industry past month stock have rally compare industry gain same period current level be also better return regulatory approval aforementioned product reflect surmodic peripheral angioplasty procedure particularly drug delivery space surmodic pta balloon catheter offer deliverability lesion cross leverage company proprietary serene hydrophilic coating serene hydrophilic coating be proficient avoid friction particulate company proprietary balloon catheter technology combine surmodic advanced process ensure ultra low tip entry cross profile transition achieve product performance development surmodic low profile pta catheter be step forward company strategy be provider whole product vascular solution medical device customer surmodic now have complete capability design development high volume manufacturing wide variety highly differentiate balloon catheter specialty catheter solution complete suite house capability state art facility ballinasloe ireland surmodic control step manufacturing process produce high quality reliable balloon catheter flip side company anticipate increase expense second half fiscal be increase investment related surveil dcbtrial other proprietary product estimate revision latest estimate revision trend have be favorable company current year estimate moved north compare none opposite direction last month result zack consensus estimate full year earning have moved cent share takeaccording report market research future global peripheral artery disease market be expect reach worth cagr period consider huge potential market believe latest development be strategic fit zack rank key pickssurmodic carry zack rank hold few better rank medical stock medical sector include edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx hold zack rank buy see complete list today zack rank strong buy stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx have long term expect earning growth rate stock have gain last year promising stock pick keep eye news story computer hacking identity theft become increasingly commonplace cybersecurity industry look promising investment opportunity stock buy zack just release cybersecurity investor guide locking profit help answer question new special report give information need make well inform investment choice space more importantly also highlight cybersecurity pick strong profit potential get new investing guide now
698,IDXX,idexx laboratory inc idxx free report record second quarter earning share ep cent constant exchange rate cer year year report basis further report figure surpass zack consensus estimate cent strong top line growth second quarter drive earning revenue detailidexx second quarter revenue rise year year organic basis beating zack consensus estimate year year increase be drive strong global gain companion animal group cag diagnostic recur revenue include double digit organic revenue gain consumable reference lab well strong acceptance rapid assay veterinary software service diagnostic imaging system idexx laboratory inc price consensus ep surprise idexx laboratory inc price consensus ep surprise idexx laboratory inc quotesegmental analysisidexx derive revenue operate segment cag water livestock poultry dairy lpd other second quarter cag revenue rise organically year year water segment revenue be prior year quarter organically lpd revenue meanwhile increase organically revenue other segment rise organically marginsgross profit increase report quarter gross margin expand basis point bps rise cost revenue sale marketing expense rise general administrative expense rise research development expense increase overall operate margin quarter improve bps financial positionidexx exit second quarter cash cash equivalent end first quarter year date net cash provide operate activity be compare year period guidanceidexx raise revenue outlook midpoint range earlier range reflect organic revenue growth expectation zack consensus estimate revenue be peg low end guide range management also raise ep guidance share earlier range support continue operate margin expansion align long term goal update outlook represent ep growth report basis zack consensus estimate ep be peg guide range takeidexx exit second quarter solid note earning revenue beating zack consensus estimate solid organic revenue growth buoy optimism company raise ep guidance be also encourage stellar quarterly performance be drive company companion animal business companion animal market fundamental remain solid tremendous global runway growth management unique innovation base multus modality global strategy enabled enhance commercial capability accelerate recur cag diagnostic revenue growth moreover strong top line growth quarter be drive considerable contribution rest business segment however foreign currency fluctuation be expect continue hurt company operate result lower extent expect earlier zack rank other key picksidexx currently have zack rank buy other top rank medical stock be mesa laboratory inc mlab free report insys therapeutic inc insy free report align technology inc algn free report notably insys therapeutic align technology sport zack rank strong buy mesa laboratory carry zack rank see complete list today zack rank stock here insys therapeutic have long term expect earning growth rate stock have gain last month align technology have expect long term adjust earning growth almost stock have add roughly last month mesa laboratory have positive earning surprise last quarters stock have add roughly last month make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
699,IDXX,sep issue update research report haemonetic corporation hae free report base lead provider blood management solution customer encompass blood plasma collector hospital health care provider globally stock currently carry zack rank hold haemonetic have be trading broader industry last month stock have now gain broader industry fall year year increase report sale gross margin buoy optimism haemonetic corporation price consensus haemonetic corporation price consensus haemonetic corporation quotemarket be upbeat haemonetic encourage growth plasma haemonetic management franchise company swung operate income first quarter fiscal loss year quarter haemonetic have be witness strong flourish plasma franchise quite time now management have also maintain high confidence continue growth commercial plasma collection business quarter north america plasma disposable revenue increase growth continue be lead strong end market demand plasma derive company hospital business be also progress well teg line product gain popularity worldwide teg be sanction broad set indication top market teg teg manager approval be same set indication europe australia japan flip side company have be witness sluggish revenue growth blood center franchise significantly affect result past few quarters management also doesn expect early recovery blood center outcome macroeconomic uncertainty continue challenge haemonetic management also anticipate slower expect product adoption customer reduce revenue profit also currency fluctuation stiff competition continue hamper stock other key picksa few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy cansee complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have surge last month idexx laboratory have long term expect earning growth rate stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
700,IDXX,major breakthrough diabetic business abbott free report recently announce receipt national reimbursement freestyle libre glucose monitoring system japan development have widen illinois base medical device major customer base diabetes management management population diagnosed diabetes japan be consider nation highest rate person suffering condition company state grant reimbursement also make freestyle libre system widely available more japanese person diagnosed type type diabetes insulin therapy vary age also reimbursement approval japan mark milestone abbott freestyle libre system stand partially fully cover country include france germany notably freestyle libre system be presently review fda await approval unite state abbott have be move steadily development diabetic segment july company partner bigfoot biomedical solidify footprint rapidly grow diabetes therapeutic market moreover company recently announce receipt health canada license freestyle libre flash glucose monitoring system further stimulate growth diabetes care sale segment be second quarter continue consumer acceptance freestyle libre internationally expect freestyle libre further contribute abbott top line canadian development french health ministry recently approve national reimbursement device report mordor intelligence global market diabetes care device be project reach value cagr consider market potential abbott current development diabetes care segment recent national reimbursement grant japan accelerate top line believe agee population unhealthy lifestyle rise awareness expenditure healthcare continue drive growth diabetes market however market be dominate many well establish player johnson johnson jnj be most prominent space johnson johnson also have tie base corporation successfully develop innovate insulin delivery system moreover abbott have be gain investor confidence consistently positive result last month company share price have outperformed broader industry stock have gain contrast broader industry decline company have also outperformed fall market same time frame zack rank key picksabbott carry zack rank hold few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
701,IDXX,cooper company inc coo free report report adjust earning third quarter fiscal surpass zack consensus estimate cent improve year quarter believe upside be drive robust revenue growth stock carry zack rank buy revenue increase record prior year quarter figure also beat zack consensus estimate solid top line performance be drive innovative product biofinity daily silicone hydrogel lense revenue cooper company have business segment coopervision cvi coopersurgical csi coopervision segment cvi revenue increase constant currency cc year year basis revenue continue gain company silicone hydrogel lense lead solid prospect myday clariti biofinity platform come major catalyst cvi segment robust performance toric cvi revenue multifocal cvi revenue single use sphere lense cvi revenue single use sphere lense propel solid growth multifocal revenue rise cc toric revenue increase cc year year basis single use sphere lense sale climb cc sale single use sphere lense inched cc year year geographically cvi revenue increase americas revenue asia pacific emea rise year year cc coopersurgical segment csi revenue jump cc year year basis come csi segment fertility category witness rise cc sale report quarter year year basis totale however office surgical product category csi segment inched cc cooper company inc price consensus cooper company inc price consensus cooper company inc quotemargin detailsadjust gross margin report quarter be revenue compare register year quarter gross margin improvement be fuel favorable product mix coopervision segment improve margin coopersurgical segment favorable foreign exchange adjust operate margin percentage revenue be fiscal third quarter flat year year basis guidancefiscal fiscal total revenue be expect band previously issue range revenue cvi segment be estimate previously guide range csi revenue be project range little lower previously guide range meanwhile adjust earning be anticipate band previously provide range share fourth quarter cooper company expect revenue range cvi revenue be expect csi revenue be anticipate company expect adjust earning share cooper company end third quarter fiscal solid note beating zack consensus estimate line company have always see impressive result coopervision business segment coopersurgical segment also deliver strong sale third quarter buoy robust toric performance company provide strong guidance fiscal however dampening outlook coopersurgical segment indicate loom concern furthermore intensify competition contact lens space continue increase pricing pressure company also note cooper company have complete acquisition small specialty contact lens company name procornea earlier month add lead ortho technology company lens portfolio acquisition marked company foray emerge myopia controlled market consider outstanding performance stock expect cooper company scale higher come quarters regard positive long term growth hold promise key picksa few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc notably edward lifescience sport zack rank strong buy idexx laboratory cogentix medical have zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat trail quarters company have long term expect earning growth rate cogentix medical register positive earning surprise last report quarter stock represent stellar return last year idexx laboratory deliver average earning beat trail quarters have long term expect earning growth rate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
702,IDXX,associate home care subsidiary amedisys inc am free report recently enter agreement acquire intercity home care agreement be schedule close oct intercity home care entire asset base be take associate home care post successful acquisition renown home health hospice service provider have more wide spread presence massachusettsas intercity home care have location greater boston north shore merrimack valley community moreover amedisys also gain access extend customer base expect serve client massachusett company have be make encourage move respect recently integrate personal care business last report quarter net service revenue personal care witness increase year year segment generate operate income quarter also amedisys be look forward huge growth prospect personal care segment moreover management segment be perform expectation integrate recent tuck acquisition earlier march company decide buy personal care provider east tennessee personal care service company believe acquisition expand personal care footprint outside massachusett notably management expect company have enough cash balance left make plenty such acquisition future moreover amedisys be currently explore opportunity home health hospice segment too company favorable demographic trend strategic acquisition encourage well moreover amedisys have be gain investor confidence consistent positive result past month company share price have outperformed broader industry stock have gain comparison broader industry gain company have also outperformed fall market same time frame zack rank other key picksamedisys carry zack rank buy other top rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
703,IDXX,share price align technology inc algn free report scale new week high sep eventually close nominally lower company have gain year much higher gain same frame align technology have also beat broader industry gain respect share price movement year stock have market cap further align technology estimate revision trend current year be favorable past day estimate moved moved estimate be share same time frame company also have trail quarter average positive earning surprise positive long term growth hold promise align technology inc price consensus align technology inc price consensus align technology inc company year historical growth rate be also favorable compare broader industry align technology carry zack rank hold company have impressive growth style score growth style score highlight vital metric company financial obtain clearer picture quality sustainability growth research show stock style score combine zack rank strong buy buy offer best investment opportunity growth market be upbeat exclusive distribution agreement sign patterson dental september agreement align technology itero element intraoral scanning system be available patterson dental cad cam portfolio unite state canada boost itero scanner customer base considerable extent further june align technology have announce inclusion esteem index boost investor confidence stock considerably be also encourage align technology solid second quarter performance year year increase earning revenue company encourage invisalign technology prospect growth north america international region also raise hope company recently open new invisalign technology treatment plan facility china meanwhile company multus dollar marketing campaign invisalign technology brand be encourage factor be expect boost company share price day ahead key picksa few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank lantheus holding idexx laboratory carry zack rank cansee complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last month surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
704,IDXX,abbott free report recently have initiate pivotal clinical study evaluate safety effectiveness modify version amplatzer device device be design correct common congenital heart defect pre term infant device be same larger size amplatzer duct occluder ii product clinical study be conduct patient center unite state accord abbott patent ductus arteriosus pda be life threaten vascular pathway duct heart remain open due failure fetal duct close birth case pda fail close spontaneously premature baby lead difficulty breathe fee pharmaceutical be used time close duct be less effective pre term infant current treatment option pre term infant be not responsive pharmaceutical be limit surgery however surgery be not always possible leave duct open lead fatal outcome infant breaking conventional treatment abbott be develop amplatzer duct occluder ii additional size ado ii device provide physician nonsurgical treatment option address pda defect newborn pre term infant ado ii be already approve use europe study be successful trial result support abbott application fda approval pediatric use country note abbott have be consistently try expand vascular business medical device segment be solid growth trajectory late last report second quarter medical device business sale spiked report basis also recent development include receipt fda approval full maglev heartmate left ventricular assist system also know lvad heartmate system enable physician manage advanced heart failure patient need short term hemodynamic support abbott also announce ce mark first use new confirm rx insertable cardiac monitor icm be world first smartphone compatible icm help physician identify difficult detect cardiac arrhythmia include atrial fibrillation af accord report market market global pediatric interventional cardiology market be estimate see cagr look bountiful opportunity niche space believe company latest development be strategical fit last month abbott have be trading broader industry stock have now gain industry decline zack rank key picksabbott carry zack rank hold few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy cansee complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
705,IDXX,aug issue update research report co base bioscrip inc bio free report company be lead infusion service provider strive deliver cost effective program patient stock currently have zack rank hold past month bioscrip have be trading broader industry stock have gain period industry loss market be upbeat company announcement continue offer certain core product line deal be significantly accretive bioscrip top line company progress new multus faceted core plan improve financial position be also encourage plan involve identify execute strategy accelerate core revenue growth favorable product mix drive operational efficiency improve revenue collection increase employee effectiveness further bioscrip have successfully complete home solution integration earlier year company expect core revenue well continue growth acquire asset prove accretive go forward notably bioscrip have be record persistent growth core infusion service business strong presence well competitive advantage company witness consistent rise business primarily account strong organic growth chronic nutrition other therapy have be build robust core infusion platform organic development acquisition management expect bioscrip focus fast grow core infusion business drive increase profitability company be currently track achieve previously announce home solution synergy other incremental annualize cost reduction end flip side bioscrip guidance be lackluster inclusion estimate negative impact cure act legislation large portion company revenue used come directly medicare state medicaid program other government payer however new cure act bill do not reimburse service payment administration certain drug patient home infusion pharmacy healthcare industry be also highly competitive bioscrip competitor include large well establish company higher financial marketing technological resource key picksa few better rank medical stock be idexx laboratory inc idxx free report lantheus holding inc lnth free report align technology inc algn free report align technology sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here idexx laboratory have long term expect earning growth rate stock have gain last month lantheus holding have long term expect earning growth rate stock have surge last month align technology have long term expect earning growth rate stock have rally roughly last month be reissue article correct mistake original article issue aug longer be rely
706,IDXX,civita solution inc civi free report recently announce have enter agreement acquire habilitative service inc target company provide service individual intellectual developmental disability state minnesota come back news feel acquisition be smart move part company habilitative service operate county minnesota provide continuum residential periodic service habilitative service support approximately adult residential site individual periodic program more employee habilitative service generate revenue approximately month period end transaction be however subject number close condition include expiration regulatory notice period party expect close transaction day past month civita solution have outperformed broader industry stock have gain compare only rise industry belong civita solution be lead national provider home community base health human service individual intellectual developmental physical behavioral disability other special need go forward be encourage company progress post acute specialty rehabilitation service srs adult day health adh service fastest grow business moreover company be witness steady contribution strategy grow organically acquisition also even company seem be implement cost restructure program efficiently weak margin continue mar financial also company recently slash guidance civita solution lower high end fiscal revenue guidance company project revenue range lower previous range zack rank stock considercivita solution have zack rank sell few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc notably edward lifescience sport zack rank strong buy idexx laboratory cogentix medical have zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat trail quarters company have long term expect earning growth rate cogentix medical register positive earning surprise last report quarter stock represent stellar return last year idexx laboratory deliver average earning beat trail quarters have long term expect earning growth rate simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
707,IDXX,accuray inc aray free report report loss cent share fourth quarter fiscal wider zack consensus estimate loss penny however figure be relatively narrower loss cent year quarter total revenue fourth quarter increase approximately year year beat estimate year year growth be primarily drive solid prospect americas apac region accuray also report fiscal result fiscal total revenue decrease year year basis service revenue net revenue totale product revenue net revenue totale fiscal notably accuray carry zack rank sell hint probability term accuray incorporate price consensus ep surprise accuray incorporate price consensus ep surprise accuray incorporate quotesegment analysisproduct revenue revenue segment increase system order conversion backlog revenue americas apac region buoy growth segment solid performance cyberknife tomotherapy system radixact platform be key highlight segment service revenue revenue segment see modest year year increase management lackluster performance segment be primarily due lower installation gross order update report quarter gross product order totale increase year year basis end quarter product backlog be approximately higher year year gross order performance be favorably impact company flagship radixact system cyberknife system incise multileaf collimator other platform drive sale company new tomotherapy product platform also know radixact continue contribute company top line radixact represent majority accuray tomotherapy order mix report quarter sequential basis third quarter apac japan witness stellar performance radixact tomotherapy platform radixact order japan have be extremely positive date precision system accuray also announce new precision treatment plan system recently system leverage company flagship radixact cyberknife system platform company also plan build technology precision upgrade fiscal provide significant improvement treatment speed overall throughput already exist cyberknife system ibms datum management system tomotherapy accuray also announce clearance new ibms datum management system tomotherapy be centralize database share make datum accessible multiple accurate system add flexibility improve efficiency radiation therapy department margin margin percentage net revenue contract basis point bps fourth quarter be primarily due reduce product gross margin product gross margin decrease due unfavorable product channel mix operate expense fourth quarter be almost flat year period guidanceaccuray issue guidance fiscal company project full year revenue band represent growth band approximately year year basis furthermore product revenue be expect increase band year year service revenue be likely remain flat fiscal company expect increase gross order fiscal product system backlog be expect band adjust ebitda fiscal be anticipate range year year takeaccuray report wider expect loss fourth quarter fiscal primarily due lackluster performance service revenue segment company issue solid fiscal guidance recent development order newly unveil radixact system solid revenue performance apac japanese regulatory approval radixact be key positive view however unfavorable product mix decline service revenue sluggish macro economic condition pricing headwind be major concern notably china europe see sluggish revenue fourth quarter accuray significant international presence help broaden customer base however fluctuation currency exchange rate particularly strong dollar continue adversely impact company backlog top line come quarters key picksa few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc notably edward lifescience sport zack rank strong buy idexx laboratory cogentix medical have zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat trail quarters cogentix medical register positive earning surprise last report quarter idexx laboratory deliver average earning beat trail quarters surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
708,IDXX,medtronic plc mdt free report lead global player medical technology service solution have make encourage move respect cardiac rhythm heart failure crhf business companyrecently announce ce mark approval attain stability quad mri active fixation heart lead be line company strategy focus research development high end medical device product core business line notably company be engage clinic trial evaluate attain stability quad mri active fixation heart lead unite state canada other region medtronic latest offer feature active fixation technology assist precise lead placement stability pair company quadripolar cardiac therapy defibrillator crt pacemaker crt company also initiate multicenter clinical study target enroll roughly patient site unite state canada europe hong kong malaysia global study be aim evaluate safety efficacy lead heart failure patient interestingly medtronic cardiac vascular group cvg segment account total revenue first quarter fiscal moreover company crhf sub segment be highest contributor make total cvg revenue be largely backed strong growth arrhythmia management well heartware international acquisition thus company latest development help boost performance segment medtronic strategy gain traction crhfsub segment seem be align datum provide ally market research report global cardiac monitoring cardiac rhythm management market be expect see cagr reach value believe high incidence cardiac disease due unhealthy lifestyle penetration concern company untapped market technological advancement increase awareness person continue drive global acceptance technology view encourage factor believe company european development attain stability quad mri active fixation heart lead be strategic broaden customer base however last month medtronic have be underperform broader industry stock have decline compare industry fall also underperform decline same time frame nevertheless believe latest ce mark approval boost investor confidence stock zack rank key picksmedtronic currently have zack rank hold few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have gain last month idexx laboratoriesha long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
709,IDXX,nxstage medical inc nxtm free report recently announce regulatory approval system platform fda solo home hemodialysis treatment company have also announce provide patient training new indication later year system have be flagship platform nxstage contribute significantly company top line latest development system platform be exclusively formulate new exist system patient reduce transportation cost re hospitalization rate provide dialysis care site fact solo home hemodialysis eradicate need care partner treatment procedure notably company get first only home nocturnal hemodialysis clearance way back management globally number patient fail opt home hemodialysis date due absence care partner help process latest regulatory go ahead be likely lend nxstage competitive edge expand patient base solid access clinical benefit associate home hemodialysis nxstage partner dialyze direct site latest regulatory progress closely follow solid development nxstage dialysis platform earlier month company announce subsidiary nxstage kidney care be partner dialyze direct support need patient need site skilled nursing facility snf dialysis treatment ohio nxstage now leverage system platform dialyze direct unique model treat geriatric snf patient end stage renal disease esrd nxstage be acquiredearlier month german dialysis provider fresenius medical care fms sign agreement acquire outstanding share nxstage share transaction have be value be subject close approval nxstage stockholder other customary condition note nxstage have be gain prominence market late product nxstage pureflow dialysis preparation system nx connect health nxstage system market trend buoy optimismdata market market reveal global hemodialysis peritoneal dialysis market be expect reach worth cagr nxstage continuous effort bolster dialysis unit be likely be benefit bountiful prospect niche space furthermore increase rate esrd case enhance probability nxstage outperformance niche space term share price move upover past year nxstage have add compare favorably same time frame furthermore current level be way higher broader industry gain just same time frame nxstage carry zack rank hold key picksa few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc notably edward lifescience sport zack rank strong buy idexx laboratory cogentix medical have zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat trail quarters company have long term expect earning growth rate cogentix medical register positive earning surprise last report quarter stock represent stellar return last year idexx laboratory deliver average earning beat trail quarters have long term expect earning growth rate zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
710,IDXX,aug issue update research report pleasanton base veeva system inc veev free report global provider cloud software datum solution life science industry company currently carry zack rank hold veeva have impressive run bourse year date trading industry term price performance glimpse price movement reveal veeva share have gain compare favorably industry decline company have solid track characterize consecutive earning beat trail quarters company have strengthen recur part revenue mix significant growth subscription revenue recent time moreover launch veeva vault veeva commercial cloud platform be encourage company be also support considerable strength crm platform veeva industry specific focus give significant leverage view be aptly demonstrated strong sale growth aid new business gain better pricing product innovation company knowledge different component life science industry be help build target product notably product veeva opendata provide customer datum healthcare professional hcp healthcare organization hco affiliation life science major market look ahead veeva be optimistic product pipeline include exclusive range product flagship vault commercial cloud platform product include vault ctms vault promomat dam crm engage meeting crm engage webinar glimpse last report fiscal second quarter result reveal strong revenue adjust earning top bottom line beat zack consensus estimate additionally solid year year subscription revenue growth have enhance recur part company revenue mix however flip side unfavorable foreign currency be expect hurt earning term also escalate cost expense be weigh margin last month comparative study veeva forward forward month basis multiple reflect stock have be quite overvalue key picksa few better rank medical stock be idexx laboratory inc idxx free report lantheus holding inc lnth free report edward lifescience corporation ew free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here idexx laboratory have long term expect earning growth rate stock have gain last month lantheus holding have long term expect earning growth rate stock have surge last month edward lifescience have long term expect earning growth rate stock have rally roughly last month zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
711,IDXX,headquarter delaware nj idexx laboratory inc idxx free report be developer manufacturer distributer product service primarily companion animal veterinary livestock poultry water testing dairy market company also sell series portable electrolyte blood gas analyzer human point care medical diagnostic market currently idexx have zack rank buy change follow second quarter earning report have just release see complete list today zack rank strong buy stock here have highlighted key detail just release announcement earning current zack consensus estimate be peg cent share idexx second quarter earning share come cent increase year year report basis constant currency basis figure improve year year idexx laboratory inc price ep surprise idexx laboratory inc price ep surprise idexx laboratory inc quoterevenue idexx post revenue increase year year have surpass zack consensus estimate revenue key stat business segment idexx deliver second quarter revenue cag water livestock poultry dairy lpd other segment major factor management growth business second quarter be majorly drive strength cag revenue segment company focus deliver best class diagnostic software solution support profession increase companion animal standard care have yielded high solid return quarter come guidance company have raise revenue guidance band earlier range company expect full year adjust earning range earlier range stock price follow earning release share price do not show movement pre market trading session check back later full idexx earning report later make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
712,IDXX,be second half second quarter earning season earning preview jul member index total market cap have report quarterly number putt together result see pace earning revenue growth be steadily accelerate relative pre season expectation latest scorecard say total earning member increase year year higher revenue earning beat ratio remain revenue beat ratio stand member yet release number total second quarter earning index be currently expect be higher revenue year period store medical space medical broader zack sector be absolutely exception trend improvement so far member sector have release quarterly earning result earning revenue beat standing very impressive level respectively more more company line earning announcement aggregate growth pace sector be expect pick further notably be powerful long term tailwind medical device industry include merger acquisition emerge market expansion positive demographic trend new product innovation have be major drive force sector impressive performance past few quarters even severe socio economic political instability let analyse follow major medical product company be place ahead announcement aug idexx laboratory inc idxx free report be upbeat idexx innovation base global strategy be lead cag diagnostic growth june idexx announce addition rvetlink portfolio technology application notably rvetlink be advanced inclusive referral management solution design specialty care hospital simplify referral procedure primary care specialty care veterinarian apart idexx continue display solid growth respect international expansion believe outcome endeavor be reflect company second quarter performance schedule release market open previous article show idexx be likely beat earning quarter however estimate change thereafter be not certain beat earning season be stock need have positive earning esp zack rank strong buy buy hold happen be not case here stock currently carry zack rank earning esp make surprise prediction difficult base zack methodology positive zack esp serve lead indicator likely earning surprise bullish zack rank increase predictive power esp uncover best stock buy sell re report earning esp filter idexx laboratory inc price ep surprise idexx laboratory inc price ep surprise idexx laboratory inc quote resm inc rmd free report resm effort expand business internationally be encourage company revenue performance segment third quarter fiscal be impressive expect company maintain similar trend quarter well however last quarter currency impact resm combine emea asia pacific revenue be likely dent result fiscal fourth quarter too resm be schedule report fourth quarter fiscal result aug market close company currently carry zack rank have earning esp hence be unable conclude resm be likely beat estimate quarter see complete list today zack rank stock here note sell rate stock never be consider go earning announcement read more be surprise store resm earning resm inc price ep surprise resm inc price ep surprise resm inc quote more stock news company verge apple rundid miss apple stock explosion launch iphone now look be pivotal year get emerge technology expect rock market demand soar almost nothing report suggest save life decade turn save healthcare cost bonus zack special report name breakthrough best stock exploit apple company be already strong coil potential mega gain click see right now
713,IDXX,investor be always look stock be poise beat earning season idexx laboratory inc idxx free report be such company firm have earning come pretty soon event be shape quite nicely report be idexx laboratoriesis see favorable earning estimate revision activity late be generally precursor earning beat analyst raise estimate right earning most date information possible be pretty good indicator favorable trend surface idxx report fact most accurate estimate current quarter be currently cent share idxx compare broader zack consensus estimate cent share suggest analyst have very recently bump estimate idxx give stock zack earning esp head earning season idexx laboratory inc price ep surprise idexx laboratory inc price ep surprise idexx laboratory inc quotewhy be important positive read zack earning esp have proven be very powerful produce positive surprise outperform market recent year backtest show stock have positive earning esp zack rank hold better show positive surprise nearly time have return average annual return see more top earning esp stock here give idxx have zack rank buy esp positive territory investor want consider stock ahead earning see complete list today zack rank strong buy stock here clearly recent earning estimate revision suggest good thing be ahead idexx laboratory beat be card upcoming report hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionary still leave plenty money regular investor make right trade early see zack best stock play trend
714,IDXX,market hate unknown unpredictable simmer tension korean peninsula be bit investor politician world seem be apprehensive global reaction north korea sixth also biggest nuclear weapon test sunday potential conflict north korea act forefront everyone mind stock market be tenterhook well fact accord south korean official north korea appear be set test ballistic missile back home geopolitic severe hurricane rocked wall street calm market remain skittish aftermath north korea nuclear test second potent hurricane irma expect unite state many week such fickle environment rapidly escalate be surprise investor seek asset security gold price flare treasury strengthen however feel such scenario investor look gold government security have create multus faceted screen give investor stability profit growth potential farther next quarter make sense profitsit be common knowledge wall street be obsessed bottom line be higher profit necessarily better be really true indicator stay power company earning dollar profit trump other measure hand sheer shock value do not relate profit size company sale resource shareholder capital only profitability measure reasonably work industry be ratio return generate dollar invest business most popular ratio be return equity roe favore wall street analyst investor alike however roe measure receive most attention investor community executive focus heavily metric well company exploit financial strategy increase debt leverage stock buyback funded build cash artificially maintain healthy roe conceal weaken operational profitability so let shift focus different bottom line metric garner far less attention executive investor alike return invest capital lesser know show optimally management have be direct capital control profitable investment paint clear picture efficiently company be employ capital competitive position be allow produce good return capital also focus large cap be big establish company stock market have comparatively softer risk profile virtue dominant market position global footprint relatively consistent cash flow stream company tend be more reliable investment be call current geopolitical environment also be particularly relevant assess company have large amount capital be quite difficult investor single such company need company have generate strong rois sufficiently long period time order determine robust trend so have create faceted screen shortlist such company only company have generate rois excess average last year get past screen current trail month also need be least addition ensure hone stable company have establish history generate profit screen allow only company have market capitalization north needless say company have solid zack rank too favorable zack rank show positive analyst interest brighter prospect company stock have proven mettle consistently challenge time look set outperform peer effortlessly efficient usage asset just company get screen here be boee company ba free report boee be world major aerospace firm design develop manufacture sell service support commercial jetliner satellite military aircraft human space flight missile defense launch system service globally aerospace giant generate impressive average last year boast current past month analyst have become increasingly bullish zack rank buy stock see complete list today zack rank strong buy stock here company have see sharp spike zack consensus estimate be now peg witness couple month back move denote decidedly bullish analyst sentiment stock texas instrument incorporate txn free report texas instrumentsis global semi conductor company world lead designer supplier digital signal processor analog integrate circuit past year zack rank stock generate impressive average have current analyst envision healthy future company zack consensus estimate earning trend sharply past day share thank upward estimate revision gilead science inc gild free report base foster city gilead science focus discovery development drug several indication zack rank stock generate average year time current be peg analyst have great expectation company year have be revise earning estimate upward past couple month gilead estimate inched past day idexx laboratory inc idxx free report idexx laboratory be global leader provide diagnostic detection information product animal health industry well quality assurance product service food water industry year time company record average boast current moreover analyst have become increasingly bullish zack rank stock past month upward estimate revision earning have lead sharp spike zack consensus estimate be now peg witness day moody corporation mco free report moody sprovide credit rating credit capital market economic related research datum analytical tool worldwide zack rank stock generate average last year current past couple month analyst have become increasingly bullish company upward estimate revision earning have lead sharp spike zack consensus estimate increase see month today surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
715,IDXX,healthcare space have be sticky situation incongruous incident hit back back republican take hold senate house president donald trump promise come superior healthcare plan fully repeal replace barack obama signature affordable care act aca be still hang balance jul first day ongoing debate session trump have taste success latest republican healthcare bill extensive amendment original obamacare win very narrow margin however investor be not much optimistic development promise likely consequence latest health billtrump latest bill primarily promise improve insurance coverage exist law significantly lower american premium however accord congressional budget office cbo staff joint committee taxation jct cost estimate release jul aca obamacare full repeal bill be finally sign number uninsured person increase present uninsured number further intensify uninsured elimination aca expansion eligibility medicaid elimination subsidy insurance purchase marketplace establish aca number uninsured then increase medtech insightwhile twist turn unfold capitol hill market watcher keep tab influence dramatic move have space closely related here ponder medical device stock stand gain lose political gridlock supporter republican alternative argue propose amendment be implement more person be cover portion cost be bear government needless mention lead broaden customer base medtech company have otherwise suffer notably medical device industry be happy original trump action plan promise cancellation major healthcare taxe include key taxe obamacare unpopular cadillac tax excise tax high cost healthcare plan controversial medtech tax full repeal plan get vote fraternity worry final plan still include medtech tax repeal agenda earning sneak peekmost medtech major be line report earning result next week present eco political hullabaloo lack visibility corner be able continue bullish run second quarter earning season latest earning trend also fail paint bright picture broader medical space be expect register year year earning growth mere revenue growth compare unfavorably prior quarter report earning growth revenue growth make right choicegiven numerous stock medical sector almost always muddle stock pick ability zack methodology offer relief narrow choice focuse medical device stock specialize chunk medical sector have desirable combination positive earning esp favorable zack rank zack rank strong buy buy hold earning esp be proprietary methodology identify stock have high chance surprising next earning announcement show percentage difference most accurate estimate zack consensus estimate uncover best stock buy sell re report earning esp filter research show stock combination chance positive earning surprise be high go criterion present medical device stock be poise beat estimate quarter idexx laboratory inc idxx free report headquarter delaware nj idexx laboratory inc idxx free report be developer manufacturer distributer product service primarily companion animal veterinary livestock poultry water testing dairy market idexx achieve strong organic growth international region last report first quarter drive strong global gain companion animal group cag diagnostic recur revenue double digit organic revenue gain consumable reference lab rapid assay revenue well continue expansion premium instrument install base company expect bullish trend continue upcoming release well idexx be schedule report second quarter number aug expect company beat earning estimate have zack rank earning esp dextera surgical inc dextera surgical be developer proprietary stapling device minimally invasive surgical procedure primarily develop commercialize microcutter cartridge base micro cutter device used thoracic pediatric bariatric colorectal general surgeon company be schedule report fourth quarter fiscal number aug expect company beat earning estimate have earning esp zack rank see complete list today zack rank stock here teleflex incorporate tfx free report teleflex be global provider medical technology design improve health quality person life company have diverse portfolio solution field vascular interventional access surgical anesthesia cardiac care urology emergency medicine respiratory care teleflex be schedule report second quarter number aug expect company beat earning estimate have zack rank earning esp quintile im holding inc quintile im be lead integrate information technology enabled healthcare service provider worldwide dedicate improve client clinical scientific commercial result teleflex be slate report second quarter number aug expect company beat earning estimate have zack rank earning esp zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
716,IDXX,hologic inc holx free report be slate report third quarter fiscal financial result aug close bell last quarter company deliver positive earning surprise notably hologic earning surpass zack consensus estimate past quarters average beat let see thing be shape prior announcement factor playhologic witness lackluster performance diagnostic segment last report quarter poor cytology perinatal sale particularly longer cervical cancer screening guideline interval be play spoilsport here issue still factor company performance expect segment continue perform dull upcoming quarter be also worry fact hologic blood screening divestiture be expect impede company growth momentum day ahead expect get reflect company financial performance yet be report quarter hologic have face several challenge owing unfavorable foreign currency impact have be affect company overall performance past few quarters foreign exchange headwind be expect result reduction escalate operate expense intense competition particularly tomosynthesis market continue be concern hologic quite time now company witness several challenge such restrict capital spending environment economic uncertainty europe slower sale cycle increase pricing pressure expect problem linger upcoming quarters well company get significant synergy benefit third quarter integration cynosure inc medical aesthetic system technology company hologic acquire mar mention fda have recently grant expand clearance cynosure invasive body contour product sculpture treat back inner outer thigh come product launch third quarter company receive european ce mark new panther fusion system panther fusion assay flu respiratory testing also company announce fda approval itsgenius mammography exam several other product launch also boost upcoming quarterly result overall third quarter fiscal hologic expect revenue compare prior guidance current zack consensus estimate third quarter revenue be company expectation adjust ep be project cent cent high end previous cent cent range current zack consensus estimate third quarter adjust ep be peg cent company guidance earning whispersour proven model do not conclusively show hologic be likely beat estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp hologic have earning esp be most accurate estimate zack consensus estimate be peg cent uncover best stock buy sell re report earning esp filter zack rank hologic have zack rank note caution sell rate stock go earning announcement especially company be see negative estimate revision stock considerhere be company want consider model show have right combination element come earning beat quarter dextera surgical inc have earning esp zack rank thermo fisher scientific inc tmo free report have earning esp zack rank see complete list today zack rank stock here idexx laboratory inc idxx free report have earning esp zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
717,IDXX,phibro animal health corporation pahc free report report adjust earning share ep cent fourth quarter fiscal year year adjust ep also surpass zack consensus estimate cent accord company year year improvement be primarily drive higher gross profit ratio reduce interest expense lower effective income tax rate include time item company report ep cent line year quarter full year adjust earning come increase year period also figure surpass zack consensus estimate net salesin report quarter phibro net sale be year year improvement be drive sale growth animal health mineral nutrition segment performance product fiscal register net sale year also revenue beat zack consensus estimate phibro animal health corporation price consensus ep surprise phibro animal health corporation price consensus ep surprise phibro animal health corporation quotesale segmentsnet sale animal health segment increase report quarter back volume increase nutritional specialty vaccine product group segment nutritional specialty product grow sale vaccine increase principally volume growth product poultry swine industry however sale medicated feed additive mfa other fall primarily due volume decline domestic net sale mfa other decline due reduce volume medically important antimicrobial international net sale increase drive growth asia pacific region be partially offset decline brazil due economic condition net sale mineral nutrition segment increase increase volume higher average selling price result underlie raw material commodity price increase net sale performance product segment increase be drive higher volume copper base product personal care ingredient increase average selling price copper base product however increase be partially offset lower average selling price personal care ingredient operational updatephibro fiscal fourth quarter gross profit increase year year gross margin expand basis point bps selling general administrative expense rise operate margin expand bps year year quarter financial update year date phibro generate cash flow operation compare year period capital expenditure amount period reflect reduction fiscal fy outlookphibro provide fiscal guidance company currently expect generate net sale current zack consensus estimate fall guide range phibro provide adjust ep guidance range current zack consensus estimate be lower end company guide range takephibro end fiscal fourth quarter solid note net sale adjust earning beating zack consensus estimate also year year increase front be encourage further company witness year year improvement segment be also encourage expansion gross operate margin report quarter moreover full year basis adjust earning net sale have surpass zack consensus estimate well year year increase company have provide fiscal guidance net sale adjust earning zack rank peer currently have zack rank hold few better rank medical stock be edward lifescience corp ew free report petm express inc pet free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy petm idexx carry zack rank buy see complete list today zack rank stock here edward lifescience second quarter adjust earning improve year year primarily drive strong sale growth company transcatheter heart valf business stock have gain last month idexx laboratory record second quarter ep cent cer year year report basis moreover revenue rise year year organic basis petm report earning share cent first quarter fiscal year quarter cent moreover net sale report quarter rise year year simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
718,IDXX,aug issue update research report waltham base perkinelmer inc pki free report company provide scientific instrument consumable service pharmaceutical biomedical environmental testing chemical general industrial market worldwide company currently have zack rank hold perkinelmer expand product portfolio be help company market share worldwide short span time new product have gain significant traction consumer believe product continue boost company market share area diagnostic research environment moreover perkinelmer be well position benefit investment area cancer immunotherapy well rise trend outsource instrument maintenance scientific service long term acquisition strategic partnership have be key catalyst perkinelmer year earlier year company announce plan acquire euroimmun medical laboratory diagnostic ag approximately cash deal be expect close fourth quarter acquisition euroimmun medical laboratory diagnostic expand perkinelmer reach autoimmune allergy diagnostic market acquisition also reinforce company capability pertain new infectious disease chinese market management acquisition be expect add cent cent adjust earning perkinelmer continue acquire large number company improve revenue opportunity add integration risk frequent acquisition also negatively impact balance sheet form high level goodwill intangible asset frequent acquisition be also distraction management impact organic growth stock performance share price movement past year have be unsatisfactory company represent return almost bit lower broader industry return almost company have be witness weakness academic market outside unite state furthermore lackluster performance europe impact company third party logistic second quarter estimate revision trend have be favorable perkinelmer last month current quarter estimate moved north compare movement opposite direction full year estimate moved north same time frame have have significant impact magnitude estimate current quarter estimate increase full year estimate inched same time frame key picksa few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc notably edward lifescience sport zack rank strong buy idexx laboratory cogentix medical have zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat trail quarters company have long term expect earning growth rate cogentix medical register positive earning surprise last report quarter stock represent stellar return last year idexx laboratory deliver average earning beat trail quarters have long term expect earning growth rate surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
719,IDXX,st loui mo base pharmacy benefit manager express script hold company esrx free report recently announce result new diabetes study diabetes dilemma trend diabetes medication use study person follow oral diabetes medication experience significantly fewer emergency room visit inpatient hospitalization further report reveal spend nearly less total healthcare cost compare nonadherent patient strong criticism be voiced high price specialty drug focus be better management healthcare cost consumer be become increasingly proactive healthcare decision study express script emphasize need necessary patient spending medication feel lead experience average increase diabetes drug spend regard remind investor company safeguard suite pharmacy solution be design better manage specialty spending thereby establish higher standard patient outcome portfolio also include hepatitis cure value program cholesterol care value program oncology care value program express script inflation protection program past month company have underperform broader industry stock have gain only compare rise industry belong go forward be highly upbeat company core pharmacy benefit management long term outlook include ongoing volatile healthcare market trend inflation patent expiration lower industry utilization growth other headwind furthermore expect express script continue benefit increase generic utilization shift mail order strong specialty growth age population brand drug be become increasingly expensive due double digit brand inflation constant rise price specialty drug overwhelming regulatory burden be actually pave way manifold prospect generic however express script recently announce biggest customer lead health insurer anthem inc antm free report be not likely extend pharmacy benefit management agreement be slate expiration end anthem sue express script overcharge drug operational failure management anthem refuse participate further discussion pricing concession probable adjustment agreement meanwhile second quarter anthem generate revenue worth compare second quarter zack rank key picksnotably express script currently have zack rank hold few better rank medical stock be idexx laboratory inc idxx free report lantheus holding inc lnth free report lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank strong buy stock here lantheus holding have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have rally last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
720,IDXX,growth investor generally have high risk tolerance be continuously lookout average growth stock be expect outperform broader industry respect revenue earning cash flow however apparently simple growth investment technique have drawback lack proper understand strategy often lead short list growth stock be misfit portfolio growth investor seek capital gain tend remain expose high risk bull market have be popularly say stock keep scaling new high event work however timing pullback be hard gauge insight zack latest style score system have make task quite simple help choose stock have solid performance record therefore prove be great choice investor growth style score highlight evaluation metric represent score caution investor regard growth trap help find stock have high growth potential meanwhile stock zack rank strong buy buy reflect upward trend stock earning estimate research show stock growth style score combine zack rank offer best upside potential base have identify candidate idexx laboratory idxx free report zack rank growth score prove be solid growth pick work favor idexx laboratory idexx laboratory have favorable vgm score zack style score system stand value growth momentum vgm score be simply weight combination parameter be comprehensive tool allow investor filter standard score system pick winning stock company also have favorable historical earning share ep growth rate compare broader industry historical ep growth rate consider average annual trail month ep growth rate last year actual earning stock have attractive project ep growth rate compare broader industry project earning growth rate be important informative tool assess company growth potential gauge estimate growth rate year technically consider consensus estimate current fiscal year divide ep last complete fiscal year actual report consensus not thus idexx laboratory have estimate earning growth rate beating industry next parameter be cash flow growth company cash flow be describe net cash move company idexx laboratory prove be great growth pick current cash flow growth rate stand compare industry thus company strong cash balance bolster confidence stock idexx laboratory inc free cash flow ttm idexx laboratory inc free cash flow ttm idexx laboratory inc quoteidexx laboratory also stand strong come sale relation asset profit project growth company have favorable net margin net income sale far better broader industry decline sale asset ratio support company solid growth stock comparison industry moreover project sale growth rate surpass broader industry regard take note idexx laboratory companion animal market fundamental be solid tremendous global runway growth management unique innovation base multus modality global strategy enabled enhance commercial capability accelerate recur cag diagnostic revenue growth apart idexx continue display solid growth respect international expansion company have be significantly benefitting companion animal market emerge nation demonstrate bountiful opportunity other growth stock consider other growth pick medical sector be worth mention be lantheus holding inc lnth free report amedisys inc am free report masimo corp masi free report lantheus carry zack rank growth score see complete list today zack rank stock here amedisys carry zack rank growth score masimo carry zack rank growth score surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
721,IDXX,expect idexx laboratory inc idxx free report beat expectation report second quarter result aug open bell last quarter company beat zack consensus estimate cent deliver positive earning surprise be worth note idexx have outperformed zack consensus estimate precede quarters average let take look thing be shape prior announcement likely positive surprise proven model show idexx be likely beat earning have perfect combination key ingredient zack esp idexx have earning esp most accurate estimate be cent zack consensus estimate be lower cent favorable zack esp serve meaningful lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank idexx currently carry zack rank buy note stock zack rank strong buy hold have significantly higher chance beating earning estimate conversely caution stock zack rank sell rate stock go earning announcement especially company be see negative estimate revision combination idexx zack rank esp make reasonably confident earning beat drive better expect earning idexx achieve strong organic growth international region last report first quarter drive strong global gain companion animal group cag diagnostic recur revenue include double digit organic revenue gain consumable reference lab rapid assay revenue well continue expansion idexx premium instrument install base company expect bullish trend continue upcoming quarters well overall idexx raise revenue outlook range reflect organic revenue growth expectation zack consensus estimate revenue be peg guide range idexx laboratory inc price ep surprise idexx laboratory inc price ep surprise idexx laboratory inc quoteon bottom line front company raise ep guidance share earlier range support continue operate margin expansion align long term goal update outlook represent ep growth report basis zack consensus estimate ep be peg be guide range be upbeat company innovation base global strategy be lead cag diagnostic growth june idexx announce addition rvetlink portfolio technology application notably rvetlink be advanced inclusive referral management solution design specialty care hospital simplify referral procedure primary care specialty care veterinarian apart idexx continue display solid growth respect international expansion company have be significantly benefitting companion animal market emerge nation demonstrate bountiful opportunity further management consistent share buyback reflect strong free cash flow reserve believe outcome endeavor be reflect second quarter performance flip side foreign currency fluctuation be major headwind company concern be company high reliance third party distributor purchasing dynamic distributor have significant impact company sale instrument consumable rapid assay product also company be expose higher operate expense pertain increase head count higher investment target growth acceleration geographical expansion internationally portfolio expansion also competitive landscape domestic overseas market weigh idexx performance struggle gain market share also prove be drag second quarter result other stock considerhere be other company consider model show also have right combination element post earning beat upcoming quarter becton dickinson company bdx free report have earning esp zack rank thermo fisher scientific inc tmo free report have earning esp zack rank see complete list today zack rank stock here stryker corporation syk free report have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
722,IDXX,healthequity inc hqy free report report earning cent share second quarter fiscal surpass zack consensus estimate cent figure be higher year earning cent revenue margin expansion share healthequity have gain only value year date compare unfavorably industry gain belong quarter detailsrevenue say quarter amount reflect increase year year surpass zack consensus estimate service total revenue custodial interchange revenue be year year respectively growth service revenue be drive year year increase average health saving account hsa be offset decrease service revenue average hsa decline be lead company strategy offer lower service fee hsa more volume network partner particularly higher balance healthequity state profitability hsa business model increase balance grow growth custodial revenue be support higher average daily cash aum strong year year growth interchange revenue be drive increase card spending more favorable interchange term higher spend volume jul total number hsa member company serve bank custodian increase year year total asset management aum surge year year healthequity inc price consensus ep surprise healthequity inc price consensus ep surprise healthequity inc quotefinancial conditiona jul company have cash cash equivalent marketable security outstanding debt compare favorably cash cash equivalent marketable security outstanding debt jan fiscal end jan healthequity forecast revenue range net income be forecast range result net income diluted share range cent cent adjust ebitda outlook be estimate band business outlook fiscal end jan assume project effective income tax rate approximately zack rank key pickscurrently healthequity have zack rank hold few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last month surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
723,IDXX,headquarter pleasanton veeva system inc veev free report report second quarter fiscal adjust earning cent share end jul company earning beat zack consensus estimate cent year figure cent total revenue report quarter be year quarter project increase year year be well ahead zack consensus estimate quarter service revenue be year quarter increase year year professional service revenue increase almost primarily owing strong adoption vault platform second quarter company witness number registration veeva commercial cloud platform world veeva system have many core crm project track large pharma company globe report quarter veeva system make significant progress various field geography courtesy product veeva network veeva align veeva opendata veeva crm approve email come vault platform company booking account more half total quarter cloud platform veeva system gain significant market traction zinc ahead adoption vault qualitydocs vault qms be also rise company gain considerable traction market top pharmaceutical company be standardized vault etmf platform veeva system announce entry clinical datum management space solution veeva vault edc veeva vault esource veeva system inc price consensus ep surprise veeva system inc price consensus ep surprise veeva system inc quotemargin margin veeva system expand basis point bps report quarter owing favorable revenue mix higher percentage subscription revenue company report surge bps subscription gross margin totale almost balance sheetveeva system end report quarter nearly cash short term investment versus end sequential quarter calculate billing totale quarter be ahead management guidance courtesy impressive sale performance strong service revenue fiscal end jan total revenue be anticipate band adjust operate income be likely be adjust earning be forecast cent cent third quarter fiscal end oct veeva expect total revenue range meanwhile adjust operate income be expect adjust earning be forecast cent cent takewe be upbeat veeva system product launch industry focuse approach grow global demand cloud base vault application also boost opportunity company veeva system have strengthen recur part revenue mix mark significant growth subscription revenue be well ahead service revenue moreover new launch be highly encourage view be likely fortify company position enhance growth prospect long haul zack rank key pickscurrently veeva system have zack rank hold few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc edward lifescience sport zack rank strong buy idexx laboratory cogentix medical carry zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat trail quarters cogentix medical deliver positive earning surprise last report quarter idexx laboratory deliver average earning beat trail quarters surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
724,IDXX,headquarter irvine medical device major edward lifescience corporation ew free report specialize advanced cardiovascular disease especially structural heart disease stock be healthy growth trajectory late have rally last month ahead gain broader industry stock have market cap company year historical growth rate be also favorable compare broader industry solid prospect zack rank strong buy stock be attractive pick company estimate revision trend current quarter have also be positive past day analyst moved north movement opposite direction magnitude estimate revision increase cent share same time frame let find recent positive trend be sustainable edward lifescience second quarter performance be quite promising company beating zack consensus estimate revenue earning moreover raise guidance hint brighter prospect fact guidance raise be backed strong performance company product line market be also upbeat edward lifescience recent fda approval inspiris resilium aortic valve be first class resilient heart valf company also announce receipt fda approval aortic mitral valve valve procedure used edward lifescience sapien transcatheter heart valve believe recent fda approval several product have be boost investor confidence stock be encourage edward lifescience focus build pipeline further strengthen foothold operate business company also witness growth emerge portfolio mitral tricuspid repair therapy latest plan company new ultra system include balloon delivery system next generation sheath technology be expect be available europe second half company be track initiate launch acumen hpi software suite new flotrac iq smart disposable inspiris resilium aortic valve europe japan end however stiff competition currency headwind reimbursement issue be challenge stock other key picksother top rank medical stock be idexx laboratory inc idxx free report lantheus holding inc lnth free report align technology inc algn free report align technology sport zack rank lantheus holding idexx laboratory carry zack rank buy cansee complete list today zack rank stock here align technology have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last month simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
725,IDXX,idexx laboratory inc idxx free report lead manufacturer product service primarily companion animal veterinary have rally last month beating gain stock have market cap company year historical growth rate be also favorable compare broader industry also company represent return almost better broader industry gain last year solid prospect zack rank buy stock be attractive pick moment company estimate revision trend current year have also be positive past day analyst moved north movement opposite direction magnitude estimate revision earning rise share same time frame let find recent positive trend be sustainable recently idexx end second quarter solid note earning revenue beating zack consensus estimate stellar quarterly performance be drive company companion animal business companion animal market fundamental remain solid tremendous global runway growth management unique innovation base multus modality global strategy enabled enhance commercial capability accelerate recur cag diagnostic revenue growth moreover strong top line growth quarter be drive considerable contribution rest business segment also idexx recently announce addition rvetlink portfolio technology application notably rvetlink be advanced inclusive referral management solution design specialty care hospital simplify referral procedure primary care specialty care veterinarian apart idexx continue display solid growth respect international expansion company have be significantly benefitting companion animal market emerge nation demonstrate bountiful opportunity additionally company have strong cash balance enable carry share repurchase program turn provide solid return investor flip side foreign currency fluctuation be major headwind company concern be company high reliance third party distributor purchasing dynamic distributor have significant impact company sale instrument consumable rapid assay product also company face higher operate expense pertain increase head count higher investment target growth acceleration geographical expansion unite state internationally portfolio expansion moreover competitive landscape domestic overseas market weigh idexx performance other key picksother top rank medical stock be edward lifescience corp ew free report steris plc ste free report lantheus holding inc lnth free report edward lifescience sport zack rank strong buy steris lantheus holding carry zack rank see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have gain last month steris have positive earning surprise trail quarters stock have gain last month lantheus holding have long term expect earning growth rate stock have gain last month simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
726,IDXX,medtronic plc mdt free report report financial result first quarter fiscal adjust earning share ep report quarter come surpass zack consensus estimate year year adjustment quarter primarily include certain impact restructure charge intangible asset amortization acquisition related item adjust unfavorable foreign exchange impact cent adjust ep come year year adjustment company report net income cent share year year total revenue report quarter gross constant exchange rate cer basis report basis top line miss zack consensus estimate foreign currency fluctuation affected medtronic fiscal first quarter revenue quarter review sale total revenue increase year year develop market revenue totale total revenue reflect increase cer report emerge market total revenue amount cer report medtronic plc price consensus ep surprise medtronic plc price consensus ep surprise medtronic plc quotesegment company currently generate revenue major group viz cardiac vascular group cvg minimally invasive therapy group mitg restorative therapy group rtg diabetes group cvg comprise cardiac rhythm heart failure crhf coronary structural heart csh aortic peripheral vascular division apv mitg include surgical solution patient monitoring recovery pmr division rtg include spine brain therapy specialty therapy pain therapy segment diabetes group incorporate intensive insulin management iim intensive diabetes therapy ndt diabetes service solution dss division revenue cvg improve cer report drive strong balanced growth division crhf sale be year year cer report come back growth arrhythmia management lead high teen growth atrial fibrillation solution cer amplify penetration micra transcatheter pace system strong uptake tyrx absorbable antibacterial envelope continue worldwide customer demand reveal linq insertable cardiac monitor apart heartware international acquisition drive growth heart failure division csh revenue be cer report back high constant currency growth transcatheter aortic valf result strong customer uptake corevalve evolut pro platform unite state continue demand corevalve evolut mm valve unite state well europe apv revenue register growth cer report drive continue adoption endurant iis aortic stent graft remarkable strength heli fx endoanchor system peripheral be drive low double digit growth atherectomy drug coat balloon mitg worldwide sale reach mark year year increase cer same report mid single digit growth surgical solution low single digit growth pmr rtg worldwide revenue be year year cer same report high single digit growth brain therapy mid single digit growth specialty therapy low single digit growth spine thus mitigate decline pain therapy however revenue diabetes group decrease cer same report marginsgross margin report quarter contract basis point bps increase gross profit adjust operate margin remain flat year year be owing decline research development expense be offset rise selling general administrative expense other expense report quarter be compare year period reiterate fiscal constant currency revenue ep guidance company still expect full year revenue growth range cer however company revise foreign currency fluctuation estimation be now project have positive impact fiscal year compare expect positive impact state previously zack consensus estimate revenue remain fiscal fiscal adjust earning share growth be still expect range cer currency translation be now expect have adverse impact cent positive impact cent compare earlier expectation negative impact approximately cent zack consensus estimate fiscal earning be peg moreover second quarter fiscal medtronic expect currency translation have favorable impact revenue currency translation be expect have favorable impact cent second quarter earning share takemedtronic exit fiscal fourth quarter mixed note earning ahead zack consensus estimate report revenue fail meet estimate company demonstrated improve segmental performance cer escalate cost expense continue weigh bottom line unfavorable currency translation act dampener company quarterly performance however fiscal guidance represent chance respite positive note major business group contribute solid top line growth cer highlighted sustainability group region addition display successful integration achievement synergy target be also encourage solid growth trend successfully continue well healthy global acceptance advanced therapy apart product innovation company be currently focuse geographical diversification business zack rank peer currently have zack rank hold few better rank medical stock be edward lifescience corp ew free report haemonetic corp hae free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy haemonetic idexx carry zack rank buy see complete list today zack rank stock here edward lifescience second quarter adjust earning improve stupendous year year primarily drive strong sale growth company transcatheter heart valf business stock have gain last month idexx laboratory record second quarter ep cent cer year year report basis moreover revenue rise year year organic basis haemonetic report adjust ep cent first quarter fiscal year year moreover revenue inched year year cer quarter zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
727,IDXX,aug issue update research report san francisco base mckesson corporation mck free report health care service information technology company mckesson post disappointing result first quarter fiscal adjust earning revenue miss zack consensus estimate company currently have zack rank hold quarter see strong performance distribution solution segment segment be expect keep performance fiscal weak pricing trend customer consolidation boost growth company recently acquire covermymed approximately come guidance distribution solution business revenue growth be expect witness robust growth year year basis upside be expect be drive market growth acquisition mckesson expect gaap earning diluted share fiscal end mar adjust earning same period be expect range diluted share flipside pricing pressure independent retail pharmacy channel be headwind mckesson enter fiscal assumption brand inflation mid single digit first quarter slightly surpass expectation mckesson have be witness increase price competition independent retail pharmacy channel eventually result reduce volume company continue see competitive market selling generic pharmaceutical however mckesson expect overcome independent pharmacy sell side pricing impact end second quarter fiscal furthermore cutthroat competition niche market currency headwind reimbursement issue remain challenge stock performance estimate revision trendover last month mckesson have be trading broader industry company have gain compare favorably broader industry return just current level be also higher return only same time frame estimate revision trend mckesson have be unfavorable moment current quarter analyst moved south compare movement opposite direction last month result magnitude full year estimate fall same time frame key picksa few better rank stock broader medical sector be edward lifescience corporation ew free report masimo corporation masi free report idexx laboratory inc idxx free report notably edward lifescience sport zack rank strong buy idexx laboratory masimo corporation have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock have return last month masimo yielded strong return year date stock have long term expect earning growth rate idexx laboratory have long term expect earning growth rate additionally stock represent impressive year return hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
728,IDXX,renown information technology service provider healthcare organization allscript healthcare solution inc mdrx free report recently announce dbmotion solution platform have be select south western sydney phn swsphn deliver integrate care notably dbmotion solution be allscript proprietary community platform come back news allscript dbmotion integrate discrete real time patient datum diverse care setting health information technology system single patient record provider such synchronize information entire system enable provider easily access manage information familiar workflow facilitate better care disease management swsphn be not profit health organization focuse support general practitioner practice nurse other primary health provider aim improve access quality local health care whole community be first asia pacific organization select dbmotion solution platform dbmotion solution support swsphn overall goal improve clinical excellence advancement lead quality care also help swsphn collaborate internationally recognize dbmotion site locate unite state canada israel past month allscript have outperformed broader industry stock have increase compare only gain industry belong allscript be lead provider healthcare information technology solution management be focuse various restructure initiative such streamline operational efficiency increase cater client need go forward believe favorable demographic trend reinforce supportive regulatory environment be expect sustain growth demand service zack rank key picksallscript carry zack rank hold few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last month surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
729,IDXX,initiative enhance clinical development japan parexel international corporation global service company provider clinical research logistic have form alliance osaka international cancer institute bolster patient enrollment clinical trial oncology hematology management osaka leverage parexel expertise provide wide range potential treatment option cancer patient believe solid advancement clinical trial scientific expertise oncology segment fortify parexel foothold niche market oncology regard oncology be largest fastest grow therapeutic area parexel fact segment grow average past year however believe initiative help parexel drive top bottom line solid long term expect earning growth rate hold promise regard furthermore service market be healthy parexel enjoy competitive edge space solid prospect asia pacificparexel growth story asia pacific have be compelling japan company have lead position company be well position advantage outsource market be relatively underpenetrated parexel have operation tokyo kobe osaka japan report third quarter fiscal paraxel business asia have more double last year cagr almost apart japan company see solid prospect china world second largest pharmaceutical market witness double digit growth share shine brightparexel have have impressive run bourse last month company have gain compare favorably broader industry addition stock have also outperformed return same time frame estimate revision trend current quarter full year have be stable last month notably zack consensus estimate current quarter full year stand cent respectively same time frame parexel have zack rank hold bottom lineapart fortify hold oncology space parexel be focuse expedite activity area protocol design study start trial execution regulatory submission product company provide broad range clinical research consult medical communication technology solution service pharmaceutical biotechnology medical deviceindustry worldwide fact global market trend seem favorable moment market be anticipate reach worth cagr persistence market research expect parexel gain significant traction related ancillary market courtesy favorable trend latest partnership key picksa few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report stryker corporation syk free report notably edward lifescience sport zack rank strong buy idexx laboratory stryker corporation have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock represent impressive year date return idexx laboratory have long term expect earning growth rate notably stock represent stellar year date return stryker represent impressive year date return stock have long term expect earning growth rate zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
730,IDXX,aug issue update research report north kansa city mo base cerner corporation cern free report lead global provider healthcare information technology solution hcit stock currently carry zack rank hold believe cerner have solid growth opportunity revenue cycle management rcm suite solution fact segment have be strong contributor recent time revwork service deliver solid performance fact booking second quarter be time high year year basis secondary growth driver cerner be population health ph management platform notably company clinch high number large contract ph platform last report quarter cerner offer exposure worldwide healthcare automation international operation provide more diversify revenue stream past company have win contract well middle east furthermore cerner constantly pursue complementary business acquisition enable expand solution device offering service flipside company operate hcit space be intensely competitive fast evolve subject rapid technological change share price estimate revisioncerner have impressive run bourse last month trading industry term price performance glimpse price movement reveal cerner share have gain compare favorably rise industry belong flip side estimate revision trend current year remain unfavorable estimate move south last month compare only movement opposite direction company current estimate slip past month key picksa few better rank medical stock be idexx laboratory inc idxx free report lantheus holding inc lnth free report align technology inc algn free report align technology sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here idexx laboratory have long term expect earning growth rate stock have gain last month lantheus holding have long term expect earning growth rate stock have surge last month align technology have long term expect earning growth rate stock have rally roughly last month zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
731,IDXX,aug issue update research report irvine base quality system inc qsii free report lead developer marketer healthcare information system stock currently carry zack rank sell quality system have unimpressive run bourse last month trading industry term price performance glimpse price movement reveal quality system share have lose compare unfavorably industry decline quality system post stellar first quarter fiscal beating zack consensus estimate count however quarter witness lower professional service sale fall almost year year be primarily tough comparison year earlier quarter unimpressive performance new software platform recent quarters be particularly upbeat solid performance company total software hardware related segment however growth segment be partially offset lower software license hardware sale other concern sluggish global economy intensify competition strict regulatory environment be primary headwind recur revenue stream be positive quality system mostly come lower margin electronic datum interchange edi revenue cycle management rcm service quality system continue acquire business improve revenue opportunity aggravate integration risk company frequent acquisition impact balance sheet well overall organic growth limit quality system expansion plan worsen risk profile positive note quality system continue focus grow presence rcm population health solution market be expect drive dividend come quarters key picksa few better rank medical stock be idexx laboratory inc idxx free report lantheus holding inc lnth free report align technology inc algn free report align technology sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here idexx laboratory have long term expect earning growth rate stock have gain last month lantheus holding have long term expect earning growth rate stock have surge last month align technology have long term expect earning growth rate stock have rally roughly last month zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
732,IDXX,california base align technology inc algn free report recently sign distribution agreement patterson dental business unit patterson company inc pdco free report exclusive agreement effective september align technology itero element intraoral scanning system be available part patterson dental cad cam portfolio unite state canada thus believe align technology slatest deal boost itero scanner customer base considerable extent be also optimistic company expand work flow option lead itero scanner context align technology recently launch software upgrade itero element intraoral scanner be capable compare patient scan time latest timelapse technology also align technology collaborate exocad gmbh march integrate portfolio result high tech solution efficient scanning design manufacturing house dental prosthesis february company announce addition digital nobel biocare implant itero intraoral scanner portfolio interestingly revenue scanner service improve substantial last report second quarter moreover company see increase adoption itero scanner invisalign case submission instead pvs impression especially north america thereby drive invisalign utilization line latest development itero scanner space align technology latest deal buoy optimism report medgadget global market dental scanner be project see cagr period consider market potential align technology current development scanner service space collaboration seem be strategic believe unhealthy lifestyle rise awareness expenditure healthcare continue drive growth dental scanner market however market be dominate many well establish player dentsply sirona be prominent align technology have be gain investor confidence consistent positive result past month company share price have outperformed broader industry stock have gain broader industry fall company have also outperformed gain market same time frame zack rank key picksalign technology currently have zack rank hold few better rank medical stock be edward lifescience corporation ew free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy idexx laboratory carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have rally roughly last month simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
733,IDXX,cheme corporation che free report lead manufacturer product service primarily companion animal veterinary have gain last month thus beating gain stock have market cap company year expect growth rate be also impressive company further represent return almost substantially higher industry gain last year solid prospect zack rank buy stock be attractive pick moment company estimate revision trend current year have also be positive past day estimate moved north movement opposite direction magnitude estimate revision earning share rise same time frame let find recent positive trend be sustainable cheme second quarter performance be quite promising bottom line significantly improve year year basis stellar performance be drive company increase average net medicare reimbursement rate average daily census keep momentum encourage revenue growth raise guidance further indicate company brighter prospect promising outlook roto rooter segment bottom line also support company estimation improve operate result upcoming quarters fact view raise be backed company expectation significant gain roto rooter business cheme vita business be trouble past few quarters due certain admission coding change initiate center medicare medicaid service cms however management recently note recent admission trend have be positive continue come quarters second quarter vita perform well financially operationally thereby surpass company estimate additionally company strong cash balance enable carry share repurchase program turn provide solid return investor other key picksother top rank medical stock be idexx laboratory inc idxx free report lantheus holding inc lnth free report align technology inc algn free report align technology sport zack rank strong buy lantheus holding idexx laboratory carry zack rank see complete list today zack rank stock here idexx laboratory have long term expect earning growth rate stock have gain last month lantheus holding have long term expect earning growth rate stock have surge last month align technology have long term expect earning growth rate stock have rally roughly last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
734,IDXX,aug issue update research report elmsford ny base bioscrip inc bio free report company be lead infusion service provider strive deliver cost effective program patient stock currently have zack rank hold past month bioscrip have be trading broader industry stock have gain period industry loss market be upbeat company announcement continue offer certain core product line deal be significantly accretive bioscrip top line company progress new multus faceted core plan improve financial position be also encourage plan involve identify execute strategy accelerate core revenue growth favorable product mix drive operational efficiency improve revenue collection increase employee effectiveness further bioscrip have successfully complete home solution integration earlier year company expect core revenue well continue growth acquire asset prove accretive go forward notably bioscrip have be record persistent growth core infusion service business strong presence well competitive advantage company witness consistent rise business primarily account strong organic growth chronic nutrition other therapy have be build robust core infusion platform organic development acquisition management expect bioscrip focus fast grow core infusion business drive increase profitability company be currently track achieve previously announce home solution synergy other incremental annualize cost reduction end flip side bioscrip guidance be lackluster inclusion estimate negative impact cure act legislation large portion company revenue used come directly medicare state medicaid program other government payer however new cure act bill do not reimburse service payment administration certain drug patient home infusion pharmacy healthcare industry be also highly competitive bioscrip competitor include large well establish company higher financial marketing technological resource key picksa few better rank medical stock be idexx laboratory inc idxx free report lantheus holding inc lnth free report align technology inc algn free report align technology sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy cansee complete list today zack rank stock here idexx laboratory have long term expect earning growth rate stock have gain last month lantheus holding have long term expect earning growth rate stock have surge last month align technology have long term expect earning growth rate stock have rally roughly last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
735,IDXX,aug issue update research report warsaw base zimmer biomet holding inc zbh free report lead musculoskeletal healthcare company design distribute orthopedic reconstructive product spine bone heal thoracic product dental implant related surgical product last month zimmer biomet be trading industry factor macroeconomic uncertainty pricing pressure unfavorable currency fluctuation stock have now lose compare industry gain company deliver dull second quarter result expect downside continue upcoming period management company be still fight headwind such slump knee business shortage supply product thus lead inability recapture lose customer unite state gain new one also trim guidance add concern indicate slim chance recovery ahead market also seem be apprehensive departure zimmer biomet decade old ceo david dvorak notably year tenure zimmer biomet have transform global leader musculoskeletal healthcare combination organic growth strategic acquisition company revenue have double phase have introduce broad portfolio technology solution personalize service only time tell step drovak leave adverse impact company business currently remain sideline further visibility be obtain matter positive note look forward ongoing synergy ldr hold acquisition broaden complement company musculoskeletal offer be line strategy grow inorganic mean focuse mega merger management be also strive develop strong spine portfolio order cash opportunity company spine offering such mobi cervical disc prosthesis vitality spinal fixation system show considerable progress performance zimmer biomet have be late work strengthen foothold emerge market provide long term opportunity company strategic investment region several quarters view enhance operational sale performance be yielding result zack rank key pickszimmer biomet currently carry zack rank sell better rank medical stock be idexx laboratory inc idxx free report lantheus holding inc lnth free report align technology inc algn free report align technology sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here idexx laboratory have long term expect earning growth rate stock have gain last month lantheus holding have long term expect earning growth rate stock have surge last month align technology have long term expect earning growth rate stock have rally roughly last month surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
736,IDXX,share pennsylvania base biotelemetry inc beat free report rally new week high aug close tad lower represent strong year date return approximately better same time frame biotelemetry provide cardiac monitoring service cardiac monitoring device manufacturing stock sport zack rank strong buy majority last month company share price have considerably outperformed broader industry stock have rally last month outshine industry return just same time frame notably biotelemetry have market cap take stable performance stock consideration expect biotelemetry scale higher come quarters company long term growth also hold promise regard growth catalystsq result solid biotelemetry exit second quarter strong note earning exceed zack consensus estimate revenue meeting same revenue increase year year primarily drive increase healthcare revenue owing rise mcot patient notably marked consecutive quarter year year revenue growth company also register growth segment be encourage note company be putt effort product innovation research development however decline gross margin be matter concern lifewatch acquisition july biotelemetry announce acquisition lifewatch ag deal value buyout biotelemetry enhance position wireless medicine space expand product profile customer base cardiac monitoring diagnostic service space management expect acquisition yield significant synergy next month company make product be utilize remotely monitoring cardiac care patient guidance strong raise full year revenue guidance be encourage post acquisition lifewatch biotelemetry currently expect full year revenue range zack consensus estimate full year revenue be peg company expect revenue third quarter fourth quarter company also expect time expense related acquisition approximately be further expect be reflect third quarter result estimate revision trend estimate revision trend biotelemetry be favorable moment full year analyst moved north compare movement opposite direction last month result full year estimate jump same time frame current quarter analyst moved north compare movement opposite direction last month zack consensus estimate current quarter rise cent same time frame biotelemetry inc price consensus biotelemetry inc price consensus biotelemetry inc quotekey picksother top rank stock broader medical sector be edward lifescience corporation ew free report masimo corporation masi free report idexx laboratory inc idxx free report notably edward lifescience sport zack rank idexx laboratory masimo corporation have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock have return last month masimo yielded strong return year date stock have long term expect earning growth rate idexx laboratory have long term expect earning growth rate additionally stock represent impressive year return hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
737,IDXX,sep issue update research report quest diagnostic inc dgx free report major commercial laboratory service provider stock currently carry zack rank hold last month quest diagnostic have be trading broader industry last share price movement stock have gain contrast decline broader industry same time frame company earning last report second quarter exceed estimate revenue lag same company have witness significant growth infectious disease testing prescription drug monitoring wellness business be currently refocusing core diagnostic information service business discipline capital deployment finally raise guidance indicate chance continuation bullish trend addition alliance hospital integrate delivery network be other growth driver company be particularly positive peacehealth acquisition pacific northwest be expect bolster growth rest be also encourage launch qherit quest diagnostic july qherit pan ethnic expand carrier screen be panel test heritable disease mentioned new screening guideline issue march american college gynecology acog further company have complete previously announce acquisition laboratory business med fusion clear point late quest diagnostic come upgrade long term growth outlook base new extend point strategy generate shareholder value accelerate growth drive operational excellence however be concern tough organic volume scenario also last month comparative study quest diagnostic forward basis multiple reflect stock be quite overvalue tough competitive landscape reimbursement headwind be other concern key pickssome better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last month zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
738,IDXX,medtronic plc mdt free report mazor robotic ltd recently announce amendment exist partnership be initially sign distribute range mazor product modification company have enter next phase agreement earlier expect mazor robotic be israel base medical device company field robotic surgical guidance system meanwhile medtronic assume right exclusive worldwide distribution mazor system mazor robotic spine surgery system make third tranche investment mazor robotic early payment come back achievement certain pre agree sale marketing target advance grow demand mazor system also act favor follow third installment medtronic total investment mazor robotic rise partnership help company get platform explore development product spine market medtronic be make consistent effort expand spine business restorative therapy group rtg last report first quarter fiscal rtg report year year revenue increase constant exchange rate spine business witness low single digit growth also rtg company have announce plan launch solera voyager fixation system accord report mordor intelligence global market spinal surgery device be estimate reach worth cagr take bountiful opportunity niche space consideration believe company latest development be strategic last month medtronic have underperform broader industry last share price movement stock lose compare gain broader industry period zack rank key picksmedtronic carry zack rank sell few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy cansee complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last month zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
739,IDXX,hologic inc holx free report have moved step forward core breast health business new product add kitty company have announce have commercially launch brevera breast biopsy system corlumina imaging technology unite state company real time breast biopsy verification system enhance patient experience streamline entire biopsy process notably brevera system claim be world first only breast biopsy solution combine tissue acquisition real time imaging sample verification advanced post biopsy handle integrate system design breast biopsy technical method increase biopsy accuracy real time imaging thus help perform fast efficient procedure cost save manner hologic new advancement be major breakthrough radiologist be hitherto conduct stereotactic breast biopsy procedure diagnose breast cancer conventional practice be time consume well uncomfortable patient brevera system image tissue sample be obtain right procedure room few second only good news be highly sophisticated technology potentially save minute patient cut procedure time almost hologic also claim brevera system proprietary corlumina imaging technology help improve multiple department health system also feature pacs integration advanced image sharing transfer patient record significantly breast health segment hologic have reshape strategy continuous innovation leadership position mammography latest brevera routine be affirm prone biopsy system management be hopeful brevera begin boost growth add more meaningful contribution also june hologic have announce fda labele genius mammography exam better standard mammography routine breast cancer screening woman dense breast hologic be pretty confident strong adoption brevera breast biopsy system market look forward company consistent effort flourish field woman health regard be important mention immense growth opportunity healthcare market hold present datum provide market market breast imaging market be expect reach cagr however more search reveal global breast biopsy market advance cagr period research market datum publish business wire last month company share price have underperform broader industry stock have lose compare broader industry fall zack rank key pickshologic carry zack rank hold few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have surge last month idexx laboratory have long term expect earning growth rate stock have gain last month zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
740,IDXX,pra health science prah free report announce have price underwritten secondary public offer share common stock offer be expect close aug subject customary close condition last report sale price company common stock aug be share jun company have total cash cash investment worth compare dec month period end jun company generate cash operation pra health science be also strive effectively manage overhead function cut expense notably backlog increase approximately year year second quarter approximately share pra health science have increase last month compare industry increase believe pra have therapeutic expertise area be largest pharmaceutical development include oncology central nervous system inflammation infectious disease company provide client most flexible clinical development service offering include traditional project base phase phase iv service well embed functional outsource service company have invest medical informatic clinical technology design enhance efficiency improve study predictability provide better transparency client clinical development process pra health science be world lead global contract research organization revenue company provide outsourced clinical development service biotechnology pharmaceutical industry pra global clinical development platform include approximately office north america europe asia latin america south africa australia middle east approximately employee worldwide pra have perform approximately clinical trial worldwide addition pra have participate pivotal supportive trial lead food drug administration international regulatory approval more drug zack rank key pickscurrently pra health science have zack rank hold few better rank stock broader medical sector be edward lifescience corporation ew free report fresenius medical care corporation fms free report idexx laboratory inc idxx free report notably edward lifescience fresenius medical sport zack rank strong buy idexx laboratory have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock have return last month fresenius medical yielded strong return year date stock have long term expect earning growth rate idexx laboratory have long term expect earning growth rate additionally stock represent impressive year return make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
741,IDXX,molecular diagnostic personalize medicine major myriad genetic inc mygn free report achieve milestone endopredict test get positive coverage decision palmetto gba medicare administrative contractor assess molecular diagnostic technology notably endopredict be myriad genetic next generation multigene prognostic test breast cancer test provide information help doctor devise personalize treatment plan follow full implementation decision myriad genetic have coverage breast cancer patient post implementation decision consider endopredict have be used clinically more patient areconfident grow adaptability test post medicare coverage approval report provide gbi research global breast cancer treatment market reach worth cagr thus company clearly have bountiful prospect market also note company have recently receive extend medicare coverage prolasis test regard note past month myriad genetic have be trading broader industry stock have gain higher industry gain recent genetic announce bracanalysis cdx companion diagnostic test successfully identify brca mutate patient metastatic breast cancer olympiad trial respond better treatment olaparib standard chemotherapy also myriad genetic present favorable finding bracanalysis cdx test successfully identify patient metastatic breast cancer phase olympiad study zack rank key picksmyriad genetic carry zack rank hold few better rank medical stock be idexx laboratory inc idxx free report lantheus holding inc lnth free report align technology inc algn free report align technology sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy cansee complete list today zack rank stock here align technology have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last month surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
742,IDXX,headquarter sunnyvale accuray inc aray free report recently announce boise base summit cancer center have initiate cancer treatment radixact treatment delivery system notably radixact system leverage company flagship tomotherapy platform radixact system provide complex treatment such craniospinal total marrow irradiation add functionality summit cancer center have capability perform stereotactic radiosurgery srs stereotactic body radiotherapy sbrt spare normal tissue maintain optimal treatment efficacy radixact system have be design deliver image guide intensity modulate radiation therapy extremely precise form radiation therapy platform gain japanese regulatory approval shonin approval last quarter be expect start formal treatment fourth quarter regard glimpse preliminary fourth quarter result reveal accuray expect approximately gross product order solid growth gross order be buoy full commercial launch radixact system continue strong demand company flagship cyberknife system stock price estimate revision trendaccuray have have unimpressive run bourse last year company have lose way wider broader industry rally almost moreover current level compare unfavorably gain furthermore estimate revision stock have be unfavorable full year estimate deteriorate cent loss cent share owing bearish analyst sentiment accuray carry zack rank sell signify term takeaccuray top line growth be highly dependent cyberknife tomotherapy system sale however system involve significant capital spending many healthcare provider be reluctant spend primarily due sluggish macro economic condition mar revenue long haul however company have be gain ground series positive tiding regulatory front recently notable one accuray receive clearance fda idms datum management system july key picksa few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report stryker corporation syk free report notably edward lifescience sport zack rank strong buy idexx laboratory stryker corporation have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock represent impressive year date return idexx laboratory have long term expect earning growth rate notably stock represent stellar year date return stryker represent impressive year date return stock have long term expect earning growth rate surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
743,IDXX,palo alto base manufacturer medical device software varian medical system inc var free report announce have sign distribution agreement toledo base bionix radiation therapy agreement varian medical distribute bionix propreitory brachytherapy applicator varian market bionix esophageal applicator app anorectal applicator ar north america applicator app be disposable brachytherapy applicator be design specifically treatment cancer app feature independently operable balloon maintain central position source catheter straight curved anatomy allow closer proximity target source maintain distance healthy tissue second applicator ar be disposable brachytherapy applicator be design specifically treatment anal rectal cancer dual balloon design ar allow exophytic tumor press closer source catheter create ability deliver very high dose tumor spare healthy tissue future trendwe note global radiotherapy market be expect reach worth cagr take bountiful prospect global niche space consideration latest development boost investor confidence share price performancea promising portfolio combine robust initiative have be favore zack rank hold company have deliver positive earning surprise last quarters note share varian medical have decline past month broader industry grow same time frame takevarian medical operate technology drive environment success depend innovation frequent product update company have be successful front evident year year expansion top line company have approximately revenue opportunity various oncology imaging component product next year apart enjoy dominant market share conventional radiotherapy believe proton therapy hold significant promise varian medical be probeam compact proton therapy system be superior other external beam radiotherapy precisely locate cancerous tumor cause lesser side effect surround tissue proton therapy system used same interface used company truebeam platform finally company strong overseas presence be expect enable leverage opportunity emerge market line grow demand cancer treatment overseas market varian medical sale europe africa particularly asia be grow faster rate domestic market do medical stock interest check theseinvestor consider better rank stock same sector such edward lifescience corporation ew free report fresenius medical care corporation fms free report idexx laboratory inc idxx free report notably edward lifescience fresenius medical sport zack rank strong buy idexx laboratory have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock have return last month fresenius medical yielded strong return year date stock have long term expect earning growth rate idexx laboratory have long term expect earning growth rate additionally stock represent impressive year return simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
744,IDXX,sep issue update research report gnc holding inc gnc free report lead global specialty retailer product health wellness include vitamin mineral herbal supplement sport nutrition diet company currently carry zack rank hold past year gnc holding have be underperform broader industry company have lose compare decline broader industry period weak margin significant decline revenue year year basis raise concern tough competition change consumer preference federal trade commission ftc regulation continue challenge moreover pittsburgh pa base company exit second quarter disappointing note revenue miss zack consensus estimate earning exceed consensus estimate year year decline front be dampening decline be attribute lower sale company canada manufacturing wholesale segment positive note second quarter management witness positive response new gnc plan company have start incorporating change operation also management be currently work product pricing innovation moreover new consumer enrollment mygnc reward program launch gnc storefront amazon buoy optimism gnc holding be develop product formula address unmet customer need be also expand customer brand raw mega man woman ultra mega gnc probiotic also company prospect international business strong cash position be encourage management expect continue capitalize international revenue opportunity addition franchise store exist market expansion new high growth market growth product distribution exist new market second quarter company international business drive increase revenue rise operate income apart strong commerce business china company witness improvement trend mexico south korea hong kong meanwhile nutritional supplement industry be characterize rapid frequent change demand product new product introduction apart gnc holding international competitor include large pharmacy chain major supermarket chain other big base company global operation management fear face stiff competition company fail function effectively attempt do so require price reduction turn hurt margin key picksa few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last year zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
745,IDXX,second half have already start citizen vote president donald trump capitol hill have yet witness abolishment obamacare wall dollar have be strong selling pressure year ongoing uncertainty economic agenda trump mount speculation fed implement third rate hike year give such volatile economic condition investor feel intimidate regard investment scenario fact increase volatility back significant increase cboe volatility index vix indicate bearish market prospect apart domestic event issue escalate north korea japan tension terror attack spain also result market be subdue now medtechat present focal point capitol hill seem be tax cut feel only hogwash unite gop banner divisive summer apocalyptic battle obamacare repeal such political conundrum market watcher keep tab medical space fraternity worry final trump care plan still include medtech tax repeal agenda meanwhile old template plan promise eradicate infamous medical device tax cadillac tax excise tax high cost healthcare plan be not bad deal such uproar question emerge be medical product player stand gain lose selection right stock be quite ardent task little care precision make job easy give current lack clarity let concentrate powerful long term tailwind medical device industry include merger acquisition emerge market expansion positive demographic trend new product innovation have be drive force sector impressive performance severe socio economic political instability wide gamut medical device come here rescue zack industry classification medical device be broadly group medical sector zack sector further sub divide important area medical instrument medical product medical dental supply screening criteriain article have picked winner aforementioned area have trade higher index past year also base strong fundamental strategic implementation plan execution certain positive catalyst carry huge upside potential high probability outperform market index come day zack have design style score system compare parameter stock peer group analysis stock be attractive value perspective stock currently flaunt zack rank strong buy buy vgm score here stand value growth momentum score be weight combination metric such score allow eliminate negative aspect stock select winner market capitalization be multus billion testify strong liquidity estimate revision trend be significantly positive earning growth expectation be finally industry lower market position call more upside second half top picksmedical dental dental supply industry be currently rank have significantly climb last week rank industry have outperformed register gain past month index other hand have shed space be bullish vwr corporation headquarter radnor pa vwr corporation be independent worldwide provider product service solution laboratory production facility price surge approximately year date zack rank stock be attractive pick earning company be expect grow year see see complete list today zack rank strong buy stock here medical instrument industry be currently rank have significantly climb last week rank industry have outperformed register gain year date index other hand have shed space be bullish idexx laboratory inc idxx free report headquarter delaware nj idexx laboratory be developer manufacturer distributer product service primarily companion animal veterinary livestock poultry water testing dairy market company also sell series portable electrolyte blood gas analyzer human point care medical diagnostic market price surge approximately year date zack rank stock be attractive pick earning company be expect grow year medical product industry be currently rank have significantly climb last week rank industry have outperformed register gain year date index other hand have rise only space be bullish nephew plc snn free report headquarter london unite kingdom nephew be manufacturer distributor advanced medical device sport medicine joint reconstruction trauma wound management area price surge approximately year date zack rank stock be attractive pick earning company be expect grow year bottom lineat moment future medtech industry look bright courtesy expand global population rise popularity digital healthcare service rapid development technological know incorporation healthcare sector global medtech sale expect grow cagr more evaluate ltd believe aforementioned stock be promising addition healthcare portfolio backed positive momentum share price solid future earning growth projection more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
746,IDXX,patterson company inc pdco free report report first quarter fiscal adjust earning cent share continue operation outpaced zack consensus estimate cent figure however come lower year quarterly figure cent net sale continue operation dip year quarter miss zack consensus estimate quarter detailscome animal health platform total sale sale increase almost year year basis sale consumable grow year year however other service product platform witness year year decline sale patterson company dental platform total sale sale decline year year approximately consumable sale dental platform drop year year sale other service product decrease sale dental equipment software dip patterson company inc price consensus ep surprise patterson company inc price consensus ep surprise patterson company inc quotefinancial conditioncash cash equivalent be jul compare apr report quarter patterson repurchase approximately share company also disburse cash dividend shareholder first quarter company affirm adjust earning range share fiscal gaap earning be expect be range diluted share zack rank key pickspatterson company currently have zack rank sell few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc edward lifescience sport zack rank strong buy idexx laboratory cogentix medical carry zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat trail quarters cogentix medical deliver positive earning surprise last report quarter idexx laboratory deliver average earning beat trail quarters simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
747,IDXX,growth stock be most exciting pick market high flyer captivate investor attention produce big gain well however also lead downside growth story be so be important find company be still see strong growth prospect business such company be well position future earning growth be idexx laboratory inc idxx free report firm be medical instrument industry see ep growth last year be look great year too fact current growth estimate year call earning share growth furthermore long term growth rate be currently impressive suggest pretty good prospect long haul idexx laboratory inc price consensus idexx laboratory inc price consensus idexx laboratory inc wasn enough stock have actually see estimate rise past month current fiscal year thank rise earning estimate idxx have zack rank buy further underscore potential outperformance company see complete list today zack rank strong buy stock here so be look fast grow stock be still see plenty opportunity horizon make sure consider idxx not only do have double digit earning growth prospect impressive zack rank suggest analyst believe better day be ahead idxx well simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
748,IDXX,sep issue update research report idexx laboratory inc idxx free report lead molecular diagnostic company stock currently have zack rank buy be encourage note idexx continue demonstrate solid global growth potent international expansion international revenue last report second quarter grow high single digit drive organic rise cag diagnostic recur revenue gain water business indicated continue consumable revenue gain support strong catalyst instrument customer base average testing utilization idexx derive lion share revenue companion animal group segment cag second quarter cag organic revenue rise low double digit year year basis support cag diagnostic recur organic well cag instrument revenue growth believe management innovation base global strategy be lead growth cag diagnostic also idexx recently announce addition rvetlink portfolio technological application notably rvetlink be advanced inclusive referral management solution design specialty care hospital simplify referral procedure primary care specialty care veterinarian additionally company have strong cash balance enable carry share repurchase program turn provide solid return investor flipside last month idexx have be trading broader industry respect share price movement stock have rally period comparison gain broader industry idexx high dependence third party distributor intense competition continue threat moreover grow international expansion company companion animal diagnostic business be likely suffer adverse currency fluctuation competitive landscape overseas market weigh company well other key picksa few other top rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report amedisys inc am free report edward lifescience sport zack rank strong buy lantheus holding amedisys carry zack rank see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month amedisys have long term expect earning growth rate stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
749,IDXX,base audubon pa lead musculoskeletal implant company globus medical inc gmed free report announce receipt approval excelsius gps robotic guidance navigation system fda fact positive tiding regulatory front have favore globus medical company have already clinch ce mark excelsius gps january system support minimally invasive open orthopedic neurosurgical procedure screw placement application system be exclusively design limit radiation exposure reorganize assist implant placement excelsius gps system work different imaging modality excelsius gps integrate globus medical implant instrument be compatible pre operative ct intra operative ct fluoroscopic imaging modality globus medical be gear worldwide launch include logistic supply chain manufacturing support excelsius gps system fact technology have encourage globus medical increase investment technology acquisition distribution channel share performance estimate revision trendover last month globus medical have be trading broader industry company have lose much wider broader industry decline current level also compare unfavorably decline only same time frame estimate revision trend globus medical have be unfavorable late current quarter analyst moved south compare movement opposite direction last month result magnitude current quarter estimate fall cent share same time frame viewpointa research report technavio expect global musculoskeletal disorder therapeutic market see cagr approximately believe globus medical latest regulatory progress lend competitive edge global niche space meanwhile stock have zack rank sell signify probability term contrary stock long term expect earning growth rate instill confidence investor add positive company be debt free end just report second quarter globus medical reaffirm guidance full year sale approximately adjust earning share key picksa few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report stryker corporation syk free report notably edward lifescience sport zack rank strong buy idexx laboratory stryker have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock represent impressive year date return idexx laboratory have long term expect earning growth rate notably stock represent stellar year date return stryker represent solid year date return stock have long term expect earning growth rate surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
750,IDXX,aug issue update research report walgreen boot alliance inc wba free report illinois base lead pharmacy lead health wellbeing enterprise stock currently carry zack rank hold walgreen have outperformed industry respect share price movement last month stock have gain ahead industry rise period walgreen shelving rite aid rad free report acquisition deal come huge setback company investor buyout deal have once promise strong platform develop company brand presence well overall future business growth however delve deal latest detail believe be still much hope new agreement enable walgreen purchase nearly half rite aid business deal value almost third original price more specifically acquirer take nearly store distribution center related inventory rite aid cash notably latter run store state district columbia jun apart contract financial outcome be pretty attractive post new transaction initial close walgreen expect be modestly accretive adjust diluted net earning share first full year synergy new takeover be expect excess be entirely realize year initial close walgreen modify merger contract also extend growth strategy offer additional operational financial benefit help company expand optimize retail pharmacy network key market include northeast partial consolidation rite aid help walgreen gain competitive edge company new strategic pharmacy tie up several recent program include skin product launch vaccination be encourage earlier year company partner communication service provider wpp operate develop multiple marketing communication channel retail wholesale business well health beauty product brand walgreen boot also inked multus year partnership agreement global express delivery service provider fedex corporation alliance be aim offer convenient access fedex drop pickup service several walgreen boot location unite state last few year slowdown generic introduction increase reimbursement pressure generic drug cost inflation have be hamper company margin significantly also walgreen boot face obstacle increase competition tough industry condition even company continue gain decent market share other traditional drug store retailer major mass merchant namely target wal mart be track expand pharmacy business risk other channel such supermarket mail order operation also threat addition industry condition remain challenge insurer slash reimbursement rate raise prescription co payment currency fluctuation weak macroeconomic environment delay walgreen boot long impending buyout rite aid emerge other headwind key pickssome better rank medical stock be align technology inc algn free report idexx laboratory inc idxx free report align technology sport zack rank strong buy idexx laboratory carry zack rank buy see complete list today zack rank stock here idexx laboratory have long term expect earning growth rate stock have gain last month lantheus holding have long term expect earning growth rate stock have surge last month align technology have long term expect earning growth rate stock have rally roughly last month surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
